



(19) Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 0 612 846 B1

## (12) EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
16.08.2000 Bulletin 2000/33(51) Int. Cl.<sup>7</sup>: C12N 15/27, C12P 21/02,  
C07K 14/53, G06F 17/50

(21) Application number: 94101207.2

(22) Date of filing: 27.01.1994

## (54) G-CSF analog compositions and methods

.G-CSF Analoge und Verfahren zu ihrer Herstellung  
Analogue de G-CSF et méthodes pour les obtenir

(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE

(30) Priority: 28.01.1993 US 10099

(43) Date of publication of application:  
31.08.1994 Bulletin 1994/35(83) Declaration under Rule 28(4) EPC (expert  
solution)(60) Divisional application:  
99113571.6 / 0 974 655  
99112115.3 / 0 965 638  
98113221.0 / 0 890 640(73) Proprietor: AMGEN INC.  
Thousand Oaks, CA 91320-1789 (US)(72) Inventor: Osslund, Timothy  
Camarillo, California 93010 (US)(74) Representative:  
Brown, John David et al  
FORRESTER & BOEHMERT  
Franz-Joseph-Strasse 38  
80801 München (DE)(56) References cited:  
EP-A- 0 344 796 EP-A- 0 456 200  
WO-A-87/01132 WO-A-88/01775  
WO-A-89/05824 WO-A-93/25687

- DISSERTATION ABSTRACTS INTERNATIONAL B. vol. 54, no. 3 , September 1993 page 1239 T. OSSLUND ET AL 'The structure of granulocyte-colony stimulating factor'
- PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA vol. 90 , June 1993 , WASHINGTON US pages 5167 - 5171 C.P. HILL ET AL 'The structure of Granulocyte-colony-stimulating factor and its relationship to other growth factors'
- CELL STRUCTURE AND FUNCTION vol. 17, no. 1 , February 1992 pages 61 - 65 MASAHIRO ISHIKAWA ET AL 'The substitution of Cysteine 17 of recombinant human G-CSF with Alanine greatly enhanced its stability'
- BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 159, no. 1 , 28 February 1989 , DULUTH, MINNESOTA US pages 103 - 111 TETSURO KUGA ET AL 'Mutagenesis of human granulocyte colony stimulating factor'
- BIOCHEMISTRY vol. 30 , 1991 , EASTON, PA US pages 4151 - 4159 L. ABRAHMSSEN ET AL 'Engineering subtilisin and its substrates for efficient ligation of peptide bonds in aqueous solution'
- SCIENCE vol. 258 , 20 November 1992 , LANCASTER, PA US pages 1358 - 1362 J. PANDIT ET AL 'Three-dimensional Structure of dimeric human recombinant Macrophage Colony-Stimulating Factor'

---

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- JOURNAL OF CELLULAR BIOCHEMISTRY  
SUPPL 0 no. 17B , 26 JANUARY-10 FEBRUARY  
1993 page 78 J. E. LAYTON ET AL 'Interaction  
of G-CSF with its receptor : Dissociation of  
biological activity and Receptor binding'
  - JOURNAL OF APPLIED CRYSTALLOGRAPHY  
vol. 20 , 1987 pages 366 - 373 M.J. COX ET AL  
'Experiments with automated protein  
crystallization'
  - POUR LA SCIENCE vol. 183 , January 1993  
pages 76 - 82 A. OLSON ET AL 'Voir les  
Molécules biologiques'
  - PROTEIN ENGINEERING 1987 , ALAN R. LISS,  
INC. pages 35 - 44 M. KARPLUS 'The  
prediction and Analysis of mutant strutures'
-

**Description****Field of the Invention**

5 [0001] This invention relates to granulocyte colony stimulating factor ("G-CSF") analogs.

**Background**

10 [0002] Hematopoiesis is controlled by two systems: the cells within the bone marrow microenvironment and growth factors. The growth factors, also called colony stimulating factors, stimulate committed progenitor cells to proliferate and to form colonies of differentiating blood cells. One of these factors is granulocyte colony stimulating factor, herein called G-CSF, which preferentially stimulates the growth and development of neutrophils, indicating a potential use in neutropenic states. Welte et al., PNAS-USA 82: 1526-1530 (1985); Souza et al., Science 232: 61-65 (1986) and Gabrilove, J. Seminars in Hematology 26: (2) 1-14 (1989).

15 [0003] In humans, endogenous G-CSF is detectable in blood plasma. Jones et al., Bailliere's Clinical Hematology 2 (1): 83-111 (1989). G-CSF is produced by fibroblasts, macrophages, T cells, trophoblasts, expression product of a single copy gene comprised of four exons and five introns located on chromosome seventeen. Transcription of this locus produces a mRNA species which is differentially processed, resulting in two forms of G-CSF mRNA, one version coding for a protein of 177 amino acids, the other coding for a protein of 174 amino acids, Nagata et al., EMBO J 5: 575-581 (1986), and the form comprised of 174 amino acids has been found to have the greatest specific *in vivo* biological activity. G-CSF is species cross-reactive, such that when human G-CSF is administered to another mammal such as a mouse, canine or monkey, sustained neutrophil leukocytosis is elicited. Moore et al., PNAS-USA 84: 7134-7138 (1987).

20 [0004] Human G-CSF can be obtained and purified from a number of sources. Natural human G-CSF (nhG-CSF) can be isolated from the supernatants of cultured human tumor cell lines. The development of recombinant DNA technology, see, for instance, U.S. Patent 4,810,643 (Souza) incorporated herein by reference, has enabled the production of commercial scale quantities of G-CSF in glycosylated form as a product of eukaryotic host cell expression, and of G-CSF in non-glycosylated form as a product of prokaryotic host cell expression.

25 [0005] G-CSF has been found to be useful in the treatment of indications where an increase in neutrophils will provide benefits. For example, for cancer patients, G-CSF is beneficial as a means of selectively stimulating neutrophil production to compensate for hematopoietic deficits resulting from chemotherapy or radiation therapy. Other indications include treatment of various infectious diseases and related conditions, such as sepsis, which is typically caused by a metabolite of bacteria. G-CSF is also useful alone, or in combination with other compounds, such as other cytokines, for growth or expansion of cells in culture, for example, for bone marrow transplants.

30 [0006] Signal transduction, the way in which G-CSF effects cellular metabolism, is not currently thoroughly understood. G-CSF binds to a cell-surface receptor which apparently initiates the changes within particular progenitor cells, leading to cell differentiation.

35 [0007] Various altered G-CSF's have been reported. Generally, for design of drugs, certain changes are known to have certain structural effects. For example, deleting one cysteine could result in the unfolding of a molecule which is, in its unaltered state, is normally folded via a disulfide bridge. There are other known methods for adding, deleting or substituting amino acids in order to change the function of a protein.

40 [0008] Recombinant human G-CSF mutants have been prepared, but the method of preparation does not include overall structure/function relationship information. For example, the mutation and biochemical modification of Cys 18 has been reported. Kuga et al., Biochem. Biophys. Res. Comm 159: 103-111 (1989); Lu et al., Arch. Biochem. Biophys. 268: 81-92 (1989).

45 [0009] In U.S. Patent No. 4, 810, 643, entitled, "Production of Pluripotent Granulocyte Colony-Stimulating Factor" (as cited above), polypeptide analogs and peptide fragments of G-CSF are disclosed generally. Specific G-CSF analogs disclosed include those with the cysteins at positions 17, 36, 42, 64, and 74 (of the 174 amino acid species or of those having 175 amino acids, the additional amino acid being an N-terminal methionine) substituted with another amino acid, (such as serine), and G-CSF with an alanine in the first (N-terminal) position.

50 [0010] EP 0 335 423 entitled "Modified human G-CSF" reportedly discloses the modification of at least one amino group in a polypeptide having hG-CSF activity.

[0011] EP 0 272 703 entitled "Novel Polypeptide" reportedly discloses G-CSF derivatives having an amino acid substituted or deleted at or "in the neighborhood" of the N terminus.

55 [0012] EP 0 459 630, entitled "Polypeptides" reportedly discloses derivatives of naturally occurring G-CSF having at least one of the biological properties of naturally occurring G-CSF and a solution stability of at least 35% at 5 mg/ml in which the derivative has at least Cys<sup>17</sup> of the native sequence replaced by a Ser<sup>17</sup> residue and Asp<sup>27</sup> of the native sequence replaced by a Ser<sup>27</sup> residue.

[0013] EP 0 256 843 entitled "Expression of G-CSF and Muteins Thereof and Their Uses" reportedly discloses a

modified DNA sequence encoding G-CSF wherein the N-terminus is modified for enhanced expression of protein in recombinant host cells, without changing the amino acid sequence of the protein.

[0014] EP 0 243 153 entitled "Human G-CSF Protein Expression" reportedly discloses G-CSF to be modified by inactivating at least one yeast KEX2 protease processing site for increased yield in recombinant production using yeast.

5 [0015] Shaw, U.S. Patent No. 4,904,584, entitled "Site-Specific Homogeneous Modification of Polypeptides," reportedly discloses lysine altered proteins.

[0016] WO/9012874 reportedly discloses cysteine altered variants of proteins.

[0017] Australian patent application Document No. AU-A-10948/92, entitled, "Improved Activation of Recombinant Proteins" reportedly discloses the addition of amino acids to either terminus of a G-CSF molecule for the purpose of aiding in the folding of the molecule after prokaryotic expression.

10 [0018] Australian patent application Document No. AU-A-76380/91, entitled, "Muteins of the Granulocyte Colony Stimulating Factor (G-CSF)" reportedly discloses muteins of the granulocyte stimulating factor G-CSF in the sequence Leu-Gly-His-Ser-Leu-Gly-Ile at position 50-56 of G-CSF with 174 amino acids, and position 53 to 59 of the G-CSF with 177 amino acids, or/and at least one of the four histidine residues at positions 43, 79, 156 and 170 of the mature G-

15 CSF with 174 amino acids or at positions 46, 82, 159, or 173 of the mature G-CSF with 177 amino acids.

[0019] GB 2 213 821, entitled "Synthetic Human Granulocyte Colony Stimulating Factor Gene" reportedly discloses a synthetic G-CSF-encoding nucleic acid sequence incorporating restriction sites to facilitate the cassette mutagenesis of selected regions, and flanking restriction sites to facilitate the incorporation of the gene into a desired expression system.

20 [0020] G-CSF has reportedly been crystallized to some extent, e.g., EP 344 796, and the overall structure of G-CSF has been surmised, but only on a gross level. Bazan, Immunology Today 11: 350-354 (1990); Parry et al., J. Molecular Recognition 8: 107-110 (1988). To date, there have been no reports of the overall structure of G-CSF, and no systematic studies of the relationship of the overall structure and function of the molecule, studies which are essential to the systematic design of G-CSF analogs. Accordingly, there exists a need for a method of this systematic design of G-

25 CSF analogs, and the resultant compositions.

### Summary of the Invention

[0021] The three dimensional structure of G-CSF has now been determined to the atomic level. From this three-dimensional structure, one can now forecast with substantial certainty how changes in the composition of a G-CSF molecule may result in structural changes. These structural characteristics may be correlated with biological activity to design and produce G-CSF analogs.

30 [0022] Although others had speculated regarding the three dimensional structure of G-CSF, Bazan, Immunology Today 11: 350-354 (1990); Parry et al., J. Molecular Recognition 8: 107-110 (1988), these speculations were of no help to those wishing to prepare G-CSF analogs either because the surmised structure was incorrect (Parry et al., *supra*) and/or because the surmised structure provided no detail correlating the constituent moieties with structure. The present determination of the three-dimensional structure to the atomic level is by far the most complete analysis to date, and provides important information to those wishing to design and prepare G-CSF analogs. For example, from the present three dimensional structural analysis, precise areas of hydrophobicity and hydrophilicity have been determined.

35 [0023] Relative hydrophobicity is important because it directly relates to the stability of the molecule. Generally, biological molecules, found in aqueous environments, are externally hydrophilic and internally hydrophobic; in accordance with the second law of thermodynamics provides, this is the lowest energy state and provides for stability. Although one could have speculated that G-CSF's internal core would be hydrophobic, and the outer areas would be hydrophilic, one would have had no way of knowing specific hydrophobic or hydrophilic areas. With the presently provided knowledge of areas of hydrophobicity/philicity, one may forecast with substantial certainty which changes to the G-CSF molecule will affect the overall structure of the molecule.

40 [0024] As a general rule, one may use knowledge of the geography of the hydrophobic and hydrophilic regions to design analogs in which the overall G-CSF structure is not changed, but change does affect biological activity ("biological activity" being used here in its broadest sense to denote function). One may correlate biological activity to structure.

45 If the structure is not changed, and the mutation has no effect on biological activity, then the mutation has no biological function. If, however, the structure is not changed and the mutation does affect biological activity, then the residue (or atom) is essential to at least one biological function. Some of the present working examples were designed to provide no change in overall structure, yet have a change in biological function.

50 [0025] Based on the correlation of structure to biological activity, the present invention relates to G-CSF analogs. These analogs are molecules which have more, fewer, different or modified amino acid residues from the G-CSF amino acid sequence. The modifications may be by addition, substitution, or deletion of one or more amino acid residues. The modification may include the addition or substitution of analogs of the amino acids themselves, such as peptidomimetics or amino acids with altered moieties such as altered side groups. The G-CSF used as a basis for comparison may

- be of human, animal or recombinant nucleic acid-technology origin (although the working examples disclosed herein are based on the recombinant production of the 174 amino acid species of human G-CSF, having an extra N-terminus methionyl residue). The analogs may possess functions different from natural human G-CSF molecule, or may exhibit the same functions, or varying degrees of the same functions. For example, the analogs may be designed to have a higher or lower biological activity, have a longer shelf-life or a decrease in stability, be easier to formulate, or more difficult to combine with other ingredients. The analogs may have no hematopoietic activity, and may therefore be useful as an antagonist against G-CSF effect (as, for example, in the overproduction of G-CSF). From time to time herein the present analogs are referred to as proteins or peptides for convenience, but contemplated herein are other types of molecules, such as peptidomimetics or chemically modified peptides.
- [0026] In another aspect, the present disclosure relates to related compositions containing a G-CSF analog as an active ingredient. The term, "related composition," as used herein, is meant to denote a composition which may be obtained once the identity of the G-CSF analog is ascertained (such as a G-CSF analog labeled with a detectable label, related receptor or pharmaceutical composition). Also considered a related composition are chemically modified versions of the G-CSF analog, such as those having attached at least one polyethylene glycol molecule.
- [0027] For example, one may prepare a G-CSF analog to which a detectable label is attached, such as a fluorescent, chemiluminescent or radioactive molecule.
- [0028] Another example is a pharmaceutical composition which may be formulated by known techniques using known materials, see, e.g., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pennsylvania 18042) pages 1435-1712, which are herein incorporated by reference. Generally, the formulation will depend on a variety of factors such as administration, stability, production concerns and other factors. The G-CSF analog may be administered by injection or by pulmonary administration via inhalation. Enteric dosage forms may also be available for the present G-CSF analog compositions, and therefore oral administration may be effective. G-CSF analogs may be inserted into liposomes or other microcarriers for delivery, and may be formulated in gels or other compositions for sustained release. Although preferred compositions will vary depending on the use to which the composition will be put, generally, for G-CSF analogs having at least one of the biological activities of natural G-CSF, preferred pharmaceutical compositions are those prepared for subcutaneous injection or for pulmonary administration via inhalation, although the particular formulations for each type of administration will depend on the characteristics of the analog.
- [0029] Another example of related composition is a receptor for the present analog. As used herein, the term "receptor" indicates a moiety which selectively binds to the present analog molecule. For example, antibodies, or fragments thereof, or "recombinant antibodies" (see Huse et al., *Science* 246:1275 (1989)) may be used as receptors. Selective binding does not mean only specific binding (although binding-specific receptors are encompassed herein), but rather that the binding is not a random event. Receptors may be on the cell surface or intra- or extra-cellular, and may act to effectuate, inhibit or localize the biological activity of the present analogs. Receptor binding may also be a triggering mechanism for a cascade of activity indirectly related to the analog itself. Also contemplated herein are nucleic acids, vectors containing such nucleic acids and host cells containing such nucleic acids which encode such receptors.
- [0030] Another example of a related composition is a G-CSF analog with a chemical moiety attached. Generally, chemical modification may alter biological activity or antigenicity of a protein, or may alter other characteristics, and these factors will be taken into account by a skilled practitioner. As noted above, one example of such chemical moiety is polyethylene glycol. Modification may include the addition of one or more hydrophilic or hydrophobic polymer molecules, fatty acid molecules, or polysaccharide molecules. Examples of chemical modifiers include polyethylene glycol, alkylpolyethylene glycols, Di-poly(amino acids), polyvinylpyrrolidone, polyvinyl alcohol, pyran copolymer, acetic acid/acylation, propionic acid, palmitic acid, stearic acid, dextran, carboxymethyl cellulose, pullulan, or agarose. See, Francis, *Focus on Growth Factors* 3: 4-10 (May 1992) (published by Mediscript, Mountview Court, Friern Barnet Lane, London N20 OLD, UK). Also, chemical modification may include an additional protein or portion thereof, use of a cytotoxic agent, or an antibody. The chemical modification may also include lecithin.
- [0031] In another aspect, the present disclosure relates to nucleic acids encoding such analogs. The nucleic acids may be DNAs or RNAs or derivatives thereof, and will typically be cloned and expressed on a vector, such as a phage or plasmid containing appropriate regulatory sequences. The nucleic acids may be labeled (such as using a radioactive, chemiluminescent, or fluorescent label) for diagnostic or prognostic purposes, for example. The nucleic acid sequence may be optimized for expression, such as including codons preferred for bacterial expression. The nucleic acid and its complementary strand, and modifications thereof which do not prevent encoding of the desired analog are here contemplated.
- [0032] In another aspect, the present disclosure relates to host cells containing the above nucleic acids encoding the present analogs. Host cells may be eukaryotic or prokaryotic, and expression systems may include extra steps relating to the attachment (or prevention) of sugar groups (glycosylation), proper folding of the molecule, the addition or deletion of leader sequences or other factors incident to recombinant expression.
- [0033] In another aspect the present disclosure relates to antisense nucleic acids which act to prevent or modify the

type or amount of expression of such nucleic acid sequences. These may be prepared by known methods.

[0034] In another aspect of the present disclosure, the nucleic acids encoding a present analog may be used for gene therapy purposes, for example, by placing a vector containing the analog-encoding sequence into a recipient so the nucleic acid itself is expressed inside the recipient who is in need of the analog composition. The vector may first be placed in a carrier, such as a cell, and then the carrier placed into the recipient. Such expression may be localized or systemic. Other carriers include non-naturally occurring carriers, such as liposomes or other microcarriers or particles, which may act to mediate gene transfer into a recipient.

[0035] The present disclosure also provides for computer programs for the expression (such as visual display) of the G-CSF or analog three dimensional structure, and further, a computer program which expresses the identity of each constituent of a G-CSF molecule and the precise location within the overall structure of that constituent, down to the atomic level. Set forth below is one example of such program. There are many currently available computer programs for the expression of the three dimensional structure of a molecule. Generally, these programs provide for inputting of the coordinates for the three dimensional structure of a molecule (i.e., for example, a numerical assignment for each atom of a G-CSF molecule along an x, y, and z axis), means to express (such as visually display) such coordinates, means to alter such coordinates and means to express an image of a molecule having such altered coordinates. One may program crystallographic information, i.e., the coordinates of the location of the atoms of a G-CSF molecule in three dimension space, wherein such coordinates have been obtained from crystallographic analysis of said G-CSF molecule, into such programs to generate a computer program for the expression (such as visual display) of the G-CSF three dimensional structure. Also provided, therefore, is a computer program for the expression of G-CSF analog three dimensional structure. Preferred is the computer program Insight II, version 4, available from Biosym, San Diego, California, with the coordinates as set forth in FIGURE 5 input. Preferred expression means is on a Silicon Graphics 320 VGX computer, with Crystal Eyes glasses (also available from Silicon Graphics), which allows one to view the G-CSF molecule or its analog stereoscopically. Alternatively, the present G-CSF crystallographic coordinates and diffraction data are also deposited in the Protein Data Bank, Chemistry Department, Brookhaven National Laboratory, Upton, New York 119723, USA. One may use these data in preparing a different computer program for expression of the three dimensional structure of a G-CSF molecule or analog thereof. Therefore, another aspect of the present invention is a computer program for the expression of the three dimensional structure of a G-CSF molecule. Also provided is said computer program for visual display of the three dimensional structure of a G-CSF molecule; and further, said program having means for altering such visual display. Apparatus useful for expression of such computer program, particularly for the visual display of the computer image of said three dimensional structure of a G-CSF molecule or analog thereof is also therefore here provided, as well as means for preparing said computer program and apparatus.

[0036] The computer program is useful for preparation of G-CSF analogs because one may select specific sites on the G-CSF molecule for alteration and readily ascertain the effect the alteration will have on the overall structure of the G-CSF molecule. Selection of said site for alteration will depend on the desired biological characteristic of the G-CSF analog. If one were to randomly change said G-CSF molecule (r-met-hu-G-CSF) there would be 175<sup>20</sup> possible substitutions, and even more analogs having multiple changes, additions or deletions. By viewing the three dimensional structure wherein said structure is correlated with the composition of the molecule, the selection for sites of alteration is no longer a random event, but sites for alteration may be determined rationally.

[0037] As set forth above, identity of the three dimensional structure of G-CSF, including the placement of each constituent down to the atomic level has now yielded information regarding which moieties are necessary to maintain the overall structure of the G-CSF molecule. One may therefore select whether to maintain the overall structure of the G-CSF molecule when preparing a G-CSF analog of the present invention, or whether (and how) to change the overall structure of the G-CSF molecule when preparing a G-CSF analog of the present invention. Optionally, once one has prepared such analog, one may test such analog for a desired characteristic.

[0038] One may, for example, seek to maintain the overall structure possessed by a non-altered natural or recombinant G-CSF molecule. The overall structure is presented in Figures 2, 3, and 4, and is described in more detail below. Maintenance of the overall structure may ensure receptor binding, a necessary characteristic for an analog possessing the hematopoietic capabilities of natural G-CSF (if no receptor binding, signal transduction does not result from the presence of the analog). It is contemplated that one class of G-CSF analogs will possess the three dimensional core structure of a natural or recombinant (non-altered) G-CSF molecule, yet possess different characteristics, such as an increased ability to selectively stimulate neutrophils. Another class of G-CSF analogs are those with a different overall structure which diminishes the ability of a G-CSF analog molecule to bind to a G-CSF receptor, and possesses a diminished ability to selectively stimulate neutrophils as compared to non-altered natural or recombinant G-CSF.

[0039] For example, it is now known which moieties within the internal regions of the G-CSF molecule are hydrophobic, and, correspondingly, which moieties on the external portion of the G-CSF molecule are hydrophilic. Without knowledge of the overall three dimensional structure, preferably to the atomic level as provided herein, one could not forecast which alterations within this hydrophobic internal area would result in a change in the overall structural conformation of the molecule. An overall structural change could result in a functional change, such as lack of receptor bind-

ing, for example, and therefore, diminishment of biological activity as found in non-altered G-CSF. Another class of G-CSF analogs is therefore G-CSF analogs which possess the same hydrophobicity as (non-altered) natural or recombinant G-CSF. More particularly, another class of G-CSF analogs possesses the same hydrophobic moieties within the four helical bundle of its internal core as those hydrophobic moieties possessed by (non-altered) natural or recombinant G-CSF yet have a composition different from said non-altered natural or recombinant G-CSF.

[0040] Another example relates to external loops which are structures which connect the internal core (helices) of the G-CSF molecule. From the three dimensional structure -- including information regarding the spatial location of the amino acid residues -- one may forecast that certain changes in certain loops will not result in overall conformational changes. Therefore, another class of G-CSF analogs provided herein is that having an altered external loop but possessing the same overall structure as (non-altered) natural or recombinant G-CSF. More particularly, another class of G-CSF analogs provided herein are those having an altered external loop, said loop being selected from the loop present between helices A and B; between helices B and C; between helices C and D; between helices D and A, as those loops and helices are identified herein. More particularly, said loops, preferably the AB loop and/or the CD loop are altered to increase the half life of the molecule by stabilizing said loops. Such stabilization may be by connecting all or a portion of said loop(s) to a portion of an alpha helical bundle found in the core of a G-CSF (or analog) molecule. Such connection may be via beta sheet, salt bridge, disulfide bonds, hydrophobic interaction or other connecting means available to those skilled in the art, wherein such connecting means serves to stabilize said external loop or loops. For example, one may stabilize the AB or CD loops by connecting the AB loop to one of the helices within the internal region of the molecule.

[0041] The N-terminus also may be altered without change in the overall structure of a G-CSF molecule, because the N-terminus does not effect structural stability of the internal helices, and, although the external loops are preferred for modification, the same general statements apply to the N-terminus.

[0042] Additionally, such external loops may be the site(s) for chemical modification because in (non-altered) natural or recombinant G-CSF such loops are relatively flexible and tend not to interfere with receptor binding. Thus, there would be additional room for a chemical moiety to be directly attached (or indirectly attached via another chemical moiety which serves as a chemical connecting means). The chemical moiety may be selected from a variety of moieties available for modification of one or more function of a G-CSF molecule. For example, an external loop may provide sites for the addition of one or more polymer which serves to increase serum half-life, such as a polyethylene glycol molecule. Such polyethylene glycol molecule(s) may be added wherein said loop is altered to include additional lysines which have reactive side groups to which polyethylene glycol moieties are capable of attaching. Other classes of chemical moieties may also be attached to one or more external loops, including but not limited to other biologically active molecules, such as receptors, other therapeutic proteins (such as other hematopoietic factors which would engender a hybrid molecule), or cytotoxic agents (such as diphtheria toxin). This list is of course not complete; one skilled in the art possessed of the desired chemical moiety will have the means to effect attachment of said desired moiety to the desired external loop. Therefore, another class of the present G-CSF analogs includes those with at least one alteration in an external loop wherein said alteration provides for the addition of a chemical moiety such as at least one polyethylene glycol molecule.

[0043] Deletions, such as deletions of sites recognized by proteins for degradation of the molecule, may also be effectual in the external loops. This provides alternative means for increasing half-life of a molecule otherwise having the G-CSF receptor binding and signal transduction capabilities (i.e., the ability to selectively stimulate the maturation of neutrophils). Therefore, another class of the present G-CSF analogs includes those with at least one alteration in an external loop wherein said alteration decreases the turnover of said analog by proteases. Preferred loops for such alterations are the AB loop and the CD loop. One may prepare an abbreviated G-CSF molecule by deleting a portion of the amino acid residues found in the external loops (identified in more detail below), said abbreviated G-CSF molecule may have additional advantages in preparation or in biological function.

[0044] Another example relates to the relative charges between amino acid residues which are in proximity to each other. As noted above, the G-CSF molecule contains a relatively tightly packed four helical bundle. Some of the faces on the helices face other helices. At the point (such as a residue) where a helix faces another helix, the two amino acid moieties which face each other may have the same charge, and thus tend to repel each other, which lends instability to the overall molecule. This may be eliminated by changing the charge (to an opposite charge or a neutral charge) of one or both of the amino acid moieties so that there is no repelling. Therefore, another class of G-CSF analogs includes those G-CSF analogs having been altered to modify instability due to surface interactions, such as electron charge location.

[0045] The present invention relates to methods for designing G-CSF analogs and related compositions and the products of those methods. The end products of the methods may be the G-CSF analogs as defined above or related compositions. For instance, the examples disclosed herein demonstrate (a) the effects of changes in the constituents (i.e., chemical moieties) of the G-CSF molecule on the G-CSF structure and (b) the effects of changes in structure on biological function. Essentially, therefore, an aspect of the present invention is a method for preparing a G-CSF analog

comprising the steps of:

- (a) viewing at an amino acid or atomic level information conveying the three dimensional structure of a G-CSF molecule as set forth in Figure 5 wherein the chemical moieties, such as each amino acid residue or each atom of each amino acid residue, of the G-CSF molecule are correlated with said structure;
- 5 (b) selecting from said information a site on a G-CSF molecule for alteration;
- (c) preparing a G-CSF analog molecule having such alteration; and
- (d) optionally, testing such G-CSF analog molecule for a desired characteristic.

10 [0046] One may use the here provided computer programs for a computer-based method for preparing a G-CSF analog. Another aspect of the present invention is therefore a method for preparing a G-CSF analog according to the method of the preceding paragraph based on the use of a computer comprising the steps of:

- 15 (a) providing computer expression of the three dimensional structure of a G-CSF molecule wherein the chemical moieties, such as each amino acid residue or each atom of each amino acid residue, of the G-CSF molecule are correlated with said structure;
- (b) selecting from said computer expression a site on a G-CSF molecule for alteration;
- (c) preparing a G-CSF molecule having such alteration; and
- (d) optionally, testing such G-CSF molecule for a desired characteristic.

20 [0047] More specifically, the present invention provides a method for preparing a G-CSF analog comprising the steps of:

- 25 (a) viewing at the amino acid or atomic level the three dimensional structure of a G-CSF molecule as set forth in Figure 5 via a computer, said computer programmed (i) to express the coordinates of a G-CSF molecule in three dimensional space, and (ii) to allow for entry of information for alteration of said G-CSF expression and viewing thereof;
- (b) selecting a site on said visual image of said G-CSF molecule for alteration;
- (c) entering information for said alteration on said computer;
- 30 (d) viewing a three dimensional structure of said altered G-CSF molecule via said computer;
- (e) optionally repeating steps (a)-(e);
- (f) preparing a G-CSF analog with said alteration; and
- (g) optionally testing said G-CSF analog for a desired characteristic.

35 [0048] In another aspect, the present disclosure relates to methods of using the present G-CSF analogs and related compositions and methods for the treatment or protection of mammals, either alone or in combination with other hematopoietic factors or drugs in the treatment of hematopoietic disorders. It is contemplated that one aspect of designing G-CSF analogs will be the goal of enhancing or modifying the characteristics non-modified G-CSF is known to have.

40 [0049] For example, the analogs may possess enhanced or modified activities, so, where G-CSF is useful in the treatment of (for example) neutropenia, the present compositions and methods may also be of such use.

[0050] Another example is the modification of G-CSF for the purpose of interacting more effectively when used in combination with other factors particularly in the treatment of hematopoietic disorders. One example of such combination use is to use an early-acting hematopoietic factor (i.e., a factor which acts earlier in the hematopoiesis cascade on relatively undifferentiated cells) and either simultaneously or in seriatim use of a later-acting hematopoietic factor, such as G-CSF or analog thereof (as G-CSF acts on the CFU-GM lineage in the selective stimulation of neutrophils). The methods and compositions may be useful in therapy involving such combinations or "cocktails" of hematopoietic factors.

45 [0051] The compositions and methods may also be useful in the treatment of leukopenia, myelogenous leukemia, severe chronic neutropenia, aplastic anemia, glycogen storage disease, mucositis, and other bone marrow failure states. The compositions and methods may also be useful in the treatment of hematopoietic deficits arising from chemotherapy or from radiation therapy. The success of bone marrow transplantation, or the use of peripheral blood progenitor cells for transplantation, for example, may be enhanced by application of the present compositions (proteins or nucleic acids for gene therapy) and methods. The compositions and methods may also be useful in the treatment of infectious diseases, such as in the context of wound healing, burn treatment, bacteremia, septicemia, fungal infections, endocarditis, osteomyelitis, infection related to abdominal trauma, infections not responding to antibiotics, pneumonia and the treatment of bacterial inflammation may also benefit from the application of the compositions and methods. In addition, the compositions and methods may be useful in the treatment of leukemia based upon a reported ability to differentiate leukemic cells. Welte et al., PNAS-USA 82: 1526-1530 (1985). Other applications include the treatment of individuals with tumors, using the compositions and methods, optionally in the presence of receptors (such as antibody-

ies) which bind to the tumor cells. For review articles on therapeutic applications, see Lieshke and Burgess, N Engl J Med. 327: 28-34 and 99-106 (1992) both of which are herein incorporated by reference.

[0052] The compositions and methods may also be useful to act as intermediaries in the production of other moieties; for example, G-CSF has been reported to influence the production of other hematopoietic factors and this function (if ascertained) may be enhanced or modified via the present compositions and/or methods.

[0053] The compositions related to the present G-CSF analogs, such as receptors, may be useful to act as an antagonist which prevents the activity of G-CSF or an analog. One may obtain a composition with some or all of the activity of non-altered G-CSF or a G-CSF analog, and add one or more chemical moieties to alter one or more properties of such G-CSF or analog. With knowledge of the three dimensional conformation, one may forecast the best geographic location for such chemical modification to achieve the desired effect.

[0054] General objectives in chemical modification may include improved half-life (such as reduced renal, immunological or cellular clearance), altered bioactivity (such as altered enzymatic properties, dissociated bioactivities or activity in organic solvents), reduced toxicity (such as concealing toxic epitopes, compartmentalization, and selective biodistribution), altered immunoreactivity (reduced immunogenicity, reduced antigenicity or adjuvant action), or altered physical properties (such as increased solubility, improved thermal stability, improved mechanical stability, or conformational stabilization). See Francis, Focus on Growth Factors 3: 4-10 (May 1992) (published by Mediscript, Mountview Court, Friern Barnet Lane, London N20 0LD, UK).

[0055] The examples below are illustrative of the present invention and are not intended as a limitation. It is understood that variations and modifications will occur to those skilled in the art, and it is intended that the appended claims cover all such equivalent variations which come within the scope of the invention as claimed.

#### Detailed Description of the Drawings

##### [0056]

FIGURE 1 is an illustration of the amino acid sequence of the 174 amino acid species of G-CSF with an additional N-terminal methionine (Seq. ID No.: 1) (Seq. ID No.: 2).

FIGURE 2 is a topology diagram of the crystalline structure of G-CSF, as well as hGH, pGH, GM-CSF, INF- $\beta$ , IL-2, and IL-4. These illustrations are based on inspection of cited references. The length of secondary structural elements are drawn in proportion to the number of residues. A, B, C, and D helices are labeled according to the scheme used herein for G-CSF. For INF- $\beta$ , the original labeling of helices is indicated in parentheses. FIGURE 3 is an "ribbon diagram" of the three dimensional structure of G-CSF. Helix A is amino acid residues 11-39 (numbered according to Figure 1, above), helix B is amino acid residues 72-91, helix C is amino acid residues 100-123, and helix D is amino acid residues 143-173. The relatively short 3<sup>10</sup> helix is at amino acid residues 45-48, and the alpha helix is at amino acid residues 48-53. Residues 93-95 form almost one turn of a left handed helix.

FIGURE 4 is a "barrel diagram" of the three dimensional structure of G-CSF. Shown in various shades of gray are the overall cylinders and their orientations for the three dimensional structure of G-CSF. The numbers indicate amino acid residue position according to FIGURE 1 above.

FIGURE 5 is a list of the coordinates used to generate a computer-aided visual image of the three-dimensional structure of G-CSF. The coordinates are set forth below. The columns correspond to separate field:

- (i) Field 1 (from the left hand side) is the atom,
- (ii) Field 2 is the assigned atom number,
- (iii) Field 3 is the atom name (according to the periodic table standard nomenclature, with CB being carbon atom Beta, CG is Carbon atom Gamma, etc.);
- (iv) Field 4 is the residue type (according to three letter nomenclature for amino acids as found in, e.g., Stryer, Biochemistry, 3d Ed., W.H. Freeman and Company, N.Y. 1988, inside back cover);
- (v) Fields 5-7 are the x-axis, y-axis and z-axis positions of the atom;
- (vi) Field 8 (often a "1.00") designates occupancy at that position;
- (vii) Field 9 designates the B-factor;
- (viii) Field 10 designates the molecule designation. Three molecules (designated a, b, and c) of G-CSF crystallized together as a unit. The designation a, b, or c indicates which coordinates are from which molecule. The number after the letter (1, 2, or 3) indicates the assigned amino acid residue position, with molecule A having assigned positions 10-175, molecule B having assigned positions 210-375, and molecule C having assigned positions 410-575. These positions were so designated so that there would be no overlap among the three molecules which crystallized together. (The "W" designation indicates water).

FIGURE 6 is a schematic representation of the strategy involved in refining the crystallization matrix for parameters

involved in crystallization. The crystallization matrix corresponds to the final concentration of the components (salts, buffers and precipitants) of the crystallization solutions in the wells of a 24 well tissue culture plate. These concentrations are produced by pipetting the appropriate volume of stock solutions into the wells of the microtiter plate. To design the matrix, the crystallographer decides on an upper and lower concentration of the component. These upper and lower concentrations can be pipetted along either the rows (e.g., A1-A6, B1-B6, C1-C6 or D1-D6) or along the entire tray (A1-D6). The former method is useful for checking reproducibility of crystal growth of a single component along a limited number of wells, whereas the later method is more useful in initial screening. The results of several stages of refinement of the crystallization matrix are illustrated by a representation of three plates. The increase in shading in the wells indicates a positive crystallization result which, in the final stages, would be X-ray quality crystals but in the initial stages could be oil droplets, granular precipitates or small crystals approximately less than 0.05 mm in size. Part A represents an initial screen of one parameter in which the range of concentration between the first well (A1) and last well (D6) is large and the concentration increase between wells is calculated as ((concentration A1)-(concentration D6))/23. Part B represents that in later stages of the crystallization matrix refinement of the concentration spread between A1 and D6 would be reduced which would result in more crystals formed per plate. Part C indicates a final stage of matrix refinement in which quality crystals are found in most wells of the plate.

#### Detailed Description of the Invention

[0057] The present invention grows out of the discovery of the three dimensional structure of G-CSF. This three dimensional structure has been expressed via computer program for stereoscopic viewing. By viewing this stereoscopically, structure-function relationships identified and G-CSF analogs have been designed and made.

#### The Overall Three Dimensional Structure of G-CSF

[0058] The G-CSF used to ascertain the structure was a non-glycosylated 174 amino acid species having an extra N-terminal methionine residue incident to bacterial expression. The DNA and amino acid sequence of this G-CSF are illustrated in FIGURE 1.

[0059] Overall, the three dimensional structure of G-CSF is predominantly helical, with 103 of the 175 residues forming a 4-alpha-helical bundle. The only other secondary structure is found in the loop between the first two long helices where a 4 residue  $3^{10}$  helix is immediately followed by a 6 residue alpha helix. As shown in FIGURE 2, the overall structure has been compared with the structure reported for other proteins: growth hormone (Abdel-Meguid et al., PNAS-USA 84: 6434 (1987) and Vos et al., Science 255: 305-312 (1992)), granulocyte macrophage colony stimulating factor (Diederichs et al., Science 254: 1779-1782 (1991), interferon- $\beta$  (Sendra et al., EMBO J. 11: 3193-3201 (1992)), interleukin-2 (McKay Science 257: 1673-1677 (1992)) and interleukin-4 (Powers et al., Science 256: 1673-1677 (1992), and Smith et al., J. Mol. Biol. 224: 899-904 (1992)). Structural similarity among these growth factors occurs despite the absence of similarity in their amino acid sequences.

[0060] Presently, the structural information was correlation of G-CSF biochemistry, and this can be summarized as follows (with sequence position 1 being at the N-terminus):

Sequence Position	Description of Structure	Analysis
1-10	Extended chain	Deletion causes no loss of biological activity
Cys 18	Partially buried	Reactive with DTNB and Thimersosol but not with iodo-acetate
34	Alternative splice site	Insertion reduces biological activity
20-47 (inclusive)	Helix A, first disulfide and portion of AB helix	Predicted receptor binding region based on neutralizing antibody data
20, 23, 24	Helix A	Single alanine mutation of residue(s) reduces biological activity. Predicted receptor binding (Site B).
165-175 (inclusive)	Carboxy terminus	Deletion reduces biological activity

[0061] This biochemical information, having been gleaned from antibody binding studies, see Layton et al., Biochemistry 26: 23815-23823 (1991), was superimposed on the three-dimensional structure in order to design G-CSF analogs. The design, preparation, and testing of these G-CSF analogs is described in Example 1 below.

5    EXAMPLE 1

[0062] This Example describes the preparation of crystalline G-CSF, the visualization of the three dimensional structure of recombinant human G-CSF via computer-generated image, the preparation of analogs, using site-directed mutagenesis or nucleic acid amplification methods, the biological assays and HPLC analysis used to analyze the G-CSF analogs, and the resulting determination of overall structure/function relationships. All cited publications are herein incorporated by reference.

A. Use of Automated Crystallization

[0063] The need for a three-dimensional structure of recombinant human granulocyte colony stimulating factor (r-hu-G-CSF), and the availability of large quantities of the purified protein, led to methods of crystal growth by incomplete factorial sampling and seeding. Starting with the implementation of incomplete factorial crystallization described by Jancarik and Kim, J. Appl. Crystallogr. 24: 409 (1991) solution conditions that yielded oil droplets and birefringence aggregates were ascertained. Also, software and hardware of an automated pipetting system were modified to produce some 400 different crystallization conditions per day. Weber, J. Appl. Crystallogr. 20: 366-373 (1987). This procedure led to a crystallization solution which produced r-hu-G-CSF crystals.

[0064] The size, reproducibility and quality of the crystals was improved by a seeding method in which the number of "nucleation initiating units" was estimated by serial dilution of a seeding solution. These methods yielded reproducible growth of 2.0 mm r-hu-G-CSF crystals. The space group of these crystals is P<sub>2</sub>1<sub>2</sub>1<sub>2</sub>1 with cell dimensions of a=90 Å, b=110 Å and c=49 Å, and they diffract to a resolution of 2.0 Å.

1. Overall Methodology

[0065] To search for the crystallizing conditions of a new protein, Carter and Carter, J. Biol. Chem. 254: 12219-12223 (1979) proposed the incomplete factorial method. They suggested that a sampling of a large number of randomly selected, but generally probable, crystallizing conditions may lead to a successful combination of reagents that produce protein crystallization. This idea was implemented by Jancarik and Kim, J. Appl. Crystallogr. 24: 409(1991), who described 32 solutions for the initial crystallization trials which cover a range of pH, salts and precipitants. Here we describe an extension of their implementation to an expanded set of 70 solutions. To minimize the human effort and error of solution preparation, the method has been programmed for an automatic pipetting machine.

[0066] Following Weber's method of successive automated grid searching (SAGS), J.Cryst. Growth 90: 318-324(1988), the robotic system was used to generate a series of solutions which continually refined the crystallization conditions of temperature, pH, salts and precipitant. Once a solution that could reproducibly grow crystals was determined, a seeding technique which greatly improved the quality of the crystals was developed. When these methods were combined, hundreds of diffraction quality crystals (crystals diffracting to at least about 2.5 Angstroms, preferably having at least portions diffracting to below 2 Angstroms, and more preferably, approximately 1 Angstrom) were produced in a few days.

[0067] Generally, the method for crystallization, which may be used with any protein one desires to crystallize, comprises the steps of:

- (a) combining aqueous aliquots of the desired protein with either (i) aliquots of a salt solution, each aliquot having a different concentration of salt; or (ii) aliquots of a precipitant solution, each aliquot having a different concentration of precipitant, optionally wherein each combined aliquot is combined in the presence of a range of pH;  
 (b) observing said combined aliquots for precrystalline formations, and selecting said salt or precipitant combination and said pH which is efficacious in producing precrystalline forms, or, if no precrystalline forms are so produced, increasing the protein starting concentration of said aqueous aliquots of protein;  
 (c) after said salt or said precipitant concentration is selected, repeating step (a) with said previously unselected solution in the presence of said selected concentration; and  
 (d) repeating step (b) and step (a) until a crystal of desired quality is obtained.

[0068] The above method may optionally be automated, which provides vast savings in time and labor. Preferred protein starting concentrations are between 10mg/ml and 20mg/ml, however this starting concentration will vary with the protein (the G-CSF below was analyzed using 33mg/ml). A preferred range of salt solution to begin analysis with is

(NaCl) of 0-2.5M. A preferred precipitant is polyethylene glycol 8000, however, other precipitants include organic solvents (such as ethanol), polyethylene glycol molecules having a molecular weight in the range of 500-20,000, and other precipitants known to those skilled in the art. The preferred pH range is pH 4.5 , 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, and 9.0. Precrystallization forms include oils, birefringement precipitants, small crystals (< approximately 0.05 mm), medium crystals (approximately 0.5 to .5 mm) and large crystals (> approximately 0.5 mm). The preferred time for waiting to see a crystalline structure is 48 hours, although weekly observation is also preferred, and generally, after about one month, a different protein concentration is utilized (generally the protein concentration is increased). Automation is preferred, using the Accuflex system as modified. The preferred automation parameters are described below.

[0069] Generally, protein with a concentration between 10 mg/ml and 20 mg/ml was combined with a range of NaCl solutions from 0-2.5 M, and each such combination was performed (separately) in the presence of the above range of concentrations. Once a precrystallization structure is observed, that salt concentration and pH range are optimized in a separate experiment, until the desired crystal quality is achieved. Next, the precipitant concentration, in the presence of varying levels of pH is also optimized. When both are optimized, the optimal conditions are performed at once to achieve the desired result (this is diagrammed in FIGURE 6).

15 a. Implementation of an automated pipetting system

[0070] Drops and reservoir solutions were prepared by an Accuflex pipetting system (ICN Pharmaceuticals, Costa Mesa, CA) which is controlled by a personal computer that sends ASCII codes through a standard serial interface. The pipetter samples six different solutions by means of a rotating valve and pipettes these solutions onto a plate whose translation in a x-y coordinate system can be controlled. The vertical component of the system manipulates a syringe that is capable both of dispensing and retrieving liquid.

[0071] The software provided with the Accuflex was based on the SAGS method as proposed by Cox and Weber, J.Appl. Crystallogr. 20: 366-373 (1987). This method involves the systematic variation of two major crystallization parameters, pH and precipitant concentration, with provision to vary two others. While building on these concepts, the software used here provided greater flexibility in the design and implementation of the crystallization solutions used in the automated grid searching strategy. As a result of this flexibility the present software also created a larger number of different solutions. This is essential for the implementation of the incomplete factorial method as described in that section below.

[0072] To improve the speed and design of the automated grid searching strategy, the Accuflex pipetting system required software and hardware modifications. The hardware changes allowed the use of two different micro-titer trays, one used for handing drop and one used for sitting drop experiments, and a Plexiglas tray which held 24 additional buffer, salt and precipitant solutions. These additional solutions expanded the grid of crystallizing conditions that could be surveyed.

[0073] To utilize the hardware modifications, the pipetting software was written in two subroutines; one subroutine allows the crystallographer to design a matrix of crystallization solutions based on the concentrations of their components and the second subroutine to translate these concentrations into the computer code which pipettes the proper volumes of the solutions into the crystallization trays. The concentration matrices can be generated by either of two programs. The first program (MRF, available from Amgen, Inc., Thousand Oaks, CA) refers to a list of stock solution concentrations supplied by the crystallographer and calculates the required volume to be pipette to achieve the designated concentration. The second method, which is preferred, incorporates a spread sheet program (Lotus ) which can be used to make more sophisticated gradients of precipitants or pH. The concentration matrix created by either program is interpreted by the control program (SUX, a modification of the program found in the Accuflex pipetter originally and available from Amgen, Inc., Thousand Oaks, CA) and the wells are filled accordingly.

45 b. Implementation of the Incomplete Factorial Method

[0074] The convenience of the modified pipetting system for preparing diverse solutions improved the implementation of an expanded incomplete factorial method. The development of a new set of crystallization solutions having "random" components was generated using the program INFAC, Carter et al., J.Cryst. Growth 90: 60-73(1988) which produced a list containing 96 random combinations of one factor from three variables. Combinations of calcium and phosphate which immediately precipitated were eliminated, leaving 70 distinct combinations of precipitants, salts and buffers. These combinations were prepared using the automated pipetter and incubated for 1 week. The mixtures were inspected and solutions which formed precipitants were prepared again with lower concentrations of their components. This was repeated until all wells were clear of precipitant.

c. Crystallization of r-hu-G-CSF

[0075] Several different crystallization strategies were used to find a solution which produced x-ray quality crystals. These strategies included the use of the incomplete factorial method, refinement of the crystallization conditions using successive automated grid searches (SAGS), implementation of a seeding technique and development of a crystal production procedure which yielded hundreds of quality crystals overnight. Unless otherwise noted the screening and production of r-hu-G-CSF crystals utilized the hanging drop vapor diffusion method. Atinsen et al., Physical principles of protein crystallization. In: Eisenberg (ed.), Advances in Protein Chemistry 41: 1-33 (1991).

[0076] The initial screening for crystallization conditions of r-hu-G-CSF used the Jancarik and Kim, J.Appl.Crystallogr. 24: 409(1991) incomplete factorial method which resulted in several solutions that produced "precrystallization" results. These results included birefringent precipitants, oils and very small crystals (< .05 mm). These precrystallizations solutions then served as the starting points for systematic screening.

[0077] The screening process required the development of crystallization matrices. These matrices corresponded to the concentration of the components in the crystallization solutions and were created using the IBM-PC based spread sheet Lotus™ and implemented with the modified Accuflex pipetting system. The strategy in designing the matrices was to vary one crystallization condition (such as salt concentration) while holding the other conditions such as pH, and precipitant concentration constant. At the start of screening, the concentration range of the varied condition was large but the concentration was successively refined until all wells in the micro-titer tray produced the same crystallization result. These results were scored as follows: crystals, birefringement precipitate, granular precipitate, oil droplets and amorphous mass. If the concentration of a crystallization parameter did not produce at least a precipitant, the concentration of that parameter was increased until a precipitant formed. After each tray was produced, it was left undisturbed for at least two days and then inspected for crystal growth. After this initial screening, the trays were then inspected on a weekly basis.

[0078] From this screening process, two independent solutions with the same pH and precipitant but differing in salts (MgCl<sub>2</sub>, LiSO<sub>4</sub>) were identified which produced small (0.1 x 0.05 x 0.05 mm) crystals. Based on these results, a new series of concentration matrices were produced which varied MgCl<sub>2</sub> with respect to LiSO<sub>4</sub> while keeping the other crystallization parameters constant. This series of experiments resulted in identification of a solution which produced diffraction quality crystals (> approximately 0.5 mm) in about three weeks. To find this crystallization growth solution (100 mM Mes pH 5.8, 380 mM MgCl<sub>2</sub>, 220 mM LiSO<sub>4</sub> and 8% PEG 8k) approximately 8,000 conditions had been screened which consumed about 300 mg of protein.

[0079] The size of the crystals depended on the number of crystals forming per drop. Typically 3 to 5 crystals would be formed with average size of (1.0 x 0.7 x 0.7 mm). Two morphologies which had an identical space group (P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>) and unit cell dimensions a=90.2, b=110.2, c=49.5 were obtained depending on whether or not seeding (see below) was implemented. Without seeding, the r-hu-G-CSF crystals had one long flat surface and rounded edges.

[0080] When seeding was employed, crystals with sharp faces were observed in the drop within 4 to 6 hours (0.05 by 0.05 by 0.05 mm). Within 24 hours, crystals had grown to (0.7 by 0.7 by 0.7 mm) and continued to grow beyond 2 mm depending on the number of crystals forming in the drop.

d. Seeding and determination of nucleation initiation sites.

[0081] The presently provided method for seeding crystals establishes the number of nucleation initiation units in each individual well used (here, after the optimum conditions for growing crystals had been determined). The method here is advantageous in that the number of "seeds" affects the quality of the crystals, and this in turn affects the degree of resolution. The present seeding here also provides advantages in that with seeding, G-CSF crystal grows in a period of about 3 days, whereas without seeding, the growth takes approximately three weeks.

[0082] In one series of production growth (see methods), showers of small but well defined crystals were produced overnight (<0.01 x 0.01 x 0.01 mm). Crystallization conditions were followed as described above except that a pipette tip employed in previously had been reused. Presumably, the crystal showering effect was caused by small nucleation units which had formed in the used tip and which provided sites of nucleation for the crystals. Addition of a small amount (0.5 ul) of the drops containing the crystal showers to a new drop under standard production growth conditions resulted in a shower of crystals overnight. This method was used to produce several trays of drops containing crystal showers which we termed "seed stock".

[0083] The number of nucleation initiation units (NIU) contained within the "seed stock" drops was estimated to attempt to improve the reproducibility and quality of the r-hu-GCSF crystals. To determine the number of NIU in the "seed stock", an aliquot of the drop was serially diluted along a 96 well microtiter plate. The microtiter plate was prepared by adding 50 ul of a solution containing equal volumes of r-hu-G-CSF (33 mg/ml) and the crystal growth solution (described above) in each well. An aliquot (3 ul) of one of the "seed stock" drops was transferred to the first well of the microtiter plate. The solution in the well was mixed and 3 ul was then transferred to the next well along the row of the

microtiter plate. Each row of the microtiter plate was similarly prepared and the tray was sealed with plastic tape. Overnight, small crystals formed in the bottom of the wells of the microtiter plate and the number of crystals in the wells were correlated to the dilution of the original "seed stock". To produce large single crystals, the "seed stock" drop was appropriately diluted into fresh CGS and then an aliquot of this solution containing the NIU was transferred to a drop

[0084] Once crystallization conditions had been optimized, crystals were grown in a production method in which 3 ml each of CGS and r-hu-G-CSF (33 mg/ml) were mixed to create 5 trays (each having 24 wells). This method included the production of the refined crystallization solution in liter quantities, mixing this solution with protein and placing the protein/crystallization solution in either hanging drop or sitting drop trays. This process typically yielded 100 to 300 quality crystals (>0.5 mm) in about 5 days.

#### 10 e. Experimental Methods

##### Materials

[0085] Crystallographic information was obtained starting with r-hu-met-G-CSF with the amino acid sequence as provided in FIGURE 1 with a specific activity of  $1.0 \pm 0.6 \times 10^8$  U/mg (as measured by cell mitogenesis assay in a 10 mM acetate buffer at pH 4.0 (in Water for Injection) at a concentration of approximately 3 mg/ml solution was concentrated with an Amicon concentrator at 75 psi using a YM10 filter. The solution was typically concentrated 10 fold at 4°C and stored for several months.

##### 20 Initial Screening

[0086] Crystals suitable for X-ray analysis were obtained by vapor-diffusion equilibrium using hanging drops. For preliminary screening, 7  $\mu$ l of the protein solution at 33 mg/ml (as prepared above) was mixed with an equal volume of the well solution, placed on siliconized glass plates and suspended over the well solution utilizing Linbro tissue culture plates (Flow Laboratories, McLean, Va). All of the pipetting was performed with the Accuflex pipettor, however, trays were removed from the automated pipettor after the well solutions had been created and thoroughly mixed for at least 10 minutes with a table top shaker. The Linbro trays were then returned to the pipettor which added the well and protein solutions to the siliconized cover slips. The cover slips were then inverted and sealed over 1 ml of the well solutions with silicon grease.

[0087] The components of the automated crystallization system are as follows. A PC-DOS computer system was used to design a matrix of crystallization solutions based on the concentration of their components. These matrices were produced with either MRF or the Lotus spread sheet (described above). The final product of these programs is a data file. This file contains the information required by the SUX program to pipette the appropriate volume of the stock solutions to obtain the concentrations described in the matrices. The SUX program information was passed through a serial I/O port and used to dictate to the Accuflex pipetting system the position of the valve relative to the stock solutions, the amount of solution to be retrieved, and then pipetted into the wells of the microtiter plates and the X-Y position of each well (the column/row of each well). Addition information was transmitted to the pipettor which included the Z position (height) of the syringe during filling as well as the position of a drain where the system pauses to purge the syringe between fillings of different solutions. The 24 well microtiter plate (either Linbro or Cryschem) and cover slip holder was placed on a plate which was moved in the X-Y plane. Movement of the plate allowed the pipettor to position the syringe to pipette into the wells. It also positioned the coverslips and vials and extract solutions from these sources. Prior the pipetting, the Linbro microtiter plates had a thin film of grease applied around the edges of the wells. After the crystallization solutions were prepared in the wells and before they were transferred to the cover slips, the microtiter plate was removed from the pipetting system, and solutions were allowed to mix on a table top shaker for ten minutes. After mixing, the well solution was either transferred to the cover slips (in the case of the hanging drop protocol) or transferred to the middle post in the well (in the case of the sitting drop protocol). Protein was extracted from a vial and added to the coverslip drop containing the well solution (or to the post). Plastic tape was applied to the top of the Cryschem plate to seal the wells.

##### 50 Production Growth

[0088] Once conditions for crystallization had been optimized, crystal growth was performed utilizing a "production" method. The crystallization solution which contained 100 mM Mes pH 5.8, 380 mM MgCl<sub>2</sub>, 220 mM LiSO<sub>4</sub>, and 8% PEG 8K was made in 1 liter quantities. Utilizing an Eppendorf syringe pipettor, 1 ml aliquots of this solution were pipetted into each of the wells of the Linbro plate. A solution containing 50% of this solution and 50% G-CSF (33 mg/ml) was mixed and pipetted onto the siliconized cover slips. Typical volumes of these drops were between 50 and 100  $\mu$ l and because of the large size of these drops, great care was taken in flipping the coverslips and suspending the drops over

the wells.

#### Data Collection

- 5 [0089] The structure has been refined with X-PLOR (Bruniger, X-PLOR version 3.0, A system for crystallography and NMR, Yale University, New Haven CT) against 2.2Å data collected on an R-AXIS (Molecular Structure, Corp. Houston, TX) imaging plate detector.

#### f. Observations

- 10 [0090] As an effective recombinant human therapeutic, r-hu-G-CSF has been produced in large quantities and gram levels have been made available for structural analysis. The crystallization methods provided herein are likely to find other applications as other proteins of interest become available. This method can be applied to any crystallographic project which has large quantities of protein (approximately >200 mg). As one skilled in the art will recognize, 15 the present materials and methods may be modified and equivalent materials and methods may be available for crystallization of other proteins.

#### B. Computer Program For Visualizing The Three Dimensional Structure of G-CSF

- 20 [0091] Although diagrams, such as those in the Figures herein, are useful for visualizing the three dimensional structure of G-CSF, a computer program which allows for stereoscopic viewing of the molecule is contemplated as preferred. This stereoscopic viewing, or "virtual reality" as those in the art sometimes refer to it, allows one to visualize the structure in its three dimensional form from every angle in a wide range of resolution, from macromolecular structure down to the atomic level. The computer programs contemplated herein also allow one to change perspective of the 25 viewing angle of the molecule, for example by rotating the molecule. The contemplated programs also respond to changes so that one may, for example, delete, add, or substitute one or more images of atoms, including entire amino acid residues, or add chemical moieties to existing or substituted groups, and visualize the change in structure.

- [0092] Other computer based systems may be used; the elements being: (a) a means for entering information, such as orthogonal coordinates or other numerically assigned coordinates of the three dimensional structure of G-CSF; 30 (b) a means for expressing such coordinates, such as visual means so that one may view the three dimensional structure and correlate such three dimensional structure with the composition of the G-CSF molecule, such as the amino acid composition; (c) optionally, means for entering information which alters the composition of the G-CSF molecule expressed, so that the image of such three dimensional structure displays the altered composition.

- [0093] The coordinates for the preferred computer program used are presented in FIGURE 5. The preferred computer program is Insight II, version 4, available from Biosym in San Diego, CA. For the raw crystallographic structure, the observed intensities of the diffraction data ("F-obs") and the orthogonal coordinates are also deposited in the Protein Data Bank, Chemistry Department, Brookhaven National Laboratory, Upton, New York 19723, USA and these are 35 herein incorporated by reference.

- [0094] Once the coordinates are entered into the Insight II program, one can easily display the three dimensional 40 G-CSF molecule representation on a computer screen. The preferred computer system for display is Silicon Graphics 320 VGX (San Diego, CA). For stereoscopic viewing, one may wear eyewear (Crystal Eyes, Silicon Graphics) which allows one to visualize the G-CSF molecule in three dimensions stereoscopically, so one may turn the molecule and envision molecular design.

- [0095] Thus, the present invention provides a method of designing or preparing a G-CSF analog with the aid of a 45 computer comprising:

- (a) providing said computer with the means for displaying the three dimensional structure of a G-CSF molecule including displaying the composition of moieties of said G-CSF molecule, preferably displaying the three dimensional location of each amino acid, and more preferably displaying the three dimensional location of each atom of 50 a G-CSF molecule;
- (b) viewing said display;
- (c) selecting a site on said display for alteration in the composition of said molecule or the location of a moiety; and
- (d) preparing a G-CSF analog with such alteration.

- 55 [0096] The alteration may be selected based on the desired structural characteristics of the end-product G-CSF analog, and considerations for such design are described in more detail below. Such considerations include the location and compositions of hydrophobic amino acid residues, particularly residues internal to the helical structures of a G-CSF molecule which residues, when altered, alter the overall structure of the internal core of the molecule and may prevent

receptor binding; the location and compositions of external loop structures, alteration of which may not affect the overall structure of the G-CSF molecule.

[0097] FIGURES 2-4 illustrate the overall three dimensional conformation in different ways. The topological diagram, the ribbon diagram, and the barrel diagram all illustrate aspects of the conformation of G-CSF.

5 [0098] FIGURE 2 illustrates a comparison between G-CSF and other molecules. There is a similarity of architecture, although these growth factors differ in the local conformations of their loops and bundle geometrics. The up-up-down-down topology with two long crossover connections is conserved, however, among all six of these molecules, despite the dissimilarity in amino acid sequence.

10 [0099] FIGURE 3 illustrates in more detail the secondary structure of recombinant human G-CSF. This ribbon diagram illustrates the handedness of the helices and their positions relative to each other.

[0100] FIGURE 4 illustrates in a different way the conformation of recombinant human G-CSF. This "barrel" diagram illustrates the overall architecture of recombinant human G-CSF.

### C. Preparation of Analogs Using M13 Mutagenesis

15 [0101] This example relates to the preparation of G-CSF analogs using site directed mutagenesis techniques involving the single stranded bacteriophage M13, according to methods published in PCT Application No. WO 85/00817 (Souza et al., published February 28, 1985, herein incorporated by reference). This method essentially involves using a single-stranded nucleic acid template of the non-mutagenized sequence, and binding to it a smaller oligonucleotide containing the desired change in the sequence. Hybridization conditions allow for non-identical sequences to hybridize and the remaining sequence is filled in to be identical to the original template. What results is a double stranded molecule, with one of the two strands containing the desired change. This mutagenized single strand is separated, and used itself as a template for its complementary strand. This creates a double stranded molecule with the desired change.

20 [0102] The original G-CSF nucleic acid sequence used is presented in FIGURE 1, and the oligonucleotides containing the mutagenized nucleic acid(s) are presented in Table 2. Abbreviations used herein for amino acid residues and nucleotides are conventional, see Stryer, Biochemistry, 3d Ed., W.H. Freeman and Company, N.Y., N.Y. 1988, inside back cover.

25 [0103] The original G-CSF nucleic acid sequence was first placed into vector M13mp21. The DNA from single stranded phage M13mp21 containing the original G-CSF sequence was then isolated, and resuspended in water. For each reaction, 200 ng of this DNA was mixed with a 1.5 pmole of phosphorylated oligonucleotide (Table 2) and suspended in 0.1M Tris, 0.01M MgCl<sub>2</sub>, 0.005M DTT, 0.1mM ATP, pH 8.0. The DNAs were annealed by heating to 65°C and slowly cooling to room temperature.

30 [0104] Once cooled, 0.5mM of each ATP, dATP, dCTP, dGTP, TTP, 1 unit of T4 DNA ligase and 1 unit of Klenow fragment of *E. coli* polymerase 1 were added to the 1 unit of annealed DNA in 0.1M Tris, 0.025M NaCl, 0.01M MgCl<sub>2</sub>, 0.01M DTT, pH 7.5.

35 [0105] The now double stranded, closed circular DNA was used to transfet *E. coli* without further purification. Plaques were screened by lifting the plaques with nitrocellulose filters, and then hybridizing the filters with single stranded DNA end-labeled with P<sup>32</sup> for 1 hour at 55-60°C. After hybridization, the filters were washed at 0-3°C below the melt temperature of the oligo (2°C for A-T, 4°C for G-C) which selectively left autoradiography signals corresponding to plaques with phage containing the mutated sequence. Positive clones were confirmed by sequencing.

40 [0106] Set forth below are the oligonucleotides used for each G-CSF analog prepared via the M13 mutagenesis method. The nomenclature indicates the residue and the position of the original amino acid (e.g., Lysine at position 17), and the residue and position of the substituted amino acid (e.g., arginine 17). A substitution involving more than one residue is indicated via superscript notation, with commas between the noted positions or a semicolon indicating different residues. Deletions with no substitutions are so noted. The oligonucleotide sequences used for M13-based mutagenesis are next indicated; these oligonucleotides were manufactured synthetically, although the method of preparation is not critical, any nucleic acid synthesis method and/or equipment may be used. The length of the oligo is also indicated. As indicated above, these oligos were allowed to contact the single stranded phage vector, and then single nucleotides were added to complete the G-CSF analog nucleic acid sequence.

50

55

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Table 2

G-CSE ANALOGS	SEQUENCES (5' -> 3')	Length (nucleotides)	Seq_ID
Lys17->Arg17	CTT TCT GCT GCG TTG TCT GGA ACA	24	3
Lys24->Arg24	ACA GGT TCG TAT CCA GGG TG	23	4
Lys35->Arg35	CAC TGC AAG AAC GTC TGT GCG CT	23	5
Lys41->Arg41	CGC TAC TTA CCG TCT GTG CCA TC	23	6
Lys17, 24, 35-> Arg17, 24, 35	CTT TCT GCT GCG TTG TCT GGA ACA ACA GGT TCG TCG TAT CCA GGG TG CAC TGC AAG AAC GTC TGT GCG CT	24 23 23	7 8 9
Lys17, 24, 41-> Arg17, 24, 41	CTT TCT GCT GCG TTG TCT GGA ACA ACA GGT TCG TCG TAT CCA GGG TG CGC TAC TTA CCG TCT GTC CCA TC	24 23 23	10 11 12
Lys17, 35, 41-> Arg17, 35, 41	CTT TCT GCT GCG TTG TCT GGA ACA CAC TGC AAG AAC GTC TGT GCG CT CGC TAC TTA CCG TCT GTG CCA TC ACA GGT TCG TCG TAT CCA GGG TG	24 23 23 23	13 14 15 16
Lys24, 35, 41-> Arg24, 35, 41	CAC TGC AAG AAC GTC TGT GCG CT CGC TAC TTA CCG TCT GTG CCA TC	23 23	17 18

Table 2 (con't.)

S-CSE ANALOGS	SEQUENCES(5'-> 3')	Length(nucleotides)	Seq_ID
Lys <sup>17</sup> ,24,35,41->	CTT TCT GCT GCG TTG TCT GGA ACA	24	19
Arg <sup>17</sup> ,24,35,41	ACA GGT TCG TCG TAT CCA GGG TG	23	20
	CAC TGC AAG AAC GTC TGT GCG CT	23	21
	CGC TAC TTA CCG TCT GTG CCA TC	23	22
Cys <sup>18</sup> ->Ala <sup>18</sup>	TCT GCT GAA AGC TCT GGA ACA GG	23	23
Gln <sup>68</sup> ->Glu <sup>68</sup>	CTT GTC CAT CTG AAG CTC TTC AG	23	24
Cys <sup>37</sup> ,43->	GAA AAA CTG TCC GCT ACT TAC AAA	37	25
Ser <sup>37</sup> ,43	CTG TCC CAT CCG G		
Gln <sup>26</sup> ->Ala <sup>26</sup>	TTC GTA AAA TCG CGG GTG ACG G	22	26
Gln <sup>174</sup> ->Ala <sup>174</sup>	TCA TCT GGC TGC GCC GTA ATA G	22	27
Arg <sup>170</sup> ->Ala <sup>170</sup>	CCG TGT TCT GGC TCA TCT GGC T	22	28
Arg <sup>167</sup> ->Ala <sup>167</sup>	GAA GTA TCT TAC GCT GTT CTG CGT	24	29
Deletion 167	GAA GTA TCT TAC TAA GTT CTG CGT C	25	30
Lys <sup>41</sup> ->Ala <sup>41</sup>	CGC TAC TTA CGC ACT GTG CCA T	22	31
His <sup>44</sup> ->Lys <sup>44</sup>	CAA ACT GTG CAA GCC GGA AGA G	22	32
Glu <sup>47</sup> ->Ala <sup>47</sup>	CAT CCC GAA GCA CTG GTA CTG C	22	33

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

Table 2 (con't.)

G-CSF ANALOGS	SEQUENCES (5'-> 3')	Length(nucleotides)	Seq.ID
Arg23->Ala23	GGA ACA GGT TGC TAA AAT CCA GG	23	34
Lys24->Ala24	GAA CAG GTT CGT GCG ATC CAG GGT G	25	35
Glu20->Ala20	GAA ATG TCT GGC ACA GGT TCG T	22	36
Asp28->Ala28	TCC AGG GTG CCG GTG CTG C	19	37
Met127->Glu127	AAG AGC TCG GTG AGG CAC CAG CT	23	38
Met138->Glu138	CTC AAG GTG CTG AGC CGG CAR TC	23	39
Met127->Leu127	GAG CTC GGT CTG GCA CCA GC	20	40
Met138->Leu138	TCA AGG TGC TCT GCC GGC ATT	21	41
Ser13->Ala13	TCT GCC GCA AGC CTT TCT GCT GA	23	42
Lys17->Ala17	CTT TCT GCT GGC ATG TCT GGA ACA	24	43
Gln121->Ala121	CTA TTT GGC AAG CGA TGG AAG AGC	24	44
Glu124->Ala124	CAG ATG GAA GCG CTC GGT ATG	21	45

Table 2 (con't'l)

G-CSF ANALOGS	SEQUENCES (5' -> 3')	Length(nucleotides)	Seq_ID
Met127,138->	GAG CTC GGT CTG GCA CCA GC	20	46
Leu127,138	TCA AGG TGC TCT GCC GGC ATT	21	47
**Glu20->Ala20; Ser13->Gly13	GAA ATG TCT GGC ACA GGT TCG T	22	48

\*\* This analog came about during the preparation of G-CSF analog Glu20->Ala20. As several clones were being sequenced to identify the Glu20->Ala20 analog, the Glu20->Ala20; Ser13->Gly13 analog was identified. This double mutant was the result of an *in vitro* Klenow DNA polymerase reaction mistake.

D. Preparation of G-CSF Analogs Using DNA Amplification

[0107] This example relates to methods for producing G-CSF analogs using a DNA amplification technique. Essentially, DNA encoding each analog was amplified in two separate pieces, combined, and then the total sequence itself amplified. Depending upon where the desired change in the original G-CSF DNA was to be made, internal primers were used to incorporate the change, and generate the two separate amplified pieces. For example, for amplification of the 5' end of the desired analog DNA, a 5' flanking primer (complementary to a sequence of the plasmid upstream from the G-CSF original DNA) was used at one end of the region to be amplified, and an internal primer, capable of hybridizing to the original DNA but incorporating the desired change, was used for priming the other end. The resulting amplified region stretched from the 5' flanking primer through the internal primer. The same was done for the 3' terminus, using a 3' flanking primer (complementary to a sequence of the plasmid downstream from the G-CSF original DNA) and an internal primer complementary to the region of the intended mutation. Once the two "halves" (which may or may not be equal in size, depending on the location of the internal primer) were amplified, the two "halves" were allowed to connect. Once connected, the 5' flanking primer and the 3' flanking primer were used to amplify the entire sequence containing the desired change.

[0108] If more than one change is desired, the above process may be modified to incorporate the change into the internal primer, or the process may be repeated using a different internal primer. Alternatively, the gene amplification process may be used with other methods for creating changes in nucleic acid sequence, such as the phage based mutagenesis technique as described above. Examples of process for preparing analogs with more than one change are described below.

[0109] To create the G-CSF analogs described below, the template DNA used was the sequence as in FIGURE 1 plus certain flanking regions (from a plasmid containing the G-CSF coding region). These flanking regions were used as the 5' and 3' flanking primers and are set forth below. The amplification reactions were performed in 40 ul volumes containing 10 mM Tris-HCl, 1.5 mM MgCl<sub>2</sub>, 50 mM KCl, 0.1 mg/ml gelatin, pH 8.3 at 20°C. The 40 ul reactions also contained 0.1mM of each dNTP, 10 pmoles of each primer, and 1 ng of template DNA. Each amplification was repeated for 15 cycles. Each cycle consisted of 0.5 minutes at 94°C, 0.5 minutes at 50°C, and 0.75 minutes at 72°C. Flanking primers were 20 nucleotides in length and internal primers were 20 to 25 nucleotides in length. This resulted in multiple copies of double stranded DNA encoding either the front portion or the back portion of the desired G-CSF analog.

[0110] For combining the two "halves," one fortieth of each of the two reactions was combined in a third DNA amplification reaction. The two portions were allowed to anneal at the internal primer location, as their ends bearing the mutation were complementary, and following a cycle of polymerization, give rise to a full length DNA sequence. Once so annealed, the whole analog was amplified using the 5' and 3' flanking primers. This amplification process was repeated for 15 cycles as described above.

[0111] The completed, amplified analog DNA sequence was cleaved with XbaI and XhoI restriction endonuclease to produce cohesive ends for insertion into a vector. The cleaved DNA was placed into a plasmid vector, and that vector was used to transform *E. coli*. Transformants were challenged with kanamycin at 50 ug/ml and incubated at 30°C. Production of G-CSF analog protein was confirmed by polyacrylamide gel electrophoresis of a whole cell lysate. The presence of the desired mutation was confirmed by DNA sequence analysis of plasmid purified from the production isolate. Cultures were then grown, and cells were harvested, and the G-CSF analogs were purified as set forth below.

[0112] Set forth below in Table 3 are the specific primers used for each analog made using gene amplification.

Table 3

Analog Seq. ID	Internal Primer(5'->3')	
His <sup>44</sup> ->Ala <sup>44</sup>	5'primer-TTCCGGAGCGCACAGTTG	49
	3'primer-CAAACTGTGGGCTCCGGAAGAGC	50
Thr <sup>117</sup> ->Ala <sup>117</sup>	5'primer-ATGCCAAATTGCAGTAGCAAAG	51
	3'primer-CTTGCTACTGCAATTGGCAACA	52
Asp <sup>110</sup> ->Ala <sup>110</sup>	5'primer-ATCAGCTACTGCTAGCTGCAGA	53
	3'primer-TCTGCAGCTAGCAGTAGCTGACT	54
Gln <sup>21</sup> ->Ala <sup>21</sup>	5'primer-TTACGAACCGCTTCAGACATT	55
	3'primer-AATGTCTGGAAGCGGTCGTAAT	56

Table 3 (continued)

Analog Seq. ID	Internal Primer(5'->3')	
Asp <sup>113</sup> ->Ala <sup>113</sup>	5'primer-GTAGCAAATGCAGCTACATCTA	57
	3'primer-TAGATGTAGCTGCATTGCTACTAC	58
His <sup>53</sup> ->Ala <sup>53</sup>	5'primer-CCAAGAGAACGCCACCGCAG	59
	3'primer-CTGCTGGGTGCTTCTCTGGGA	60
For each analog, the following 5' flanking primer was used:		
	5'-CACTGGCGGTGATAATGAGC	61
For each analog, the following 3' flanking primer was used:		
	3'-GGTCATTACGGACCGGATC	62

15

1. Construction of Double Mutation

[0113] To make G-CSF analog Gln<sup>12,21</sup>->Glu<sup>12,21</sup>, two separate DNA amplifications were conducted to create the two DNA mutations. The template DNA used was the sequence as in FIGURE 1 plus certain flanking regions (from a plasmid containing the G-CSF coding region). The precise sequences are listed below. Each of the two DNA amplification reactions were carried out using a Perkin Elmer/Cetus DNA Thermal Cycler. The 40 ul reaction mix consisted of 1X PCR Buffer (Cetus), 0.2 mM each of the 4 dNTPs (Cetus), 50 pmoles of each primer oligonucleotide, 2 ng of G-CSF template DNA (on a plasmid vector), and 1 unit of Taq polymerase (Cetus). The amplification process was carried out for 30 cycles. Each cycle consisted of 1 minute at 94°C, 2 minutes at 50°C, and 3 minutes at 72°C.

[0114] DNA amplification "A" used the oligonucleotides:

5' CCACTGGCGGTGATACTGAGC 3' (Seq. ID 63) and

5' AGCAGAAAGCTTCCGGCAGAGAAGCAGGA 3' (Seq. ID 64)

[0115] DNA amplification "B" used the oligonucleotides:

5' GCCGCAAAGCTTCTGCTGAAATGTCCTGAAAGAGGTTCTGAAATCCAGGGTGA 3' (Seq. ID 65) and

5' CTGGAATGCAGAAGCAAATGCCGGCATAGCACCTTCAGTCGGTTGCAGAGCTGGTGCCA 3' (Seq. ID 66)

[0116] From the 109 base pair double stranded DNA product obtained after DNA amplification "A", a 64 base pair XbaI to HindIII DNA fragment was cut and isolated that contained the DNA mutation Gln<sup>12</sup>->Glu<sup>12</sup>. From the 509 base pair double stranded DNA product obtained after DNA amplification "B", a 197 base pair HindIII to BsmI DNA fragment was cut and isolated that contained the DNA mutation Gln<sup>21</sup>->Glu<sup>21</sup>.

[0117] The "A" and "B" fragments were ligated together with a 4.8 kilo-base pair XbaI to BsmI DNA plasmid vector fragment. The ligation mix consisted of equal molar DNA restriction fragments, ligation buffer (25 mM Tris-HCl pH 7.8, 10 mM MgCl<sub>2</sub>, 2 mM DTT, 0.5 mM rATP, and 100 ug/ml BSA) and T4 DNA ligase and was incubated overnight at 14°C. The ligated DNA was then transformed into *E. coli* FM5 cells by electroporation using a Bio Rad Gene Pulsar apparatus (BioRad, Richmond, CA). A clone was isolated and the plasmid construct verified to contain the two mutations by DNA sequencing. This 'intermediate' vector also contained a deletion of a 193 base pair BsmI to BsmI DNA fragment. The final plasmid vector was constructed by ligation and transformation (as described above) of DNA fragments obtained by cutting and isolating a 2 kilo-base pair SstI to BamHI DNA fragment from the intermediate vector, a 2.8 kbp SstI to EcoRI DNA fragment from the plasmid vector, and a 360 bp BamHI to EcoRI DNA fragment from the plasmid vector.

[0118] The final construct was verified by DNA sequencing the G-CSF gene. Cultures were grown, and the cells were harvested, and the G-CSF analogs were purified as set forth below.

[0119] As indicated above, any combination of mutagenesis techniques may be used to generate a G-CSF analog nucleic acid (and expression product) having one or more than one alteration. The two examples above, using M13-based mutagenesis and gene amplification-based mutagenesis, are illustrative.

50

E. Expression of G-CSF Analog DNA

[0119] The G-CSF analog DNAs were then placed into a plasmid vector and used to transform *E. coli* strain FM5 (ATCC#53911). The present G-CSF analog DNAs contained on plasmids and in bacterial host cells are available from the American Type Culture Collection, Rockville, MD, and the accession designations are indicated below.

[0120] One liter cultures were grown in broth containing 10g tryptone, 5g yeast extract and 5g NaCl) at 30°C until reaching a density at A<sup>600</sup> of 0.5, at which point they were rapidly heated to 42°C. The flasks were allowed to continue shaking at for three hours.

[0121] Other prokaryotic or eukaryotic host cells may also be used, such as other bacterial cells, strains or species, mammalian cells in culture (COS, CHO or other types) insect cells or multicellular organs or organisms, or plant cells or multicellular organs or organisms, and a skilled practitioner will recognize the appropriate host. The present G-CSF analogs and related compositions may also be prepared synthetically, as, for example, by solid phase peptide synthesis methods, or other chemical manufacturing techniques. Other cloning and expression systems will be apparent to those skilled in the art.

5 F. Purification of G-CSF Analog Protein

[0122] Cells were harvested by centrifugation (10,000 x G, 20 minutes, 4°C). The pellet (usually 5 grams) was resuspended in 30 ml of 1mM DTT and passed three times through a French press cell at 10,000 psi. The broken cell suspension was centrifuged at 10,000g for 30 minutes, the supernatant removed, and the pellet resuspended in 30-40 ml water. This was recentrifuged at 10,000 x G for 30 minutes, and this pellet was dissolved in 25 ml of 2% Sarkosyl and 50mM Tris at pH 8. Copper sulfate was added to a concentration of 40uM, and the mixture was allowed to stir for at least 15 hours at 15-25°C. The mixture was then centrifuged at 20,000 x G for 30 minutes. The resultant solubilized protein mixture was diluted four-fold with 13.3 mM Tris, pH 7.7, the Sarkosyl was removed, and the supernatant was then applied to a DEAE-cellulose (Whatman DE-52) column equilibrated in 20mM Tris, pH 7.7. After loading and washing the column with the same buffer, the analogs were eluted with 20mM Tris /NaCl (between 35mM to 100mM depending on the analog, as indicated below), pH 7.7. For most of the analogs, the eluent from the DEAE column was adjusted to a pH of 5.4, with 50% acetic acid and diluted as necessary (to obtain the proper conductivity) with 5mM sodium acetate pH 5.4. The solution was then loaded onto a CM-sepharose column equilibrated in 20 mM sodium acetate, pH 5.4. The column was then washed with 20mM NaAc, pH 5.4 until the absorbance at 280 nm was approximately zero. The G-CSF analog was then eluted with sodium acetate/NaCl in concentrations as described below in Table 4. The DEAE column eluents for those analogs not applied to the CM-sepharose column were dialyzed directly into 10mM NaAc, pH 4.0 buffer. The purified G-CSF analogs were then suitably isolated for in vitro analysis. The salt concentrations used for eluting the analogs varied, as noted above. Below, the salt concentrations for the DEAE cellulose column and for the CM-sepharose column are listed:

30

**Table 4**  
**Salt Concentrations**

35

<u>Analog</u>	<u>DEAE Cellulose</u>	<u>CM-Sepharose</u>
Lys <sup>17</sup> ->Arg <sup>17</sup>	35mM	37.5mM
Lys <sup>24</sup> ->Arg <sup>24</sup>	35mM	37.5mM
Lys <sup>35</sup> ->Arg <sup>35</sup>	35mM	37.5mM
Lys <sup>41</sup> ->Arg <sup>41</sup>	35mM	37.5mM
Lys <sup>17, 24, 35-&gt;Arg<sup>17, 24, 35</sup></sup>	35mM	37.5mM
Lys <sup>17, 35, 41-&gt;Arg<sup>17, 35, 41</sup></sup>	35mM	37.5mM

40

45

50

55

Table 4 Con't

	<u>Analog</u>	<u>DEAE Cellulose</u>	<u>CM-Sepharose</u>
5	Lys <sup>24, 35, 41-</sup>	35mM	37.5mM
	>Arg <sup>24, 35, 41</sup>		
10	Lys <sup>17, 24, 35, 41</sup>	35mM	37.5mM
	->Arg <sup>17, 24, 35, 41</sup>		
15	Lys <sup>17, 24, 41-</sup>	35mM	37.5mM
	>Arg <sup>17, 24, 41</sup>		
	Gln <sup>68-&gt;Glu<sup>68</sup></sup>	60mM	37.5mM
20	Cys <sup>37, 43-&gt;Ser<sup>37, 43</sup></sup>	40mM	37.5mM
	Gln <sup>26-&gt;Ala<sup>26</sup></sup>	40mM	40mM
25	Gln <sup>174-&gt;Ala<sup>174</sup></sup>	40mM	40mM
	Arg <sup>170-&gt;Ala<sup>170</sup></sup>	40mM	40mM
	Arg <sup>167-&gt;Ala<sup>167</sup></sup>	40mM	40mM
30	Deletion 167*	N/A	N/A
	Lys <sup>41-&gt;Ala<sup>41</sup></sup>	160mM	40mM
	His <sup>44-&gt;Lys<sup>44</sup></sup>	40mM	60mM
35	Glu <sup>47-&gt;Ala<sup>47</sup></sup>	40mM	40mM
	Arg <sup>23-&gt;Ala<sup>23</sup></sup>	40mM	40mM
	Lys <sup>24-&gt;Ala<sup>24</sup></sup>	120mM	40mM
40	Glu <sup>20-&gt;Ala<sup>20</sup></sup>	40mM	60mM
	Asp <sup>28-&gt;Ala<sup>28</sup></sup>	40mM	80mM
	Met <sup>127-&gt;Glu<sup>127</sup></sup>	80mM	40mM
45	Met <sup>138-&gt;Glu<sup>138</sup></sup>	80mM	40mM
	Met <sup>127-&gt;Leu<sup>127</sup></sup>	40mM	40mM
	Met <sup>138-&gt;Leu<sup>138</sup></sup>	40mM	40mM
	Cys <sup>18-&gt;Ala<sup>18</sup></sup>	40mM	37.5mM
50	Gln <sup>12, 21-&gt;Glu<sup>12, 21</sup></sup>	60mM	37.5mM
	Gln <sup>12, 21, 68-</sup>	60mM	37.5mM
	>Glu <sup>12, 21, 68</sup>		
	Glu <sup>20-&gt;Ala<sup>20</sup></sup> ;		
	Ser <sup>13</sup>		
	->Gly <sup>13</sup>	40mM	80mM

Table 4 Con't

	<u>Analog</u>	<u>DEAE Cellulose</u>	<u>CM-Sepharose</u>
5	Met <sup>127,138-</sup>	40mM	40mM
	>Leu <sup>127,138</sup>		
10	Ser <sup>13-&gt;Ala<sup>13</sup></sup>	40mM	40mM
	Lys <sup>17-&gt;Ala<sup>17</sup></sup>	80mM	40mM
	Gln <sup>121-&gt;Ala<sup>121</sup></sup>	40mM	60mM
15	Gln <sup>21-&gt;Ala<sup>21</sup></sup>	50mM	Gradient 0 -150mM
	His <sup>44-&gt;Ala<sup>44**</sup></sup>	40mM	N/A
	His <sup>53-&gt;Ala<sup>53**</sup></sup>	50mM	N/A
20	Asp <sup>110-&gt;Ala<sup>110**</sup></sup>	40mM	N/A
	Asp <sup>113-&gt;Ala<sup>113**</sup></sup>	40mM	N/A
	Thr <sup>117-&gt;Ala<sup>117**</sup></sup>	50mM	N/A
	Asp <sup>28-&gt;Ala<sup>28</sup></sup> ;	50mM	N/A
25	Asp <sup>110</sup>		
	Ala <sup>110**</sup>		
	Glu <sup>124-&gt;Ala<sup>124**</sup></sup>	40mM	40mM

30           \* For Deletion 167, the data are unavailable.  
       \*\* For these analogs, the DEAE cellulose column alone  
       was use for purification.

35 [0123] The above purification methods are illustrative, and a skilled practitioner will recognize that other means are available for obtaining the present G-CSF analogs.

40 **G. Biological Assays**

[0124] Regardless of which methods were used to create the present G-CSF analogs, the analogs were subject to assays for biological activity. Tritiated thymidine assays were conducted to ascertain the degree of cell division. Other biological assays, however, may be used to ascertain the desired activity. Biological assays such as assaying for the ability to induce terminal differentiation in mouse WEHI-3B (D+) leukemic cell line, also provides indication of G-CSF activity. See Nicola, et al., Blood 54: 614-27 (1979). Other *in vitro* assays may be used to ascertain biological activity. See Nicola, Annu. Rev. Biochem. 58: 45-77 (1989). In general, the test for biological activity should provide analysis for the desired result, such as increase or decrease in biological activity (as compared to non-altered G-CSF), different biological activity (as compared to non-altered G-CSF), receptor affinity analysis, or serum half-life analysis. The list is incomplete, and those skilled in the art will recognize other assays useful for testing for the desired end result.

[0125] The <sup>3</sup>H-thymidine assay was performed using standard methods. Bone marrow was obtained from sacrificed female Balb C mice. Bone marrow cells were briefly suspended, centrifuged, and resuspended in a growth medium. A 160 ul aliquot containing approximately 10,000 cells was placed into each well of a 96 well micro-titer plate. Samples of the purified G-CSF analog(as prepared above) were added to each well, and incubated for 68 hours. Tritiated thymidine was added to the wells and allowed to incubate for 5 additional hours. After the 5 hour incubation time, the cells were harvested, filtered, and thoroughly rinsed. The filters were added to a vial containing scintillation fluid. The beta emissions were counted (LKB Betaplate scintillation counter). Standards and analogs were analyzed in triplicate, and samples which fell substantially above or below the standard curve were re-assayed with the proper dilution.

The results reported here are the average of the triplicate analog data relative to the unaltered recombinant human G-CSF standard results.

H. HPLC Analysis

5

[0126] High pressure liquid chromatography was performed on purified samples of analog. Although peak position on a reverse phase HPLC column is not a definitive indication of structural similarity between two proteins, analogs which have similar retention times may have the same type of hydrophobic interactions with the HPLC column as the non-altered molecule. This is one indication of an overall similar structure.

10

[0127] Samples of the analog and the non-altered recombinant human G-CSF were analyzed on a reverse phase (0.46 x 25 cm) Vydac 214TP54 column (Separations Group, Inc. Hesperia, CA). The purified analog G-CSF samples were prepared in 20 mM acetate and 40 mM NaCl solution buffered at pH 5.2 to a final concentration of 0.1 mg/ml to 5 mg/ml, depending on how the analog performed in the column. Varying amounts (depending on the concentration) were loaded onto the HPLC column, which had been equilibrated with an aqueous solution containing 1% isopropanol, 15 52.8% acetonitrile, and .38% trifluoro acetate (TFA). The samples were subjected to a gradient of 0.86%/minute acetonitrile, and .002% TFA.

15

I. Results

20

[0128] Presented below are the results of the above biological assays and HPLC analysis. Biological activity is the average of triplicate data and reported as a percentage of the control standard (non-altered G-CSF). Relative HPLC peak position is the position of the analog G-CSF relative to the control standard (non-altered G-CSF) peak. The "+" or "-" symbols indicate whether the analog HPLC peak was in advance of or followed the control standard peak (in minutes). Not all of the variants had been analyzed for relative HPLC peak, and only those so analyzed are included below.

25

Also presented are the American Type Culture Collection designations for *E. coli* host cells containing the nucleic acids coding for the present analogs, as prepared above.

30

35

40

45

50

55

Table 5

Seq. ID	Variant	Analog	Relative HPLC Peak	ATCC No.	% Normal G-CSF Activity
67	1	Lys17->Arg17	N/A	69184	N/A
68	2	Lys24->Arg24	N/A	69185	N/A
69	3	Lys35->Arg35	N/A	69186	N/A
70	4	Lys41->Arg41	N/A	69187	N/A
71	5	Lys17, 24, 35->Arg17, 24, 35	N/A	69189	N/A
72	6	Lys17, 35, 41->Arg17, 35, 41	N/A	69192	N/A
73	7	Lys24, 35, 41->Arg24, 35, 41	N/A	69191	N/A
74	8	Lys17, 24, 35, 41 ->Arg17, 24, 35, 41	N/A	69193	N/A
75	9	Lys17, 24, 41->Arg17, 24, 41	N/A	69190	N/A
76	10	Gln68->Glu68	N/A	69196	N/A
77	11	Cys37, 43->Ser37, 43	N/A	69197	N/A
78	12	Gln26->Ala26	+ .96	69201	51%
79	13	Gln174->Ala174	+ .14	69202	100%
80	14	Arg170->Ala170	+ .78	69203	100%

Table 5 Con't.

Seq. ID	Variant	Analog	Relative HPLC Peak			ATCC No.	% Normal G-CSF Activity
81	15	Arg167->Ala167	+.54	69204			110%
82	16	Deletion 167	-.99	69207		N/A	
83	17	Lys41->Ala41	+.25	69208			81%
84	18	His44->Lys44	-1.53	69212			70%
85	19	Glu47->Ala47	+.14	69205			0%
86	20	Arg23->Ala23	-.03	69206			31%
87	21	Lys24->Ala24	+1.95	69213			0%
88	22	Glu20->Ala20	-0.07	69211			0%
89	23	Asp28->Ala28	-.30	69210			147%
90	24	Met127->Glu127	N/A	69223			N/A
91	25	Met138->Glu138	N/A	69222			N/A
92	26	Met127->Leu127	N/A	69198			N/A
93	27	Met138->Leu138	N/A	69199			N/A
94	28	Cys18->Ala18	N/A	69188			N/A
95	29	Gln12,21->Glu12,21	N/A	69194			N/A
96	30	Gln12,21,68->Glu12,21,68	N/A	69195			N/A
97	31	Glu20->Ala20; Ser13	+1.74	69209			0%

Table 5 Con't

Seq. ID	Variant	Analog	Relative		% Normal G-CSF	Activity
			HPIC Peak	ATCC No.		
->Gly13						
98	32	Met127,138->Leu127,138	+1.43	69200	98%	
99	33	Ser13->Ala13	0	69221	110%	
100	34	Lys17->Ala17	+.50	69226	70%	
101	35	Gln121->Ala121	+2.7	69225	100%	
102	36	Gln21->Ala21	+0.63	69217	9.6%	
103	37	H1s44->Ala44	+1.52	69215	10.8%	
104	38	H1s53->Ala53	+0.99	69219	8.3%	
105	39	Asp110->Ala110	+1.97	69216	29%	
106	40	Asp113->Ala113	-0.34	69218	0%	
107	41	Thr117->Ala117	+0.4	69214	9.7%	
108	42	Asp28->Ala28; Asp110 Ala110	+3.2	69220	20.6%	

Table 5 Con't.

Seq. ID	Variant	Analog	Relative		% Normal	
			HPLC Peak	ATCC No.	G-CSF	Activity
109	43	Glu124->Ala124	+0.16	69224	75%	
110	44	Phe114->Val 114, T117->A117**	+0.53		0%	

\*\*This analog was apparently a result of an inadvertent error in the oligo which was used to prepare number 41, above (Thr117->Ala 117), and thus was prepared identically to the process used for that analog.  
"N/A" indicates data which are not available.

1. Identification of Structure-Function Relationships

[0129] The first step used to design the present analogs was to determine what moieties are necessary for structural integrity of the G-CSF molecule. This was done at the amino acid residue level, although the atomic level is also available for analysis. Modification of the residues necessary for structural integrity results in change in the overall structure of the G-CSF molecule. This may or may not be desirable, depending on the analog one wishes to produce. The working examples here were designed to maintain the overall structural integrity of the G-CSF molecule, for the purpose of maintain G-CSF receptor binding of the analog to the G-CSF receptor (as used in this section below, the "G-CSF receptor" refers to the natural G-CSF receptor, found on hematopoietic cells). It was assumed, and confirmed by the studies presented here, that G-CSF receptor binding is a necessary step for at least one biological activity, as determined by the above biological assays.

[0130] As can be seen from the figures, G-CSF (here, recombinant human met-G-CSF) is an antiparallel 4-alpha helical bundle with a left-handed twist, and with overall dimensions of 45 Å x 30Å x 24Å. The four helices within the bundle are referred to as helices A, B, C and D, and their connecting loops are known as the AB, BC and CD loops. The helix crossing angles range from -167.5° to -159.4°. Helices A, B, and C are straight, whereas helix D contains two kinds of structural characteristics, at Gly 150 and Ser 160 (of the recombinant human met-G-CSF). Overall, the G-CSF molecules is a bundle of four helices, connected in series by external loops. This structural information was then correlated with known functional information. It was known that residues (including methionine at position 1) 47, 23, 24, 20, 21, 44, 53, 113, 110, 28 and 114 may be modified, and the effect on biological activity would be substantial.

[0131] The majority of single mutations which lowered biological activity were centered around two regions of G-CSF that are separated by 30Å, and are located on different faces of the four helix bundle. One region involves interactions between the A helix and the D helix. This is further confirmed by the presence of salt bridges in the non-altered molecule as follows:

25

30

35

Atom	Helix	Atom	Helix	Distance
Arg 170 N1	D	Tyr 166 OH	A	3.3
Tyr 166 OH	D	Arg 23 N2	A	3.3
Glu 163 OE1	D	Arg 23 N1	A	2.8
Arg 23 N1	A	Gln 26 OE1	A	3.1
Gln 159 NE2	D	Gln 26 O	A	3.3

[0132] Distances reported here were for molecule A, as indicated in FIGURE 5 (wherein three G-CSF molecules crystallized together and were designated as A, B, and C). As can be seen, there is a web of salt bridges between helix A and helix D, which act to stabilize the helix A structure, and therefore affect the overall structure of the G-CSF molecule.

[0133] The area centering around residues Glu 20, Arg 23 and Lys 24 are found on the hydrophilic face of the A helix (residues 20-37). Substitution of the residues with the non-charged alanine residue at positions 20 and 23 resulted in similar HPLC retention times, indicating similarity in structure. Alteration of these sites altered the biological activity (as indicated by the present assays). Substitution at Lys 24 altered biological activity, but did not result in a similar HPLC retention time as the other two alterations.

[0134] The second site at which alteration lowered biological activity involves the AB helix. Changing glutamine at position 47 to alanine (analog no. 19, above) reduced biological activity (in the thymidine uptake assay) to zero. The AB helix is predominantly hydrophobic, except at the amino and carboxy termini; it contains one turn of a 3<sup>10</sup> helix. There are two histidines at each termini (His 44 and His 56) and an additional glutamate at residue 46 which has the potential to form a salt bridge to His 44. The fourier transformed infra red spectrographic analysis (FTIR) of the analog suggests this analog is structurally similar to the non-altered recombinant G-CSF molecule. Further testing showed that this analog would not crystallize under the same conditions as the non-altered recombinant molecule.

[0135] Alterations at the carboxy terminus (Gln 174, Arg 167 and Arg 170) had little effect on biological activity. In contrast, deletion of the last eight residues (167-175) lowered biological activity. These results may indicate that the deletion destabilizes the overall structure which prevents the mutant from proper binding to the G-CSF receptor (and thus initiating signal transduction).

[0136] Generally, for the G-CSF internal core -- the internal four helix bundle lacking the external loops --the hydrophobic internal residues are essential for structural integrity. For example, in helix A, the internal hydrophobic residues

are (with methionine being position 1) Phe 14, Cys 18, Val 22, Ile 25, Ile 32 and Leu 36. Generally, for the G-CSF internal core -- the internal four helix bundle lacking the external loops --the hydrophobic internal residues are essential for structural integrity. For example, in helix A, the internal hydrophobic residues are (with methionine being position 1 as in FIGURE 1) Phe 14, Cys 18, Val 22, Ile 25, Ile 32 and Leu 36. The other hydrophobic residues (again with the met at position 1) are: helix B, Ala 72, Leu 76, Leu 79, Leu 83, Tyr 86, Leu 90 Leu 93; helix C, Leu 104, Leu 107, Val 111, Ala 114, Ile 118, Met 122; and helix D, Val 154, Val 158, Phe 161, Val 164, Val 168, Leu 172.

[0137] The above biological activity data, from the presently prepared G-CSF analogs, demonstrate that modification of the external loops interfere least with G-CSF overall structure. Preferred loops for analog preparation are the AB loop and the CD loop. The loops are relatively flexible structures as compared to the helices. The loops may contribute to the proteolysis of the molecule. G-CSF is relatively fast acting *in vivo* as the purpose the molecule serves is to generate a response to a biological challenge, i.e., selectively stimulate neutrophils. The G-CSF turnover rate is also relatively fast. The flexibility of the loops may provide a "handle" for proteases to attach to the molecule to inactivate the molecule. Modification of the loops to prevent protease degradation, yet have (via retention of the overall structure of non-modified G-CSF) no loss in biological activity may be accomplished.

[0138] This phenomenon is probably not limited to the G-CSF molecule but may also be common to the other molecules with known similar overall structures, as presented in Figure 2. Alteration of the external loop of, for example hGH, Interferon B, IL-2, GM-CSF and IL-4 may provide the least change to the overall structure. The external loops on the GM-CSF molecule are not as flexible as those found on the G-CSF molecule, and this may indicate a longer serum life, consistent with the broader biological activity of GM-CSF. Thus, the external loops of GM-CSF may be modified by releasing the external loops from the beta-sheet structure, which may make the loops more flexible (similar to those G-CSF) and therefore make the molecule more susceptible to protease degradation (and thus increase the turnover rate).

[0139] Alteration of these external loops may be effected by stabilizing the loops by connection to one or more of the internal helices. Connecting means are known to those in the art, such as the formation of a beta sheet, salt bridge, disulfide bonding or hydrophobic interactions, and other means are available. Also, deletion of one or more moieties, such as one or more amino acid residues or portions thereof, to prepare an abbreviated molecule and thus eliminate certain portions of the external loops may be effected.

[0140] Thus, by alteration of the external loops, preferably the AB loop (amino acids 58-72 of r-hu-met G-CSF) or the CD loop (amino acids 119 to 145 of r-hu-met-G-CSF), and less preferably the amino terminus (amino acids 1-10), one may therefore modify the biological function without elimination of G-CSF receptor binding. For example, one may: (1) increase half-life (or prepare an oral dosage form, for example) of the G-CSF molecule by, for example, decreasing the ability of proteases to act on the G-CSF molecule or adding chemical modifications to the G-CSF molecule, such as one or more polyethylene glycol molecules or enteric coatings for oral formulation which would act to change some characteristic of the G-CSF molecule as described above, such as increasing serum or other half-life or decreasing antigenicity; (2) prepare a hybrid molecule, such as combining G-CSF with part or all of another protein such as another cytokine or another protein which effects signal transduction via entry through the cell through a G-CSF receptor transport mechanism; or (3) increase the biological activity as in, for example, the ability to selectively stimulate neutrophils (as compared to a non-modified G-CSF molecule). This list is not limited to the above exemplars.

[0141] Another aspect observed from the above data is that stabilizing surface interactions may affect biological activity. This is apparent from comparing analogs 23 and 40. Analog 23 contains a substitution of the charged asparagine residue at position 28 for the neutrally-charged alanine residue in that position, and such substitution resulted in a 50% increase in the biological activity (as measured by the disclosed thymidine uptake assays). The asparagine residue at position 28 has a surface interaction with the asparagine residue at position 113; both residues being negatively charged, there is a certain amount of instability (due to the repelling of like charged moieties). When, however the asparagine at position 113 is replaced with the neutrally-charged alanine, the biological activity drops to zero (in the present assay system). This indicates that the asparagine at position 113 is critical to biological activity, and elimination of the asparagine at position 28 serves to increase the effect that asparagine at position 113 possesses.

[0142] The domains required for G-CSF receptor binding were also determined based on the above analogs prepared and the G-CSF structure. The G-CSF receptor binding domain is located at residues (with methionine being position 1) 11-57 (between the A and AB helix) and 100-118 (between the B and C helices). One may also prepare abbreviated molecules capable of binding to a G-CSF receptor and initiate signal transduction for selectively stimulating neutrophils by changing the external loop structure and having the receptor binding domains remain intact.

[0143] Residues essential for biological activity and presumably G-CSF receptor binding or signal transduction have been identified. Two distinct sites are located on two different regions of the secondary structure. What is here called "Site A" is located on a helix which is constrained by salt bridge contacts between two other members of the helical bundle. The second site, "Site B" is located on a relatively more flexible helix, AB. The AB helix is potentially more sensitive to local pH changes because of the type and position of the residues at the carboxy and amino termini. The functional importance of this flexible helix may be important in a conformationally induced fit when binding to the G-CSF receptor. Additionally, the extended portion of the D helix is also indicated to be a G-CSF receptor binding domain, as

ascertained by direct mutational and indirect comparative protein structure analysis. Deletion of the carboxy terminal end of r-hu-met-G-CSF reduces activity as it does for hGH, see, Cunningham and Wells, *Science* **244**: 1081-1084 (1989). Cytokines which have similar structures, such as IL-6 and GM-CSF with predicted similar topology also center their biological activity along the carboxy end of the D helix, see Bazan, *Immunology Today* **11**: 350-354 (1990)

5 [0144] A comparison of the structures and the positions of G-CSF receptor binding determinants between G-CSF and hGH suggests both molecules have similar means of signal transduction. Two separate G-CSF receptor binding sites have been identified for hGH De Vos et al., *Science* **255**: 306-32 (1991). One of these binding sites (called "Site I") is formed by residues on the exposed faces of hGH's helix 1, the connection region between helix 1 and 2, and helix 4. The second binding site (called "Site II") is formed by surface residues of helix 1 and helix 3.

10 [0145] The G-CSF receptor binding determinates identified for G-CSF are located in the same relative positions as those identified for hGH. The G-CSF receptor binding site located in the connecting region between helix A and B on the AB helix (Site A) is similar in position to that reported for a small piece of helix (residues 38-47) of hGH. A single point mutation in the AB helix of G-CSF significantly reduces biological activity (as ascertained in the present assays), indicating the role in a G-CSF receptor-ligand interface. Binding of the G-CSF receptor may destabilize the  $3^{10}$  helical 15 nature of this region and induce a conformation change improving the binding energy of the ligand/G-CSF receptor complex.

20 [0146] In the hGH receptor complex, the first helix of the bundle donates residues to both of the binding sites required to dimerize the hGH receptor. Mutational analysis of the corresponding helix of G-CSF (helix A) has identified three residues which are required for biological activity. Of these three residues, Glu 20 and Arg 24 lie on one face of 25 the helical bundle towards helix C, whereas the side chain of Arg 23 (in two of the three molecules in the asymmetric unit) points to the face of the bundle towards helix D. The position of side chains of these biologically important residues indicates that similar to hGH, G-CSF may have a second G-CSF receptor binding site along the interface between helix A and helix C. In contrast with the hGH molecule, the amino terminus of G-CSF has a limited biological role as deletion 30 of the first 11 residues has little effect on the biological activity.

35 [0147] As indicated above (see FIGURE 2, for example), G-CSF has a topological similarity with other cytokines. A correlation of the structure with previous biochemical studies, mutational analysis and direct comparison of specific residues of the hGH receptor complex indicates that G-CSF has two receptor binding sites. Site A lies along the interface of the A and D helices and includes residues in the small AB helix. Site B also includes residues in the A helix but lies along the interface between helices A and C. The conservation of structure and relative positions of biologically important residues between G-CSF and hGH is one indication of a common method of signal transduction in that the receptor is bound in two places. It is therefore found that G-CSF analogs possessing altered G-CSF receptor binding domains may be prepared by alteration at either of the G-CSF receptor binding sites (residues 20-57 and 145-175).

[0148] Knowledge of the three dimensional structure and correlation of the composition of G-CSF protein makes possible a systematic, rational method for preparing G-CSF analogs. The above working examples have demonstrated 40 that the limitations of the size and polarity of the side chains within the core of the structure dictate how much change the molecule can tolerate before the overall structure is changed.

45

50

55

## SEQUENCE LISTING

## 5 (1) GENERAL INFORMATION:

(i) APPLICANT: Amgen Inc.  
 (ii) TITLE OF INVENTION: G-CSF ANALOG COMPOSITIONS AND  
 METHODS

10 (iii) NUMBER OF SEQUENCES: 110

(iv) CORRESPONDENCE ADDRESS:  
 (A) ADDRESSEE: Amgen Inc.  
 (B) STREET: Amgen Center, 1840 DeHavilland Drive  
 (C) CITY: Thousand Oaks  
 (D) STATE: California  
 (E) COUNTRY: United States of America  
 (F) ZIP: 91320-1789  
 (v) COMPUTER READABLE FORM:  
 (A) MEDIUM TYPE: Floppy disk  
 (B) COMPUTER: IBM PC compatible  
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS

## 25 (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 565 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 30..554

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TCTAGAAAAAA ACCAAGGGAGG TAATAAAATA ATG ACT CCA TTA GGT CCT GCT TCT  
 Met Thr Pro Leu Gly Pro Ala Ser  
 1 5

53

40 TCT CTG CCG CAA AGC TTT CTG CTG AAA TGT CTG GAA CAG GTT CGT AAA  
 Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg Lys  
 10 15 20

101

45 ATC CAG GGT GAC GGT GCT GCA CTG CAA GAA AAA CTG TGC GCT ACT TAC  
 Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala Thr Tyr  
 25 30 35 40

149

50

55

	AAA CTG TGC CAT CCG GAA GAG CTG GTA CTG CTG GGT CAT TCT CTT GGG Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly 45 50 55	197
5	ATC CCG TGG GCT CCG CTG TCT TCT TGT CCA TCT CAA GCT CTT CAG CTG Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu 60 65 70	245
10	GCT GGT TGT CTG TCT CAA CTG CAT TCT GGT CTG TTC CTG TAT CAG GGT Ala Gly Cys Leu Ser Gln Leu His Ser Gly Leu Phe Leu Tyr Gln Gly 75 80 85	293
	CTT CTG CAA GCT CTG GAA GGT ATC TCT CCG GAA CTG GGT CCG ACT CTG Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu Gly Pro Thr Leu 90 95 100	341
15	GAC ACT CTG CAG CTA GAT GTA GCT GAC TTT GCT ACT ACT ATT TGG CAA Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp Gln 110 115 120	389
20	CAG ATG GAA GAG CTC GGT ATG GCA CCA GCT CTG CAA CCG ACT CAA GGT Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly 125 130 135	437
	GCT ATG CCG GCA TTC GCT TCT GCA TTC CAG CGT CGT GCA GGA GGT GTA Ala Met Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val 140 145 150	485
25	CTG GTT GCT TCT CAT CTG CAA TCT TTC CTG GAA GTA TCT TAC CGT GTT Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val 155 160 165	533
30	CTG CGT CAT CTG GCT CAG CCG TAATAGAATT C Leu Arg His Leu Ala Gln Pro 170 175	565

## (i) INFORMATION FOR SEQ ID NO:2:

35	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 175 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear
	(ii) MOLECULE TYPE: protein
40	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
	Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu 1 5 10 15
45	Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu 20 25 30
	Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45

50

55

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

5 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

10 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

15 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

20 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:3:

- 25 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 24 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

C<sub>1</sub>TCTGCTG CGTTGTCTGG AACAA

24

## (35) (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 23 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

45 ACAGGGTTCGT CGTATCCAGG GTG

23

50

55

## (2) INFORMATION FOR SEQ ID NO:5:

- 5           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 23 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

10           (ii) MOLECULE TYPE: DNA

15           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CACTGCAAAGA ACGTCTGTGC GCT

23

## (2) INFORMATION FOR SEQ ID NO:6:

- 15           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 23 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

20           (ii) MOLECULE TYPE: DNA

25           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CGCTACTTAC CGTCTGTGCC ATC

23

## (2) INFORMATION FOR SEQ ID NO:7:

- 30           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 24 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

35           (ii) MOLECULE TYPE: DNA

40           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CTTTCTGCTG CGTTGTCTGG AACA

24

## (2) INFORMATION FOR SEQ ID NO:8:

- 45           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 23 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

50           (ii) MOLECULE TYPE: DNA

50

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ACAGGTTCGT CGTATCCAGG GTG

23

5

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CTGCAAGA ACGTCTGTGC GCT

23

15

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CTTTCTGCTG CGTTGTCCTGG AACAA

24

20

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ACAGGTTCGT CGTATCCAGG GTG

23

30

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single

40

50

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CGCTACTTAC CGTCTGTCCC ATC

23

10 (2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

20 CTTTCTGCTG CGTTGTCTGG AACAA

24

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TTGCAAAGA ACGTCTGTGC GCT

23

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

45 CGCTACTTAC CGTCTGTGCC ATC

23

50

55

## (2) INFORMATION FOR SEQ ID NO:16:

- 5           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 23 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

10           (ii) MOLECULE TYPE: DNA

10           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ACAGGTTCGT CGTATCCAGG GTG

23

## 15           (2) INFORMATION FOR SEQ ID NO:17:

- 20           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 23 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

20           (ii) MOLECULE TYPE: DNA

20           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

25           CACTGCAAGA ACGTCTGTGC GCT

23

## 25           (2) INFORMATION FOR SEQ ID NO:18:

- 30           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 23 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

35           (ii) MOLECULE TYPE: DNA

35           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

40           CGCTACTTAC CGTCTGTGCC ATC

23

## 40           (2) INFORMATION FOR SEQ ID NO:19:

- 45           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 24 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

45           (ii) MOLECULE TYPE: DNA

50

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CTTTCTGCTG CGTGTCTGG AACA

24

5

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

.. AGGTCGT CGTATCCAGG GTG

23

20 (2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CACTGCAAGA ACGTCTGTGC GCT

23

30

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CGCTACTTAC CGTCTGTGCC ATC

23

45

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

50

55

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

TCTGCTGAAA GCTCTGGAAC AGG

23

10 (2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 23 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

15 . (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

20 CTTGTCCATC TGAAGCTCTT CAG

23

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 37 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: DNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

C<sup>-</sup> AAAACTGT CCGCTACTTA CAAACTGTCC CATCCGG

37

35 (2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 22 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

45 TTCTGTAAT CGCGGGTGAC GG

22

50

55

## (2) INFORMATION FOR SEQ ID NO:27:

- 5           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 22 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

10           (ii) MOLECULE TYPE: DNA

10           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

TCATCTGGCT GCGCCGTAAT AG

22

## (2) INFORMATION FOR SEQ ID NO:28:

- 15           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 22 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

20           (ii) MOLECULE TYPE: DNA

20           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

25           CCGTGTTCTG GCTCATCTGG CT

22

## (2) INFORMATION FOR SEQ ID NO:29:

- 30           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 24 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

35           (ii) MOLECULE TYPE: DNA

35           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GAAGTATCTT ACGCTGTTCT GCGT

24

## (2) INFORMATION FOR SEQ ID NO:30:

- 40           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 25 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

45           (ii) MOLECULE TYPE: DNA

50

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GAAGTATCTT ACTAAGTTCT GCGTC

25

5

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

~CTACTTAC GCACTGTGCC AT

22

(2) INFORMATION FOR SEQ ID NO:32:

20

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

CAAACGTGCA AAGCCGGAAG AG

22

30

(2) INFORMATION FOR SEQ ID NO:33:

35

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

CATCCGGAAG CACTGGTACT GC

22

45

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single

50

55

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

GGAACAGGTT GCTAAAATCC AGG

23

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GAACAGGTTC GTGCGATCCA GGGTG

25

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

C<sup>-</sup>ATGTCTG GCACAGGTTC GT

22

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

TCCAGGGTGC CGGTGCTGC

19

45

50

55

## (2) INFORMATION FOR SEQ ID NO:38:

- 5           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 23 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

10           (ii) MOLECULE TYPE: DNA

10           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

AAGAGCTCGG TGAGGCACCA GCT

23

## 15           (2) INFORMATION FOR SEQ ID NO:39:

- 15           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 23 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

20           (ii) MOLECULE TYPE: DNA

20           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

25           CTCAAGGTGC TGAGCCGGCA TTC

23

## 25           (2) INFORMATION FOR SEQ ID NO:40:

- 30           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 20 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

35           (ii) MOLECULE TYPE: DNA

35           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GAGCTCGGTC TGGCACCAAGC

20

## 40           (2) INFORMATION FOR SEQ ID NO:41:

- 40           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 21 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

45           (ii) MOLECULE TYPE: DNA

50

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

TCAAGGTGCT CTGCCGGCAT T

21

5

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

.. TGCCGCAA GCCTTTCTGC TGA

23

20

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

CTTTCTGCTG GCATGTCTGG AACA

24

30

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

CTATTTGGCA AGCGATGGAA GAGC

24

45

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

50

55

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

CAGATGGAAG CGCTCGGTAT G

21

10 (2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15 . (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

20 GAGCTCGGTC TGGCACCAAGC

20

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: DNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

~~T~~AAGGTGCT CTGCCGGCAT T

21

35 (2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

40 . (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

45 GAAATGTCTG GCACAGGTTC GT

22

50

55

## (2) INFORMATION FOR SEQ ID NO:49:

- 5           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 19 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

10           (ii) MOLECULE TYPE: DNA

10           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

TTCCGGAGCG CACAGTTTG

19

## 15           (2) INFORMATION FOR SEQ ID NO:50:

- (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 23 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

20           (ii) MOLECULE TYPE: DNA

20           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

25           CGAGAAGGCC TCGGGTGTCA AAC

23

## 25           (2) INFORMATION FOR SEQ ID NO:51:

- 30           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 22 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

35           (ii) MOLECULE TYPE: DNA

35           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

ATGCCAAATT GCAGTAGCAA AG

22

## 40           (2) INFORMATION FOR SEQ ID NO:52:

- 45           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 24 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

45           (ii) MOLECULE TYPE: DNA

50

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

ACAAACGGTTT AACGTCATCG TTTC

24

5

(2) INFORMATION FOR SEQ ID NO:53:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

..(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

...TAGCTACT GCTAGCTGCA GA

22

15

(2) INFORMATION FOR SEQ ID NO:54:

20

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

TCAGTCGATG ACGATCGACG TCT

23

30

(2) INFORMATION FOR SEQ ID NO:55:

35

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

TTACGAACCG CTTCCAGACA TT

22

45

(2) INFORMATION FOR SEQ ID NO:56:

50

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 25 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single

55

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

TAAAAATGCTT GGCGAAGGTC TGTAA

25

10 (2) INFORMATION FOR SEQ ID NO:57:

### (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

20 GTAGCAAATG CAGCTACATC TA

22

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

TCATCGTT TACGTCGATG TAGAT

25

35 (2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

CCAAGAGAAG CACCCAGCAG

20

50

55

## (2) INFORMATION FOR SEQ ID NO:60:

- 5           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 22 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

10           (ii) MOLECULE TYPE: DNA

10           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

AGGGTTCTCT TCGTGGGTGTC TC

22

## 15           (2) INFORMATION FOR SEQ ID NO:61:

- 20           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 20 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

20           (ii) MOLECULE TYPE: DNA

25           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

CACTGGCGGT GATAATGAGC

20

## 25           (2) INFORMATION FOR SEQ ID NO:62:

- 30           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 19 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

35           (ii) MOLECULE TYPE: DNA

35           (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

CTAGGCCAGG CATTACTGG

19

## 40           (2) INFORMATION FOR SEQ ID NO:63:

- 45           (i) SEQUENCE CHARACTERISTICS:  
               (A) LENGTH: 21 base pairs  
               (B) TYPE: nucleic acid  
               (C) STRANDEDNESS: single  
               (D) TOPOLOGY: linear

45           (ii) MOLECULE TYPE: DNA

50

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

CCACTGGCGG TGATACTGAG C

21

5

(2) INFORMATION FOR SEQ ID NO:64:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 33 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

AGCAGAAAGC TTTCCGGCAG AGAAGAAGCA GGA

33

20

(2) INFORMATION FOR SEQ ID NO:65:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 54 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: DNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

GCCGCAAAGC TTTCTGCTGA AATGTCTGGA AGAGGTTCGT AAAATCCAGG GTGA

54

(2) INFORMATION FOR SEQ ID NO:66:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 59 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

CTGGAATGCA GAAGCAAATG CGGGCATAGC ACCTTCAGTC GGTTGCAGAG CTGGTGCCA

59

45

(2) INFORMATION FOR SEQ ID NO:67:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

50

55

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

5 Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
   1                       5                       10                       15

10 Arg Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
   20                      25                       30

15 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
   35                      40                       45

20 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
   50                      55                       60

25 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
   65                      70                       75                       80

30 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
   85                      90                       95

35 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
   100                    105                       110

40 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
   115                    120                       125

45 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
   130                    135                       140

50 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
   145                    150                       155                       160

55 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
   165                    170                       175

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
   1                       5                       10                       15

50 Lys Cys Leu Glu Gln Val Arg Arg Ile Gln Gly Asp Gly Ala Ala Leu  
   20                      25                       30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

5 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

10 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

15 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

20 Phe Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

25 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:69:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

40 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Arg Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

45 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

50 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

5 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

10 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

15

•(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

30 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Arg Leu Cys His Pro Glu Glu Leu  
 35 40 45

35 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

40 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

45 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

50 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

55

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
165 170 175

5

(2) INFORMATION FOR SEQ ID NO:71:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 175 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear  
iii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

15 Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
       1                   5                   10                   15  
 20 Ile Cys Leu Glu Gln Val Arg Arg Ile Gln Gly Asp Gly Ala Ala Leu  
       20                   25                   30  
 25 Gln Glu Arg Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
       35                   40                   45  
 30 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
       50                   55                   60  
 35 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
       65                   70                   75                   80  
 40 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
       85                   90                   95  
 45 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
       100                  105                  110  
 50 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
       115                  120                  125  
 55 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
       130                  135                  140  
 60 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
       145                  150                  155                  160  
 65 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
       165                  170                  175

45

(2) INFORMATION FOR SEQ ID NO:72:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 175 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

Arg Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Arg Leu Cys Ala Thr Tyr Arg Leu Cys His Pro Glu Glu Leu  
 35 40 45

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## 35 (2) INFORMATION FOR SEQ ID NO:73:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

Lys Cys Leu Glu Gln Val Arg Arg Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Arg Leu Cys Ala Thr Tyr Arg Leu Cys His Pro Glu Glu Leu  
 35 40 45

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60  
 5 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80  
 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95  
 10 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110  
 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125  
 15 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140  
 Leu Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160  
 20 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

25 (2) INFORMATION FOR SEQ ID NO:74:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 175 amino acids
  - (B) TYPE: amino acid
  - (C) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

35 Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15  
 Arg Cys Leu Glu Gln Val Arg Arg Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30  
 40 Gln Glu Arg Leu Cys Ala Thr Tyr Arg Leu Cys His Pro Glu Glu Leu  
 35 40 45  
 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60  
 45 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80  
 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95  
 50 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125  
 5 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140  
 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160  
 10 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:75:

- 15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15  
 25 Arg Cys Leu Glu Gln Val Arg Arg Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30  
 30 Gln Glu Lys Leu Cys Ala Thr Tyr Arg Leu Cys His Pro Glu Glu Leu  
 35 40 45  
 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60  
 35 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 50 70 75 80  
 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95  
 40 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110  
 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125  
 45 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140  
 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160  
 50 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:76:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Met	Thr	Pro	Leu	Gly	Pro	Ala	Ser	Ser	Leu	Pro	Gln	Ser	Phe	Leu	Leu
1															15
Lys	Cys	Leu	Glu	Gln	Val	Arg	Lys	Ile	Gln	Gly	Asp	Gly	Ala	Ala	Leu
															30
Gln	Glu	Lys	Leu	Cys	Ala	Thr	Tyr	Lys	Leu	Cys	His	Pro	Glu	Glu	Leu
															45
Val	Leu	Leu	Gly	His	Ser	Leu	Gly	Ile	Pro	Trp	Ala	Pro	Leu	Ser	Ser
															60
Cys	Pro	Ser	Glu	Ala	Leu	Gln	Leu	Ala	Gly	Cys	Leu	Ser	Gln	Leu	His
															80
Ser	Gly	Leu	Phe	Leu	Tyr	Gln	Gly	Leu	Leu	Gln	Ala	Leu	Glu	Gly	Ile
															95
Ser	Pro	Glu	Leu	Gly	Pro	Thr	Leu	Asp	Thr	Leu	Gln	Leu	Asp	Val	Ala
															110
Asp	Phe	Ala	Thr	Thr	Ile	Trp	Gln	Gln	Met	Glu	Glu	Leu	Gly	Met	Ala
															125
Pro	Ala	Leu	Gln	Pro	Thr	Gln	Gly	Ala	Met	Pro	Ala	Phe	Ala	Ser	Ala
															140
Leu	Gln	Arg	Arg	Ala	Gly	Gly	Val	Leu	Val	Ala	Ser	His	Leu	Gln	Ser
															160
Phe	Leu	Glu	Val	Ser	Tyr	Arg	Val	Leu	Arg	His	Leu	Ala	Gln	Pro	
165															
170															
175															

## (2) INFORMATION FOR SEQ ID NO:77:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

5 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Ser Ala Thr Tyr Lys Leu Ser His Pro Glu Glu Leu  
 35 40 45

10 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

15 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

20 . r Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

25 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

30 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:78:

- 35 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear
- 40 (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

45 Lys Cys Leu Glu Gln Val Arg Lys Ile Ala Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

50 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

5 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

10 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

15 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

20

## (2) INFORMATION FOR SEQ ID NO:79:

## (i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

35 Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

40 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

45 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

50 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

5 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Ala Pro  
 165 170 175

10

## (2) INFORMATION FOR SEQ ID NO:80:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

25 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

30 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

35 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

40 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

45 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

50 Phe Leu Glu Val Ser Tyr Arg Val Leu Ala His Leu Ala Gln Pro  
 165 170 175

55

## (2) INFORMATION FOR SEQ ID NO:81:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

Met	Thr	Pro	Leu	Gly	Pro	Ala	Ser	Ser	Leu	Pro	Gln	Ser	Phe	Leu	Leu
1															15
Lys	Cys	Leu	Glu	Gln	Val	Arg	Lys	Ile	Gln	Gly	Asp	Gly	Ala	Ala	Leu
															30
G' n	Glu	Lys	Leu	Cys	Ala	Thr	Tyr	Lys	Leu	Cys	His	Pro	Glu	Glu	Leu
															45
Val	Leu	Leu	Gly	His	Ser	Leu	Gly	Ile	Pro	Trp	Ala	Pro	Leu	Ser	Ser
															60
Cys	Pro	Ser	Gln	Ala	Leu	Gln	Leu	Ala	Gly	Cys	Leu	Ser	Gln	Leu	His
65															80
Ser	Gly	Leu	Phe	Leu	Tyr	Gln	Gly	Leu	Leu	Gln	Ala	Leu	Glu	Gly	Ile
															95
Ser	Pro	Glu	Leu	Gly	Pro	Thr	Leu	Asp	Thr	Leu	Gln	Leu	Asp	Val	Ala
30															110
Asp	Phe	Ala	Thr	Thr	Ile	Trp	Gln	Gln	Met	Glu	Glu	Leu	Gly	Met	Ala
115															125
Pro	Ala	Leu	Gln	Pro	Thr	Gln	Gly	Ala	Met	Pro	Ala	Phe	Ala	Ser	Ala
35															140
Phe	Gln	Arg	Arg	Ala	Gly	Gly	Val	Leu	Val	Ala	Ser	His	Leu	Gln	Ser
145															160
Phe	Leu	Glu	Val	Ser	Tyr	Ala	Val	Leu	Arg	His	Leu	Ala	Gln	Pro	
40															175
165															

## (2) INFORMATION FOR SEQ ID NO:82:

## 45 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 174 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## 50 (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

5 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

10 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

15 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

20 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

25 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

30 Phe Leu Glu Val Ser Tyr Val Leu Arg His Leu Ala Gln Pro  
 165 170 174

## (2) INFORMATION FOR SEQ ID NO:83:

35 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

45 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Ala Leu Cys His Pro Glu Glu Leu  
 35 40 45

50 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln L u Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

5 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

10 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

15 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

20

## (2) INFORMATION FOR SEQ ID NO:84:

## (i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

35 ' s Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys Lys Pro Glu Glu Leu  
 35 40 45

40 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

45 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

50 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

5 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

10

## (2) INFORMATION FOR SEQ ID NO:85:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

25 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Ala Leu  
 35 40 45

30 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

35 S-Tyr Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

40 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

45 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

50 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

55

## (2) INFORMATION FOR SEQ ID NO:86:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

Met	Thr	Pro	Leu	Gly	Pro	Ala	Ser	Ser	Leu	Pro	Gln	Ser	Phe	Leu	Leu
1				5					10				15		
Lys	Cys	Leu	Glu	Gln	Val	Ala	Lys	Ile	Gln	Gly	Asp	Gly	Ala	Ala	Leu
			20					25					30		
G'z	Glu	Lys	Leu	Cys	Ala	Thr	Tyr	Lys	Leu	Cys	His	Pro	Glu	Glu	Leu
			35				40				45				
Val	Leu	Leu	Gly	His	Ser	Leu	Gly	Ile	Pro	Trp	Ala	Pro	Leu	Ser	Ser
			50			55				60					
Cys	Pro	Ser	Gln	Ala	Leu	Gln	Leu	Ala	Gly	Cys	Leu	Ser	Gln	Leu	His
	65				70				75				80		
Ser	Gly	Leu	Phe	Leu	Tyr	Gln	Gly	Leu	Leu	Gln	Ala	Leu	Glu	Gly	Ile
			85				90					95			
Ser	Pro	Glu	Leu	Gly	Pro	Thr	Leu	Asp	Thr	Leu	Gln	Leu	Asp	Val	Ala
			100				105				110				
Asp	Phe	Ala	Thr	Thr	Ile	Trp	Gln	Gln	Met	Glu	Glu	Leu	Gly	Met	Ala
	115					120				125					
Pro	Ala	Leu	Gln	Pro	Thr	Gln	Gly	Ala	Met	Pro	Ala	Phe	Ala	Ser	Ala
	130				135				140						
Phe	Gln	Arg	Arg	Ala	Gly	Gly	Val	Leu	Val	Ala	Ser	His	Leu	Gln	Ser
	145				150				155				160		
Phe	Leu	Glu	Val	Ser	Tyr	Arg	Val	Leu	Arg	His	Leu	Ala	Gln	Pro	
			165				170				175				

## (2) INFORMATION FOR SEQ ID NO:87:

## 45 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## 50 (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

Lys Cys Leu Glu Gln Val Arg Ala Ile Gln Gly Asp Gly Ala Ala Leu  
 5 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 10 35 40 45

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 15 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 20 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 25 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 30 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 35 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 40 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 45 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 50 165 170 175

## (2) INFORMATION FOR SEQ ID NO:88:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

Lys Cys Leu Ala Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 25 35 40 45

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 30 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

5 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

10 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

15 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

20 Ile Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:89:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

35 Ile Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Ala Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

40 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

45 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

50 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

5 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

10

## (2) INFORMATION FOR SEQ ID NO:90:

## (i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

25 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

30 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

35 S-- Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

40 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Glu Ala  
 115 120 125

45 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

50 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

55

(2) INFORMATION FOR SEQ ID NO:91:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
1 5 10 15

Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
           20                   25                   30

G' n Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

20 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
65 70 75 80

25 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala

**30**                   **100**     -                   **105**     -                   **110**

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
115 120 125

35 Pro Ala Leu Gin Pro Thr Gin Gly Ala Glu Pro Ala Phe Ala Ser Ala  
130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
145 150 155 160

(2) INFORMATION FOR SEQ ID NO:92:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

5 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

10 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

15 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

20 S : Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Leu Ala  
 115 120 125

25 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

30 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:93:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

45 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

50 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

5 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

10 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Leu Pro Ala Phe Ala Ser Ala  
 130 135 140

15 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

20 . Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:94:

25 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

35 . Ala Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

40 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

45 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

50 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

5 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

10 (2) INFORMATION FOR SEQ ID NO:95:

15 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: protein

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Glu Ser Phe Leu Leu  
 1 5 10 15

25 Lys Cys Leu Glu Glu Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

30 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

35 F r Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

40 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

45 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

50 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:96:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

Met	Thr	Pro	Leu	Gly	Pro	Ala	Ser	Ser	Leu	Pro	Glu	Ser	Phe	Leu	Leu
1				5					10				15		
Lys	Cys	Leu	Glu	Glu	Val	Arg	Lys	Ile	Gln	Gly	Asp	Gly	Ala	Ala	Leu
		20					25						30		
Cys	Glu	Lys	Leu	Cys	Ala	Thr	Tyr	Lys	Leu	Cys	His	Pro	Glu	Glu	Leu
	35					40				45					
Val	Leu	Leu	Gly	His	Ser	Leu	Gly	Ile	Pro	Trp	Ala	Pro	Leu	Ser	Ser
	50				55				60						
Cys	Pro	Ser	Glu	Ala	Leu	Gln	Leu	Ala	Gly	Cys	Leu	Ser	Gln	Leu	His
	65				70				75				80		
Ser	Gly	Leu	Phe	Leu	Tyr	Gln	Gly	Leu	Leu	Gln	Ala	Leu	Glu	Gly	Ile
		85				90				95					
Ser	Pro	Glu	Leu	Gly	Pro	Thr	Leu	Asp	Thr	Leu	Gln	Leu	Asp	Val	Ala
		100				105				110					
Asp	Phe	Ala	Thr	Thr	Ile	Trp	Gln	Gln	Met	Glu	Glu	Leu	Gly	Met	Ala
	115					120				125					
Pro	Ala	Leu	Gln	Pro	Thr	Gln	Gly	Ala	Met	Pro	Ala	Phe	Ala	Ser	Ala
		130			135				140						
Phe	Gln	Arg	Arg	Ala	Gly	Gly	Val	Leu	Val	Ala	Ser	His	Leu	Gln	Ser
	145				150				155				160		
Phe	Leu	Glu	Val	Ser	Tyr	Arg	Val	Leu	Arg	His	Leu	Ala	Gln	Pro	
		165				170				175					

## (2) INFORMATION FOR SEQ ID NO:97:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Gly Phe Leu Leu  
 1 5 10 15

5 Lys Cys Leu Ala Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

10 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

15 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

20 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

25 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

30 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

35 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

40 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

45 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:98:

- 35 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 175 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

- 40 (ii) MOLECULE TYPE: protein

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 45 1 5 10 15

Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

50 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60  
 5 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80  
 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95  
 10 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110  
 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Leu Ala  
 115 120 125  
 15 Pro Ala Leu Gln Pro Thr Gln Gly Ala Leu Pro Ala Phe Ala Ser Ala  
 130 135 140  
 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160  
 20 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175  
 25 (2) INFORMATION FOR SEQ ID NO:99:  
 30 (i) SEQUENCE CHARACTERISTICS:  
     (A) LENGTH: 175 amino acids  
     (B) TYPE: amino acid  
     (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: protein  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:  
 35 ' t Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ala Phe Leu Leu  
     1               5               10               15  
 40 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
     20               25               30  
 45 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
     35               40               45  
 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60  
 45 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
     65               70               75               80  
 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 55 85 90 95  
 50 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
     100               105               110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

5 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

10 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:100:

## 15 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## 20 (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 25 1 5 10 15

Ala Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

30 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

35 ~ s Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 55 70 75 80

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

40 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

45 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

50 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:101:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

Met	Thr	Pro	Leu	Gly	Pro	Ala	Ser	Ser	Leu	Pro	Gln	Ser	Phe	Leu	Leu
1					5					10					15
Lys	Cys	Leu	Glu	Gln	Val	Arg	Lys	Ile	Gln	Gly	Asp	Gly	Ala	Ala	Leu
					20			25						30	
Cys	Glu	Lys	Leu	Cys	Ala	Thr	Tyr	Lys	Leu	Cys	His	Pro	Glu	Glu	Leu
					35			40						45	
Val	Leu	Leu	Gly	His	Ser	Leu	Gly	Ile	Pro	Trp	Ala	Pro	Leu	Ser	Ser
					50			55			60				
Cys	Pro	Ser	Gln	Ala	Leu	Gln	Leu	Ala	Gly	Cys	Leu	Ser	Gln	Leu	His
					65		70			75				80	
Ser	Gly	Leu	Phe	Leu	Tyr	Gln	Gly	Leu	Leu	Gln	Ala	Leu	Glu	Gly	Ile
					85			90						95	
Ser	Pro	Glu	Leu	Gly	Pro	Thr	Leu	Asp	Thr	Leu	Gln	Leu	Asp	Val	Ala
					100			105						110	
Asp	Phe	Ala	Thr	Thr	Ile	Trp	Gln	Ala	Met	Glu	Glu	Leu	Gly	Met	Ala
					115			120						125	
Pro	Ala	Leu	Gln	Pro	Thr	Gln	Gly	Ala	Met	Pro	Ala	Phe	Ala	Ser	Ala
					130		135				140				
Phe	Gln	Arg	Arg	Ala	Gly	Gly	Val	Leu	Val	Ala	Ser	His	Leu	Gln	Ser
					145		150			155				160	
Phe	Leu	Glu	Val	Ser	Tyr	Arg	Val	Leu	Arg	His	Leu	Ala	Gln	Pro	
					165			170						175	

## (2) INFORMATION FOR SEQ ID NO:102:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

5 Lys Cys Leu Glu Ala Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

10 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

15 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

20 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

25 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

30 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:103:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

45 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys Ala Pro Glu Glu Leu  
 35 40 45

50 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

5 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

10 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

15 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

20 ... Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:104:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

35 ... Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

40 Val Leu Leu Gly Ala Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

45 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

50 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

5 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

10

## (2) INFORMATION FOR SEQ ID NO:105:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

25 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

30 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

35 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

40 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Ala Val Ala  
 100 105 110

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

45 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

50 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:106:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

Met	Thr	Pro	Leu	Gly	Pro	Ala	Ser	Ser	Leu	Pro	Gln	Ser	Phe	Leu	Leu
1				5					10				15		
Lys	Cys	Leu	Glu	Gln	Val	Arg	Lys	Ile	Gln	Gly	Asp	Gly	Ala	Ala	Leu
			20				25						30		
Cys	Glu	Lys	Leu	Cys	Ala	Thr	Tyr	Lys	Leu	Cys	His	Pro	Glu	Glu	Leu
	35					40					45				
Val	Leu	Leu	Gly	His	Ser	Leu	Gly	Ile	Pro	Trp	Ala	Pro	Leu	Ser	Ser
	50				55					60					
Cys	Pro	Ser	Gln	Ala	Leu	Gln	Leu	Ala	Gly	Cys	Leu	Ser	Gln	Leu	His
	65				70					75			80		
Ser	Gly	Leu	Phe	Leu	Tyr	Gln	Gly	Leu	Leu	Gln	Ala	Leu	Glu	Gly	Ile
		85						90					95		
Ser	Pro	Glu	Leu	Gly	Pro	Thr	Leu	Asp	Thr	Leu	Gln	Leu	Asp	Val	Ala
		100				105					110				
Ala	Phe	Ala	Thr	Thr	Ile	Trp	Gln	Gln	Met	Glu	Glu	Leu	Gly	Met	Ala
		115				120					125				
Pro	Ala	Leu	Gln	Pro	Thr	Gln	Gly	Ala	Met	Pro	Ala	Phe	Ala	Ser	Ala
		130			135					140					
Phe	Gln	Arg	Arg	Ala	Gly	Gly	Val	Leu	Val	Ala	Ser	His	Leu	Gln	Ser
	145				150					155			160		
Phe	Leu	Glu	Val	Ser	Tyr	Arg	Val	Leu	Arg	His	Leu	Ala	Gln	Pro	
		165				170					175				

## (2) INFORMATION FOR SEQ ID NO:107:

## 45 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## 50 (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

5 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

10 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 65 70 75 80

15 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

20 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

25 Asp Phe Ala Thr Ala Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

30 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:108:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

45 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Ala Gly Ala Ala Leu  
 20 25 30

Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

50 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 55 60

Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His				
65	70	75	80	
Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile				
5	85	90	95	
Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Ala Val Ala				
10	100	105	110	
Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala				
10	115	120	125	
Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala				
15	130	135	140	
Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser				
15	150	155	160	
Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro				
20	165	170	175	

## (2) INFORMATION FOR SEQ ID NO:109:

25	(i) SEQUENCE CHARACTERISTICS:			
	(A) LENGTH: 175 amino acids			
	(B) TYPE: amino acid			
	(D) TOPOLOGY: linear			
30	(ii) MOLECULE TYPE: protein			
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:			
35	Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu			
	1	5	10	15
-s	Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu			
	20	25	30	
40	Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu			
	35	40	45	
	Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser			
	50	55	60	
45	Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His			
	65	70	75	80
	Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile			
	85	90	95	
50	Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala			
	100	105	110	

Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Ala Leu Gly Met Ala  
 115 120 125

5 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

10 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO:110:

15 (i) SEQUENCE CHARACTERISTICS:  
 . (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

Met Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu  
 1 5 10 15

25 Lys Cys Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu  
 20 25 30

30 Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu  
 35 40 45

Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser  
 50 55 60

35 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His  
 55 70 75 80

Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 85 90 95

40 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala  
 100 105 110

Asp Val Ala Thr Ala Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala  
 115 120 125

45 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala  
 130 135 140

Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser  
 145 150 155 160

50 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro  
 165 170 175

**Claims**

1. A method for preparing a G-CSF analog comprising the steps of:
  - 5 (a) viewing at the amino acid or atomic level information conveying the three dimensional structure of a G-CSF molecule as set forth in Figure 5;
  - (b) selecting from said viewed information at least one site on said G-CSF molecule for alteration;
  - (c) preparing a G-CSF molecule having such alteration; and
  - (d) optionally, testing such G-CSF molecule for a desired characteristic.
- 10 2. A method for preparing a G-CSF analog according to claim 1 based on the use of a computer comprising the steps of:
  - 15 (a) providing computer expression at the amino acid or atomic level of the three dimensional structure of a G-CSF molecule as set forth in Figure 5;
  - (b) selecting from said computer expression at least one site on said G-CSF molecule for alteration;
  - (c) preparing a G-CSF molecule having such alteration; and,
  - (d) optionally, testing such G-CSF molecule for a desired characteristic.
- 20 3. A method for preparing a G-CSF analog according to claim 2 comprising:
  - 25 (a) providing said computer with the means for displaying the three dimensional structure of a G-CSF molecule as set forth in Figure 5; including displaying the composition of moieties of said G-CSF molecule, preferably displaying the three dimensional location of each amino acid, and more preferably displaying the three dimensional location of each atom of a G-CSF molecule;
  - (b) viewing said display;
  - (c) selecting a site on said display for alteration in the composition of said molecule or the location of a moiety; and
  - (d) preparing a G-CSF analog with such alteration.
- 30 4. A computer-based method for preparing a G-CSF analog comprising the steps of:
  - 35 (a) viewing at the amino acid or atomic level the three dimensional structure of a G-CSF molecule as set forth in Figure 5; via a computer, said computer having been previously programmed (i) to express the coordinates of a G-CSF molecule in three dimensional space, and (ii) to allow for entry of information for alteration of said G-CSF expression and viewing thereof;
  - (b) selecting a site on said visual image of said G-CSF molecule for alteration;
  - (c) entering information for said alteration on said computer;
  - (d) viewing a three dimensional structure of said altered G-CSF molecule via said computer;
  - 40 (e) optionally repeating steps (a)-(e) above;
  - (f) preparing a G-CSF analog with said alteration; and
  - (g) optionally testing said G-CSF analog for a desired characteristic.

**Patentansprüche**

- 45 1. Verfahren zur Herstellung eines G-CSF-Analogs, welches die Schritte umfaßt:
  - (a) Betrachten, auf dem Aminosäure- oder Atomniveau, von Information, welche die dreidimensionale Struktur eines G-CSF-Moleküls, wie angegeben in Fig. 5, vermittelt;
  - 50 (b) Auswählen, aus besagter betrachteten Information, von wenigstens einer Stelle auf besagtem G-CSF-Molekül für eine Veränderung;
  - (c) Herstellen eines G-CSF-Moleküls mit einer solchen Veränderung; und
  - 55 (d) fakultativ, Testen eines solchen G-CSF-Moleküls auf eine gewünschte Eigenschaft.
2. Verfahren zur Herstellung eines G-CSF-Analogs nach Anspruch 1, auf der Basis der Verwendung eines Compu-

ters, welches die Schritte umfaßt:

- (a) Bereitstellen einer Computerdarstellung, auf dem Aminosäure- oder Atomniveau, der dreidimensionalen Struktur eines G-CSF-Moleküls, wie angegeben in Fig. 5;
- 5 (b) Auswählen, aus besagter Computerdarstellung, von wenigstens einer Stelle auf besagtem G-CSF-Molekül für eine Veränderung;
- 10 (c) Herstellen eines G-CSF-Moleküls mit einer solchen Veränderung; und
- 15 (d) fakultativ, Testen eines solchen G-CSF-Moleküls auf eine gewünschte Eigenschaft.

3. Verfahren zur Herstellung eines G-CSF-Analogs nach Anspruch 2, welches umfaßt:

- 15 (a) Versetzen besagten Computers mit Mitteln zum Anzeigen der dreidimensionalen Struktur eines G-CSF-Moleküls, wie angegeben in Fig. 5, einschließlich Anzeigen der Zusammensetzung der Einheiten besagten G-CSF-Moleküls, vorzugsweise Anzeigen der dreidimensionalen Anordnung jeder Aminosäure und bevorzugter Anzeigen der dreidimensionalen Anordnung jedes Atoms eines G-CSF-Moleküls;
- 20 (b) Betrachten besagter Ansicht;
- (c) Auswählen einer Stelle auf besagter Ansicht für eine Veränderung in der Zusammensetzung besagten Moleküls oder der Anordnung einer Einheit; und
- 25 (d) Herstellen eines G-CSF-Analogs mit solch einer Änderung.

4. Computergestütztes Verfahren zur Herstellung eines G-CSF-Analogs, welches die Schritte umfaßt:

- 30 (a) Betrachten, auf dem Aminosäure- oder Atomniveau, der dreidimensionalen Struktur eines G-CSF-Moleküls, wie angegeben in Fig. 5, über einen Computer, wobei besagter Computer zuvor so programmiert worden ist, daß er (i) die Koordinaten eines G-CSF-Moleküls im dreidimensionalen Raum darstellt und (ii) die Eingabe von Information zur Veränderung besagter G-CSF-Darstellung und Betrachtung derselben ermöglicht;
- 35 (b) Auswählen einer Stelle auf besagtem visuellen Bild besagten G-CSF-Moleküls für eine Veränderung;
- (c) Eingeben der Information für besagte Veränderung in besagten Computer;
- (d) Betrachten einer dreidimensionalen Struktur besagten veränderten G-CSF-Moleküls über besagten Computer;
- 40 (e) fakultativ, Wiederholen der Schritte (a) - (e) oben;
- (f) Herstellen eines G-CSF-Analogs mit besagter Veränderung; und
- 45 (g) fakultativ, Testen besagten G-CSF-Analogs auf eine gewünschte Eigenschaft.

### Revendications

1. Procédé pour préparer un analogue de G-CSF, comprenant les étapes de :

- 50 (a) visualiser au niveau atomique ou des acides aminés des informations fournissant la structure tridimensionnelle d'une molécule de G-CSF comme indiqué sur la figure 5,
- (b) choisir à partir desdites informations visualisées au moins un site sur ladite molécule de G-CSF pour altération ;
- 55 (c) préparer une molécule de G-CSF ayant une telle altération ; et
- (d) éventuellement, tester une telle molécule de G-CSF en ce qui concerne une caractéristique souhaitée.

2. Procédé pour préparer un analogue de G-CSF selon la revendication 1, basé sur l'utilisation d'un ordinateur, com-

5 prenant les étapes de :

- 5 (a) fournir l'expression par ordinateur au niveau atomique ou des acides aminés de la structure tridimensionnelle d'une molécule de G-CSF comme indiqué sur la figure 5,
- (b) choisir à partir de ladite expression par ordinateur au moins un site sur ladite molécule de G-CSF pour altération ;
- (c) préparer une molécule de G-CSF ayant une telle altération ; et
- (d) éventuellement, tester une telle molécule de G-CSF en ce qui concerne une caractéristique souhaitée.

10 3. Procédé pour préparer un analogue de G-CSF selon la revendication 2, comprenant :

- 15 (a) munir ledit ordinateur des moyens pour afficher la structure tridimensionnelle d'une molécule de G-CSF comme indiqué sur la figure 5 incluant l'affichage de la composition des fractions de ladite molécule de G-CSF, en affichant de préférence l'emplacement tridimensionnel de chaque acide aminé, et, plus préféablement, en affichant l'emplacement tridimensionnel de chaque atome d'une molécule de G-CSF ;
- (b) visualiser ledit affichage ;
- (c) choisir un site sur ledit affichage pour altération de la composition de ladite molécule ou de l'emplacement d'une fraction ; et
- (d) préparer un analogue de G-CSF ayant une telle altération.

20 4. Procédé assisté par ordinateur pour préparer un analogue de G-CSF, comprenant les étapes de :

- 25 (a) visualiser au niveau atomique ou des acides aminés la structure tridimensionnelle d'une molécule de G-CSF comme indiqué sur la figure 5 via un ordinateur, ledit ordinateur ayant été préalablement programmé (i) pour exprimer les coordonnées d'une molécule de G-CSF dans l'espace tridimensionnel, et (ii) pour permettre l'entrée des informations pour l'altération de ladite expression de G-CSF et sa visualisation ;
- (b) choisir un site sur ladite image visuelle de ladite molécule de G-CSF pour altération ;
- (c) entrer des informations pour ladite altération dans ledit ordinateur ;
- (d) visualiser une structure tridimensionnelle de ladite molécule de G-CSF altérée via ledit ordinateur ;
- (e) répéter éventuellement les étapes (a) - (e) ci-dessus ;
- (f) préparer un analogue de G-CSF ayant ladite altération ; et
- (g) tester éventuellement ledit analogue de G-CSF en ce qui concerne une caractéristique souhaitée.

35

40

45

50

55

Met Thr Pro Leu Gly Pro Ala  
 TCTAGAAACCAAGGAGGTATAATAAAT ATG ACT CCA TTA GGT CCT CCT  
  
 Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu Glu Gln  
 TCT TCT CTG CCG CAA ACC TTT CTG CTG AAA TGT CTG GAA CAG  
  
 Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu  
 GTT CGT AAA ATC CAG GGT GAC GGT GCT GCA CTG CAA GAA AAA CTG  
  
 Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu  
 TGC GCT ACT TAC AAA CTG TGC CAT CCG GAA GAG CTG GTA CTG CTG  
  
 Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro  
 GGT CAT TCT CTT GGG ATC CCG TGG GCT CCG CTG TCT TGT CCA  
  
 Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His Ser  
 TCT CAA GCT CTT CAG CTG GCT GGT TGT CTG TCT CAA CTG CAT TCT  
  
 Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile  
 GGT CTG TTC CTG TAT CAG GGT CTT CTG CAA GCT CTG GAA GGT ATC  
  
 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val  
 TCT CCG GAA CTG GGT CCG ACT CTG GAC ACT CTG CAG CTA GAT GTA  
  
 Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly  
 GCT GAC TTT GCT ACT ACT ATT TGG CAA CAG ATG GAA GAG CTC GGT  
  
 Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe  
 ATG GCA CCA GCT CTG CAA CCG ACT CAA GGT GCT ATG CCG GCA TTC  
  
 Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser  
 GCT TCT GCA TTC CAG CGT GCA GGA GGT GTA CTG GTT GCT TCT  
  
 His Leu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His  
 CAT CTG CAA TCT TTC CTG GAA GTA TCT TAC CGT GTT CTG CGT CAT  
  
 Leu Ala Gln Pro OC AM  
 CTG GCT CAG CCG TAA TAG AATTC

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4

EP 0 612 846 B1

卷之五

FIGURE 5

ATOM	101	CB	GLU	20	52.053	55.334	-1.167	1.00	35.25	A1
ATOM	102	CG	GLU	20	52.508	55.504	-0.260	1.00	43.21	A1
ATOM	103	CD	GLU	20	53.948	54.947	-0.407	1.00	51.06	A1
ATOM	104	OE1	GLU	20	54.320	54.660	-1.546	1.00	56.78	A1
ATOM	105	OE2	GLU	20	54.708	54.766	-0.570	1.00	51.57	A1
ATOM	106	C	GLU	20	50.230	57.117	-1.326	1.00	33.25	A1
ATOM	107	O	GLU	20	49.432	57.291	-0.380	1.00	33.30	A1
ATOM	108	N	GLN	21	50.660	58.167	-0.044	1.00	32.33	A1
ATOM	109	H	GLN	21	51.270	58.004	-2.794	1.00	0.00	A1
ATOM	110	CA	GLN	21	50.275	59.538	-1.742	1.00	31.00	A1
ATOM	111	CB	GLN	21	51.326	60.489	-2.340	1.00	32.37	A1
ATOM	112	CG	GLN	21	52.436	60.530	-1.272	1.00	38.01	A1
ATOM	113	CD	GLN	21	53.622	61.460	-1.504	1.00	42.67	A1
ATOM	114	OE1	GLN	21	54.008	62.236	-0.615	1.00	43.63	A1
ATOM	115	NE2	GLN	21	54.256	61.448	-2.567	1.00	42.31	A1
ATOM	116	HE1	GLN	21	53.965	60.840	-3.384	1.00	0.00	A1
ATOM	117	HE2	GLN	21	55.026	62.052	-2.730	1.00	0.00	A1
ATOM	118	C	GLN	21	48.094	59.765	-2.286	1.00	28.51	A1
ATOM	119	O	GLN	21	48.027	60.242	-1.563	1.00	28.65	A1
ATOM	120	N	VAL	22	48.682	59.319	-3.521	1.00	25.85	A1
ATOM	121	H	VAL	22	49.448	58.980	-4.013	1.00	0.00	A1
ATOM	122	CA	VAL	22	47.382	59.303	-4.161	1.00	24.94	A1
ATOM	123	CB	VAL	22	47.508	58.614	-5.526	1.00	24.09	A1
ATOM	124	CG1	VAL	22	46.154	58.378	-6.096	1.00	19.97	A1
ATOM	125	CG2	VAL	22	48.752	59.479	-6.498	1.00	25.82	A1
ATOM	126	C	VAL	22	46.410	58.549	-3.216	1.00	25.65	A1
ATOM	127	O	VAL	22	45.428	59.190	-2.860	1.00	29.31	A1
ATOM	128	N	ARG	23	46.643	57.291	-2.759	1.00	23.93	A1
ATOM	129	H	ARG	23	47.440	56.819	-3.056	1.00	0.00	A1
ATOM	130	CA	ARG	23	45.667	56.593	-1.892	1.00	20.67	A1
ATOM	131	CB	ARG	23	46.104	55.135	-1.635	1.00	20.45	A1
ATOM	132	CG	ARG	23	46.375	54.321	-2.904	1.00	17.51	A1
ATOM	133	CD	ARG	23	45.095	54.446	-3.769	1.00	21.54	A1
ATOM	134	NE	ARG	23	45.076	53.437	-4.809	1.00	24.82	A1
ATOM	135	HE	ARG	23	45.642	52.647	-4.701	1.00	0.00	A1
ATOM	136	CZ	ARG	23	44.323	53.556	-5.904	1.00	27.69	A1
ATOM	137	NH1	ARG	23	43.567	54.669	-6.006	1.00	29.51	A1
ATOM	138	NH11	ARG	23	43.562	55.377	-5.303	1.00	0.00	A1
ATOM	139	NH12	ARG	23	42.956	54.730	-6.789	1.00	20.04	A1
ATOM	140	NH2	ARG	23	44.345	52.604	-6.891	1.00	24.22	A1
ATOM	141	NH1121	ARG	23	43.780	52.713	-7.709	1.00	0.00	A1
ATOM	142	NH22	ARG	23	44.936	51.802	-6.793	1.00	0.00	A1
ATOM	143	C	ARG	23	45.458	57.285	-5.560	1.00	20.56	A1
ATOM	144	O	ARG	23	44.374	57.254	-0.042	1.00	20.04	A1
ATOM	145	N	LYS	24	46.485	58.015	-0.118	1.00	22.67	A1
ATOM	146	H	LYS	24	47.291	58.105	-0.668	1.00	0.00	A1
ATOM	147	CA	LYS	24	46.431	58.729	-1.166	1.00	22.85	A1
ATOM	148	CB	LYS	24	47.811	59.255	-1.506	1.00	26.86	A1
ATOM	149	CG	LYS	24	47.821	59.661	-2.971	1.00	33.79	A1
ATOM	150	CD	LYS	24	49.121	60.265	-3.404	1.00	40.73	A1
ATOM	151	CE	LYS	24	50.258	59.258	-3.335	1.00	46.19	A1
ATOM	152	NZ	LYS	24	51.532	59.975	-3.333	1.00	51.19	A1
ATOM	153	H21	LYS	24	51.627	60.498	-4.225	1.00	0.00	A1
ATOM	154	I22	LYS	24	51.539	60.651	-2.539	1.00	0.00	A1
ATOM	155	H23	LYS	24	52.317	59.303	-3.216	1.00	0.00	A1
ATOM	156	C	LYS	24	45.455	59.893	-1.101	1.00	21.66	A1
ATOM	157	O	LYS	24	44.507	63.834	-1.439	1.00	20.44	A1
ATOM	158	N	ILE	25	44.588	60.668	-1.962	1.00	20.90	A1
ATOM	159	H	ILE	25	45.549	60.696	-0.944	1.00	21.06	A1
ATOM	160	I1E	ILE	25	46.242	60.509	-0.629	1.00	0.00	A1
ATOM	160	CA	ILE	25	44.667	61.841	-0.115	1.00	22.54	A1
ATOM	161	CB	ILE	25	45.075	62.694	-1.367	1.00	22.45	A1
ATOM	162	CG2	ILE	25	44.097	63.826	-1.244	1.00	22.79	A1
ATOM	163	CG1	ILE	25	46.475	62.230	-1.136	1.00	21.63	A1
ATOM	164	CD	ILE	25	41.737	59.713	-1.437	1.00	20.12	A1
ATOM	165	C	ILE	25	41.739	58.539	-2.341	1.00	R.P.	A1
ATOM	166	O	ILE	25	41.339	61.839	-0.301	1.00	16.13	A1
ATOM	167	N	GLN	26	43.065	60.289	-1.244	1.00	22.79	A1
ATOM	168	H	GLN	26	43.842	59.936	-1.726	1.00	0.00	A1
ATOM	169	CA	GLN	26	41.732	58.351	-5.890	1.00	27.64	A1
ATOM	170	CB	GLN	26	41.721	51.819	-6.042	1.00	0.00	A1
ATOM	171	CG	GLN	26	41.743	57.649	-6.552	1.00	0.00	A1
ATOM	172	CD	GLN	26	42.163	57.996	-4.4684	1.00	24.26	A1
ATOM	173	OHE	GLN	26	40.067	59.853	-4.465	1.00	24.82	A1
ATOM	174	NIE2	GLN	26	41.952	58.622	-0.773	1.00	22.54	A1
ATOM	175	II821	GLN	26	42.891	58.420	0.576	1.00	0.00	A1
ATOM	176	II822	GLN	26	41.743	57.191	-0.367	1.00	25.55	A1
ATOM	177	C	GLN	26	40.936	59.352	-2.890	1.00	27.80	A1
ATOM	178	O	GLN	27	39.889	59.251	-3.526	1.00	29.95	A1
ATOM	179	N	GLY	27	41.683	60.460	-2.915	1.00	29.35	A1
ATOM	180	H	GLY	27	42.547	60.454	-2.448	1.00	0.00	A1
ATOM	181	CA	GLY	27	41.257	61.680	-3.624	1.00	R.P.	A1
ATOM	182	O	GLY	27	40.936	59.352	-2.890	1.00	30.13	A1
ATOM	183	O	GLY	28	43.737	62.502	-3.777	1.00	41.72	A1
ATOM	184	OD1	ASP	28	44.539	63.074	-2.995	1.00	41.95	A1
ATOM	185	OD2	ASP	28	44.063	61.811	-4.241	1.00	32.60	A1
ATOM	186	C	ASP	28	39.994	62.264	-2.960	1.00	25.81	A1
ATOM	187	CB	ASP	28	42.266	62.789	-3.552	1.00	26.21	A1
ATOM	188	CG	ASP	28	39.882	62.270	-1.631	1.00	21.93	A1
ATOM	189	GLY	29	40.660	61.950	1.135	1.00	0.00	A1	
ATOM	190	CA	GLY	29	38.729	62.694	-0.886	1.00	25.69	A1
ATOM	191	C	GLY	29	37.524	61.961	-1.418	1.00	27.36	A1
ATOM	192	O	GLY	29	36.648	62.558	-2.061	1.00	28.14	A1
ATOM	193	N	ALA	30	37.646	60.628	-1.295	1.00	27.85	A1
ATOM	194	H	ALA	30	38.442	60.288	-0.844	1.00	0.00	A1
ATOM	195	CA	ALA	30	36.633	59.655	-1.814	1.00	25.74	A1
ATOM	196	C	ALA	30	37.261	58.303	-0.556	1.00	22.15	A1
ATOM	197	O	ALA	30	36.356	59.842	3.308	1.00	27.18	A1

FIGURE 5

ATOM	203	O	AIA	30	35.194	59.772	3.754	1.00	28.842	A1
ATOM	204	N	AIA	31	37.340	60.105	4.150	1.00	27.16	A1
ATOM	205	H	AIA	31	38.253	60.114	3.809	1.00	0.00	A1
ATOM	206	CA	AIA	31	37.113	60.470	5.531	1.00	27.70	A1
ATOM	207	CB	AIA	31	38.383	60.881	6.177	1.00	27.65	A1
ATOM	208	CB	AIA	31	36.178	61.675	5.660	1.00	30.01	A1
ATOM	209	O	AIA	31	35.195	61.624	6.413	1.00	32.91	A1
ATOM	210	N	LEU	32	36.397	62.744	4.895	1.00	27.63	A1
ATOM	211	H	LEU	32	37.133	62.734	4.242	1.00	0.00	A1
ATOM	212	CA	LEU	32	35.560	63.898	4.997	1.00	28.52	A1
ATOM	213	CB	LEU	32	36.226	65.019	4.167	1.00	32.94	A1
ATOM	214	CG	LEU	32	35.658	66.472	4.091	1.00	32.54	A1
ATOM	215	CD1	LEU	32	35.516	67.082	5.499	1.00	32.87	A1
ATOM	216	CD2	LEU	32	36.555	67.667	3.181	1.00	30.97	A1
ATOM	217	C	LEU	32	34.133	63.597	4.516	1.00	27.87	A1
ATOM	218	O	LEU	32	33.169	63.869	5.250	1.00	25.93	A1
ATOM	219	N	GLN	33	33.977	63.028	3.315	1.00	27.51	A1
ATOM	220	H	GUN	33	34.787	62.826	2.802	1.00	0.00	A1
ATOM	221	CA	GUN	33	32.687	62.671	2.775	1.00	30.40	A1
ATOM	222	CB	GUN	33	32.237	61.721	1.614	1.00	29.47	A1
ATOM	223	CG	GUN	33	32.888	62.584	4.436	1.00	29.26	A1
ATOM	224	CD	GUN	33	33.015	61.869	-0.887	1.00	30.21	A1
ATOM	225	OE1	GUN	33	34.064	61.495	-1.452	1.00	29.61	A1
ATOM	226	NE2	GUN	33	31.823	61.759	-1.426	1.00	31.19	A1
ATOM	227	HE21	GUN	34	31.781	61.328	-2.302	1.00	0.00	A1
ATOM	228	HE22	GUN	34	31.047	62.060	-0.914	1.00	0.00	A1
ATOM	229	C	GIN	33	30.839	61.963	3.788	1.00	35.60	A1
ATOM	230	O	GIN	33	30.715	62.416	4.071	1.00	36.49	A1
ATOM	231	N	GIN	34	32.386	60.925	4.430	1.00	39.81	A1
ATOM	232	H	GLU	34	33.340	60.707	4.378	1.00	0.00	A1
ATOM	233	CA	GLU	34	34.541	60.131	5.304	1.00	43.24	A1
ATOM	234	CB	GLU	34	32.228	58.792	5.571	1.00	46.46	A1
ATOM	235	CG	GLU	34	33.274	58.721	6.624	1.00	55.01	A1
ATOM	236	CD	GLU	34	32.777	58.092	7.930	1.00	60.29	A1
ATOM	237	OE1	GLU	34	37.183	57.186	8.412	1.00	63.26	A1
ATOM	238	OE2	GLU	34	31.774	58.594	8.459	1.00	60.44	A1
ATOM	239	C	GLU	34	31.218	60.877	6.564	1.00	43.59	A1
ATOM	240	O	GLU	34	30.175	60.631	7.161	1.00	44.87	A1
ATOM	241	N	LYS	35	32.045	61.811	6.998	1.00	44.80	A1
ATOM	242	H	LYS	35	32.923	61.931	6.569	1.00	0.00	A1
ATOM	243	CA	LYS	35	31.674	62.634	8.134	1.00	45.43	A1
ATOM	244	CB	LYS	35	32.861	63.364	8.686	1.00	47.67	A1
ATOM	245	CG	LYS	35	33.701	62.414	9.510	1.00	52.75	A1
ATOM	246	CD	LYS	35	35.084	63.021	9.548	1.00	57.55	A1
ATOM	247	CE	LYS	35	36.067	62.099	10.238	1.00	60.35	A1
ATOM	248	NZ	LYS	35	35.810	62.064	11.669	1.00	62.91	A1
ATOM	249	HH1	LYS	35	34.838	61.733	11.840	1.00	0.00	A1
ATOM	250	HH2	LYS	35	35.930	63.011	12.078	1.00	0.00	A1
ATOM	251	H23	LYS	35	36.477	61.405	12.119	1.00	0.00	A1
ATOM	252	C	LYS	35	30.630	63.660	7.697	1.00	44.45	A1
ATOM	253	O	LYS	35	29.730	63.999	8.478	1.00	44.61	A1
ATOM	254	N	LRY	36	30.652	64.190	6.480	1.00	41.21	A1
ATOM	255	H	LRY	36	31.343	64.157	5.636	1.00	0.00	A1
ATOM	256	CA	LRY	36	29.647	65.157	6.441	1.00	40.25	A1
ATOM	257	CH	LRY	36	30.070	65.899	4.889	1.00	39.04	A1
ATOM	258	CG	LRY	36	31.253	66.834	4.335	1.00	34.49	A1
ATOM	259	CD1	LRY	36	31.430	67.404	3.571	1.00	32.08	A1
ATOM	260	CD2	LRY	36	31.034	67.939	5.928	1.00	35.05	A1
ATOM	261	C	LRY	36	28.332	64.414	5.941	1.00	41.90	A1
ATOM	262	O	LRY	36	27.267	64.828	6.431	1.00	42.30	A1
ATOM	263	CYS	37	28.392	63.251	5.309	1.00	42.64	A1	
ATOM	264	H	CYS	37	29.250	62.904	5.020	1.00	0.00	A1
ATOM	265	CA	CYS	37	27.216	62.469	5.084	1.00	43.54	A1
ATOM	266	C	CYS	37	26.638	62.026	6.362	1.00	44.65	A1
ATOM	267	O	CYS	37	25.426	61.997	6.046	1.00	46.40	A1
ATOM	268	CB	CYS	37	27.474	61.240	4.313	1.00	44.60	A1
ATOM	269	SG	CYS	37	26.133	60.038	4.530	1.00	41.86	A1
ATOM	270	N	ALA	38	27.465	61.734	7.342	1.00	45.36	A1
ATOM	271	H	ALA	38	27.433	61.707	7.202	1.00	0.00	A1
ATOM	272	CA	ALA	38	26.932	61.261	8.592	1.00	48.03	A1
ATOM	273	CB	ALA	38	27.869	60.140	9.108	1.00	46.64	A1
ATOM	274	C	ALA	38	26.748	62.358	9.624	1.00	48.89	A1
ATOM	275	O	ALA	38	26.103	62.085	10.621	1.00	50.72	A1
ATOM	276	IG1	TIR	39	29.749	64.481	10.355	1.00	0.00	A1
ATOM	277	IG2	TIR	39	27.900	66.655	11.729	1.00	51.62	A1
ATOM	278	C	TIR	39	25.775	65.466	10.937	1.00	52.17	A1
ATOM	279	CH	TIR	39	28.179	65.593	10.690	1.00	51.76	A1
ATOM	280	CG1	TIR	39	29.294	64.826	11.126	1.00	52.65	A1
ATOM	281	IG1	TIR	39	29.749	64.481	10.355	1.00	0.00	A1
ATOM	282	CG2	TIR	39	24.729	66.561	8.165	1.00	52.54	A1
ATOM	283	C	TIR	39	25.775	65.466	10.937	1.00	52.17	A1
ATOM	284	O	TIR	39	24.886	65.082	10.781	1.00	52.15	A1
ATOM	285	N	TIR	40	25.751	65.720	8.738	1.00	52.84	A1
ATOM	286	H	TIR	40	26.420	65.331	8.139	1.00	0.00	A1
ATOM	287	CA	TIR	40	24.277	69.746	10.378	1.00	56.20	A1
ATOM	288	CB	TIR	40	25.314	67.812	7.996	1.00	52.15	A1
ATOM	289	CG	TIR	40	26.399	68.458	8.552	1.00	54.11	A1
ATOM	290	CD1	TIR	40	27.678	68.341	8.062	1.00	56.50	A1
ATOM	291	CE1	TIR	40	26.719	68.934	8.724	1.00	58.28	A1
ATOM	292	CD2	TIR	40	26.122	69.144	9.714	1.00	54.86	A1
ATOM	293	CE2	TIR	40	27.170	69.746	10.378	1.00	56.20	A1
ATOM	294	CZ	TIR	40	28.453	69.642	9.872	1.00	58.26	A1
ATOM	295	OH	TIR	40	29.513	70.463	1.00	61.00	A1	
ATOM	296	IIH	TIR	40	30.179	70.443	9.782	1.00	61.00	A1
ATOM	297	C	TIR	40	24.035	65.911	6.981	1.00	51.75	A1
ATOM	298	O	TIR	40	23.662	66.578	6.024	1.00	51.52	A1
ATOM	299	N	LYS	41	23.941	64.600	6.965	1.00	50.54	A1
ATOM	300	H	LYS	41	24.474	64.064	7.583	1.00	0.00	A1
ATOM	301	CA	LYS	41	23.112	63.805	6.029	1.00	50.48	A1
ATOM	302	CB	LYS	41	21.641	63.989	6.540	1.00	50.62	A1
ATOM	303	CG	LYS	41	21.387	63.326	7.911	1.00	52.11	A1
ATOM	304	CD	LYS	41	20.112	63.678	8.574	1.00	55.54	A1

FIGURE: 5

ATOM	305	CE LYS	41	19.578	63.087	9.820	1.00	58.79	A1
ATOM	306	NZ LYS	41	18.374	63.648	10.457	1.00	58.31	A1
ATOM	307	HZ1 LYS	41	17.605	63.688	9.757	1.00	0.00	A1
ATOM	308	HZ2 LYS	41	18.578	64.607	10.803	1.00	0.00	A1
ATOM	309	HZ3 LYS	41	18.084	63.043	11.252	1.00	0.00	A1
ATOM	310	C LYS	41	23.251	64.318	4.588	1.00	49.92	A1
ATOM	311	O LYS	41	22.312	64.124	3.793	1.00	51.49	A1
ATOM	312	N ILEU	42	24.432	64.893	4.246	1.00	48.28	A1
ATOM	313	H ILEU	42	25.103	65.050	4.937	1.00	0.00	A1
ATOM	314	CA ILEU	42	24.742	65.286	2.859	1.00	46.61	A1
ATOM	315	CB ILEU	42	25.565	66.574	2.757	1.00	44.69	A1
ATOM	316	CG ILEU	42	24.807	67.802	3.218	1.00	42.63	A1
ATOM	317	CD1 ILEU	42	25.718	68.580	4.097	1.00	43.29	A1
ATOM	318	CD2 ILEU	42	24.283	68.590	2.045	1.00	41.26	A1
ATOM	319	C LEU	42	25.580	64.124	2.397	1.00	45.46	A1
ATOM	320	O LEU	42	26.766	64.017	2.711	1.00	46.32	A1
ATOM	321	N CYS	43	24.882	63.193	1.754	1.00	44.09	A1
ATOM	322	H CYS	43	23.915	63.353	1.619	1.00	0.00	A1
ATOM	323	CA CYS	43	25.480	61.951	1.358	1.00	42.87	A1
ATOM	324	C CYS	43	25.448	61.846	-0.123	1.00	41.62	A1
ATOM	325	O CYS	43	25.762	60.805	-0.666	1.00	41.99	A1
ATOM	326	CB CYS	43	24.716	60.796	2.026	1.00	41.77	A1
ATOM	327	SG CYS	43	24.523	61.011	3.835	1.00	45.91	A1
ATOM	328	N HIS	44	25.507	62.846	-0.882	1.00	42.90	A1
ATOM	329	H HIS	44	24.841	63.721	-0.491	1.00	0.00	A1
ATOM	330	CA HIS	44	25.069	62.680	-2.320	1.00	44.60	A1
ATOM	331	CB HIS	44	23.653	62.264	-2.825	1.00	48.40	A1
ATOM	332	CG HIS	44	20.085	60.935	-2.310	1.00	50.37	A1
ATOM	333	CD2 HIS	44	22.178	60.844	-1.272	1.00	50.52	A1
ATOM	334	ND1 HIS	44	23.358	59.689	-2.713	1.00	52.28	A1
ATOM	335	HD1 HIS	44	24.130	59.394	-3.251	1.00	0.00	A1
ATOM	336	CE1 HIS	44	22.652	58.873	-1.955	1.00	51.92	A1
ATOM	337	NE2 HIS	44	21.947	59.565	-1.091	1.00	50.53	A1
ATOM	338	HE2 HIS	44	21.990	59.189	-0.466	1.00	0.00	A1
ATOM	339	C HIS	44	25.522	63.941	-3.047	1.00	43.69	A1
ATOM	340	O HIS	44	24.765	64.906	-3.108	1.00	43.00	A1
ATOM	341	N PRO	45	26.710	63.978	-3.667	1.00	43.07	A1
ATOM	342	CD PRO	45	27.785	62.995	-3.501	1.00	42.17	A1
ATOM	343	CA PRO	45	27.133	65.024	-4.570	1.00	42.50	A1
ATOM	344	CB PRO	45	28.380	64.466	-5.217	1.00	39.76	A1
ATOM	345	CG PRO	45	28.995	63.680	-4.123	1.00	39.09	A1
ATOM	346	C PRO	45	26.071	65.423	-5.585	1.00	44.49	A1
ATOM	347	O PRO	45	25.876	66.612	-5.801	1.00	45.36	A1
ATOM	348	N GLU	46	25.334	64.501	-6.225	1.00	45.36	A1
ATOM	349	H GLU	46	25.464	63.561	-5.996	1.00	0.00	A1
ATOM	350	CA GLU	46	24.406	64.806	-7.319	1.00	45.46	A1
ATOM	351	CB GLU	46	23.952	63.515	-7.997	1.00	50.54	A1
ATOM	352	CG GLU	46	24.462	63.460	-9.445	1.00	58.48	A1
ATOM	353	CD GLU	46	23.637	64.215	-10.502	1.00	64.93	A1
ATOM	354	OE1 GLU	46	23.642	65.455	-10.516	1.00	68.55	A1
ATOM	355	OE2 GLU	46	22.995	63.554	-11.332	1.00	68.31	A1
ATOM	356	C GLU	46	23.181	65.584	-6.937	1.00	42.96	A1
ATOM	357	O GLU	46	22.532	66.273	-7.748	1.00	41.71	A1
ATOM	358	N GLU	47	22.919	65.563	-5.654	1.00	41.96	A1
ATOM	359	H GLU	47	23.507	65.098	-5.028	1.00	0.00	A1
ATOM	360	CA GLU	47	21.818	66.301	-5.144	1.00	41.21	A1
ATOM	361	CB GLU	47	21.294	65.487	-3.963	1.00	41.74	A1
ATOM	362	CG GLU	47	21.409	65.925	-2.515	1.00	46.07	A1
ATOM	363	CD GLU	47	20.812	64.907	-1.547	1.00	47.86	A1
ATOM	364	OE1 GLU	47	19.847	64.225	-1.910	1.00	50.99	A1
ATOM	365	OE2 GLU	47	21.313	64.780	-0.427	1.00	49.47	A1
ATOM	366	C GLU	47	22.295	67.718	-4.809	1.00	44.04	A1
ATOM	367	O GLU	48	21.532	68.547	-4.702	1.00	44.60	A1
ATOM	368	N LEU	48	23.567	68.015	-5.121	1.00	43.05	A1
ATOM	369	H LEU	48	24.140	67.310	-5.465	1.00	0.00	A1
ATOM	370	CA LEU	48	24.166	69.318	-4.904	1.00	42.32	A1
ATOM	371	CB LEU	48	25.223	69.201	-3.858	1.00	40.56	A1
ATOM	372	CG LEU	48	24.439	69.994	-6.098	1.00	42.37	A1
ATOM	373	CD1 LEU	48	24.566	69.366	-7.347	1.00	41.52	A1
ATOM	374	CD2 LEU	48	23.951	68.602	-7.362	1.00	0.00	A1
ATOM	375	C LEU	49	25.191	69.822	-8.578	1.00	41.34	A1
ATOM	376	O LEU	49	24.792	69.937	-6.166	1.00	42.97	A1
ATOM	377	V AL	49	25.439	68.769	-2.830	1.00	47.50	A1
ATOM	378	I VAL	49	24.740	71.214	-9.028	1.00	44.98	A1
ATOM	379	H VAL	49	25.401	71.901	-9.814	1.00	46.04	A1
ATOM	380	N LEU	50	23.565	71.602	-8.550	1.00	46.16	A1
ATOM	381	CD1 VAL	49	23.081	70.933	-6.006	1.00	0.00	A1
ATOM	382	CG2 VAL	49	23.913	73.968	-8.779	1.00	45.25	A1
ATOM	383	C VAL	49	24.740	71.214	-9.028	1.00	44.98	A1
ATOM	384	O VAL	49	21.469	72.769	-8.264	1.00	46.43	A1
ATOM	385	CD1 LEU	50	20.443	73.718	-8.760	1.00	44.16	A1
ATOM	386	H LEU	50	20.259	73.558	-10.243	1.00	44.79	A1
ATOM	387	CA LEU	50	19.159	73.400	-8.079	1.00	44.66	A1
ATOM	388	CB LEU	50	23.632	73.968	-7.917	1.00	45.85	A1
ATOM	389	O LEU	51	23.996	74.889	-8.484	1.00	44.52	A1
ATOM	390	N LEU	51	23.543	73.764	-6.606	1.00	45.44	A1
ATOM	391	CD1 LEU	51	23.489	72.958	-6.189	1.00	0.00	A1
ATOM	392	CB LEU	51	24.676	74.656	-5.805	1.00	46.04	A1
ATOM	393	O LEU	51	24.860	74.084	-4.435	1.00	45.54	A1
ATOM	394	CG LEU	51	25.741	74.931	-3.535	1.00	47.78	A1
ATOM	395	CD1 LEU	51	25.146	76.320	-5.322	1.00	47.14	A1
ATOM	396	CA LEU	51	25.902	74.202	-2.219	1.00	46.54	A1
ATOM	397	CB LEU	51	26.064	74.845	-6.436	1.00	46.77	A1
ATOM	398	O LEU	51	26.551	75.966	-6.612	1.00	47.62	A1
ATOM	399	N GLY	52	26.702	73.736	-6.809	1.00	44.84	A1
ATOM	400	H GLY	52	26.306	72.869	-6.578	1.00	0.00	A1
ATOM	401	CA GLY	52	27.989	73.758	-7.453	1.00	47.11	A1
ATOM	402	C GLY	52	27.984	74.533	-8.750	1.00	42.47	A1

ATOM	407	O	GLY	S2	28.853	75.364	-8.983	1.00 42.06	A1	458	O	PRO	S8	37.187	73.599	-9.691	1.00 47.75	A1
ATOM	408	N	IHS	S3	27.047	74.307	-9.653	1.00 42.02	A1	459	N	TRP	S9	37.030	72.927	-11.816	1.00 50.37	A1
ATOM	409	H	IHS	S3	26.366	73.624	-9.471	1.00 0.00	A1	460	H	TRP	S9	36.888	73.141	-12.760	1.00 0.00	A1
ATOM	410	CA	IHS	S3	27.009	75.104	-10.861	1.00 42.23	A1	461	CA	TRP	S9	37.524	71.595	-11.482	1.00 51.78	A1
ATOM	411	CB	IHS	S3	25.842	74.689	-11.706	1.00 42.21	A1	462	CB	TRP	S9	36.435	70.562	-11.857	1.00 49.06	A1
ATOM	412	CG	IHS	S3	26.076	73.399	-12.460	1.00 44.60	A1	463	CG	TRP	S9	35.254	70.712	-10.889	1.00 46.17	A1
ATOM	413	CD2	IHS	S3	25.112	72.774	-13.200	1.00 47.49	A1	464	CD2	TRP	S9	35.320	70.845	-9.521	1.00 44.06	A1
ATOM	414	ND1	IHS	S3	27.180	72.669	-12.578	1.00 46.76	A1	465	CD2	TRP	S9	33.998	71.027	-12.205	1.00 44.14	A1
ATOM	415	HD1	IHS	S3	28.039	72.853	-12.139	1.00 0.00	A1	466	C13	TRP	S9	36.274	70.842	-8.536	1.00 44.03	A1
ATOM	416	CE1	IHS	S3	26.954	71.641	-13.346	1.00 46.90	A1	467	CD1	TRP	S9	33.972	70.794	-11.354	1.00 45.17	A1
ATOM	417	NE2	IHS	S3	27.074	71.725	-13.707	1.00 50.22	A1	468	NE1	TRP	S9	33.229	70.994	-10.297	1.00 45.17	A1
ATOM	418	HE2	IHS	S3	25.237	71.033	-14.739	1.00 0.00	A1	469	HE1	TRP	S9	32.301	71.312	-10.332	1.00 0.00	A1
ATOM	419	C	IHS	S3	26.893	76.585	-10.536	1.00 42.72	A1	470	C12	TRP	S9	33.215	71.215	-7.916	1.00 45.60	A1
ATOM	420	O	IHS	S3	27.622	77.399	-11.068	1.00 42.03	A1	471	C23	TRP	S9	35.893	71.028	-7.243	1.00 45.25	A1
ATOM	421	N	SER	S4	26.099	76.920	-9.335	1.00 45.08	A1	472	C12	TRP	S9	34.565	71.214	-6.938	1.00 46.43	A1
ATOM	422	II	SER	S4	25.673	76.210	-9.001	1.00 0.00	A1	473	C	TRP	S9	36.815	71.435	-12.256	1.00 52.84	A1
ATOM	423	CA	SER	S4	25.792	78.278	-9.177	1.00 46.92	A1	474	O	TRP	S9	38.842	71.372	-13.372	1.00 54.96	A1
ATOM	424	CB	SER	S4	24.516	78.181	-8.289	1.00 48.86	A1	475	N	ALA	60	39.912	70.834	-11.777	1.00 51.97	A1
ATOM	425	OG	SER	S4	23.521	77.616	-9.112	1.00 53.06	A1	476	H	ALA	60	39.857	70.269	-10.977	1.00 0.00	A1
ATOM	426	RG	SER	S4	23.465	76.677	-8.918	1.00 0.00	A1	477	CA	ALA	60	41.108	70.870	-12.609	1.00 52.18	A1
ATOM	427	C	SER	S4	26.939	79.033	-8.549	1.00 47.92	A1	478	CB	ALA	60	42.303	70.610	-11.748	1.00 51.75	A1
ATOM	428	O	SER	S4	27.038	80.264	-8.655	1.00 49.60	A1	479	C	ALA	60	41.055	69.857	-13.746	1.00 52.16	A1
ATOM	429	N	IEI	S5	27.637	78.223	-7.933	1.00 47.59	A1	480	O	ALA	60	40.545	68.760	-13.530	1.00 52.17	A1
ATOM	430	H	IEU	S5	27.638	77.322	-7.791	1.00 0.00	A1	481	N	PRO	61	41.435	70.145	-14.986	1.00 51.54	A1
ATOM	431	CA	IEI	S5	29.075	78.810	-7.401	1.00 45.27	A1	482	CD	PRO	61	41.370	70.576	-15.622	1.00 54.76	A1
ATOM	432	CB	IEU	S5	29.552	77.913	-6.243	1.00 45.49	A1	483	CA	PRO	61	41.691	69.145	-15.993	1.00 55.57	A1
ATOM	433	CG	LEU	S5	28.840	77.992	-4.074	1.00 41.30	A1	484	CB	PRO	61	41.792	69.918	-17.310	1.00 54.95	A1
ATOM	434	CD1	LEU	S5	28.876	76.596	-4.299	1.00 49.52	A1	485	CG	PRO	61	42.211	71.297	-16.901	1.00 54.05	A1
ATOM	435	CD2	LEU	S5	29.530	76.921	-3.862	1.00 45.69	A1	486	C	PRO	61	42.934	70.630	-15.690	1.00 57.54	A1
ATOM	436	C	LEU	S5	30.133	78.889	-8.492	1.00 43.63	A1	487	PRO	61	43.757	68.661	-14.834	1.00 57.20	A1	
ATOM	437	O	LEU	S5	31.147	79.350	-8.272	1.00 43.24	A1	488	N	LEU	62	43.040	67.271	-16.486	1.00 59.98	A1
ATOM	438	N	GLY	S6	28.855	78.383	-9.675	1.00 43.55	A1	489	II	LEU	62	42.285	67.067	-17.077	1.00 0.00	A1
ATOM	439	H	GLY	S6	28.984	77.975	-9.828	1.00 0.00	A1	490	CA	LEU	62	44.184	66.370	-16.471	1.00 63.64	A1
ATOM	440	CA	GLY	S6	30.814	78.390	-10.753	1.00 45.59	A1	491	CB	LEU	62	44.062	65.417	-15.260	1.00 64.72	A1
ATOM	441	C	GLY	S6	32.182	77.811	-10.392	1.00 46.76	A1	492	CG	LEU	62	44.194	64.371	-17.845	1.00 66.57	A1
ATOM	442	O	GLY	S6	33.171	78.213	-11.015	1.00 47.31	A1	493	CD1	LEU	62	57.448	63.159	-19.422	1.00 65.44	A2
ATOM	443	N	ILE	S7	32.247	76.685	-9.412	1.00 47.49	A1	494	CD2	LEU	62	57.716	62.495	-18.117	1.00 64.98	A2
ATOM	444	H	ILE	S7	31.392	76.594	-9.042	1.00 0.00	A1	495	C	LEU	62	44.214	65.611	-17.912	1.00 65.69	A2
ATOM	445	CA	ILE	S7	33.406	76.249	-8.950	1.00 48.28	A1	496	OT1	LEU	62	44.455	66.302	-18.844	1.00 66.47	A2
ATOM	446	CB	ILE	S7	33.144	75.172	-7.863	1.00 47.79	A1	497	OT2	LEU	62	44.194	64.371	-17.845	1.00 66.57	A2
ATOM	447	CG2	ILE	S7	34.457	74.591	-7.348	1.00 46.85	A1	498	CB	LEU	72	54.827	65.301	-18.316	1.00 67.40	A2
ATOM	448	CG1	ILE	S7	32.338	75.764	-6.701	1.00 45.09	A1	499	CG	LEU	72	56.469	64.643	-21.261	1.00 63.40	A2
ATOM	449	CD	ILE	S7	31.859	74.739	-5.659	1.00 41.23	A1	500	CD1	LEU	72	56.719	61.408	-17.913	1.00 61.50	A2
ATOM	450	C	ILE	S7	34.276	75.602	-10.115	1.00 49.15	A1	501	CD2	LEU	72	59.107	61.901	-18.121	1.00 61.22	A2
ATOM	451	O	ILE	S7	33.678	74.935	-10.968	1.00 49.04	A1	502	C	LEU	72	55.897	63.084	-18.76	1.00 65.40	A2
ATOM	452	N	PRO	S8	35.596	75.817	-10.248	1.00 49.75	A1	503	O	ILE	72	56.427	65.301	-18.316	1.00 67.40	A2
ATOM	453	CD	PRO	S8	36.402	76.743	-9.433	1.00 50.94	A1	504	HT1	ILE	72	56.469	64.643	-21.261	1.00 60.00	A2
ATOM	454	CA	PRO	S8	36.411	75.228	-11.302	1.00 50.72	A1	505	HT2	ILE	72	54.827	64.355	-20.951	1.00 60.00	A2
ATOM	455	CB	PRO	S8	37.525	76.241	-11.488	1.00 50.92	A1	506	N	ILE	72	55.795	63.983	-20.899	1.00 66.29	A2
ATOM	456	CG	PRO	S8	37.814	76.663	-10.041	1.00 50.82	A1	507	HT3	ILE	72	55.066	63.076	-21.449	1.00 60.00	A2
ATOM	457	C	PRO	S8	36.916	73.845	-10.875	1.00 50.36	A1	508	CA	ILE	72	56.064	63.714	-19.512	1.00 64.91	A2

FIGURE 5

ATOM	509 N	ALA	73	56.807	66.046	-19.086	1.00	64.54	A2	49.154	64.895	-11.151	1.00	45.18	A2
ATOM	510 H	ALA	73	57.690	65.194	-19.432	1.00	60.00	A2	49.634	63.534	-11.957	1.00	48.06	A2
ATOM	511 CA	ALA	73	56.707	67.433	-18.615	1.00	62.55	A2	49.756	64.986	-9.969	1.00	46.03	A2
ATOM	512 CB	ALA	73	57.553	68.314	-19.529	1.00	64.84	A2	49.366	66.265	-11.170	1.00	44.49	A2
ATOM	513 C	ALA	73	55.319	68.024	-18.539	1.00	60.37	A2	48.645	68.059	-10.199	1.00	44.20	A2
ATOM	514 O	ALA	73	54.801	68.180	-17.456	1.00	59.42	A2	50.556	68.814	-11.429	1.00	44.94	A2
ATOM	515 N	GLY	74	54.693	68.226	-19.691	1.00	59.72	A2	51.115	68.548	-12.085	1.00	46.00	A2
ATOM	516 H	GLY	74	55.212	68.174	-20.514	1.00	0.00	A2	51.060	69.788	-10.360	1.00	44.79	A2
ATOM	517 CA	GLY	74	53.336	68.728	-19.816	1.00	59.99	A2	52.456	70.221	-10.816	1.00	44.58	A2
ATOM	518 C	GLY	74	52.327	68.114	-18.865	1.00	60.27	A2	53.030	71.031	-9.690	1.00	44.75	A2
ATOM	519 O	GLY	74	51.880	68.796	-17.935	1.00	60.80	A2	53.484	70.497	-8.517	1.00	44.48	A2
ATOM	520 N	CYS	75	51.945	66.850	-19.030	1.00	59.60	A2	53.083	72.343	-9.567	1.00	44.24	A2
ATOM	521 H	CYS	75	52.160	66.358	-19.839	1.00	0.00	A2	52.842	73.004	-10.255	1.00	0.00	A2
ATOM	522 CA	CYS	75	51.002	66.276	-18.078	1.00	60.17	A2	53.530	72.641	-8.376	1.00	44.47	A2
ATOM	523 CB	CYS	75	50.670	64.801	-18.464	1.00	64.08	A2	53.772	71.520	-7.748	1.00	46.16	A2
ATOM	524 SC	CYS	75	49.832	64.732	-20.096	1.00	73.47	A2	54.103	71.444	-6.024	1.00	0.00	A2
ATOM	525 C	CYS	75	51.502	66.346	-16.642	1.00	56.73	A2	54.094	70.978	-10.299	1.00	44.40	A2
ATOM	526 O	CYS	75	52.793	66.748	-15.765	1.00	55.82	A2	54.643	71.294	-9.131	1.00	44.28	A2
ATOM	527 N	LEU	76	52.423	66.142	-16.396	1.00	53.93	A2	54.733	71.670	-11.309	1.00	45.14	A2
ATOM	528 H	LEU	76	52.423	66.043	-17.137	1.00	0.00	A2	54.036	71.459	-12.176	1.00	0.00	A2
ATOM	529 CA	LEU	76	53.325	66.156	-15.044	1.00	52.94	A2	54.103	71.444	-6.024	1.00	45.41	A2
ATOM	530 CB	LEU	76	54.798	65.754	-15.181	1.00	50.81	A2	48.612	73.347	-12.692	1.00	45.51	A2
ATOM	531 CG	LEU	76	55.575	65.051	-14.090	1.00	49.02	A2	49.594	73.444	-13.292	1.00	46.27	A2
ATOM	532 CD1	LEU	76	54.852	63.740	-13.698	1.00	46.76	A2	50.058	72.670	-13.643	1.00	0.00	A2
ATOM	533 CD2	LEU	76	56.951	64.633	-14.623	1.00	47.67	A2	54.344	72.266	-10.855	1.00	44.45	A2
ATOM	534 C	LEU	76	53.325	66.156	-15.044	1.00	52.94	A2	54.604	73.064	-10.256	1.00	46.84	A2
ATOM	535 O	LEU	76	52.731	67.716	-13.244	1.00	53.50	A2	46.946	71.010	-11.092	1.00	42.16	A2
ATOM	536 N	SER	77	53.137	68.553	-15.301	1.00	53.91	A2	47.513	70.411	-11.614	1.00	0.00	A2
ATOM	537 H	SER	77	53.322	68.361	-16.242	1.00	0.00	A2	45.569	70.461	-9.139	1.00	59.30	A2
ATOM	538 CA	SER	77	52.882	69.932	-14.942	1.00	54.93	A2	44.542	70.843	-8.544	1.00	59.64	A2
ATOM	539 CB	SER	77	53.425	70.035	-16.040	1.00	58.32	A2	45.676	70.032	-8.521	1.00	37.57	A2
ATOM	540 OG	SER	77	54.806	70.587	-16.310	1.00	63.35	A2	47.413	69.693	-9.075	1.00	0.00	A2
ATOM	541 HG	SER	77	54.949	69.637	-16.315	1.00	0.00	A2	46.026	70.007	-7.057	1.00	38.07	A2
ATOM	542 C	SER	77	53.882	70.172	-14.759	1.00	53.47	A2	46.133	69.202	-6.748	1.00	35.67	A2
ATOM	543 O	SER	77	50.982	70.965	-13.899	1.00	53.54	A2	43.071	67.736	-7.275	1.00	32.51	A2
ATOM	544 N	GIN	78	50.509	69.501	-15.512	1.00	51.82	A2	49.442	67.145	-7.319	1.00	29.77	A2
ATOM	545 H	GIN	78	50.857	68.901	-16.207	1.00	0.00	A2	47.160	66.973	-6.288	1.00	28.71	A2
ATOM	546 CA	GIN	78	49.074	69.619	-15.349	1.00	50.74	A2	48.186	71.386	-6.354	1.00	38.38	A2
ATOM	547 CB	GIN	78	46.269	68.877	-16.451	1.00	54.31	A2	46.392	71.627	-5.719	1.00	38.05	A2
ATOM	548 CG	GIN	78	47.420	69.784	-17.160	1.00	58.59	A2	47.366	72.338	-7.108	1.00	40.34	A2
ATOM	549 CD	GIN	78	46.557	68.940	-18.071	1.00	62.32	A2	47.804	72.076	-7.944	1.00	0.00	A2
ATOM	550 OE1	GIN	78	47.005	68.260	-18.998	1.00	65.94	A2	47.414	73.703	-6.688	1.00	41.54	A2
ATOM	551 NE2	GIN	78	45.269	68.889	-17.800	1.00	63.17	A2	48.163	74.511	-7.693	1.00	46.88	A2
ATOM	552 HE21	GIN	78	44.973	69.327	-16.972	1.00	0.00	A2	48.715	75.777	-6.988	1.00	55.49	A2
ATOM	553 HE22	GIN	78	44.704	68.444	-18.456	1.00	0.00	A2	49.521	75.622	-5.849	1.00	55.34	A2
ATOM	554 C	GIN	78	48.591	69.065	-14.011	1.00	48.17	A2	48.396	77.053	-7.469	1.00	55.79	A2
ATOM	555 O	GIN	78	47.691	69.618	-13.368	1.00	46.31	A2	50.004	76.737	-5.195	1.00	57.60	A2
ATOM	556 N	LEU	79	49.236	67.988	-13.564	1.00	45.89	A2	48.892	78.156	-6.796	1.00	57.25	A2
ATOM	557 II	LEU	79	49.920	67.584	-14.140	1.00	0.00	A2	49.688	78.002	-5.667	1.00	58.64	A2
ATOM	558 CA	LEU	79	48.919	67.359	-12.294	1.00	44.54	A2	45.994	74.191	-6.591	1.00	40.37	A2
ATOM	559 CH	LEU	79	49.617	66.015	-12.259	1.00	45.06	A2						

Figure 5

FIGURE 5

ATOM	713	II	IIE	96	35.357	74.94	6.841	1.00	0.00	A2	ATOM	764	C <sub>α</sub>	PRO	102	40.799	68.687	13.776	1.00	41.402	A2
ATOM	714	CA	IIE	96	33.760	73.632	7.312	1.00	42.12	A2	ATOM	765	C	PRO	102	41.364	67.795	10.331	1.00	47.15	A2
ATOM	715	CB	IIE	96	33.665	72.233	6.800	1.00	36.33	A2	ATOM	766	O	PRO	102	42.358	67.854	9.600	1.00	38.88	A2
ATOM	716	CG2	IIE	96	32.248	71.768	6.789	1.00	34.79	A2	ATOM	767	N	TIR	103	40.223	67.167	10.045	1.00	45.36	A2
ATOM	717	CG1	IIE	96	34.091	72.157	5.374	1.00	35.35	A2	ATOM	768	II	TIR	103	39.406	67.223	10.662	1.00	40.00	A2
ATOM	718	CD	IIE	96	34.051	70.743	4.738	1.00	33.64	A2	ATOM	769	CA	TIR	103	40.051	66.386	8.843	1.00	44.62	A2
ATOM	719	C	IIE	96	33.106	73.633	6.709	1.00	44.74	A2	ATOM	770	CH	TIR	103	38.592	65.888	8.715	1.00	44.97	A2
ATOM	720	O	IIE	96	32.220	74.716	8.841	1.00	44.59	A2	ATOM	771	O <sub>1</sub>	TIR	103	16.336	65.240	9.936	1.00	45.43	A2
ATOM	721	N	SER	97	33.467	73.154	9.780	1.00	46.84	A2	ATOM	772	IIG1	TIR	103	36.011	65.896	10.548	1.00	40.00	A2
ATOM	722	H	SER	97	34.243	72.553	9.706	1.00	46.00	A2	ATOM	773	CG2	TIR	103	36.312	64.892	7.594	1.00	41.79	A2
ATOM	723	CA	SER	97	32.900	73.359	11.105	1.00	48.91	A2	ATOM	774	C	TIR	103	40.417	67.215	7.625	1.00	34.61	A2
ATOM	724	CB	SER	97	31.804	72.343	11.347	1.00	49.60	A2	ATOM	775	O	TIR	103	41.099	66.665	6.738	1.00	38.16	A2
ATOM	725	OG	SER	97	32.211	71.120	11.954	1.00	52.85	A2	ATOM	776	N	LEU	104	40.054	68.498	7.529	1.00	32.45	A2
ATOM	726	IIG	SER	97	31.406	70.573	11.942	1.00	0.00	A2	ATOM	777	H	LEU	104	39.504	68.923	8.229	1.00	0.00	A2
ATOM	727	C	SER	97	34.045	73.142	12.077	1.00	50.64	A2	ATOM	778	CA	LEU	104	40.471	69.267	6.370	1.00	30.49	A2
ATOM	728	O	SER	97	35.035	72.538	11.678	1.00	52.78	A2	ATOM	779	CB	LEU	104	39.616	70.430	6.242	1.00	35.51	A2
ATOM	729	N	PRO	98	34.063	73.474	13.348	1.00	52.12	A2	ATOM	780	CG	LEU	104	38.356	69.996	5.611	1.00	36.61	A2
ATOM	730	CD	PRO	98	33.002	74.170	14.016	1.00	52.90	A2	ATOM	781	CD1	LEU	104	37.722	70.621	6.381	1.00	39.43	A2
ATOM	731	CA	PRO	98	34.195	73.200	14.257	1.00	54.94	A2	ATOM	782	CD2	LEU	104	38.416	70.794	4.132	1.00	37.89	A2
ATOM	732	CB	PRO	98	34.750	73.717	15.600	1.00	54.78	A2	ATOM	783	C	LEU	104	41.904	69.777	6.414	1.00	28.48	A2
ATOM	733	CG	PRO	98	33.772	74.777	15.182	1.00	55.48	A2	ATOM	784	O	LEU	104	42.583	69.825	5.936	1.00	28.47	A2
ATOM	734	PRO	98	35.591	71.723	14.336	1.00	56.75	A2	ATOM	785	N	ASP	105	42.449	69.949	5.714	1.00	26.99	A2	
ATOM	735	O	PRO	98	36.738	71.274	14.468	1.00	57.85	A2	ATOM	786	H	ASP	105	41.903	69.912	8.386	1.00	0.00	A2
ATOM	736	N	GLU	99	34.509	70.971	14.714	1.00	58.21	A2	ATOM	787	CA	ASP	105	43.822	70.307	7.613	1.00	26.67	A2
ATOM	737	H	GLU	99	35.652	71.400	14.028	1.00	0.00	A2	ATOM	788	CB	ASP	105	44.139	70.584	9.036	1.00	31.06	A2
ATOM	738	CA	GLU	99	34.545	69.537	14.781	1.00	55.48	A2	ATOM	789	CG	ASP	105	43.436	71.808	9.593	1.00	15.46	A2
ATOM	739	CB	GLU	99	35.111	69.104	12.304	1.00	63.30	A2	ATOM	790	O	ASP	105	43.085	72.776	8.836	1.00	34.42	A2
ATOM	740	CG	GLU	99	32.950	67.702	14.852	1.00	71.04	A2	ATOM	791	OD1	ASP	105	43.244	71.816	10.808	1.00	39.10	A2
ATOM	741	CD	GLU	99	32.076	66.838	13.962	1.00	76.95	A2	ATOM	792	C	ASP	105	44.701	69.206	7.032	1.00	28.90	A2
ATOM	742	OE1	GLU	99	32.209	65.608	14.079	1.00	80.63	A2	ATOM	793	O	ASP	105	45.515	69.479	6.715	1.00	29.62	A2
ATOM	743	OEZ	GLU	99	31.293	67.392	13.153	1.00	77.99	A2	ATOM	794	N	TIR	106	44.415	67.950	7.401	1.00	26.86	A2
ATOM	744	C	GLU	99	35.298	69.025	13.074	1.00	55.31	A2	ATOM	795	H	TIR	106	43.674	67.826	8.029	1.00	0.00	A2
ATOM	745	O	GLU	99	36.251	68.270	13.210	1.00	55.96	A2	ATOM	796	CA	TIR	106	45.143	66.770	6.935	1.00	24.81	A2
ATOM	746	N	LEU	100	34.916	69.475	11.891	1.00	51.23	A2	ATOM	797	CB	TIR	106	44.558	65.656	6.894	1.00	31.53	A2
ATOM	747	H	LEU	100	34.214	70.159	11.841	1.00	0.00	A2	ATOM	798	O <sub>1</sub>	TIR	106	44.640	65.566	6.894	1.00	31.53	A2
ATOM	748	CA	LEU	100	35.577	69.052	10.678	1.00	48.08	A2	ATOM	799	HIG1	TIR	106	44.069	66.223	9.242	1.00	0.00	A2
ATOM	749	CB	LEU	100	34.627	69.341	9.374	1.00	45.52	A2	ATOM	800	CG2	TIR	106	45.728	64.220	7.011	1.00	20.90	A2
ATOM	750	CG	LEU	100	33.544	68.317	9.674	1.00	45.39	A2	ATOM	801	C	TIR	106	45.073	66.684	5.460	1.00	23.75	A2
ATOM	751	CD1	LEU	100	32.207	68.972	9.458	1.00	46.40	A2	ATOM	802	O	TIR	106	45.065	66.411	4.812	1.00	24.68	A2
ATOM	752	CD2	LEU	100	33.851	67.245	8.677	1.00	47.48	A2	ATOM	803	N	LEU	107	43.887	66.917	4.946	1.00	24.50	A2
ATOM	753	C	LEU	100	36.956	69.629	10.368	1.00	46.77	A2	ATOM	804	H	LEU	107	43.145	67.176	5.518	1.00	0.00	A2
ATOM	754	O	LEU	100	37.578	69.244	9.357	1.00	46.62	A2	ATOM	805	LA	LEU	107	43.668	66.783	3.531	1.00	27.29	A2
ATOM	755	N	GLY	101	37.441	70.505	11.272	1.00	45.40	A2	ATOM	806	CB	LEU	107	42.158	66.913	3.273	1.00	25.45	A2
ATOM	756	H	GLY	101	36.893	70.704	12.056	1.00	0.00	A2	ATOM	807	CG	LEU	107	41.642	66.888	1.863	1.00	26.74	A2
ATOM	757	CA	GLY	101	38.703	71.338	11.126	1.00	42.52	A2	ATOM	808	CD1	LEU	107	42.095	65.649	1.158	1.00	26.41	A2
ATOM	758	C	GLY	101	39.885	70.334	10.798	1.00	40.73	A2	ATOM	809	CD2	LEU	107	40.140	66.915	1.914	1.00	27.62	A2
ATOM	759	O	GLY	101	40.475	70.402	9.710	1.00	40.69	A2	ATOM	810	C	LEU	107	44.485	67.848	7.819	1.00	26.01	A2
ATOM	760	N	PRO	102	40.250	69.441	11.708	1.00	38.61	A2	ATOM	811	O	LEU	107	45.154	67.555	1.813	1.00	30.77	A2
ATOM	761	CD	PRO	102	39.676	69.350	13.027	1.00	39.26	A2	ATOM	812	N	GIN	108	44.540	69.055	3.373	1.00	28.52	A2
ATOM	762	CA	PRO	102	41.390	68.566	11.606	1.00	37.30	A2	ATOM	813	H	GIN	108	44.030	69.221	4.194	1.00	0.00	A2
ATOM	763	CR	PRO	102	41.294	67.690	12.775	1.00	39.36	A2	ATOM	814	CA	GIN	108	45.343	70.132	2.792	1.00	28.18	A2

FIGURE 5

ATOM	815	CB	GLN	108	45.138	71.363	3.630	1.00	30.15	A2	ATOM	866	II	PHE	114	51.344	66.164	-1.361	1.00	0.00	A2
ATOM	816	CG	GLN	108	43.711	71.787	3.542	1.00	32.67	A2	ATOM	867	CA	PHE	114	52.109	65.328	-3.103	1.00	27.84	A2
ATOM	817	CD	GLN	108	43.192	4.048	5.125	1.00	35.24	A2	ATOM	868	CB	PHE	114	50.708	64.794	-3.226	1.00	23.18	A2
ATOM	818	OE1	GLN	108	43.085	73.484	5.125	1.00	36.07	A2	ATOM	869	CG	PHE	114	50.565	63.928	-4.420	1.00	21.04	A2
ATOM	819	NE2	GLN	108	44.189	74.044	3.213	1.00	33.58	A2	ATOM	870	CD1	PHE	114	51.623	63.225	-4.948	1.00	24.05	A2
ATOM	820	HE21	GLN	108	44.582	73.701	2.386	1.00	0.00	A2	ATOM	871	CD2	PHE	114	49.369	63.914	-5.046	1.00	22.37	A2
ATOM	821	HE22	GLN	108	44.195	74.986	3.471	1.00	0.00	A2	ATOM	872	CE1	PHE	114	51.476	62.514	-6.102	1.00	24.54	A2
ATOM	822	C	GLN	108	46.840	69.842	2.675	1.00	26.40	A2	ATOM	873	CE2	PHE	114	49.211	63.207	-6.212	1.00	21.14	A2
ATOM	823	O	GLN	108	47.450	69.955	1.597	1.00	27.57	A2	ATOM	874	CZ	PHE	114	50.261	62.509	-6.741	1.00	24.71	A2
ATOM	824	N	LEU	109	47.388	69.473	3.833	1.00	25.81	A2	ATOM	875	C	MIE	114	52.453	66.291	-4.190	1.00	29.20	A2
ATOM	825	H	LEU	109	46.795	69.495	4.615	1.00	0.00	A2	ATOM	876	O	PHE	114	53.072	65.883	-5.156	1.00	30.84	A2
ATOM	826	CA	LEU	109	48.764	69.003	4.043	1.00	27.96	A2	ATOM	877	N	ALA	115	52.057	67.554	-4.058	1.00	31.99	A2
ATOM	827	CB	LEU	109	48.951	68.637	5.513	1.00	29.41	A2	ATOM	878	H	ALA	115	51.446	67.768	-3.317	1.00	0.00	A2
ATOM	828	CG	LEU	109	48.712	69.771	6.520	1.00	31.76	A2	ATOM	879	CA	ALA	115	52.422	68.655	-4.952	1.00	31.29	A2
ATOM	829	CD1	LEU	109	48.750	69.188	7.933	1.00	29.16	A2	ATOM	880	CB	ALA	115	51.824	69.939	-4.420	1.00	30.65	A2
ATOM	830	CD2	LEU	109	49.724	70.889	6.285	1.00	32.19	A2	ATOM	881	C	ALA	115	53.936	68.787	-4.916	1.00	31.31	A2
ATOM	831	C	LEU	109	49.168	67.790	3.186	1.00	26.80	A2	ATOM	882	O	ALA	115	54.539	68.823	-6.044	1.00	30.36	A2
ATOM	832	O	LEU	109	50.214	67.721	2.544	1.00	26.81	A2	ATOM	883	N	TIR	116	54.551	68.846	-8.813	1.00	32.20	A2
ATOM	833	N	ASP	110	48.305	66.807	3.090	1.00	25.98	A2	ATOM	884	H	TIR	116	54.013	68.910	-2.992	1.00	0.00	A2
ATOM	834	H	ASP	110	47.471	66.885	3.860	1.00	0.00	A2	ATOM	885	CA	TIR	116	55.969	68.897	-3.656	1.00	34.91	A2
ATOM	835	CA	ASP	110	48.590	65.684	2.250	1.00	23.32	A2	ATOM	886	CB	TIR	116	56.325	69.953	-2.150	1.00	35.78	A2
ATOM	836	CB	ASP	110	47.577	64.570	2.553	1.00	26.34	A2	ATOM	887	OG1	TIR	116	55.564	70.038	-1.576	1.00	35.58	A2
ATOM	837	CG	ASP	110	47.905	63.878	3.894	1.00	31.10	A2	ATOM	888	HG1	TIR	116	54.942	69.644	-0.939	1.00	0.00	A2
ATOM	838	OD1	ASP	110	47.670	63.493	4.324	1.00	34.98	A2	ATOM	889	CG2	TIR	116	57.816	69.050	-2.981	1.00	35.48	A2
ATOM	839	OD2	ASP	110	48.958	64.107	4.535	1.00	34.01	A2	ATOM	890	C	TIR	116	56.714	67.726	-4.304	1.00	31.14	A2
ATOM	840	C	ASP	110	48.557	66.138	0.842	1.00	21.31	A2	ATOM	891	O	TIR	116	57.641	67.937	-5.066	1.00	31.27	A2
ATOM	841	O	ASP	110	49.493	65.711	0.165	1.00	20.63	A2	ATOM	892	N	TIR	117	56.318	66.485	-4.045	1.00	31.05	A2
ATOM	842	N	VAL	111	46.627	66.998	3.363	1.00	20.80	A2	ATOM	893	HH	TIR	117	55.615	66.366	-3.466	1.00	0.00	A2
ATOM	843	H	VAL	111	46.900	67.310	0.944	1.00	0.00	A2	ATOM	894	CA	TIR	117	56.840	65.269	-4.630	1.00	40.23	A2
ATOM	844	CA	VAL	111	47.711	67.454	-0.019	1.00	20.44	A2	ATOM	895	CB	TIR	117	55.909	64.090	-4.216	1.00	31.99	A2
ATOM	845	CB	VAL	111	46.531	68.364	-1.376	1.00	23.60	A2	ATOM	896	OG1	TIR	117	56.149	63.920	-2.820	1.00	41.66	A2
ATOM	846	CG1	VAL	111	46.615	68.946	-2.808	1.00	23.04	A2	ATOM	897	HG1	TIR	117	55.659	65.914	-2.886	1.00	0.00	A2
ATOM	847	CG2	VAL	111	45.289	67.497	-1.371	1.00	24.30	A2	ATOM	898	CG2	TIR	117	56.110	62.781	-8.452	1.00	38.74	A2
ATOM	848	C	VAL	111	49.006	68.214	-1.245	1.00	20.82	A2	ATOM	899	C	TIR	117	56.082	65.417	-6.134	1.00	43.42	A2
ATOM	849	O	VAL	111	49.617	68.006	-2.103	1.00	19.22	A2	ATOM	900	O	TIR	117	57.934	65.253	-6.749	1.00	46.29	A2
ATOM	850	N	ALA	112	49.442	69.063	-0.267	1.00	21.84	A2	ATOM	901	H	ILE	118	55.773	65.777	-1.741	1.00	45.87	A2
ATOM	851	H	ALA	112	48.839	69.190	0.492	1.00	0.00	A2	ATOM	902	I	ILE	118	54.962	65.942	-6.200	1.00	0.00	A2
ATOM	852	CA	ALA	112	50.708	69.803	-0.295	1.00	24.16	A2	ATOM	903	CA	ILE	118	55.659	65.914	-8.182	1.00	47.97	A2
ATOM	853	CB	ALA	112	50.861	70.561	1.011	1.00	22.69	A2	ATOM	904	CB	ILE	118	54.170	66.271	-8.452	1.00	47.69	A2
ATOM	854	C	ALA	112	51.931	68.478	-0.486	1.00	26.58	A2	ATOM	905	CG2	ILE	118	54.041	66.930	-9.835	1.00	47.04	A2
ATOM	855	O	ALA	112	52.778	69.026	-1.390	1.00	32.53	A2	ATOM	906	CG1	ILE	118	53.302	65.011	-8.244	1.00	44.00	A2
ATOM	856	N	ASP	113	52.086	67.852	0.343	1.00	30.21	A2	ATOM	912	CA	TRP	119	53.651	63.883	-9.236	1.00	41.71	A2
ATOM	857	H	ASP	113	51.507	67.817	1.130	1.00	0.00	A2	ATOM	908	C	ILE	118	56.647	66.932	-8.724	1.00	50.60	A2
ATOM	858	CA	ASP	113	53.084	66.846	0.166	1.00	31.70	A2	ATOM	909	O	ILE	118	57.390	66.636	-9.681	1.00	49.96	A2
ATOM	859	CB	ASP	113	52.706	65.659	0.953	1.00	36.31	A2	ATOM	910	N	TNP	119	56.697	68.061	-8.015	1.00	54.65	A2
ATOM	860	CG	ASP	113	53.170	65.758	2.337	1.00	42.27	A2	ATOM	911	H	TNP	119	56.164	68.135	-7.192	1.00	0.00	A2
ATOM	861	OD1	ASP	113	52.559	65.109	3.203	1.00	46.37	A2	ATOM	912	CA	TRP	119	57.575	69.142	-8.399	1.00	58.98	A2
ATOM	862	OD2	ASP	113	54.160	66.461	2.589	1.00	48.93	A2	ATOM	913	CB	TRP	119	57.392	70.367	-7.477	1.00	59.84	A2
ATOM	863	C	ASP	113	53.315	66.361	-1.239	1.00	32.81	A2	ATOM	914	CG	TRP	119	58.051	71.529	-8.196	1.00	62.4	A2
ATOM	864	O	ASP	113	54.443	66.308	-1.754	1.00	36.25	A2	ATOM	915	CID2	TRP	119	57.596	72.211	-9.307	1.00	61.74	A2
ATOM	865	N	PHE	114	52.187	65.978	-1.830	1.00	30.94	A2	ATOM	916	CID2	TRP	119	58.699	72.955	-9.043	1.00	62.55	A2

FIGURE: 5

ATOM	917	CE3 TRP	119	56.465	72.414	-0.080	1.00 66.02	A2	ATOM	968	V GLU	123	68.558	-12.356	1.00 78.22	A2	
ATOM	918	CD1 TRP	119	59.322	71.870	-7.863	1.00 64.12	A2	ATOM	969	N GLU	124	64.504	67.110	-10.765	1.00 77.66	A2
ATOM	919	NE1 TRP	119	59.680	72.727	-8.784	1.00 65.00	A2	ATOM	970	H GLU	124	63.867	66.852	-10.060	1.00 0.00	A2
ATOM	920	HE1 TRP	119	60.568	73.140	-8.828	1.00 0.00	A2	ATOM	971	CA GLU	124	65.574	66.215	-11.167	1.00 78.47	A2
ATOM	921	C22 TRP	119	58.776	73.794	-10.714	1.00 62.90	A2	ATOM	972	CB GLU	124	65.600	65.051	-10.195	1.00 80.71	A2
ATOM	922	C23 TRP	119	56.469	73.157	-11.170	1.00 65.18	A2	ATOM	973	CG GLU	124	64.387	64.132	-10.150	1.00 84.21	A2
ATOM	923	CH2 TRP	119	57.591	73.887	-11.481	1.00 64.40	A2	ATOM	974	CD GLU	124	64.375	63.248	-8.908	1.00 85.51	A2
ATOM	924	C TRP	119	59.021	68.664	-8.352	1.00 61.26	A2	ATOM	975	OE1 GLU	124	64.733	63.729	-7.824	1.00 86.94	A2
ATOM	925	O TRP	119	59.748	68.788	-9.343	1.00 62.12	A2	ATOM	976	OEQ GLU	124	64.006	62.075	-9.024	1.00 86.51	A2
ATOM	926	N GLN	120	59.447	68.065	-7.249	1.00 62.91	A2	ATOM	977	C GLU	124	65.534	65.705	-12.612	1.00 78.01	A2
ATOM	927	H GLN	120	58.911	67.961	-6.519	1.00 0.00	A2	ATOM	978	O GLU	124	66.480	65.057	-13.060	1.00 78.91	A2
ATOM	928	CA GLN	120	60.716	67.504	-7.113	1.00 65.16	A2	ATOM	979	N LFU	125	64.460	65.943	-13.363	1.00 77.11	A2
ATOM	929	CB GLN	120	60.900	66.800	-5.780	1.00 66.56	A2	ATOM	980	H LFU	125	63.606	66.340	-12.945	1.00 0.00	A2
ATOM	930	CG GLN	120	60.627	67.678	-4.582	1.00 67.18	A2	ATOM	981	CA LFU	125	63.061	64.832	-14.771	1.00 76.24	A2
ATOM	931	CD GLN	120	60.125	65.907	-3.284	1.00 67.77	A2	ATOM	982	CB LFU	125	63.060	64.827	-14.952	1.00 76.88	A2
ATOM	932	OE1 GLN	120	61.221	67.465	-2.319	1.00 69.31	A2	ATOM	983	CG LFU	125	62.392	64.382	-16.263	1.00 76.63	A2
ATOM	933	NE2 GLN	120	60.305	65.654	-3.129	1.00 67.39	A2	ATOM	984	CD1 LFU	125	63.350	63.754	-17.276	1.00 76.67	A2
ATOM	934	HE21 GLN	120	59.903	65.174	-3.977	1.00 0.00	A2	ATOM	985	CD2 LFU	125	61.309	63.402	-15.839	1.00 75.81	A2
ATOM	935	HE22 GLN	120	60.441	65.282	-7.234	1.00 0.00	A2	ATOM	986	C LFU	125	64.306	66.827	-15.648	1.00 75.84	A2
ATOM	936	C GLN	120	61.169	66.509	-8.272	1.00 66.22	A2	ATOM	987	O LFU	125	64.759	66.788	-16.871	1.00 75.36	A2
ATOM	937	O GLN	120	62.326	66.411	-8.662	1.00 66.50	A2	ATOM	988	N GLY	126	64.759	67.968	-15.027	1.00 75.90	A2
ATOM	938	N GLN	121	60.202	65.745	-8.706	1.00 67.10	A2	ATOM	989	H GLY	126	64.741	67.976	-14.056	1.00 0.00	A2
ATOM	939	H GLN	121	59.307	65.754	-8.303	1.00 0.00	A2	ATOM	990	CA GLY	126	64.968	69.213	-15.736	1.00 77.58	A2
ATOM	940	CA GLN	121	60.410	64.878	-9.812	1.00 68.66	A2	ATOM	991	C GLY	126	63.697	69.814	-16.330	1.00 78.64	A2
ATOM	941	CB GLN	121	59.292	63.971	-10.070	1.00 67.96	A2	ATOM	992	O GLY	126	63.735	70.716	-17.146	1.00 78.55	A2
ATOM	942	CG GLN	121	59.614	62.937	-11.178	1.00 68.89	A2	ATOM	993	MET	127	62.524	69.343	-15.933	1.00 80.00	A2
ATOM	943	CD GLN	121	60.940	62.236	-10.852	1.00 71.37	A2	ATOM	994	II MET	127	62.522	68.603	-15.293	1.00 0.00	A2
ATOM	944	OE1 GLN	121	61.212	61.706	-9.777	1.00 71.70	A2	ATOM	995	CA MET	127	61.266	69.902	-16.415	1.00 81.46	A2
ATOM	945	NE2 GLN	121	61.879	62.262	-11.786	1.00 74.41	A2	ATOM	996	CB MET	127	60.191	68.802	-16.361	1.00 81.86	A2
ATOM	946	HE21 GLN	121	61.707	62.779	-12.627	1.00 0.00	A2	ATOM	997	CG MET	127	60.708	67.599	-17.147	1.00 82.66	A2
ATOM	947	HE22 GLN	121	62.736	61.859	-11.541	1.00 0.00	A2	ATOM	998	SD MET	127	59.682	66.115	-17.282	1.00 81.70	A2
ATOM	948	C GLN	121	60.760	65.743	-11.045	1.00 70.48	A2	ATOM	999	CE MET	127	60.236	65.610	-18.900	1.00 81.23	A2
ATOM	949	O GLN	121	61.671	65.436	-11.827	1.00 70.94	A2	ATOM	1000	C MET	127	60.847	71.131	-15.599	1.00 81.18	A2
ATOM	950	N MET	122	60.019	66.846	-11.236	1.00 71.67	A2	ATOM	1001	OT1 MET	127	61.267	71.958	-16.142	1.00 81.86	A2
ATOM	951	H MET	122	59.351	67.081	-10.555	1.00 0.00	A2	ATOM	1002	OT2 MET	127	61.267	71.285	-14.446	1.00 81.04	A2
ATOM	952	CA MET	122	60.190	67.688	-12.412	1.00 72.62	A2	ATOM	1003	CB MET	128	39.323	80.595	-4.492	1.00 59.19	A1
ATOM	953	CB MET	122	59.173	68.819	-12.448	1.00 73.12	A2	ATOM	1004	CG MET	128	40.123	79.298	-4.421	1.00 57.97	A1
ATOM	954	CG MET	122	57.880	68.343	-13.083	1.00 73.64	A2	ATOM	1005	SD MET	128	40.561	78.973	-6.145	1.00 60.45	A1
ATOM	955	SD MET	122	56.669	69.662	-13.295	1.00 75.44	A2	ATOM	1006	CE MET	128	41.129	77.310	-6.351	1.00 61.48	A1
ATOM	956	CE MET	122	55.649	69.349	-11.861	1.00 76.43	A2	ATOM	1007	CT MET	128	37.021	81.012	-5.654	1.00 60.26	A1
ATOM	957	C MET	122	61.565	68.201	-12.411	1.00 73.72	A2	ATOM	1008	O MET	128	36.812	82.262	-5.181	1.00 62.08	A1
ATOM	958	O MET	122	62.240	68.287	-13.441	1.00 73.03	A2	ATOM	1009	HT1 MET	128	35.995	80.424	-5.012	1.00 57.62	A1
ATOM	959	N GLU	123	61.991	68.697	-11.223	1.00 74.74	A2	ATOM	1010	HT2 MET	128	36.313	81.257	-7.529	1.00 0.00	A3
ATOM	960	H GLU	123	61.372	68.617	-10.466	1.00 0.00	A2	ATOM	1011	N MET	128	36.039	81.784	-6.639	1.00 60.49	A1
ATOM	961	CA GLU	123	63.305	69.262	-11.018	1.00 75.95	A2	ATOM	1012	HT3 MET	128	39.665	81.816	-6.768	1.00 0.00	A3
ATOM	962	CB GLU	123	63.484	69.665	-9.597	1.00 75.77	A2	ATOM	1013	CA MET	128	38.445	80.672	-5.787	1.00 60.51	A1
ATOM	963	CG GLU	123	62.644	70.906	-9.500	1.00 79.11	A2	ATOM	1014	N PRO	139	36.497	81.600	-6.075	1.00 0.00	A3
ATOM	964	CD GLU	123	62.651	71.529	-8.122	1.00 83.02	A2	ATOM	1015	CD PRO	139	36.028	79.060	-6.448	1.00 58.10	A1
ATOM	965	OH1 GLU	123	62.741	72.763	-8.057	1.00 84.15	A2	ATOM	1016	CA PRO	139	34.654	80.538	-5.142	1.00 54.67	A1
ATOM	966	OH2 GLU	123	62.543	70.789	-7.133	1.00 84.45	A2	ATOM	1017	CB PRO	139	33.870	79.323	-5.525	1.00 54.54	A1
ATOM	967	C GLU	123	(4.411)	68.180	-11.386	1.00 77.17	A2	ATOM	1018	CG PRO	139	34.945	78.290	-5.755	1.00 58.70	A1

ATOM	1019	C	PRO	139	34.588	80.6/5	-3.664	1.00	52.24	A3
ATOM	1020	O	PRO	139	35.507	80.6/3	-2.882	1.00	51.89	A3
ATOM	1021	N	ALA	140	33.499	81.547	-3.342	1.00	49.86	A3
ATOM	1022	H	ALA	140	32.789	81.676	-4.005	1.00	0.00	A3
ATOM	1023	CA	ALA	140	33.234	81.926	-1.994	1.00	49.39	A3
ATOM	1024	CB	ALA	140	32.966	83.413	-1.895	1.00	49.94	A3
ATOM	1025	C	ALA	140	31.978	81.153	-1.590	1.00	49.25	A3
ATOM	1026	O	ALA	140	30.889	81.162	-2.205	1.00	49.06	A3
ATOM	1027	N	PIE	141	32.293	80.442	-0.506	1.00	47.48	A3
ATOM	1028	H	PIE	141	33.190	80.580	-0.122	1.00	0.00	A3
ATOM	1029	CA	PIE	141	31.401	79.552	-0.208	1.00	45.66	A3
ATOM	1030	CB	PIE	141	32.215	78.305	-0.792	1.00	40.28	A3
ATOM	1031	CG	PIE	141	32.684	77.404	-0.349	1.00	35.35	A3
ATOM	1032	CD1	PIE	141	33.966	77.397	-0.830	1.00	37.69	A3
ATOM	1033	CD2	PIE	141	32.174	75.895	-2.133	1.00	34.00	A3
ATOM	1034	CE1	PIE	141	34.358	76.807	-1.956	1.00	36.69	A3
ATOM	1035	CE2	PIE	141	31.449	76.001	-2.614	1.00	37.29	A3
ATOM	1036	CZ	PIE	141	32.731	83.546	0.879	1.00	46.54	A3
ATOM	1037	C	PIE	141	31.584	80.664	1.242	1.00	46.54	A3
ATOM	1038	O	PIE	141	30.067	81.452	0.843	1.00	47.38	A3
ATOM	1039	N	ALA	142	29.624	81.295	-0.020	1.00	0.00	A3
ATOM	1040	H	ALA	142	28.774	80.201	2.303	1.00	46.06	A3
ATOM	1041	CA	ALA	142	29.581	82.564	1.668	1.00	45.04	A3
ATOM	1042	CB	ALA	142	28.731	81.129	3.161	1.00	44.17	A3
ATOM	1043	C	ALA	142	28.703	82.132	2.802	1.00	45.27	A3
ATOM	1044	O	ALA	142	28.343	81.002	3.584	1.00	47.38	A3
ATOM	1045	N	SER	143	28.318	80.860	2.899	1.00	43.36	A3
ATOM	1046	H	SER	143	28.777	79.145	4.602	1.00	39.79	A3
ATOM	1047	CA	SER	143	27.377	80.392	3.897	1.00	41.94	A3
ATOM	1048	CB	SER	143	26.016	80.129	4.132	1.00	38.50	A3
ATOM	1049	OG	SER	143	25.323	78.918	3.536	1.00	48.18	A3
ATOM	1050	HG	SER	143	24.455	78.974	3.098	1.00	0.00	A3
ATOM	1051	C	SER	143	26.964	76.420	5.627	1.00	41.58	A3
ATOM	1052	O	SER	143	26.763	78.452	4.132	1.00	42.07	A3
ATOM	1053	N	ALA	144	27.218	76.775	5.683	1.00	39.10	A3
ATOM	1054	H	ALA	144	26.449	79.312	5.960	1.00	0.00	A3
ATOM	1055	CA	ALA	144	27.566	77.586	6.411	1.00	39.22	A3
ATOM	1056	CB	ALA	144	26.982	77.598	7.802	1.00	36.97	A3
ATOM	1057	C	ALA	144	26.964	76.420	5.627	1.00	42.07	A3
ATOM	1058	O	ALA	144	27.706	75.448	5.444	1.00	36.46	A3
ATOM	1059	N	PIE	145	26.519	76.407	5.076	1.00	40.77	A3
ATOM	1060	H	PIE	145	25.149	77.203	5.110	1.00	0.00	A3
ATOM	1061	CA	PIE	145	25.307	75.234	4.312	1.00	39.31	A3
ATOM	1062	CB	PIE	145	23.877	75.396	3.798	1.00	36.46	A3
ATOM	1063	CG	PIE	145	23.477	74.452	2.641	1.00	31.91	A3
ATOM	1064	CD1	PIE	145	23.579	74.900	1.323	1.00	29.02	A3
ATOM	1065	CD2	PIE	145	23.013	73.185	2.916	1.00	29.40	A3
ATOM	1066	CE1	PIE	145	23.225	74.100	0.277	1.00	28.34	A3
ATOM	1067	CE2	PIE	145	22.661	72.389	1.858	1.00	28.80	A3
ATOM	1068	CZ	PIE	145	22.764	72.831	0.549	1.00	30.58	A3
ATOM	1069	C	PIE	145	26.266	75.071	3.120	1.00	40.44	A3
ATOM	1070	U	PHE	145	26.556	73.938	2.607	1.00	40.55	A3
ATOM	1071	N	GIN	146	26.745	76.232	2.619	1.00	51.11	A3
ATOM	1072	H	GIN	146	26.437	77.013	3.015	1.00	6.01	A3
ATOM	1073	CA	GIN	146	27.460	76.763	1.511	1.00	40.01	A3
ATOM	1074	CB	GIN	146	27.907	77.630	1.054	1.00	40.92	A3
ATOM	1075	CG	GIN	146	26.884	78.016	0.049	1.00	45.26	A3
ATOM	1076	CD	GIN	146	27.171	79.440	0.522	1.00	45.47	A3
ATOM	1077	OEI	GIN	146	27.851	80.253	0.034	1.00	47.57	A3
ATOM	1078	NE2	GIN	146	26.689	79.793	-1.459	1.00	40.50	A3
ATOM	1079	W121	GIN	146	26.149	79.149	-2.120	1.00	0.00	A3
ATOM	1080	III22	GIN	146	26.913	80.690	-2.021	1.00	0.00	A3
ATOM	1081	C	GIN	146	29.005	75.670	1.836	1.00	37.25	A3
ATOM	1082	O	GIN	146	29.634	75.093	0.950	1.00	36.24	A3
ATOM	1083	N	ARG	147	29.511	75.775	3.054	1.00	36.17	A3
ATOM	1084	H	ARG	147	29.044	76.300	3.738	1.00	0.00	A3
ATOM	1085	CA	ARG	147	30.798	75.180	3.357	1.00	35.68	A3
ATOM	1086	CB	ARG	147	31.299	75.574	4.713	1.00	37.12	A3
ATOM	1087	CG	ARG	147	31.730	77.016	4.697	1.00	42.68	A3
ATOM	1088	CD	ARG	147	32.034	77.494	6.093	1.00	45.54	A3
ATOM	1089	NE	ARG	147	32.614	78.774	5.877	1.00	58.21	A3
ATOM	1090	HE	ARG	147	34.475	75.252	5.045	1.00	0.00	A3
ATOM	1091	C2	ARG	147	33.519	79.373	6.742	1.00	6.77	A3
ATOM	1092	NII1	ARG	147	33.905	78.868	7.936	1.00	6.46	A3
ATOM	1093	HII1	ARG	147	34.545	79.379	8.510	1.00	6.60	A3
ATOM	1094	HII12	ARG	147	33.561	79.980	8.239	1.00	0.00	A3
ATOM	1095	NII2	ARG	147	33.946	80.584	6.403	1.00	44.80	A3
ATOM	1096	N	ALA	148	34.599	81.049	6.399	1.00	0.00	A3
ATOM	1097	III22	ARG	147	33.665	80.996	5.541	1.00	0.00	A3
ATOM	1098	C	ARG	147	30.570	73.702	3.347	1.00	34.91	A3
ATOM	1099	O	ARG	147	31.233	73.050	2.539	1.00	4.56	A3
ATOM	1100	N	ALA	148	29.544	73.194	4.040	1.00	4.44	A3
ATOM	1101	H	ALA	148	28.926	73.816	4.482	1.00	0.00	A3
ATOM	1102	CA	ALA	148	27.358	71.754	4.172	1.00	34.92	A3
ATOM	1103	CB	ALA	148	28.217	71.426	5.163	1.00	34.95	A3
ATOM	1104	C	ALA	148	29.077	70.095	2.845	1.00	41.40	A3
ATOM	1105	O	ALA	148	29.765	70.141	2.557	1.00	44.51	A3
ATOM	1106	N	ALA	149	28.169	71.657	2.077	1.00	42.60	A3
ATOM	1107	H	ALA	149	27.662	72.424	4.411	1.00	0.00	A3
ATOM	1108	CA	ALA	149	27.890	71.134	0.757	1.00	32.70	A3
ATOM	1109	CB	ALA	149	26.595	71.774	0.299	1.00	51.91	A3
ATOM	1110	C	ALA	149	31.017	72.608	-0.913	1.00	41.79	A3
ATOM	1111	O	ALA	149	32.997	71.261	-1.265	1.00	41.77	A3
ATOM	1112	N	GLY	150	29.867	72.401	-0.052	1.00	43.58	A3
ATOM	1113	H	GLY	150	29.724	73.035	0.682	1.00	0.00	A3
ATOM	1114	CA	GLY	150	31.017	72.561	-0.258	1.00	43.75	A3
ATOM	1115	C	GLY	150	32.113	71.621	-1.265	1.00	41.49	A3
ATOM	1116	O	GLY	150	32.997	71.261	-1.265	1.00	41.77	A3
ATOM	1117	N	GLY	151	32.075	71.161	0.773	1.00	29.84	A3
ATOM	1118	H	GLY	151	31.412	71.524	1.394	1.00	0.00	A3
ATOM	1119	CA	GLY	151	33.018	70.166	1.243	1.00	42.16	A3
ATOM	1120	C	GLY	151	32.764	68.903	0.419	1.00	43.04	A3

FIGURE 5

ATOM	1121	O	GLY	151	33.664	68.501	-0.349	1.00	35.66	A3	ATOM	1172	C	IIS	157	37.291	65.476	-7.269	1.00	29.68	A3
ATOM	1122	N	VAL	152	31.486	68.418	0.451	1.00	31.87	A3	ATOM	1173	O	IIS	157	37.930	65.059	-8.219	1.00	29.45	A3
ATOM	1123	H	VAL	152	30.867	68.906	1.040	1.00	0.00	A3	ATOM	1174	N	LEU	158	37.801	65.669	-5.326	1.00	0.03	A3
ATOM	1124	CA	VAL	152	30.970	67.240	-0.275	1.00	29.61	A3	ATOM	1175	H	LEU	159	37.213	65.901	-5.326	1.00	29.74	A3
ATOM	1125	CB	VAL	152	29.419	67.145	-0.125	1.00	27.63	A3	ATOM	1176	CA	LEU	158	39.216	65.419	-5.826	1.00	31.94	A3
ATOM	1126	CG1	VAL	152	28.883	66.035	-0.976	1.00	27.37	A3	ATOM	1177	CB	LEU	158	39.609	65.949	-4.373	1.00	28.66	A3
ATOM	1127	CG2	VAL	152	29.002	66.766	1.279	1.00	24.74	A3	ATOM	1178	CC	LEU	158	41.008	65.751	-4.859	1.00	24.12	A3
ATOM	1128	C	VAL	152	31.351	67.394	-1.762	1.00	29.91	A3	ATOM	1179	CD1	LEU	158	41.990	66.378	-4.776	1.00	20.87	A3
ATOM	1129	O	VAL	152	31.805	66.329	-3.393	1.00	31.75	A3	ATOM	1180	CD2	LEU	158	41.099	66.330	-2.477	1.00	24.86	A3
ATOM	1130	N	LEU	153	31.236	68.452	-2.361	1.00	29.26	A3	ATOM	1181	C	LEU	158	29.468	63.994	-6.027	1.00	31.46	A3
ATOM	1131	H	LEU	153	30.881	69.219	-1.860	1.00	0.00	A3	ATOM	1182	O	LEU	158	40.298	63.609	-6.844	1.00	30.58	A3
ATOM	1132	CA	LEU	153	31.559	68.607	-3.756	1.00	26.77	A3	ATOM	1183	N	GLN	159	38.652	62.525	-5.430	1.00	35.54	A3
ATOM	1133	CB	LEU	153	30.881	69.858	-4.160	1.00	28.22	A3	ATOM	1184	II	GLN	159	38.011	63.676	-4.748	1.00	0.00	A3
ATOM	1134	CG	LEU	153	29.943	69.894	-5.316	1.00	30.67	A3	ATOM	1185	CA	GLN	159	38.594	61.792	-5.447	1.00	35.73	A3
ATOM	1135	CD1	LEU	153	28.580	69.281	-5.090	1.00	26.48	A3	ATOM	1186	CB	GLN	159	37.308	61.492	-4.813	1.00	37.26	A3
ATOM	1136	CD2	LEU	153	29.741	71.365	-5.496	1.00	34.46	A3	ATOM	1187	CG	GLN	159	37.064	60.063	-4.450	1.00	45.61	A3
ATOM	1137	C	LEU	153	33.032	68.620	-4.111	1.00	26.08	A3	ATOM	1188	CD	GLN	159	37.755	59.611	-3.256	1.00	46.54	A3
ATOM	1138	O	LEU	153	33.419	68.187	-5.212	1.00	26.78	A3	ATOM	1189	OE1	GLN	159	38.142	58.443	-3.232	1.00	46.29	A3
ATOM	1139	N	VAL	154	33.902	69.180	-3.269	1.00	26.12	A3	ATOM	1190	NE2	GLN	159	37.916	60.456	-2.224	1.00	47.82	A3
ATOM	1140	H	VAL	154	31.931	67.557	-6.693	1.00	0.00	A3	ATOM	1191	HE1	GLN	159	37.577	61.364	-2.289	1.00	0.00	A3
ATOM	1141	CA	VAL	154	35.310	69.259	-3.611	1.00	26.23	A3	ATOM	1192	HE2	GLN	159	38.412	60.101	-1.447	1.00	0.00	A3
ATOM	1142	CB	VAL	154	36.057	70.299	-2.692	1.00	26.51	A3	ATOM	1193	C	GLN	159	38.686	61.381	-6.721	1.00	36.24	A3
ATOM	1143	CG1	VAL	154	37.578	70.180	-2.942	1.00	25.01	A3	ATOM	1194	O	GLN	159	39.632	60.690	-7.322	1.00	38.97	A3
ATOM	1144	CG2	VAL	154	35.931	67.550	-3.375	1.00	26.80	A3	ATOM	1195	IG1	SER	160	37.824	61.896	-7.794	1.00	35.48	A3
ATOM	1145	C	VAL	154	36.678	67.353	-2.416	1.00	0.00	A3	ATOM	1196	II	SER	160	37.142	62.540	-7.498	1.00	0.00	A3
ATOM	1146	O	VAL	154	35.635	67.259	-3.611	1.00	26.23	A3	ATOM	1197	CA	SER	160	37.869	61.564	-9.703	1.00	34.96	A3
ATOM	1147	N	ALA	155	35.635	67.241	-2.199	1.00	24.76	A3	ATOM	1198	CB	SER	160	36.645	62.100	-9.863	1.00	37.54	A3
ATOM	1148	H	ALA	155	35.084	67.758	-1.570	1.00	0.00	A3	ATOM	1199	CG	SER	160	35.587	62.732	-9.942	1.00	44.81	A3
ATOM	1149	CA	ALA	155	36.095	65.940	-1.782	1.00	25.21	A3	ATOM	1200	IG2	SER	160	35.340	61.689	-8.387	1.00	0.00	A3
ATOM	1150	CB	ALA	155	35.463	65.572	-0.457	1.00	25.25	A3	ATOM	1201	C	SER	160	39.090	63.095	-9.972	1.00	31.65	A3
ATOM	1151	C	ALA	155	35.708	64.946	-2.841	1.00	26.27	A3	ATOM	1202	O	SER	160	39.605	61.382	-10.785	1.00	35.42	A3
ATOM	1152	O	ALA	155	36.594	64.288	-3.398	1.00	26.76	A3	ATOM	1203	N	PHE	161	39.615	63.293	-9.595	1.00	33.82	A3
ATOM	1153	N	SER	156	34.450	64.982	-3.282	1.00	29.96	A3	ATOM	1204	II	PHE	161	39.203	63.796	-8.864	1.00	0.00	A3
ATOM	1154	H	SER	156	33.790	65.577	-2.868	1.00	0.00	A3	ATOM	1205	CA	PHE	161	40.820	63.850	-10.216	1.00	31.21	A3
ATOM	1155	CA	SER	156	34.034	64.105	-4.354	1.00	32.17	A3	ATOM	1206	CB	PHE	161	41.110	65.254	-9.629	1.00	31.65	A3
ATOM	1156	CB	SER	156	32.531	64.519	-4.544	1.00	34.23	A3	ATOM	1207	CG	PHE	161	42.453	65.481	-10.062	1.00	24.92	A3
ATOM	1157	OG	SER	156	32.000	64.195	-5.079	1.00	39.35	A3	ATOM	1208	CD1	PHE	161	42.696	66.228	-11.389	1.00	22.08	A3
ATOM	1158	HG	SER	156	31.120	63.815	-5.851	1.00	0.00	A3	ATOM	1209	CD2	PHE	161	43.464	66.021	-9.135	1.00	23.63	A3
ATOM	1159	C	SER	156	34.845	64.338	-5.632	1.00	33.46	A3	ATOM	1210	CE1	PHE	161	43.941	66.695	-11.767	1.00	21.06	A3
ATOM	1160	O	SER	156	35.411	63.808	-6.174	1.00	34.62	A3	ATOM	1211	CE2	PHE	161	44.701	66.493	-9.528	1.00	20.28	A3
ATOM	1161	N	HS	157	35.054	65.576	-6.133	1.00	33.90	A3	ATOM	1212	CZ	PHE	161	44.939	66.826	-10.832	1.00	17.04	A3
ATOM	1162	H	HS	157	34.771	66.349	-5.605	1.00	0.00	A3	ATOM	1213	C	PIE	161	42.008	62.907	-9.943	1.00	31.77	A3
ATOM	1163	CA	IIS	157	35.821	65.773	-7.383	1.00	31.19	A3	ATOM	1214	O	PIE	161	42.786	62.579	-10.645	1.00	32.65	A3
ATOM	1164	CB	IIS	157	35.707	67.209	-7.900	1.00	32.59	A3	ATOM	1215	N	LEU	162	42.117	62.434	-8.690	1.00	31.57	A3
ATOM	1165	CG	IIS	157	34.369	67.449	-8.566	1.00	31.11	A3	ATOM	1216	II	LEU	162	41.420	62.691	-8.054	1.00	0.00	A3
ATOM	1166	CD2	IIS	157	34.127	67.394	-9.928	1.00	30.78	A3	ATOM	1217	CA	LEU	162	43.186	61.574	-8.232	1.00	31.21	A3
ATOM	1167	ND1	IIS	157	33.223	67.666	-7.942	1.00	32.36	A3	ATOM	1218	CB	LEU	162	43.204	61.433	-6.743	1.00	25.81	A3
ATOM	1168	IDI	IIS	157	33.080	67.773	-6.979	1.00	0.00	A3	ATOM	1219	CG	LEU	162	43.693	62.674	-6.003	1.00	26.02	A3
ATOM	1169	CE1	IIS	157	32.293	67.732	-8.875	1.00	32.01	A3	ATOM	1220	CD1	LEU	162	43.594	62.455	-8.690	1.00	25.74	A3
ATOM	1170	NI2	IIS	157	32.838	67.571	-10.060	1.00	29.16	A3	ATOM	1221	CD2	LEU	162	45.107	62.954	-6.415	1.00	27.04	A3
ATOM	1171	HE2	IIS	157	32.327	67.621	-10.895	1.00	0.00	A3	ATOM	1222	C	LEU	162	43.061	60.212	-8.813	1.00	31.21	A3

FIGURE 5

ATOM	1223	O	LEU	162	44.107	59.654	-9.070	1.00 36.51	A3	ATOM	1274	CG1	VAL	168	46.687	60.431	-16.706	1.00 66.78	A3
ATOM	1224	N	GLU	163	41.926	59.589	-9.082	1.00 37.24	A3	ATOM	1275	CG2	VAL	168	48.278	60.879	-14.840	1.00 68.47	A3
ATOM	1225	H	GLU	163	41.072	60.002	-8.826	1.00 0.00	A3	ATOM	1276	C	VAL	168	49.572	58.339	-15.459	1.00 66.45	A3
ATOM	1226	CA	GLU	163	41.975	58.327	-9.771	1.00 40.47	A3	ATOM	1277	O	VAL	168	50.458	58.183	-16.302	1.00 66.22	A3
ATOM	1227	CB	GLU	163	40.566	57.716	-9.835	1.00 45.38	A3	ATOM	1278	N	LEU	169	49.823	58.241	-14.317	1.00 68.83	A3
ATOM	1228	CG	GLU	163	40.264	56.975	-8.576	1.00 51.64	A3	ATOM	1279	H	LEU	169	49.102	58.404	-13.536	1.00 60.00	A3
ATOM	1229	CD	GLU	163	41.291	55.889	-8.126	1.00 57.97	A3	ATOM	1280	CA	LEU	169	51.141	57.899	-13.695	1.00 71.81	A3
ATOM	1230	OE1	GLU	163	40.897	54.722	-8.092	1.00 62.01	A3	ATOM	1281	CB	LEU	169	51.249	58.228	-12.188	1.00 71.54	A3
ATOM	1231	OE2	GLU	163	42.466	56.180	-7.832	1.00 59.17	A3	ATOM	1282	CG	LEU	169	51.137	59.732	-11.813	1.00 70.64	A3
ATOM	1232	C	GLU	163	42.586	58.430	-11.142	1.00 41.34	A3	ATOM	1283	CD1	LEU	169	51.187	59.826	-10.298	1.00 69.39	A3
ATOM	1233	O	GLU	163	43.456	57.633	-11.486	1.00 42.17	A3	ATOM	1284	CD2	LEU	169	52.223	60.580	-12.491	1.00 68.49	A3
ATOM	1234	N	VAL	164	42.257	59.636	-11.920	1.00 42.28	A3	ATOM	1285	C	LEU	169	51.333	56.414	-13.979	1.00 73.61	A3
ATOM	1235	H	VAL	164	41.589	60.091	-11.615	1.00 0.00	A3	ATOM	1286	O	LEU	169	52.408	56.013	-14.429	1.00 74.75	A3
ATOM	1236	CA	VAL	164	42.911	59.609	-13.187	1.00 44.13	A3	ATOM	1287	N	ARG	170	50.309	55.583	-13.819	1.00 75.45	A3
ATOM	1237	CB	VAL	164	42.207	60.711	-13.940	1.00 45.52	A3	ATOM	1288	II	ARG	170	49.480	55.923	-13.399	1.00 0.00	A3
ATOM	1238	CG1	VAL	164	42.892	56.775	-12.278	1.00 48.79	A3	ATOM	1289	CA	ARG	170	50.364	54.179	-14.199	1.00 78.17	A3
ATOM	1239	CG2	VAL	164	40.786	60.269	-14.226	1.00 46.09	A3	ATOM	1290	CB	ARG	170	49.944	53.662	-14.004	1.00 78.45	A3
ATOM	1240	C	VAL	164	44.386	59.933	-12.991	1.00 46.13	A3	ATOM	1291	CG	ARG	170	48.394	52.506	-14.871	1.00 78.17	A3
ATOM	1241	O	VAL	164	45.192	59.473	-13.794	1.00 45.99	A3	ATOM	1292	CD	ARG	170	48.744	51.181	-14.271	1.00 77.25	A3
ATOM	1242	N	SER	165	44.879	60.677	-12.006	1.00 49.51	A3	ATOM	1293	NE	ARG	170	51.123	51.297	-12.970	1.00 76.15	A3
ATOM	1243	II	SER	165	44.297	61.173	-11.396	1.00 0.00	A3	ATOM	1294	HE	ARG	170	47.245	51.520	-12.824	1.00 0.00	A3
ATOM	1244	CA	SER	165	46.325	60.845	-11.895	1.00 53.44	A3	ATOM	1295	C2	ARG	170	48.758	50.547	-11.970	1.00 76.14	A3
ATOM	1245	CB	SER	165	46.715	61.796	-10.775	1.00 54.77	A3	ATOM	1296	NH1	ARG	170	49.973	50.017	-12.112	1.00 76.84	A3
ATOM	1246	OG	SER	165	46.049	61.618	-9.530	1.00 59.99	A3	ATOM	1297	NH1	ARG	170	50.441	50.010	-12.994	1.00 0.00	A3
ATOM	1247	HG	SER	165	45.997	60.694	-9.261	1.00 0.00	A3	ATOM	1298	NH12	ARG	170	50.456	49.570	-11.329	1.00 0.00	A3
ATOM	1248	C	SER	165	46.958	59.502	-11.630	1.00 55.15	A3	ATOM	1299	NH2	ARG	170	46.147	50.492	-10.806	1.00 77.02	A3
ATOM	1249	O	SER	165	49.026	59.227	-12.148	1.00 55.02	A3	ATOM	1300	NH121	ARG	170	47.237	50.890	-10.714	1.00 0.00	A3
ATOM	1250	N	TYR	166	46.239	58.645	-10.900	1.00 51.57	A3	ATOM	1301	NH122	ARG	170	48.301	50.023	-10.023	1.00 0.00	A3
ATOM	1251	H	TYR	166	45.374	58.948	-10.549	1.00 0.00	A3	ATOM	1302	C	ARG	170	50.870	54.052	-15.647	1.00 79.84	A3
ATOM	1252	CA	TYR	166	46.617	57.273	-10.623	1.00 61.42	A3	ATOM	1303	O	ARG	170	51.924	53.470	-15.908	1.00 80.07	A3
ATOM	1253	CB	TYR	166	45.543	56.653	-9.680	1.00 64.05	A3	ATOM	1304	N	HIS	171	50.193	54.663	-16.611	1.00 81.46	A3
ATOM	1254	CG	TYR	166	45.502	55.138	-9.682	1.00 69.00	A3	ATOM	1305	H	HIS	171	49.433	55.234	-16.359	1.00 0.00	A3
ATOM	1255	CD1	TYR	166	44.389	54.501	-10.185	1.00 71.64	A3	ATOM	1306	CA	HIS	171	50.663	54.597	-17.902	1.00 84.03	A3
ATOM	1256	CE1	TYR	166	44.367	53.130	-10.263	1.00 73.15	A3	ATOM	1307	CB	HIS	171	49.590	55.054	-16.902	1.00 86.82	A3
ATOM	1257	CD2	TYR	166	46.594	54.409	-9.257	1.00 71.27	A3	ATOM	1308	CG	HIS	171	48.496	54.037	-19.147	1.00 90.73	A3
ATOM	1258	CE2	TYR	166	46.584	53.040	-9.346	1.00 72.92	A3	ATOM	1309	CD2	His	171	47.467	53.765	-16.272	1.00 91.35	A3
ATOM	1259	C2	TYR	166	45.468	52.417	-9.862	1.00 75.71	A3	ATOM	1310	ND1	His	171	48.301	53.307	-20.248	1.00 92.24	A3
ATOM	1260	OH	TYR	166	45.474	51.038	-10.016	1.00 80.61	A3	ATOM	1311	HD1	His	171	48.687	53.287	-21.044	1.00 0.00	A3
ATOM	1261	HH	TYR	166	44.571	50.736	-10.134	1.00 0.00	A3	ATOM	1312	CE1	His	171	47.204	52.605	-20.077	1.00 92.41	A3
ATOM	1262	C	TYR	166	46.712	56.567	-11.987	1.00 62.34	A3	ATOM	1313	NE2	His	171	46.711	52.892	-18.091	1.00 92.59	A3
ATOM	1263	O	TYR	166	47.766	55.981	-12.262	1.00 63.25	A3	ATOM	1314	HE2	His	171	45.884	52.511	-18.518	1.00 0.00	A3
ATOM	1264	N	ALA	167	45.727	56.622	-12.884	1.00 61.27	A3	ATOM	1315	C	His	171	51.907	55.446	-18.232	1.00 85.42	A3
ATOM	1265	H	ALA	167	44.893	57.019	-12.678	1.00 0.00	A3	ATOM	1316	O	His	171	52.440	55.352	-19.344	1.00 85.98	A3
ATOM	1266	CA	ALA	167	45.933	55.982	-14.159	1.00 61.47	A3	ATOM	1317	N	LEU	172	52.359	56.307	-17.302	1.00 86.13	A3
ATOM	1267	CB	ALA	167	44.608	55.904	-14.904	1.00 60.98	A3	ATOM	1318	H	LEU	172	51.870	56.411	-16.463	1.00 0.00	A3
ATOM	1268	C	ALA	167	46.982	56.694	-15.020	1.00 62.19	A3	ATOM	1319	CA	LEU	172	53.550	57.133	-17.496	1.00 86.02	A3
ATOM	1269	O	ALA	167	47.719	56.000	-15.734	1.00 62.63	A3	ATOM	1320	CB	LEU	172	53.500	58.357	-16.607	1.00 86.31	A3
ATOM	1270	N	VAL	168	47.210	58.011	-14.991	1.00 63.37	A3	ATOM	1321	CG	LEU	172	54.022	59.658	-17.203	1.00 87.48	A3
ATOM	1271	H	VAL	168	46.756	58.510	-14.330	1.00 0.00	A3	ATOM	1322	CD1	LEU	172	53.436	59.919	-16.596	1.00 87.68	A3
ATOM	1272	CA	VAL	168	48.174	58.593	-15.923	1.00 65.62	A3	ATOM	1323	CD1	LEU	172	53.645	60.278	-16.251	1.00 87.95	A3
ATOM	1273	CB	VAL	168	.48.061	60.121	-16.131	1.00 66.30	A3	ATOM	1324	C	LEU	172	54.813	56.357	-17.180	1.00 85.92	A3

FIGURE 5

ATOM	1325	O	I <sub>FU</sub>	172	55.896	56.660	-17.692	1.00	86.23	A <sub>3</sub>	ATOM	1376	CD1	PHE	214	45.176	39.459	23.044	1.00	-42.77	B <sub>1</sub>
ATOM	1326	N	A <sub>I</sub>	173	54.733	55.383	-16.282	1.00	85.49	A <sub>3</sub>	ATOM	1377	CD2	PHE	214	46.816	37.794	23.410	1.00	-42.02	B <sub>1</sub>
ATOM	1327	H	A <sub>I</sub>	173	53.899	55.276	-15.769	1.00	0.00	A <sub>3</sub>	ATOM	1378	CE1	PHE	214	44.197	36.554	23.423	1.00	-41.82	B <sub>1</sub>
ATOM	1328	CA	A <sub>I</sub>	173	55.856	54.497	-16.087	1.00	85.65	A <sub>3</sub>	ATOM	1379	CE2	PHE	214	45.814	36.898	23.776	1.00	-41.70	B <sub>1</sub>
ATOM	1329	CB	A <sub>I</sub>	173	56.602	54.859	-14.809	1.00	85.01	A <sub>3</sub>	ATOM	1380	CZ	PHE	214	44.519	37.277	23.791	1.00	-41.05	B <sub>1</sub>
ATOM	1330	C	A <sub>I</sub>	173	55.330	53.073	-16.008	1.00	86.54	A <sub>3</sub>	ATOM	1381	C	PHE	214	47.109	39.656	20.321	1.00	36.54	B <sub>1</sub>
ATOM	1331	OT1	A <sub>I</sub>	173	55.505	52.347	-16.971	1.00	87.21	A <sub>3</sub>	ATOM	1382	O	PHE	214	46.735	38.566	19.889	1.00	37.99	B <sub>1</sub>
ATOM	1332	OT2	A <sub>I</sub>	173	54.650	52.707	-15.036	1.00	87.31	A <sub>3</sub>	ATOM	1383	N	I <sub>LEU</sub>	215	46.616	40.812	19.893	1.00	33.27	B <sub>1</sub>
ATOM	1333	CB	I <sub>LEU</sub>	210	45.234	42.591	25.453	1.00	52.47	B <sub>1</sub>	ATOM	1384	H	I <sub>LEU</sub>	215	47.008	41.642	20.238	1.00	0.00	B <sub>1</sub>
ATOM	1334	CG	I <sub>LEU</sub>	210	43.799	42.058	25.547	1.00	51.68	B <sub>1</sub>	ATOM	1385	CA	I <sub>LEU</sub>	215	45.504	40.864	18.966	1.00	30.48	B <sub>1</sub>
ATOM	1335	CD1	I <sub>LEU</sub>	210	43.123	42.562	26.804	1.00	53.37	B <sub>1</sub>	ATOM	1386	CB	I <sub>LEU</sub>	215	45.099	42.282	18.701	1.00	31.82	B <sub>1</sub>
ATOM	1336	CD2	I <sub>LEU</sub>	210	43.050	42.453	24.303	1.00	51.37	B <sub>1</sub>	ATOM	1387	CG	I <sub>LEU</sub>	215	43.857	42.530	17.893	1.00	32.78	B <sub>1</sub>
ATOM	1337	C	I <sub>LEU</sub>	210	46.770	44.374	24.596	1.00	50.98	B <sub>1</sub>	ATOM	1388	CD1	I <sub>LEU</sub>	215	42.727	41.963	18.737	1.00	32.95	B <sub>1</sub>
ATOM	1338	O	I <sub>LEU</sub>	210	46.475	45.167	23.790	1.00	51.76	B <sub>1</sub>	ATOM	1389	CD2	I <sub>LEU</sub>	215	43.688	44.011	17.508	1.00	28.93	B <sub>1</sub>
ATOM	1339	HT1	I <sub>LEU</sub>	210	44.382	44.922	24.471	1.00	0.00	B <sub>1</sub>	ATOM	1390	C	I <sub>LEU</sub>	215	45.811	40.232	17.648	1.00	20.57	B <sub>1</sub>
ATOM	1340	HT2	I <sub>LEU</sub>	210	45.157	45.974	25.414	1.00	0.00	B <sub>1</sub>	ATOM	1391	O	I <sub>LEU</sub>	215	44.922	39.632	17.055	1.00	31.28	B <sub>1</sub>
ATOM	1341	N	I <sub>LEU</sub>	210	44.705	45.041	25.406	1.00	53.59	B <sub>1</sub>	ATOM	1392	N	I <sub>LEU</sub>	216	47.031	40.379	17.155	1.00	29.44	B <sub>1</sub>
ATOM	1342	HT3	I <sub>LEU</sub>	210	43.855	45.012	25.997	1.00	0.00	B <sub>1</sub>	ATOM	1393	H	I <sub>LEU</sub>	216	47.677	40.935	17.646	1.00	0.00	B <sub>1</sub>
ATOM	1343	CA	I <sub>LEU</sub>	210	45.730	44.038	25.676	1.00	52.35	B <sub>1</sub>	ATOM	1394	CB	I <sub>LEU</sub>	216	47.791	40.450	15.472	1.00	28.61	B <sub>1</sub>
ATOM	1344	N	PRO	211	47.974	43.825	24.494	1.00	49.35	B <sub>1</sub>	ATOM	1395	CG	I <sub>LEU</sub>	216	48.682	41.877	14.939	1.00	26.84	B <sub>1</sub>
ATOM	1345	CD	PRO	211	48.621	43.024	25.532	1.00	49.52	B <sub>1</sub>	ATOM	1396	CC	I <sub>LEU</sub>	216	49.925	42.558	15.344	1.00	28.57	B <sub>1</sub>
ATOM	1346	CA	PRO	211	48.895	44.191	23.419	1.00	49.04	B <sub>1</sub>	ATOM	1397	CD1	I <sub>LEU</sub>	216	48.446	41.950	13.452	1.00	24.09	B <sub>1</sub>
ATOM	1347	CB	PRO	211	50.209	41.571	23.865	1.00	49.02	B <sub>1</sub>	ATOM	1398	CA	I <sub>LEU</sub>	216	47.613	38.274	16.062	1.00	31.25	B <sub>1</sub>
ATOM	1348	CG	PRO	211	49.794	43.438	24.783	1.00	49.77	B <sub>1</sub>	ATOM	1399	C	I <sub>LEU</sub>	216	47.328	37.514	15.138	1.00	29.20	B <sub>1</sub>
ATOM	1349	C	PRO	211	49.543	43.064	21.965	1.00	48.03	B <sub>1</sub>	ATOM	1400	O	I <sub>LEU</sub>	216	47.999	37.826	17.261	1.00	32.50	B <sub>1</sub>
ATOM	1350	O	PRO	211	47.872	41.896	21.622	1.00	49.05	B <sub>1</sub>	ATOM	1401	N	I <sub>YS</sub>	217	49.714	34.491	20.521	1.00	53.27	B <sub>1</sub>
ATOM	1351	N	GLN	212	49.032	44.675	21.051	1.00	46.52	B <sub>1</sub>	ATOM	1402	H	I <sub>LYS</sub>	217	48.305	36.482	17.926	1.00	0.00	B <sub>1</sub>
ATOM	1352	H	GLN	212	49.506	43.478	21.349	1.00	0.00	B <sub>1</sub>	ATOM	1403	CA	I <sub>LYS</sub>	217	48.067	36.439	17.599	1.00	34.90	B <sub>1</sub>
ATOM	1353	CA	GLN	212	48.839	44.461	19.641	1.00	45.47	B <sub>1</sub>	ATOM	1404	CB	I <sub>LYS</sub>	217	48.645	36.280	19.002	1.00	38.07	B <sub>1</sub>
ATOM	1354	CB	GLN	212	49.533	45.522	18.849	1.00	46.81	B <sub>1</sub>	ATOM	1405	CG	I <sub>LYS</sub>	217	49.394	34.978	19.109	1.00	45.25	B <sub>1</sub>
ATOM	1355	CG	GLN	212	48.482	46.139	17.999	1.00	49.55	B <sub>1</sub>	ATOM	1406	CD	I <sub>LYS</sub>	217	49.714	34.491	20.521	1.00	53.27	B <sub>1</sub>
ATOM	1356	CD	GLN	212	49.024	46.703	16.709	1.00	54.21	B <sub>1</sub>	ATOM	1407	CE	I <sub>LYS</sub>	217	50.229	33.024	20.297	1.00	59.04	B <sub>1</sub>
ATOM	1357	OE1	GLN	212	48.429	47.672	16.232	1.00	57.72	B <sub>1</sub>	ATOM	1408	N2	I <sub>LYS</sub>	217	50.213	32.135	21.467	1.00	62.10	B <sub>1</sub>
ATOM	1358	NEX	GLN	212	50.086	46.176	16.074	1.00	52.39	B <sub>1</sub>	ATOM	1409	H21	I <sub>LYS</sub>	217	49.239	32.056	21.824	1.00	0.00	B <sub>1</sub>
ATOM	1359	HE21	GLN	212	50.530	45.383	16.430	1.00	0.00	B <sub>1</sub>	ATOM	1410	H22	I <sub>LYS</sub>	217	50.830	32.512	22.214	1.00	0.00	B <sub>1</sub>
ATOM	1360	HE22	GLN	212	50.341	46.625	15.244	1.00	0.00	B <sub>1</sub>	ATOM	1411	H23	I <sub>LYS</sub>	217	50.554	31.195	21.179	1.00	0.00	B <sub>1</sub>
ATOM	1361	C	GLN	212	49.390	43.133	19.185	1.00	44.79	B <sub>1</sub>	ATOM	1412	C	I <sub>LYS</sub>	217	46.617	35.950	17.546	1.00	36.77	B <sub>1</sub>
ATOM	1362	O	GLN	212	48.939	42.520	18.208	1.00	44.01	B <sub>1</sub>	ATOM	1413	O	I <sub>LYS</sub>	217	46.311	34.913	16.886	1.00	39.58	B <sub>1</sub>
ATOM	1363	N	SER	213	50.401	42.671	19.893	1.00	44.72	B <sub>1</sub>	ATOM	1414	N	CYS	218	45.664	36.638	18.188	1.00	34.86	B <sub>1</sub>
ATOM	1364	H	SER	213	50.730	43.115	20.698	1.00	0.00	B <sub>1</sub>	ATOM	1415	H	CYS	218	45.907	37.388	16.751	1.00	0.00	B <sub>1</sub>
ATOM	1365	CA	SER	213	51.075	41.424	19.521	1.00	43.76	B <sub>1</sub>	ATOM	1416	CA	CYS	218	44.237	36.738	16.076	1.00	35.61	B <sub>1</sub>
ATOM	1366	CB	SER	213	52.220	41.124	20.354	1.00	45.29	B <sub>1</sub>	ATOM	1417	C	CYS	218	43.430	37.175	16.846	1.00	33.21	B <sub>1</sub>
ATOM	1367	OG	SER	213	51.802	41.455	21.681	1.00	52.50	B <sub>1</sub>	ATOM	1418	SC	CYS	218	43.856	36.710	20.515	1.00	35.92	B <sub>1</sub>
ATOM	1368	HG	SER	213	52.479	41.127	22.288	1.00	0.00	B <sub>1</sub>	ATOM	1419	C	CYS	218	43.766	36.189	16.652	1.00	32.89	B <sub>1</sub>
ATOM	1369	C	SER	213	50.014	40.376	19.784	1.00	40.92	B <sub>1</sub>	ATOM	1420	O	CYS	218	43.155	35.169	16.323	1.00	34.71	B <sub>1</sub>
ATOM	1370	O	SER	213	49.964	39.992	18.947	1.00	43.32	B <sub>1</sub>	ATOM	1421	N	I <sub>LEU</sub>	219	44.035	37.169	15.777	1.00	29.52	B <sub>1</sub>
ATOM	1371	N	PHE	214	49.242	40.571	20.876	1.00	38.86	B <sub>1</sub>	ATOM	1422	H	I <sub>LEU</sub>	219	44.512	37.960	16.104	1.00	0.00	B <sub>1</sub>
ATOM	1372	H	PHE	214	49.414	41.370	21.410	1.00	0.00	B <sub>1</sub>	ATOM	1423	CA	I <sub>LEU</sub>	219	43.614	37.119	14.393	1.00	27.4	B <sub>1</sub>
ATOM	1373	CA	PHE	214	48.210	39.664	21.336	1.00	37.40	B <sub>1</sub>	ATOM	1424	CB	I <sub>LEU</sub>	219	44.116	38.412	13.727	1.00	26.24	B <sub>1</sub>
ATOM	1374	CH	PHE	214	47.568	40.064	22.634	1.00	37.45	B <sub>1</sub>	ATOM	1425	CG	I <sub>LEU</sub>	219	43.884	38.768	12.241	1.00	25.07	B <sub>1</sub>
ATOM	1375	CC	PHE	214	46.494	49.080	23.035	1.00	41.01	B <sub>1</sub>	ATOM	1426	CD1	I <sub>LEU</sub>	219	42.402	38.975	11.986	1.00	26.74	B <sub>1</sub>

FIGURE 5

ATOM	1427	C D2	LIA	219	44.563	~.551	11.882	1.00	22.10	B1	ATOM	1478	LYS	224	42.791	31.235	12.048	1.00	0.00	B1	
ATOM	1428	C	LEU	219	44.121	35.867	13.634	1.00	28.24	B1	ATOM	1479	CA	LYS	224	42.714	29.411	10.994	1.00	27.70	B1
ATOM	1428	C	LEU	219	43.373	35.204	12.889	1.00	27.12	B1	ATOM	1480	CB	LYS	224	43.922	29.085	11.818	1.00	30.07	B1
ATOM	1429	O	LEU	219	45.399	35.499	13.795	1.00	28.06	B1	ATOM	1481	CG	LYS	224	44.372	27.660	11.706	1.00	36.70	B1
ATOM	1430	N	GLU	220	45.957	35.974	14.448	1.00	0.00	B1	ATOM	1482	CD	LYS	224	45.829	27.544	12.127	1.00	41.68	B1
ATOM	1431	H	GLU	220	45.963	34.411	13.048	1.00	28.39	B1	ATOM	1483	CE	LYS	224	46.303	26.478	11.131	1.00	48.16	B1
ATOM	1432	CA	GLU	220	45.134	33.193	13.354	1.00	27.30	B1	ATOM	1484	N2	LYS	224	47.750	26.492	10.913	1.00	55.57	B1
ATOM	1433	CB	GLU	220	47.376	34.198	13.469	1.00	34.25	B1	ATOM	1485	H21	LYS	224	48.230	26.241	11.801	1.00	0.00	B1
ATOM	1434	CG	GLU	220	48.049	33.019	12.666	1.00	46.36	B1	ATOM	1486	H22	LYS	224	48.057	27.436	10.606	1.00	0.00	B1
ATOM	1435	CD	GLU	220	49.545	31.794	12.907	1.00	55.51	B1	ATOM	1487	H23	LYS	224	47.998	25.792	10.183	1.00	0.00	B1
ATOM	1436	OE1	GLU	220	50.113	32.133	12.021	1.00	56.95	B1	ATOM	1488	C	LYS	224	41.464	28.598	11.347	1.00	26.27	B1
ATOM	1437	OE2	GLU	220	50.144	33.213	13.930	1.00	60.41	B1	ATOM	1489	O	LYS	224	40.970	27.810	10.510	1.00	24.82	B1
ATOM	1438	C	GLU	220	45.134	33.193	13.354	1.00	27.30	B1	ATOM	1490	N	ILE	225	40.166	28.835	12.547	1.00	24.75	B1
ATOM	1439	O	GLU	220	44.662	32.534	12.437	1.00	27.08	B1	ATOM	1491	H	ILE	225	41.308	29.487	13.151	1.00	0.00	B1
ATOM	1440	N	GIN	221	44.866	33.023	14.642	1.00	25.42	B1	ATOM	1492	CA	ILE	225	39.656	26.147	12.943	1.00	23.33	B1
ATOM	1441	H	GIN	221	45.229	33.687	15.268	1.00	0.00	B1	ATOM	1493	CB	ILE	225	39.146	28.622	14.206	1.00	18.08	B1
ATOM	1442	CA	GIN	221	44.074	31.940	15.176	1.00	26.28	B1	ATOM	1494	CG2	ILE	225	37.874	27.872	14.577	1.00	15.43	B1
ATOM	1443	CB	GIN	221	44.143	31.927	16.691	1.00	26.78	B1	ATOM	1495	CG1	ILE	225	36.894	30.413	11.803	1.00	14.38	B1
ATOM	1444	CG	GIN	221	45.555	31.456	17.011	1.00	29.19	B1	ATOM	1496	CD	ILE	225	37.787	26.967	16.749	1.00	13.51	B1
ATOM	1445	CD	GIN	221	45.752	31.067	18.442	1.00	31.98	B1	ATOM	1497	C	ILE	225	38.594	26.437	11.089	1.00	27.28	B1
ATOM	1446	OE1	GIN	221	46.472	30.162	18.808	1.00	35.98	B1	ATOM	1498	O	ILE	225	37.978	27.492	11.400	1.00	31.49	B1
ATOM	1447	NE2	GIN	221	45.110	31.736	19.347	1.00	39.31	B1	ATOM	1499	N	GLN	226	38.396	29.677	11.402	1.00	29.69	B1
ATOM	1448	HE21	GLN	221	45.263	31.423	20.746	1.00	0.00	B1	ATOM	1500	G	GLN	226	37.158	34.281	10.076	1.00	36.34	B1
ATOM	1449	HE22	GLN	221	44.571	32.514	19.111	1.00	0.00	B1	ATOM	1501	CA	GLN	226	35.450	29.969	10.313	1.00	29.12	B1
ATOM	1450	C	GIN	221	42.615	31.925	14.789	1.00	26.21	B1	ATOM	1502	CB	GLN	226	37.366	31.438	9.962	1.00	32.46	B1
ATOM	1451	O	GIN	221	42.186	30.896	14.269	1.00	30.69	B1	ATOM	1503	CG	GLN	226	36.682	32.156	11.104	1.00	36.78	B1
ATOM	1452	N	VAL	222	41.814	32.962	14.984	1.00	23.63	B1	ATOM	1504	CD	GLN	226	36.429	33.613	10.816	1.00	37.84	B1
ATOM	1453	I	VAL	222	42.199	33.746	15.426	1.00	0.00	B1	ATOM	1505	OEI	GLN	226	35.359	32.510	11.421	1.00	39.62	B1
ATOM	1454	CA	VAL	222	40.429	33.034	14.537	1.00	21.92	B1	ATOM	1506	NEP	GLN	226	36.940	29.186	8.570	1.00	26.55	B1
ATOM	1455	CB	VAL	222	39.934	33.442	14.793	1.00	21.36	B1	ATOM	1507	HE21	GLN	226	34.823	33.501	11.971	1.00	0.00	B1
ATOM	1456	CG	VAL	222	38.706	34.831	14.027	1.00	17.72	B1	ATOM	1508	HE22	GLN	226	35.153	35.057	11.287	1.00	0.00	B1
ATOM	1457	CG2	VAL	222	39.671	34.496	16.257	1.00	20.93	B1	ATOM	1509	C	GLN	226	37.714	29.293	9.007	1.00	26.82	B1
ATOM	1458	C	VAL	222	40.374	32.707	13.066	1.00	22.65	B1	ATOM	1510	O	GLN	226	36.775	28.887	8.325	1.00	27.45	B1
ATOM	1459	O	VAL	222	39.475	32.013	12.632	1.00	23.77	B1	ATOM	1511	N	GLN	227	36.940	29.186	8.570	1.00	26.55	B1
ATOM	1460	N	ARG	223	41.341	33.120	12.283	1.00	23.95	B1	ATOM	1512	H	GLY	227	39.688	29.612	9.043	1.00	0.00	B1
ATOM	1461	H	ARG	223	42.099	33.614	12.666	1.00	0.00	B1	ATOM	1513	CA	GLY	227	39.195	28.427	7.348	1.00	22.27	B1
ATOM	1462	CA	ARG	223	41.309	32.939	10.844	1.00	27.19	B1	ATOM	1514	C	GLY	227	38.832	26.949	7.574	1.00	27.65	B1
ATOM	1463	CB	ARG	223	42.294	33.935	10.283	1.00	29.76	B1	ATOM	1515	O	GLY	228	40.427	24.554	10.774	1.00	24.88	B1
ATOM	1464	CG	ARG	223	42.102	34.364	8.869	1.00	35.23	B1	ATOM	1516	N	ASP	228	40.627	24.521	11.977	1.00	33.37	B1
ATOM	1465	CD	ARG	223	42.810	33.487	7.929	1.00	41.88	B1	ATOM	1517	H	ASP	228	41.302	24.637	9.912	1.00	23.32	B1
ATOM	1466	NE	ARG	223	41.972	32.676	7.096	1.00	47.42	B1	ATOM	1518	CA	ASP	228	38.618	25.038	9.052	1.00	28.20	B1
ATOM	1467	HE	ARG	223	41.451	31.933	7.502	1.00	0.00	B1	ATOM	1519	CB	ASP	228	38.986	24.492	10.391	1.00	26.04	B1
ATOM	1468	CZ	ARG	223	41.875	31.886	5.784	1.00	46.15	B1	ATOM	1520	CG	ASP	228	40.287	26.291	6.636	1.00	26.79	B1
ATOM	1469	NH1	ARG	223	42.575	33.837	5.246	1.00	49.34	B1	ATOM	1521	OD1	ASP	228	36.390	25.739	9.639	1.00	26.74	B1
ATOM	1470	III1	ARG	223	42.522	33.989	4.259	1.00	0.00	B1	ATOM	1522	OD2	ASP	228	36.861	26.444	10.134	1.00	0.00	B1
ATOM	1471	III12	ARG	223	43.156	34.428	5.805	1.00	0.00	B1	ATOM	1523	C	ASP	228	37.120	24.830	8.992	1.00	27.11	B1
ATOM	1472	III12	ARG	223	41.178	32.161	4.952	1.00	45.74	B1	ATOM	1524	O	ASP	228	36.662	23.900	8.336	1.00	27.07	B1
ATOM	1473	III12	ARG	223	40.697	31.353	5.290	1.00	0.00	B1	ATOM	1525	N	GLY	229	36.390	25.739	9.639	1.00	26.74	B1
ATOM	1474	III12	ARG	223	41.154	32.399	3.980	1.00	0.00	B1	ATOM	1526	H	GLY	229	36.861	26.444	10.134	1.00	0.00	B1
ATOM	1475	C	ARG	223	41.624	31.492	10.430	1.00	29.13	B1	ATOM	1527	CA	GLY	229	34.946	25.723	9.673	1.00	25.97	B1
ATOM	1476	O	ARG	223	41.181	30.987	9.376	1.00	29.32	B1	ATOM	1528	C	GLY	229	34.313	25.825	8.274	1.00	24.95	B1
ATOM	1477	N	LYS	224	47.413	30.791	11.159	1.00	29.17	B1											

FIGURE 5

ATOM	1529	O	G1Y	229	33.370	25.222	7.956	1.00	25.73	B1	ATOM	1580	N2	LYS	235	37.117	17.460	2.521	1.00	41.34	H1
ATOM	1530	N	ALA	230	35.058	26.541	7.391	1.00	23.97	B1	ATOM	1581	H21	LYS	235	37.080	17.978	1.622	1.00	0.00	H1
ATOM	1531	H	ALA	230	35.871	27.026	7.654	1.00	0.00	B1	ATOM	1582	H22	LYS	235	36.854	16.466	2.363	1.00	0.00	H1
ATOM	1532	CA	ALA	230	34.530	26.688	6.061	1.00	25.94	B1	ATOM	1583	H23	LYS	235	38.080	17.497	2.911	1.00	0.00	H1
ATOM	1533	CB	ALA	230	35.193	27.652	5.312	1.00	19.76	B1	ATOM	1584	C	LYS	235	30.363	16.847	3.204	1.00	35.20	H1
ATOM	1534	C	ALA	230	34.794	25.403	5.304	1.00	29.42	B1	ATOM	1585	O	LYS	235	29.722	16.102	2.563	1.00	45.60	H1
ATOM	1535	O	ALA	230	34.014	25.061	4.423	1.00	32.07	B1	ATOM	1586	N	LEU	236	29.807	19.332	4.301	1.00	35.54	H1
ATOM	1536	N	ALA	231	35.078	24.671	5.572	1.00	32.16	B1	ATOM	1587	H	LEU	236	30.363	19.806	4.895	1.00	0.00	H1
ATOM	1537	H	ALA	231	36.556	25.045	6.175	1.00	0.00	B1	ATOM	1588	CA	LEU	236	26.691	16.849	3.064	1.00	22.40	H1
ATOM	1538	CA	ALA	231	36.141	23.364	4.957	1.00	31.99	B1	ATOM	1589	CB	LEU	236	26.093	19.918	5.894	1.00	26.65	H1
ATOM	1539	CB	ALA	231	37.489	22.647	5.428	1.00	32.77	B1	ATOM	1590	CG	LEU	236	26.791	19.441	7.148	1.00	28.24	H1
ATOM	1540	C	ALA	231	35.060	22.361	5.386	1.00	32.99	B1	ATOM	1591	CD1	LEU	236	28.703	20.460	8.268	1.00	24.44	H1
ATOM	1541	O	ALA	231	34.599	21.575	4.576	1.00	34.12	B1	ATOM	1592	CD2	LEU	236	28.132	18.163	7.587	1.00	26.66	H1
ATOM	1542	N	LEU	232	34.662	22.309	6.652	1.00	33.30	B1	ATOM	1593	C	LEU	236	27.590	19.574	3.453	1.00	34.69	H1
ATOM	1543	H	LEU	232	35.174	22.861	7.284	1.00	0.00	B1	ATOM	1594	O	LEU	236	26.691	16.849	3.064	1.00	35.13	H1
ATOM	1544	CA	LEU	232	33.550	21.506	7.165	1.00	35.33	B1	ATOM	1595	N	CYS	237	27.870	20.670	2.753	1.00	34.49	H1
ATOM	1545	CB	LEU	232	33.279	21.783	8.626	1.00	34.22	B1	ATOM	1596	H	CYS	237	28.611	21.251	1.00	0.00	H1	
ATOM	1546	CG	LEU	232	32.410	20.861	9.394	1.00	33.16	B1	ATOM	1597	CA	CYS	237	27.064	21.016	1.606	1.00	34.95	H1
ATOM	1547	CD1	LEU	232	32.119	19.545	9.451	1.00	34.59	B1	ATOM	1598	C	CYS	237	27.324	20.090	0.451	1.00	35.97	H1
ATOM	1548	CD2	LEU	232	37.107	21.381	10.800	1.00	31.32	B1	ATOM	1599	O	CYS	237	26.360	19.573	-0.019	1.00	36.09	H1
ATOM	1549	C	LEU	232	32.271	21.829	6.440	1.00	36.65	B1	ATOM	1600	CB	CYS	237	27.334	22.413	1.130	1.00	35.18	H1
ATOM	1550	O	LEU	232	31.703	20.986	5.749	1.00	36.42	B1	ATOM	1601	SG	CYS	237	26.409	22.880	-0.365	1.00	36.50	H1
ATOM	1551	N	GLN	233	31.036	23.084	6.570	1.00	38.89	B1	ATOM	1602	N	ALA	238	29.571	19.804	0.074	1.00	37.79	H1
ATOM	1552	H	GLN	233	32.378	23.719	7.087	1.00	0.00	B1	ATOM	1603	II	ALA	238	29.324	20.158	0.591	1.00	0.00	H1
ATOM	1553	CA	GLN	233	30.637	23.579	5.933	1.00	40.02	B1	ATOM	1604	CA	ALA	238	28.841	18.973	-1.090	1.00	36.80	H1
ATOM	1554	CB	GLN	233	30.572	25.077	6.162	1.00	42.25	B1	ATOM	1605	C	ALA	238	30.274	16.684	-1.403	1.00	37.35	H1
ATOM	1555	CG	GLN	233	30.590	25.398	7.636	1.00	48.22	B1	ATOM	1606	C	ALA	238	28.320	17.617	-0.911	1.00	36.49	H1
ATOM	1556	CD	GLN	233	30.021	26.879	7.983	1.00	53.75	B1	ATOM	1607	O	ALA	238	27.645	17.198	-1.809	1.00	36.54	H1
ATOM	1557	OE1	GLN	233	30.799	27.810	7.718	1.00	55.93	B1	ATOM	1608	N	TIR	239	31.019	15.668	1.709	1.00	36.80	H1
ATOM	1558	NE2	GLN	233	28.909	27.215	8.634	1.00	56.51	B1	ATOM	1609	H	TIR	239	29.236	17.391	0.192	1.00	37.00	H1
ATOM	1559	HE1	GLN	233	28.610	26.144	8.902	1.00	0.00	B1	ATOM	1610	CA	TIR	239	28.230	15.587	-0.464	1.00	41.31	H1
ATOM	1560	HE2	GLN	233	28.205	26.533	8.710	1.00	0.00	B1	ATOM	1611	CB	TIR	239	29.158	15.035	1.554	1.00	42.38	H1
ATOM	1561	C	GLN	233	30.635	23.243	4.441	1.00	39.70	B1	ATOM	1612	O	TIR	239	30.473	15.265	1.669	1.00	40.07	H1
ATOM	1562	O	GLN	233	29.631	22.777	3.898	1.00	40.20	B1	ATOM	1613	IG1	TIR	239	26.538	17.034	1.953	1.00	41.62	H1
ATOM	1563	N	GLU	234	31.744	23.377	3.736	1.00	39.32	B1	ATOM	1614	CG2	TIR	239	24.718	15.992	2.084	1.00	38.71	H1
ATOM	1564	H	GLU	234	32.544	23.750	4.163	1.00	0.00	B1	ATOM	1615	C	TIR	239	26.771	15.341	0.464	1.00	41.94	H1
ATOM	1565	CA	GLU	234	31.809	23.025	2.329	1.00	39.23	B1	ATOM	1616	O	TIR	239	26.260	14.284	1.403	1.00	41.54	H1
ATOM	1566	CB	GLU	234	33.155	23.434	1.811	1.00	40.25	B1	ATOM	1617	N	TIR	240	26.095	16.207	1.669	1.00	40.70	H1
ATOM	1567	CG	GLU	234	33.292	23.028	0.383	1.00	47.69	B1	ATOM	1618	II	TIR	240	26.538	17.034	1.953	1.00	41.55	H1
ATOM	1568	CD	GLU	234	34.733	23.056	-0.073	1.00	53.40	B1	ATOM	1619	CA	TIR	240	24.718	15.992	2.084	1.00	38.71	H1
ATOM	1569	OE1	GLU	234	34.986	23.721	-1.100	1.00	53.78	B1	ATOM	1620	CB	TIR	240	25.594	14.593	3.618	1.00	41.94	H1
ATOM	1570	OE2	GLU	234	35.568	22.400	0.590	1.00	57.55	B1	ATOM	1621	CG	TIR	240	25.524	14.926	4.193	1.00	43.37	H1
ATOM	1571	C	GLU	234	31.580	21.355	2.136	1.00	37.09	B1	ATOM	1622	CD1	TIR	240	26.475	15.243	5.149	1.00	45.06	H1
ATOM	1572	O	GLU	234	30.084	21.217	1.188	1.00	36.67	B1	ATOM	1623	CE1	TIR	240	27.420	14.283	5.529	1.00	47.35	H1
ATOM	1573	N	LYS	235	32.092	20.623	2.986	1.00	37.27	B1	ATOM	1624	CD2	TIR	240	25.518	13.643	3.641	1.00	43.89	H1
ATOM	1574	H	LYS	235	32.668	20.965	3.706	1.00	0.00	B1	ATOM	1625	CE2	TIR	240	26.442	12.690	4.003	1.00	44.77	H1
ATOM	1575	CA	LYS	235	31.832	19.177	2.942	1.00	36.27	B1	ATOM	1626	CZ	TIR	240	27.410	13.005	4.943	1.00	47.96	H1
ATOM	1576	CB	LYS	235	32.516	18.365	3.997	1.00	34.92	B1	ATOM	1627	OH	TIR	240	26.390	12.047	5.244	1.00	46.51	H1
ATOM	1577	CG	LYS	235	33.978	18.483	4.107	1.00	38.47	B1	ATOM	1628	III	TIR	240	25.207	11.117	4.992	1.00	40.00	H1
ATOM	1578	CD	LYS	235	34.762	17.999	2.921	1.00	38.07	B1	ATOM	1629	C	TYK	240	23.781	17.632	1.516	1.00	41.49	H1
ATOM	1579	CE	LYS	235	36.192	18.051	3.460	1.00	39.15	B1	ATOM	1630	O	TYK	240	22.587	16.934	1.775	1.00	41.76	H1

## FIGURE 5

ATOM	1631	N	LYS	241	24.174	18..	-	0.694	1.00	37.36	B1
ATOM	1632	H	LYS	241	25.091	18.013	0.345	1.00	0.00	B1	
ATOM	1633	CA	LYS	241	23.314	19.115	0.275	1.00	36.37	B1	
ATOM	1634	CB	LYS	241	22.173	18.648	-0.595	1.00	38.38	B1	
ATOM	1635	CG	LYS	241	22.643	17.940	-1.838	1.00	42.94	B1	
ATOM	1636	CD	LYS	241	23.468	18.809	-2.737	1.00	46.97	B1	
ATOM	1637	CE	LYS	241	23.657	18.070	-4.051	1.00	49.20	B1	
ATOM	1638	NZ	LYS	241	22.509	18.372	-4.893	1.00	51.54	B1	
ATOM	1639	H21	LYS	241	22.447	19.401	-5.038	1.00	0.00	B1	
ATOM	1640	H22	LYS	241	21.641	18.041	-4.426	1.00	0.00	B1	
ATOM	1641	H23	LYS	241	22.609	17.895	-5.811	1.00	0.00	B1	
ATOM	1642	C	LYS	241	22.720	19.904	1.429	1.00	33.37	B1	
ATOM	1643	O	LYS	241	21.728	20.580	1.223	1.00	33.90	B1	
ATOM	1644	N	LEU	242	23.286	19.453	2.648	1.00	31.40	B1	
ATOM	1645	H	LEU	242	24.055	19.260	2.756	1.00	0.00	B1	
ATOM	1646	CA	LEU	242	22.904	20.662	3.758	1.00	31.09	B1	
ATOM	1647	CB	LEU	242	23.253	20.059	5.096	1.00	26.55	B1	
ATOM	1648	CG	LEU	242	22.571	18.798	5.641	1.00	30.36	B1	
ATOM	1649	CD1	LEU	242	22.530	18.814	7.138	1.00	29.62	B1	
ATOM	1650	CD2	LEU	242	21.086	18.861	5.443	1.00	31.94	B1	
ATOM	1651	C	LEU	242	23.778	21.933	3.550	1.00	34.03	B1	
ATOM	1652	O	LEU	242	24.903	22.027	4.058	1.00	35.53	B1	
ATOM	1653	N	CYS	243	23.316	22.883	2.722	1.00	34.89	B1	
ATOM	1654	H	CYS	243	22.491	22.665	2.238	1.00	0.00	B1	
ATOM	1655	CA	CYS	243	24.051	24.083	2.377	1.00	35.42	B1	
ATOM	1656	C	CYS	243	23.492	23.535	2.975	1.00	36.85	B1	
ATOM	1657	O	CYS	243	23.956	26.400	2.565	1.00	40.10	B1	
ATOM	1658	CB	CYS	243	24.046	24.383	0.929	1.00	33.12	B1	
ATOM	1659	SG	CYS	243	24.438	22.883	0.099	1.00	38.25	B1	
ATOM	1660	N	IHS	244	22.496	25.393	3.848	1.00	35.37	B1	
ATOM	1661	H	IHS	244	21.874	27.902	1.298	1.00	36.85	B1	
ATOM	1662	CA	IHS	244	21.939	26.676	4.191	1.00	33.29	B1	
ATOM	1663	CB	IHS	244	20.655	26.987	3.340	1.00	33.64	B1	
ATOM	1664	CG	IHS	244	20.915	27.705	1.857	1.00	33.12	B1	
ATOM	1665	CD2	IHS	244	20.616	26.706	-1.214	1.00	0.00	B1	
ATOM	1666	ND1	IHS	244	21.185	24.588	4.318	1.00	0.00	B1	
ATOM	1667	HD1	IHS	244	22.648	26.201	1.778	1.00	0.00	B1	
ATOM	1668	CE1	IHS	244	21.874	27.722	-0.013	1.00	33.55	B1	
ATOM	1669	NE2	IHS	244	20.910	26.920	-0.301	1.00	35.54	B1	
ATOM	1670	HE2	IHS	244	20.616	26.706	-1.214	1.00	0.00	B1	
ATOM	1671	C	IHS	244	21.874	27.902	1.298	1.00	33.38	B1	
ATOM	1672	O	IHS	244	22.648	26.201	1.778	1.00	0.00	B1	
ATOM	1673	N	PRO	245	21.539	27.018	6.499	1.00	33.21	B1	
ATOM	1674	CD	PRO	245	23.051	27.524	6.099	1.00	31.29	B1	
ATOM	1675	CA	PRO	245	22.373	26.979	7.948	1.00	34.16	B1	
ATOM	1676	CB	PRO	245	23.490	27.799	8.467	1.00	32.85	B1	
ATOM	1677	CG	PRO	245	20.546	26.105	6.029	1.00	33.73	B1	
ATOM	1678	C	PRO	245	21.032	27.470	8.407	1.00	36.26	B1	
ATOM	1679	O	PRO	245	20.478	26.878	9.315	1.00	38.13	B1	
ATOM	1680	N	Glu	246	20.529	28.463	7.640	1.00	39.64	B1	
ATOM	1681	H	Glu	246	21.134	28.747	6.934	1.00	0.00	B1	
ATOM	1682	C	GLU	246	19.257	29.229	7.711	1.00	41.10	H1	
ATOM	1683	CB	GLU	246	19.044	30.107	6.486	1.00	44.15	H1	
ATOM	1684	CG	GLU	246	20.256	30.918	5.944	1.00	47.07	H1	
ATOM	1685	CD	GLU	246	20.813	30.539	4.558	1.00	52.63	H1	
ATOM	1686	OE1	GLU	246	22.054	30.545	4.374	1.00	54.22	H1	
ATOM	1687	OE2	GLU	246	20.002	30.250	3.656	1.00	53.39	H1	
ATOM	1688	C	GLU	246	18.071	28.298	7.819	1.00	40.57	H1	
ATOM	1689	O	GLU	246	17.308	28.338	8.791	1.00	39.00	H1	
ATOM	1690	CD	GLU	247	15.015	27.388	6.840	1.00	40.32	H1	
ATOM	1691	H	GLU	247	18.750	27.334	6.190	1.00	0.00	H1	
ATOM	1692	CA	GLU	247	17.401	26.347	6.830	1.00	50.84	H1	
ATOM	1693	CB	GLU	247	17.139	25.423	5.642	1.00	44.03	H1	
ATOM	1694	CG	GLU	247	15.915	24.868	6.329	1.00	39.49	H1	
ATOM	1695	CD	GLU	247	18.066	25.280	6.760	1.00	37.92	H1	
ATOM	1696	OE1	GLU	247	17.094	26.844	5.676	1.00	0.00	H1	
ATOM	1697	OE2	GLU	247	17.744	24.533	9.058	1.00	35.75	H1	
ATOM	1698	C	GLU	248	16.966	25.444	8.014	1.00	39.24	H1	
ATOM	1699	O	GLU	248	17.046	23.623	9.796	1.00	34.13	H1	
ATOM	1700	N	LEU	248	19.669	22.866	8.430	1.00	34.00	H1	
ATOM	1701	H	LEU	248	17.044	20.997	22.149	1.00	33.97	H1	
ATOM	1702	CA	LEU	248	18.101	24.338	9.058	1.00	36.51	H1	
ATOM	1703	CB	LEU	248	19.458	23.623	9.796	1.00	34.88	H1	
ATOM	1704	CG	LEU	248	19.669	22.866	8.430	1.00	34.00	H1	
ATOM	1705	CD1	LEU	248	17.566	26.350	10.281	1.00	41.97	H1	
ATOM	1706	CD2	LEU	248	18.620	21.810	8.322	1.00	32.33	H1	
ATOM	1707	C	LEU	248	17.871	25.031	11.155	1.00	36.51	H1	
ATOM	1708	O	LEU	248	17.736	24.370	12.186	1.00	36.31	H1	
ATOM	1709	N	VAL	249	17.663	26.350	11.146	1.00	34.88	H1	
ATOM	1710	H	VAL	249	17.566	26.635	13.406	1.00	42.61	H1	
ATOM	1711	O	VAL	249	16.912	26.716	14.594	1.00	44.77	H1	
ATOM	1712	CB	VAL	249	17.573	27.133	12.371	1.00	41.49	H1	
ATOM	1713	CG1	VAL	249	17.519	25.577	11.011	1.00	47.41	H1	
ATOM	1714	CG2	VAL	249	15.804	26.965	11.776	1.00	44.70	H1	
ATOM	1715	C	VAL	249	17.707	29.434	13.214	1.00	45.20	H1	
ATOM	1716	CD1	LEU	250	13.102	25.296	13.373	1.00	44.68	H1	
ATOM	1717	CD2	LEU	250	13.092	25.577	11.011	1.00	47.41	H1	
ATOM	1718	CA	LEU	250	11.286	26.772	12.441	1.00	46.18	H1	
ATOM	1719	CB	LEU	251	14.852	24.207	14.626	1.00	43.56	H1	
ATOM	1720	CB	LEU	250	14.457	25.537	13.987	1.00	43.96	H1	
ATOM	1721	CC	LEU	250	13.102	25.296	13.373	1.00	44.68	H1	
ATOM	1722	CD1	LEU	250	12.729	26.281	12.313	1.00	47.04	H1	
ATOM	1723	CD2	LEU	250	12.186	26.772	12.441	1.00	46.18	H1	
ATOM	1724	C	LEU	251	14.450	23.887	15.764	1.00	44.07	H1	
ATOM	1725	O	LEU	250	14.569	23.446	13.893	1.00	42.41	H1	
ATOM	1726	N	LEU	251	15.691	23.446	13.893	1.00	44.61	H1	
ATOM	1727	H	LEU	251	16.049	23.788	13.048	1.00	43.00	H1	
ATOM	1728	CA	LEU	251	16.155	22.159	14.362	1.00	40.64	H1	
ATOM	1729	CB	LEU	251	16.834	21.418	13.257	1.00	36.17	H1	
ATOM	1730	CG	LEU	251	15.906	26.629	12.267	1.00	34.16	H1	
ATOM	1731	CD1	LEU	251	14.595	21.668	11.956	1.00	34.46	H1	
ATOM	1732	CD2	LEU	251	16.875	20.619	11.050	1.00	34.71	H1	

FIGURE 5

ATOM	1733 C ILE	251	17.104	22.377	15.493	1.00	42.78	B1
ATOM	1734 O ILE	251	16.124	21.554	16.395	1.00	45.44	B1
ATOM	1735 N GLY	252	17.826	23.477	15.610	1.00	44.86	B1
ATOM	1736 H GLY	252	17.750	24.160	14.910	1.00	0.00	B1
ATOM	1737 CA GLY	252	18.734	23.711	16.719	1.00	46.68	B1
ATOM	1738 C GLY	252	18.071	23.067	16.00	49.18	B1	
ATOM	1739 O GLY	252	16.709	23.318	19.077	1.00	49.23	B1
ATOM	1740 N HIS	253	16.756	23.787	18.046	1.00	53.74	B1
ATOM	1741 H HIS	253	16.358	24.055	17.190	1.00	0.00	B1
ATOM	1742 CA HIS	253	15.659	23.649	19.197	1.00	57.46	B1
ATOM	1743 CB HIS	253	14.468	24.157	18.764	1.00	62.93	B1
ATOM	1744 CG HIS	253	13.212	23.813	19.577	1.00	68.75	B1
ATOM	1745 CD2 HIS	253	12.031	24.529	19.414	1.00	71.00	B1
ATOM	1746 ND1 HIS	253	12.980	22.654	20.419	1.00	70.67	B1
ATOM	1747 IIDI HIS	253	13.627	22.193	20.830	1.00	0.00	B1
ATOM	1748 CEI HIS	253	11.723	22.966	20.845	1.00	73.40	B1
ATOM	1749 NE2 HIS	253	11.156	23.973	20.204	1.00	72.91	B1
ATOM	1750 HE2 HIS	253	10.218	24.260	20.311	1.00	0.00	B1
ATOM	1751 C HIS	253	15.771	22.209	19.691	1.00	56.06	B1
ATOM	1752 O HIS	253	15.980	21.627	20.857	1.00	56.17	B1
ATOM	1753 N SER	254	15.395	21.435	16.724	1.00	53.46	B1
ATOM	1754 H SER	254	15.278	21.783	17.813	1.00	0.00	B1
ATOM	1755 CA SER	254	15.177	20.034	18.898	1.00	52.61	B1
ATOM	1756 CB SER	254	14.613	19.595	17.576	1.00	53.04	B1
ATOM	1757 OG SER	254	13.793	20.686	17.158	1.00	56.04	B1
ATOM	1758 IG SLN	254	15.369	20.467	16.319	1.00	0.00	B1
ATOM	1759 C SER	254	16.512	19.386	19.275	1.00	51.48	B1
ATOM	1760 O SER	254	16.595	18.639	20.245	1.00	51.90	B1
ATOM	1761 N LEU	255	15.177	19.790	18.562	1.00	49.31	B1
ATOM	1762 H LEU	255	17.430	20.480	17.889	1.00	0.00	B1
ATOM	1763 CA LEU	255	18.913	19.272	18.723	1.00	46.02	B1
ATOM	1764 CB LEU	255	19.706	19.723	17.537	1.00	44.66	B1
ATOM	1765 CG LEU	255	19.362	18.964	16.274	1.00	44.51	B1
ATOM	1766 CD1 LEU	255	19.810	19.679	15.006	1.00	43.16	B1
ATOM	1767 CD2 LEU	255	19.969	17.604	16.456	1.00	44.67	B1
ATOM	1768 C GLY	256	19.536	19.718	20.012	1.00	46.56	B1
ATOM	1769 O LEU	255	20.565	19.174	20.440	1.00	46.82	B1
ATOM	1770 N GLY	256	18.916	20.759	20.581	1.00	45.93	B1
ATOM	1771 H GLY	256	18.210	21.225	20.101	1.00	0.00	B1
ATOM	1772 CA GLY	256	19.277	21.173	21.890	1.00	46.68	B1
ATOM	1773 C GLY	256	20.669	21.866	21.970	1.00	47.28	B1
ATOM	1774 O GLY	256	21.273	21.844	23.056	1.00	49.64	B1
ATOM	1775 N ILE	257	21.143	21.441	20.849	1.00	45.74	B1
ATOM	1776 H ILE	257	20.497	22.589	20.128	1.00	0.00	B1
ATOM	1777 CA ILE	257	22.481	23.017	20.726	1.00	43.64	B1
ATOM	1778 CB ILE	257	22.684	23.363	19.257	1.00	41.54	B1
ATOM	1779 CG2 ILE	257	23.988	24.110	19.073	1.00	41.05	B1
ATOM	1780 CG1 ILE	257	22.694	22.068	18.437	1.00	40.55	B1
ATOM	1781 CD ILE	257	22.452	22.468	16.970	1.00	39.49	B1
ATOM	1782 C ILE	257	22.559	24.246	21.616	1.00	43.77	B1
ATOM	1783 O ILE	257	21.706	25.110	21.450	1.00	43.22	B1
ATOM	1784 N PRO	258	23.441	24.392	21.608	1.00	43.05	B1
ATOM	1785 CD PRO	258	24.143	23.321	23.296	1.00	44.29	B1
ATOM	1786 CA PRO	258	23.559	25.616	23.360	1.00	43.82	B1
ATOM	1787 CB PRO	258	24.295	24.612	21.00	41.97	B1	
ATOM	1788 CG PRO	258	25.107	24.064	24.186	1.00	41.79	B1
ATOM	1789 C PRO	258	24.252	26.703	22.555	1.00	46.06	B1
ATOM	1790 O PRO	258	24.983	26.513	21.560	1.00	46.59	B1
ATOM	1791 N TRP	259	23.996	27.867	21.106	1.00	46.75	B1
ATOM	1792 H TRP	259	23.918	27.921	23.994	1.00	0.00	B1
ATOM	1793 CA TRP	259	24.427	29.143	22.517	1.00	45.77	B1
ATOM	1794 CB TRP	259	23.213	30.071	22.397	1.00	46.64	B1
ATOM	1795 CG TRP	259	23.556	31.372	21.749	1.00	47.51	B1
ATOM	1796 O TRP	259	24.013	31.525	20.430	1.00	47.83	B1
ATOM	1797 CD2 TRP	259	24.154	32.688	20.392	1.00	46.47	B1
ATOM	1798 CE3 TRP	259	23.940	30.745	19.290	1.00	47.39	B1
ATOM	1799 CI2 TRP	259	23.639	32.520	22.493	1.00	48.60	R1
ATOM	1800 NE1 TRP	259	24.013	33.421	21.628	1.00	48.27	R1
ATOM	1801 HE1 TRP	259	24.224	34.344	21.970	1.00	0.00	R1
ATOM	1802 C22 TRP	259	24.531	33.486	19.195	1.00	47.40	R1
ATOM	1803 C23 TRP	259	24.317	31.344	18.697	1.00	49.07	R1
ATOM	1804 CI1 TRP	259	24.613	32.706	18.050	1.00	49.12	R1
ATOM	1805 C TRP	259	25.459	29.727	23.440	1.00	44.01	R1
ATOM	1806 O TRP	259	25.340	29.664	24.667	1.00	45.25	R1
ATOM	1807 N ALA	260	26.469	30.147	22.777	1.00	43.01	R1
ATOM	1808 H ALA	260	26.523	30.198	21.796	1.00	0.00	R1
ATOM	1809 CA ALA	260	27.493	30.973	23.482	1.00	43.48	R1
ATOM	1810 CB ALA	260	28.874	30.549	22.969	1.00	43.34	R1
ATOM	1811 C ALA	260	27.249	31.486	23.216	1.00	43.41	R1
ATOM	1812 O ALA	260	27.353	31.946	22.054	1.00	40.55	R1
ATOM	1813 C PRO	261	26.053	33.267	24.253	1.00	42.61	R1
ATOM	1814 CD PRO	261	26.527	32.807	25.036	1.00	42.33	R1
ATOM	1815 CA PRO	261	26.720	34.701	24.199	1.00	42.37	R1
ATOM	1816 CB PRO	261	27.513	36.403	23.535	1.00	41.46	R1
ATOM	1817 CG PRO	261	26.251	34.060	26.411	1.00	40.00	R1
ATOM	1818 C PRO	261	26.381	36.609	22.610	1.00	45.09	R1
ATOM	1819 N SER	262	31.903	37.157	22.964	1.00	42.55	R1
ATOM	1820 H SER	262	27.982	36.242	21.427	1.00	0.00	R1
ATOM	1821 C SER	262	32.850	36.730	21.900	1.00	44.21	R1
ATOM	1822 O SER	262	29.154	38.628	23.035	1.00	48.56	R1
ATOM	1823 CB SER	262	29.434	37.210	23.498	1.00	46.50	R1
ATOM	1824 CG SER	262	30.531	36.609	22.610	1.00	45.09	R1
ATOM	1825 CD1 SER	262	31.344	36.695	24.338	1.00	41.52	R1
ATOM	1826 CD2 SER	262	32.850	36.730	21.900	1.00	44.21	R1
ATOM	1827 C SER	262	29.154	38.628	23.035	1.00	48.56	R1
ATOM	1828 O SER	262	29.613	39.470	23.790	1.00	48.23	R1
ATOM	1829 N SER	263	28.388	38.936	21.960	1.00	51.3	R1
ATOM	1830 H SER	263	27.982	36.242	21.427	1.00	0.00	R1
ATOM	1831 CA SER	263	28.127	40.339	21.494	1.00	55.19	R1
ATOM	1832 CB SER	263	26.871	40.511	20.612	1.00	57.17	R1
ATOM	1833 CG SER	263	26.498	39.411	19.776	1.00	64.12	R1
ATOM	1834 TG SER	263	26.093	38.741	20.336	1.00	0.00	R1

FIGURE 5

ATOM	1835	C SER	263	27.909	41.354	22.600	1.00	56.15	B1	ATOM	1886	C LIR	276	37.673	35.833	26.638	1.00	47.84	H2
ATOM	1836	O SER	263	28.744	42.243	22.753	1.00	57.88	B1	ATOM	1887	O LEU	276	37.784	34.803	27.964	1.00	48.51	H2
ATOM	1837	N SER	264	26.099	41.231	23.452	1.00	56.52	B1	ATOM	1888	N ALA	277	37.074	35.840	29.804	1.00	45.56	H2
ATOM	1838	U SER	264	26.277	40.478	23.415	1.00	0.00	B1	ATOM	1889	H ALA	277	36.698	36.662	30.289	1.00	0.00	H2
ATOM	1840	C SER	264	26.716	42.204	24.494	1.00	58.28	B1	ATOM	1890	CA ALA	277	36.613	34.605	30.365	1.00	45.77	H2
ATOM	1841	OG SER	264	25.313	41.977	25.064	1.00	58.77	B1	ATOM	1891	CB ALA	277	36.147	34.810	31.783	1.00	47.87	H2
ATOM	1842	IG SER	264	25.099	40.776	25.713	1.00	58.50	B1	ATOM	1892	C ALA	277	35.442	34.111	29.542	1.00	45.34	H2
ATOM	1843	C SER	264	25.385	40.832	26.632	1.00	0.00	B1	ATOM	1893	O ALA	277	35.342	32.926	29.271	1.00	44.20	H2
ATOM	1844	O SER	264	27.800	42.168	25.584	1.00	59.95	B1	ATOM	1894	N GIN	278	34.592	35.000	29.049	1.00	45.13	H2
ATOM	1845	N CYS	265	28.948	41.484	25.466	1.00	61.37	B1	ATOM	1895	H GIN	278	34.731	35.944	29.263	1.00	0.00	H2
ATOM	1846	H CYS	265	29.192	41.114	24.596	1.00	0.00	B1	ATOM	1896	CA GIN	278	33.435	34.601	28.284	1.00	45.27	H2
ATOM	1847	CA CYS	265	29.938	41.502	26.509	1.00	62.57	B1	ATOM	1897	CB GIN	278	32.550	35.825	28.083	1.00	46.13	H2
ATOM	1848	CB CYS	265	30.991	40.418	26.285	1.00	64.32	B1	ATOM	1898	CG GIN	278	31.140	35.442	28.484	1.00	56.00	H2
ATOM	1849	SC CYS	265	32.322	40.638	27.504	1.00	71.40	B1	ATOM	1899	CD GIN	278	30.045	36.464	26.178	1.00	61.94	H2
ATOM	1850	C CYS	265	30.667	42.860	26.515	1.00	63.12	B1	ATOM	1900	OEG GIN	278	29.048	36.530	28.896	1.00	65.95	H2
ATOM	1851	OT1 CYS	265	31.065	43.360	25.444	1.00	63.44	B1	ATOM	1901	NEF GIN	278	30.080	37.291	27.132	1.00	65.55	H2
ATOM	1852	OT2 CYS	265	30.809	43.408	27.610	1.00	61.72	B1	ATOM	1902	HE21 GIN	278	30.829	37.221	26.510	1.00	0.00	H2
ATOM	1853	CB ALA	272	40.020	43.327	30.788	1.00	77.44	B2	ATOM	1903	HE22 GIN	278	29.343	37.927	27.056	1.00	0.00	H2
ATOM	1854	C ALA	272	38.698	41.201	30.601	1.00	76.53	B2	ATOM	1904	C GIN	278	33.812	33.971	26.950	1.00	43.16	H2
ATOM	1855	O ALA	272	37.525	40.873	30.361	1.00	76.81	B2	ATOM	1905	O GIN	278	33.173	33.050	26.462	1.00	40.58	H2
ATOM	1856	HT1 ALA	272	37.486	43.550	30.261	1.00	0.00	B2	ATOM	1906	N LEU	279	34.869	34.476	26.331	1.00	43.32	H2
ATOM	1857	HT2 ALA	272	37.357	42.450	28.996	1.00	0.00	B2	ATOM	1907	I LEU	279	35.328	35.227	26.767	1.00	0.00	H2
ATOM	1858	N ALA	272	37.973	43.169	29.427	1.00	76.81	B2	ATOM	1908	CA ILEU	279	35.398	33.966	25.069	1.00	42.80	H2
ATOM	1859	HT3 ALA	272	38.195	43.924	28.752	1.00	0.00	B2	ATOM	1909	CB ILEU	279	36.583	34.790	24.626	1.00	41.42	H2
ATOM	1860	CA ALA	272	39.176	42.060	29.853	1.00	77.02	B2	ATOM	1910	CG ILEU	279	36.885	35.014	23.190	1.00	40.76	H2
ATOM	1861	N ALA	273	39.485	43.547	31.487	1.00	74.93	B2	ATOM	1911	CD1 ILEU	279	36.837	33.647	23.130	1.00	41.76	H2
ATOM	1862	II ALA	273	40.334	40.963	31.745	1.00	0.00	B2	ATOM	1912	CD2 ILEU	279	36.943	33.753	22.411	1.00	40.01	H2
ATOM	1863	CA ALA	273	39.244	39.741	32.119	1.00	72.64	B2	ATOM	1913	C ILEU	279	35.876	31.554	25.341	1.00	42.92	H2
ATOM	1864	CB ALA	273	39.704	39.279	33.558	1.00	71.92	B2	ATOM	1914	O ILEU	279	35.572	31.598	24.640	1.00	42.57	H2
ATOM	1865	C ALA	273	37.872	38.599	32.118	1.00	71.60	B2	ATOM	1915	H ILEU	280	36.654	32.463	26.403	1.00	43.93	H2
ATOM	1866	A ALA	273	37.806	37.458	31.702	1.00	71.68	B2	ATOM	1916	H HIS	280	36.837	33.242	26.917	1.00	0.00	H2
ATOM	1867	N GLY	274	36.775	39.282	32.484	1.00	70.20	B2	ATOM	1917	CA HIS	280	37.215	31.223	26.850	1.00	46.12	H2
ATOM	1868	H GLY	274	36.903	40.167	32.874	1.00	0.00	B2	ATOM	1918	CB HIS	280	38.019	31.506	28.101	1.00	48.74	H2
ATOM	1869	CA GLY	274	35.412	38.758	32.475	1.00	66.78	B2	ATOM	1919	CG HIS	280	36.914	30.320	28.394	1.00	54.16	H2
ATOM	1870	C GLY	274	35.050	38.745	30.990	1.00	65.05	B2	ATOM	1920	CD2 HIS	280	40.041	30.069	27.650	1.00	56.02	H2
ATOM	1871	O GLY	274	34.627	37.320	30.709	1.00	66.44	B2	ATOM	1921	ND1 HIS	280	38.759	29.326	29.264	1.00	56.01	H2
ATOM	1872	N CYS	275	35.301	39.364	30.048	1.00	62.77	B2	ATOM	1922	HD1 HIS	280	38.012	29.203	29.890	1.00	0.00	H2
ATOM	1873	H CYS	275	35.634	40.723	30.357	1.00	0.00	B2	ATOM	1923	CE1 HIS	280	39.744	28.483	26.058	1.00	56.64	H2
ATOM	1874	CA CYS	275	35.326	39.188	28.611	1.00	59.30	B2	ATOM	1924	HE2 HIS	280	40.507	28.937	26.000	1.00	56.16	H2
ATOM	1875	C CYS	275	35.875	38.063	28.054	1.00	55.89	B2	ATOM	1925	HE2 HIS	280	41.282	28.478	27.684	1.00	0.00	H2
ATOM	1876	O CYS	275	35.445	37.152	27.351	1.00	54.41	B2	ATOM	1926	C HIS	280	36.161	30.134	27.117	1.00	45.65	H2
ATOM	1877	CB CYS	275	35.349	40.466	27.827	1.00	61.50	B2	ATOM	1927	O HIS	280	36.362	28.917	26.711	1.00	46.73	H2
ATOM	1878	SC CYS	275	34.119	40.937	26.577	1.00	66.63	B2	ATOM	1928	SER	281	35.086	30.473	27.922	1.00	41.91	H2
ATOM	1879	N LEU	276	37.124	38.114	28.506	1.00	52.23	B2	ATOM	1929	II SER	281	35.009	31.367	28.219	1.00	0.00	H2
ATOM	1880	H LEU	276	37.350	38.722	29.233	1.00	0.00	B2	ATOM	1930	CA SER	281	34.008	29.574	28.105	1.00	44.53	H2
ATOM	1881	CA LEU	276	38.091	37.163	28.066	1.00	48.93	B2	ATOM	1931	CB SER	281	33.026	30.291	29.002	1.00	44.18	H2
ATOM	1882	CB LEU	276	39.483	37.564	28.542	1.00	45.96	B2	ATOM	1932	OC SER	281	33.761	30.812	30.113	1.00	47.71	H2
ATOM	1883	CG LEU	276	40.241	36.557	27.670	1.00	43.20	B2	ATOM	1933	IG SER	281	33.288	30.648	30.931	1.00	0.00	H2
ATOM	1884	CD1 LEU	276	41.590	38.782	28.279	1.00	44.63	B2	ATOM	1934	C SER	281	33.384	29.169	26.787	1.00	44.35	H2
ATOM	1885	C12 LEU	276	40.429	38.033	26.271	1.00	40.55	B2	ATOM	1935	O SER	281	32.977	30.120	25.940	1.00	42.15	H2

FIGURE 5

ATOM	1937 II GLY	282	33.043	31.058	26.221	1.00	0.00	B2	ATOM	1988 L8 ALA	287	36.617	22.291	22.415	1.00	33.63	H2
ATOM	1938 CA GLY	282	32.363	29.869	24.632	1.00	40.65	B2	ATOM	1989 C ALA	287	34.521	20.906	22.073	1.00	33.32	H2
ATOM	1939 C GLY	282	33.175	26.937	23.755	1.00	39.06	B2	ATOM	1990 O ALA	287	34.535	19.827	21.478	1.00	33.07	H2
ATOM	1940 O GLY	282	32.584	28.075	23.107	1.00	40.10	B2	ATOM	1991 N GLY	288	34.723	21.118	23.111	1.00	33.19	H2
ATOM	1941 N LEU	283	34.514	29.066	23.776	1.00	37.39	B2	ATOM	1992 II GLY	288	35.791	21.985	23.564	1.00	0.00	H2
ATOM	1942 II LEU	283	34.880	29.807	24.304	1.00	0.00	B2	ATOM	1993 CA GLY	288	32.761	20.162	24.635	1.00	35.62	H2
ATOM	1943 CA LEU	283	35.465	28.213	23.037	1.00	35.06	B2	ATOM	1994 C GLY	288	31.744	19.606	22.636	1.00	36.81	H2
ATOM	1944 CB LEU	283	36.902	28.718	23.089	1.00	30.20	B2	ATOM	1995 O GLY	288	31.624	18.379	22.444	1.00	34.97	H2
ATOM	1945 CG LEU	283	37.167	30.001	22.302	1.00	25.73	B2	ATOM	1996 N LEU	289	31.031	20.536	21.966	1.00	36.69	H2
ATOM	1946 CD1 LEU	283	38.539	30.461	22.664	1.00	24.38	B2	ATOM	1997 II LEU	289	31.201	21.476	22.201	1.00	0.00	H2
ATOM	1947 CD2 LEU	283	37.036	29.802	20.815	1.00	21.94	B2	ATOM	1998 CA LEU	289	30.018	20.249	20.954	1.00	35.05	H2
ATOM	1948 C LEU	283	35.470	26.851	23.651	1.00	34.81	B2	ATOM	1999 CB LEU	289	29.351	21.576	20.502	1.00	36.32	H2
ATOM	1949 O LEU	283	35.314	25.059	22.947	1.00	31.09	B2	ATOM	2000 CG LEU	289	28.552	22.450	21.464	1.00	35.76	H2
ATOM	1950 N PHE	284	35.533	26.842	24.973	1.00	37.62	B2	ATOM	2001 CD1 LEU	289	28.256	23.821	20.890	1.00	31.66	H2
ATOM	1951 H PHE	284	35.567	26.686	23.467	1.00	0.00	B2	ATOM	2002 CD2 LEU	289	27.246	21.780	21.697	1.00	35.5	H2
ATOM	1952 CA PHE	284	35.485	25.596	25.710	1.00	42.51	B2	ATOM	2003 C LEU	289	30.536	19.519	19.714	1.00	34.21	H2
ATOM	1953 CB PHE	284	35.542	25.877	27.184	1.00	49.49	B2	ATOM	2004 O LEU	289	29.871	18.694	19.078	1.00	35.28	H2
ATOM	1954 CG PHE	284	36.221	24.770	27.968	1.00	58.39	B2	ATOM	2005 N LEU	290	31.756	19.902	19.355	1.00	33.25	H2
ATOM	1955 CD1 PHE	284	37.265	25.108	28.816	1.00	63.35	B2	ATOM	2006 II LEU	290	32.183	20.634	19.850	1.00	0.00	H2
ATOM	1956 CD2 PHE	284	35.810	23.453	27.861	1.00	60.84	B2	ATOM	2007 CA LEU	290	32.448	19.345	18.230	1.00	32.44	H2
ATOM	1957 CE1 PHE	284	37.900	24.124	29.563	1.00	65.86	B2	ATOM	2008 CB LEU	290	33.729	20.159	16.000	1.00	32.62	H2
ATOM	1958 CE2 PHE	284	36.444	22.480	28.605	1.00	64.49	B2	ATOM	2009 CG LEU	290	33.560	21.509	17.315	1.00	32.05	H2
ATOM	1959 C2 PHE	284	37.486	22.810	29.455	1.00	66.32	B2	ATOM	2010 CD1 LEU	290	34.869	22.189	17.349	1.00	32.58	H2
ATOM	1960 C PHE	284	34.204	24.849	25.384	1.00	41.44	B2	ATOM	2011 CD2 LEU	290	33.068	21.374	15.879	1.00	31.74	H2
ATOM	1961 O PHE	284	34.257	23.630	25.306	1.00	41.42	B2	ATOM	2012 C LEU	290	32.737	17.908	18.558	1.00	31.94	H2
ATOM	1962 N ILEU	285	33.100	25.563	25.101	1.00	41.24	B2	ATOM	2013 O LEU	290	32.432	17.772	17.772	1.00	30.50	H2
ATOM	1963 II ILEU	285	33.192	26.534	25.174	1.00	0.00	B2	ATOM	2014 N GIN	291	33.249	17.711	19.770	1.00	33.58	H2
ATOM	1964 CA LEU	285	31.781	25.025	24.730	1.00	38.92	B2	ATOM	2015 II GIN	291	33.512	16.494	20.298	1.00	0.00	H2
ATOM	1965 CB LEU	285	30.727	26.139	24.807	1.00	39.05	B2	ATOM	2016 CA GIN	291	33.499	16.372	20.311	1.00	36.39	H2
ATOM	1966 CG LEU	285	29.292	25.740	24.491	1.00	41.16	B2	ATOM	2017 C GIN	291	33.988	16.490	21.702	1.00	36.86	H2
ATOM	1967 CD1 ILEU	285	32.705	26.062	25.593	1.00	0.00	B2	ATOM	2018 CG GIN	291	34.926	15.367	21.950	1.00	39.48	H2
ATOM	1968 CD2 ILEU	285	28.472	26.971	24.339	1.00	39.60	B2	ATOM	2019 CD GIN	291	35.638	15.503	23.252	1.00	40.79	H2
ATOM	1969 C ILEU	285	31.780	24.441	23.319	1.00	37.34	B2	ATOM	2020 OE1 GIN	291	36.457	14.626	23.549	1.00	44.80	H2
ATOM	1970 O LEU	285	31.245	23.351	23.095	1.00	36.97	B2	ATOM	2021 HE2 GIN	291	35.494	16.535	24.072	1.00	42.59	H2
ATOM	1971 N TYR	286	32.352	25.172	22.372	1.00	35.26	B2	ATOM	2022 HE2 GIN	291	34.928	17.287	23.817	1.00	0.00	B2
ATOM	1972 II TYR	286	32.705	26.062	22.593	1.00	0.00	B2	ATOM	2023 HE2 GIN	291	35.910	16.463	24.958	1.00	0.00	B2
ATOM	1973 CA TYR	286	32.455	24.660	21.033	1.00	35.04	B2	ATOM	2024 C GIN	291	32.233	15.536	20.307	1.00	36.66	H2
ATOM	1974 CB TYR	286	32.891	25.790	20.122	1.00	34.44	B2	ATOM	2025 O GIN	291	32.220	14.478	19.707	1.00	37.46	H2
ATOM	1975 CG TYR	286	31.690	26.684	19.808	1.00	34.75	B2	ATOM	2026 N ALA	292	31.143	16.023	20.913	1.00	38.37	H2
ATOM	1976 CD1 TYR	286	31.433	27.819	20.469	1.00	35.67	B2	ATOM	2027 II ALA	292	31.255	16.849	21.418	1.00	0.00	B2
ATOM	1977 CE1 TYR	286	30.313	26.620	20.158	1.00	36.90	B2	ATOM	2028 CA ALA	292	29.779	15.451	20.857	1.00	39.25	H2
ATOM	1978 CD2 TYR	286	30.873	26.355	18.839	1.00	36.19	B2	ATOM	2029 CB ALA	292	28.818	16.485	21.444	1.00	40.28	H2
ATOM	1979 CE2 TYR	286	29.707	26.990	18.571	1.00	37.55	B2	ATOM	2030 C ALA	292	29.215	14.999	19.484	1.00	38.65	H2
ATOM	1980 CZ TYR	286	29.449	28.164	19.178	1.00	37.73	B2	ATOM	2031 O ALA	292	28.411	14.067	19.356	1.00	37.58	H2
ATOM	1981 OH TYR	286	28.285	28.826	18.023	1.00	38.04	B2	ATOM	2032 N LEU	293	29.614	15.702	16.410	1.00	39.00	H2
ATOM	1982 III TYR	286	28.289	29.707	19.243	1.00	0.00	B2	ATOM	2033 H LEU	293	30.149	16.513	18.574	1.00	0.00	H2
ATOM	1983 C TYR	286	33.393	23.464	20.926	1.00	34.80	B2	ATOM	2034 CA LEU	293	29.265	15.335	17.027	1.00	39.74	H2
ATOM	1984 O TYR	286	33.071	22.537	20.180	1.00	35.35	B2	ATOM	2035 CB LEU	293	29.662	16.418	16.106	1.00	37.54	H2
ATOM	1985 N ALA	287	34.527	23.339	21.636	1.00	34.66	B2	ATOM	2036 CG LEU	293	28.969	17.701	16.138	1.00	34.34	H2
ATOM	1986 II ALA	287	34.803	24.088	22.206	1.00	0.00	B2	ATOM	2037 CD1 ILEU	293	29.547	18.582	15.053	1.00	33.88	H2
ATOM	1987 CA ALA	287	35.350	22.108	21.365	1.00	34.28	H2	ATOM	2038 CD2 ILEU	293	27.503	17.462	15.918	1.00	35.63	H2

FIGURE 5

ATOM	2039	C	I1U	293	29.933	14.060	16.596	1.00	40.86	B2	ATOM	2090	C	GIN	299	34.923	12.453	6.160	1.00	51.04	R2
ATOM	2040	O	I1U	293	29.686	13.669	15.449	1.00	40.58	B2	ATOM	2091	O	GIN	299	35.796	13.186	5.718	1.00	53.38	R2
ATOM	2041	N	GLU	294	30.887	13.495	17.365	1.00	42.12	B2	ATOM	2092	N	LEU	300	34.118	12.918	7.120	1.00	48.15	R2
ATOM	2042	H	GLU	294	31.131	13.963	18.190	1.00	0.00	B2	ATOM	2093	H	LEU	300	33.382	12.351	7.437	1.00	0.00	R2
ATOM	2043	CA	GLU	294	31.598	12.533	17.076	1.00	42.89	B2	ATOM	2094	CA	I1U	300	34.277	14.220	7.745	1.00	43.32	R2
ATOM	2044	CB	GLU	294	30.806	10.984	17.485	1.00	48.38	B2	ATOM	2095	CB	LEU	300	32.656	14.719	8.021	1.00	41.31	R2
ATOM	2045	CG	GLU	294	30.715	10.614	18.972	1.00	56.26	B2	ATOM	2096	CG	LEU	300	32.071	15.546	6.974	1.00	57.94	R2
ATOM	2046	CD	GLU	294	29.271	10.408	19.486	1.00	63.70	B2	ATOM	2097	CD	I1U	300	31.872	14.824	5.668	1.00	38.34	R2
ATOM	2047	OE1	GLU	294	29.058	10.603	20.702	1.00	67.72	B2	ATOM	2098	CD2	I1U	300	30.705	15.809	7.527	1.00	37.67	R2
ATOM	2048	OE2	GLU	294	28.363	10.074	18.692	1.00	64.81	B2	ATOM	2099	C	LEU	300	35.142	14.220	9.019	1.00	42.84	R2
ATOM	2049	C	GLU	294	31.972	12.068	15.632	1.00	41.53	B2	ATOM	2100	O	LEU	300	35.558	15.278	9.541	1.00	41.56	R2
ATOM	2050	O	GLU	294	31.804	11.007	15.021	1.00	40.29	B2	ATOM	2101	N	GLY	301	35.467	13.016	9.324	1.00	40.83	R2
ATOM	2051	N	GLY	295	32.424	13.203	15.106	1.00	40.93	B2	ATOM	2102	H	GLY	301	35.157	12.221	9.046	1.00	0.00	R2
ATOM	2052	H	GLY	295	32.357	14.033	15.621	1.00	0.00	B2	ATOM	2103	CA	GLY	301	36.199	12.867	10.779	1.00	36.72	R2
ATOM	2053	CA	GLY	295	32.998	13.736	13.783	1.00	39.95	B2	ATOM	2104	C	GLY	301	37.500	13.607	10.887	1.00	37.69	R2
ATOM	2054	C	GLY	295	32.027	13.230	12.634	1.00	40.60	B2	ATOM	2105	O	GLY	301	37.665	14.406	11.409	1.00	37.31	R2
ATOM	2055	O	GLY	295	32.477	13.216	11.487	1.00	40.96	B2	ATOM	2106	N	PRO	302	36.468	13.452	9.985	1.00	37.33	R2
ATOM	2056	N	HE	296	30.728	13.296	12.898	1.00	41.16	B2	ATOM	2107	CD	PRO	302	38.353	12.630	8.790	1.00	37.77	R2
ATOM	2057	H	HE	296	30.446	13.210	13.825	1.00	0.00	B2	ATOM	2108	CA	PRO	302	39.676	14.281	9.864	1.00	31.60	R2
ATOM	2058	CA	HE	296	29.687	13.306	11.998	1.00	44.02	B2	ATOM	2109	CB	PRO	302	40.256	13.907	8.541	1.00	36.62	R2
ATOM	2059	CB	HE	296	29.683	14.580	11.009	1.00	43.49	B2	ATOM	2110	CG	PRO	302	39.047	13.487	7.745	1.00	37.94	R2
ATOM	2060	CG2	HE	296	28.288	14.685	10.421	1.00	40.56	B2	ATOM	2111	C	PRO	302	39.486	15.782	10.033	1.00	37.45	R2
ATOM	2061	CG1	HE	296	30.047	15.631	11.793	1.00	45.11	B2	ATOM	2112	O	PRO	302	40.132	16.398	9.901	1.00	38.33	R2
ATOM	2062	CD	HE	296	30.039	17.189	11.062	1.00	46.06	B2	ATOM	2113	N	TIR	303	36.547	16.311	9.204	1.00	37.05	R2
ATOM	2063	C	HE	296	29.820	12.107	10.949	1.00	46.71	B2	ATOM	2114	H	TIR	303	38.005	15.727	8.567	1.00	0.00	R2
ATOM	2064	O	HE	296	28.918	11.279	11.060	1.00	50.61	B2	ATOM	2115	CA	THK	303	38.119	17.705	9.128	1.00	35.81	R2
ATOM	2065	N	SER	297	30.767	11.875	10.019	1.00	41.21	B2	ATOM	2116	CB	THK	303	36.963	17.770	8.123	1.00	37.26	R2
ATOM	2066	H	SER	297	31.526	12.491	9.936	1.00	0.00	B2	ATOM	2117	O	TIR	303	37.416	17.161	6.909	1.00	39.64	R2
ATOM	2067	CA	SER	297	30.810	10.646	9.234	1.00	46.73	B2	ATOM	2118	HG1	THK	303	37.359	17.785	6.178	1.00	0.00	R2
ATOM	2068	CB	SER	297	30.239	10.884	7.865	1.00	45.48	B2	ATOM	2119	CG2	THK	303	36.469	19.204	7.927	1.00	38.55	R2
ATOM	2069	OC	SER	297	30.988	11.782	7.072	1.00	46.27	B2	ATOM	2120	C	THK	303	37.687	18.723	10.506	1.00	34.91	R2
ATOM	2070	IG	SER	297	30.763	10.269	6.503	1.00	0.00	B2	ATOM	2121	O	TIR	303	38.085	19.263	11.063	1.00	35.11	R2
ATOM	2071	C	SER	297	32.263	10.269	9.123	1.00	48.72	B2	ATOM	2122	N	LEU	304	36.928	17.366	11.159	1.00	34.76	R2
ATOM	2072	O	SER	297	33.120	11.122	9.391	1.00	50.55	B2	ATOM	2123	H	LEU	304	36.672	16.500	10.762	1.00	0.00	R2
ATOM	2073	N	PRO	298	32.655	9.069	8.697	1.00	49.68	B2	ATOM	2124	CA	LEU	304	36.436	17.746	12.418	1.00	31.01	R2
ATOM	2074	CD	PRO	298	31.762	7.954	8.334	1.00	50.62	B2	ATOM	2125	CB	LEU	304	35.345	16.603	12.708	1.00	30.31	R2
ATOM	2075	CA	PRO	298	34.049	8.701	8.458	1.00	50.33	B2	ATOM	2126	CG	LEU	304	34.234	17.567	13.320	1.00	31.32	R2
ATOM	2076	CB	PRO	298	33.948	7.308	7.856	1.00	51.53	B2	ATOM	2127	CD1	LEU	304	36.456	16.117	12.635	1.00	0.00	R2
ATOM	2077	CG	PRO	298	32.576	7.231	1.00	50.43	B2	ATOM	2128	CD2	LEU	304	33.921	17.616	14.692	1.00	34.43	R2	
ATOM	2078	C	PRO	298	34.795	9.692	7.579	1.00	50.08	B2	ATOM	2129	C	LEU	304	37.553	17.716	13.421	1.00	31.86	R2
ATOM	2079	O	PRO	298	35.883	10.137	7.930	1.00	50.50	B2	ATOM	2130	O	LEU	304	37.615	18.623	14.259	1.00	34.21	R2
ATOM	2080	N	GLN	299	34.173	10.066	6.469	1.00	50.48	B2	ATOM	2131	H	ASP	305	38.510	16.811	13.326	1.00	30.56	R2
ATOM	2081	H	GLN	299	33.279	9.729	6.296	1.00	0.00	B2	ATOM	2132	OD1	ASP	305	38.456	16.117	12.635	1.00	0.00	R2
ATOM	2082	CA	GLN	299	33.698	11.236	4.301	1.00	54.33	B2	ATOM	2133	CA	ASP	305	39.576	16.797	14.303	1.00	36.72	R2
ATOM	2083	CB	GLN	299	33.095	10.067	3.725	1.00	58.11	B2	ATOM	2134	CB	ASP	305	40.504	15.608	14.114	1.00	36.20	R2
ATOM	2084	CC	GLN	299	31.658	10.086	4.259	1.00	61.49	B2	ATOM	2135	CG	ASP	305	39.912	14.201	14.268	1.00	40.64	R2
ATOM	2085	CD	GLN	299	31.160	9.083	4.776	1.00	61.00	B2	ATOM	2136	OD1	ASP	305	38.976	14.940	15.103	1.00	37.52	R2
ATOM	2086	OE1	GLN	299	30.942	11.217	4.204	1.00	62.12	B2	ATOM	2137	OD2	ASP	305	40.436	13.304	13.581	1.00	42.49	R2
ATOM	2087	NE2	GLN	299	31.345	12.012	3.800	1.00	0.00	B2	ATOM	2138	C	ASP	305	40.435	18.034	14.238	1.00	27.56	R2
ATOM	2088	HE1	GLN	299	30.034	11.191	4.366	1.00	0.00	R2	ATOM	2139	O	ASP	305	40.775	18.575	15.311	1.00	24.51	R2
ATOM	2089	HE2	GLN	299							ATOM	2140	N	THK	306	40.781	18.417	12.979	1.00	24.77	R2

FIGURE 5

ATOM	2141	H	TIR	306	40.469	17.875	12.230	1.00	0.00	B2
ATOM	2142	CA	TIR	306	41.553	19.633	12.751	1.00	24.39	B2
ATOM	2143	CB	TIR	306	41.665	19.931	13.118	1.00	25.13	B2
ATOM	2144	OG1	TIR	306	42.074	18.733	10.665	1.00	25.13	B2
ATOM	2145	HG1	TIR	306	41.447	18.029	10.768	1.00	0.00	B2
ATOM	2146	CG2	TIR	306	42.690	21.037	11.089	1.00	25.77	B2
ATOM	2147	C	TIR	306	40.893	20.844	13.419	1.00	25.24	B2
ATOM	2148	O	TIR	306	41.488	21.472	14.296	1.00	27.24	B2
ATOM	2149	N	LEU	307	39.615	21.134	13.139	1.00	25.91	B2
ATOM	2150	H	LEU	307	39.125	20.547	12.520	1.00	0.00	B2
ATOM	2151	CA	LEU	307	38.900	22.228	13.764	1.00	25.53	B2
ATOM	2152	CB	LEU	307	37.571	22.170	13.142	1.00	25.09	B2
ATOM	2153	CG	LEU	307	36.530	23.097	13.588	1.00	27.93	B2
ATOM	2154	CD1	LEU	307	37.008	24.515	13.484	1.00	29.87	B2
ATOM	2155	CD2	LEU	307	35.311	22.846	12.778	1.00	28.93	B2
ATOM	2156	C	LEU	307	38.850	22.214	15.269	1.00	27.09	B2
ATOM	2157	O	LEU	307	38.454	23.253	15.925	1.00	30.03	B2
ATOM	2158	N	GLN	308	38.075	21.044	15.879	1.00	29.09	B2
ATOM	2159	H	GLN	308	38.883	20.239	15.319	1.00	0.00	B2
ATOM	2160	CA	GLN	308	38.824	20.848	17.340	1.00	79.36	B2
ATOM	2161	CB	GLN	308	38.379	19.399	17.562	1.00	29.41	B2
ATOM	2162	CG	GLN	308	37.862	19.140	18.935	1.00	32.24	B2
ATOM	2163	CD	GLN	308	37.586	17.672	19.165	1.00	34.03	B2
ATOM	2164	OE1	GLN	308	36.973	17.013	18.311	1.00	33.48	B2
ATOM	2165	NE2	GLN	308	38.053	17.117	20.299	1.00	31.67	B2
ATOM	2166	HE21	GLN	308	38.547	17.669	20.917	1.00	0.00	B2
ATOM	2167	HE22	GLN	308	37.875	16.174	20.436	1.00	0.00	B2
ATOM	2168	C	GLN	308	40.154	21.138	18.051	1.00	28.94	B2
ATOM	2169	O	GLN	308	40.196	21.796	19.101	1.00	28.44	B2
ATOM	2170	N	ILEU	309	41.269	20.671	17.460	1.00	28.78	B2
ATOM	2171	H	ILEU	309	41.157	20.120	16.655	1.00	0.00	B2
ATOM	2172	CA	ILEU	309	42.632	20.923	17.967	1.00	28.56	B2
ATOM	2173	CB	ILEU	309	43.671	20.154	17.106	1.00	26.54	B2
ATOM	2174	CG	ILEU	309	43.632	18.636	17.241	1.00	24.98	B2
ATOM	2175	CD1	ILEU	309	44.595	17.935	16.353	1.00	24.17	B2
ATOM	2176	CD2	ILEU	309	43.992	18.310	16.621	1.00	23.45	B2
ATOM	2177	C	ILEU	309	42.093	21.416	17.909	1.00	28.24	B2
ATOM	2178	O	ILEU	309	43.370	22.937	18.907	1.00	30.32	B2
ATOM	2179	N	ASP	310	42.548	23.037	16.749	1.00	26.58	B2
ATOM	2180	H	ASP	310	42.796	22.437	16.007	1.00	0.00	B2
ATOM	2181	CA	ASP	310	42.495	24.477	16.495	1.00	27.90	B2
ATOM	2182	CB	ASP	310	42.025	24.659	15.076	1.00	28.41	B2
ATOM	2183	CG	ASP	310	43.162	24.556	14.096	1.00	31.84	B2
ATOM	2184	OD1	ASP	310	42.959	24.766	12.905	1.00	31.54	B2
ATOM	2185	OD2	ASP	310	44.997	24.314	14.514	1.00	31.32	B2
ATOM	2186	C	ASP	310	41.666	25.410	17.422	1.00	27.99	B2
ATOM	2187	O	ASP	310	42.219	26.429	17.876	1.00	27.23	B2
ATOM	2188	N	VAL	311	40.374	25.086	17.725	1.00	26.29	B2
ATOM	2189	H	VAL	311	39.961	24.347	17.225	1.00	0.00	B2
ATOM	2190	CA	VAL	311	39.546	25.803	18.706	1.00	24.29	B2
ATOM	2191	CB	VAL	311	38.098	25.217	18.869	1.00	21.47	B2
ATOM	2192	CG1	VAL	311	37.341	25.915	19.949	1.00	19.01	B2
ATOM	2193	CG2	VAL	311	37.261	25.488	17.667	1.00	18.56	B2
ATOM	2194	C	VAL	311	40.270	25.638	20.020	1.00	27.21	B2
ATOM	2195	O	VAL	311	40.437	26.647	20.719	1.00	29.71	B2
ATOM	2196	N	ALA	312	40.762	24.428	20.357	1.00	27.97	B2
ATOM	2197	H	ALA	312	40.585	23.674	19.756	1.00	0.00	B2
ATOM	2198	CA	ALA	312	41.515	24.157	21.583	1.00	22.4	B2
ATOM	2199	CB	ALA	312	41.855	22.688	21.532	1.00	30.53	B2
ATOM	2200	C	ALA	312	42.778	25.026	21.784	1.00	30.06	B2
ATOM	2201	O	ALA	312	43.057	25.508	22.886	1.00	30.04	B2
ATOM	2202	OD1	ASP	313	43.554	25.286	20.735	1.00	31.43	B2
ATOM	2203	OD2	ASP	313	46.521	24.553	19.647	1.00	49.25	B2
ATOM	2204	CA	ASP	313	43.433	24.730	19.935	1.00	0.00	B2
ATOM	2205	CB	ASP	313	44.610	26.275	20.743	1.00	34.24	B2
ATOM	2206	CG	ASP	314	45.279	26.512	19.447	1.00	38.87	B2
ATOM	2207	OD1	ASP	314	46.071	25.804	18.866	1.00	44.55	B2
ATOM	2208	OD2	ASP	314	46.225	25.439	17.636	1.00	48.67	B2
ATOM	2209	CA	PIE	314	42.784	27.683	19.619	1.00	0.00	B2
ATOM	2210	CB	PIE	314	42.715	29.548	20.600	1.00	31.09	B2
ATOM	2211	CG	PIE	314	41.572	29.860	19.631	1.00	32.06	B2
ATOM	2212	CD1	PIE	314	40.174	33.870	19.622	1.00	33.57	B2
ATOM	2213	CD2	PIE	314	41.907	32.354	19.247	1.00	31.36	B2
ATOM	2214	CE1	PIE	314	39.318	32.857	19.240	1.00	29.15	B2
ATOM	2215	CE2	PIE	314	41.315	31.648	20.017	1.00	31.48	B2
ATOM	2216	CA	PIE	314	40.154	33.870	19.622	1.00	32.81	B2
ATOM	2217	CB	PIE	314	42.282	29.601	22.057	1.00	29.90	B2
ATOM	2218	CD	PIE	314	42.658	30.550	22.764	1.00	35.65	B2
ATOM	2219	N	ALA	315	41.686	26.532	21.584	1.00	29.29	B2
ATOM	2220	CA	ALA	315	41.448	27.764	23.476	1.00	0.00	B2
ATOM	2221	CB	ALA	315	40.632	27.358	24.451	1.00	31.22	B2
ATOM	2222	C	ALA	315	42.482	28.751	24.836	1.00	34.41	B2
ATOM	2223	O	ALA	315	42.361	29.437	25.833	1.00	37.66	B2
ATOM	2224	N	TIR	316	43.646	28.250	24.476	1.05	36.16	B2
ATOM	2225	CA	TIR	316	43.745	27.778	23.625	1.00	0.00	B2
ATOM	2226	CB	TIR	316	44.780	26.388	25.374	1.00	37.99	B2
ATOM	2227	O	TIR	316	45.795	27.755	25.156	1.00	41.16	B2
ATOM	2228	N	TIR	316	45.049	26.081	25.521	1.00	45.50	B2
ATOM	2229	H	TIR	317	44.316	25.900	24.913	1.00	0.00	B2
ATOM	2230	CA	TIR	317	47.152	27.415	25.888	1.01	40.31	B2
ATOM	2231	CB	TIR	317	45.458	29.710	25.177	1.00	38.47	B2
ATOM	2232	O	TIR	317	45.903	30.189	26.217	1.00	46.64	B2
ATOM	2233	OG1	TIR	317	45.620	30.287	23.970	1.00	36.53	B2
ATOM	2234	HG1	TIR	317	45.351	29.800	23.164	1.01	0.10	B2
ATOM	2235	CG2	TIR	317	46.002	31.657	23.844	1.00	37.07	B2
ATOM	2236	C	TIR	317	45.866	32.098	22.392	1.00	36.01	B2
ATOM	2237	O	TIR	317	46.752	31.352	21.575	1.00	35.41	B2

## FIGURE 5

ATOM	2243	HG1	THR	317	46.489	30.441	21.389	1.00	0.00	B2	ATOM	2294	C	GIN	321	46.112	36.315	29.562	1.00	53.30	B2
ATOM	2244	CG2	THR	317	46.109	33.566	22.156	1.00	34.30	B2	ATOM	2295	O	GIN	321	46.293	37.422	30.058	1.00	54.39	B2
ATOM	2245	C	THR	317	45.338	32.597	24.832	1.00	39.30	B2	ATOM	2296	N	MET	322	45.269	35.441	30.117	1.00	54.50	B2
ATOM	2246	O	THR	317	45.941	33.378	25.563	1.00	40.17	B2	ATOM	2297	H	MET	322	45.098	34.592	29.662	1.00	0.00	B2
ATOM	2247	N	ILE	318	44.003	32.481	24.912	1.00	40.83	B2	ATOM	2298	CA	MET	322	44.619	35.746	31.375	1.00	55.42	B2
ATOM	2248	II	ILE	318	43.554	31.819	24.342	1.00	0.00	B2	ATOM	2299	CB	MET	322	43.595	31.690	31.713	1.00	52.93	B2
ATOM	2249	CA	ILE	318	43.172	33.317	25.788	1.00	40.75	B2	ATOM	2300	CG	MET	322	42.527	34.865	30.658	1.00	51.76	B2
ATOM	2250	CB	ILE	318	41.621	32.979	25.567	1.00	37.17	B2	ATOM	2301	SD	MET	322	40.061	34.428	31.189	1.00	54.19	B2
ATOM	2251	CG2	ILE	318	40.742	33.706	26.545	1.00	34.29	B2	ATOM	2302	CE	MET	322	40.293	33.192	30.069	1.00	52.53	B2
ATOM	2252	CG1	ILE	318	41.216	33.310	24.160	1.00	31.39	B2	ATOM	2303	C	MET	322	45.700	37.422	32.432	1.00	57.69	B2
ATOM	2253	CD	ILE	318	41.626	34.457	23.614	1.00	29.66	B2	ATOM	2304	O	MET	322	45.781	36.739	33.248	1.00	57.85	B2
ATOM	2254	C	ILE	318	41.624	33.019	27.217	1.00	42.43	B2	ATOM	2305	N	GLU	323	46.652	34.900	32.319	1.00	60.28	B2
ATOM	2255	O	ILE	318	44.064	33.963	27.856	1.00	42.54	B2	ATOM	2306	H	GLU	323	46.637	34.296	31.544	1.00	0.00	B2
ATOM	2256	N	TRP	319	43.662	31.784	27.744	1.00	44.17	B2	ATOM	2307	CA	GLU	323	47.741	33.273	31.069	1.00	62.99	B2
ATOM	2257	H	TRP	319	43.537	31.008	27.163	1.00	0.00	B2	ATOM	2308	CB	GLU	323	48.558	33.635	32.957	1.00	65.81	B2
ATOM	2258	CA	TRP	319	43.994	31.633	29.142	1.00	46.90	B2	ATOM	2309	CG	GLU	323	47.640	37.423	32.918	1.00	48.36	B2
ATOM	2259	CB	TRP	319	43.891	30.179	29.597	1.00	50.64	B2	ATOM	2310	CD	GLU	323	48.303	31.125	33.310	1.00	71.21	B2
ATOM	2260	CG	TRP	319	43.998	30.094	31.131	1.00	56.05	B2	ATOM	2311	OEI	GLU	323	47.651	34.364	34.044	1.00	71.19	B2
ATOM	2261	CD2	TRP	319	43.005	30.397	32.038	1.00	58.61	B2	ATOM	2312	OEZ	GLU	323	49.451	30.900	32.884	1.00	77.43	B2
ATOM	2262	CE2	TRP	319	43.685	30.281	33.251	1.00	60.50	B2	ATOM	2313	C	GLU	323	48.648	36.124	33.418	1.00	63.96	B2
ATOM	2263	CE3	TRP	319	41.668	30.740	32.005	1.00	60.12	B2	ATOM	2314	OTI	GLU	323	48.782	36.492	34.584	1.00	64.11	B2
ATOM	2264	CD1	TRP	319	45.108	29.788	31.760	1.00	58.07	B2	ATOM	2315	OT2	GLU	323	49.167	36.725	32.449	1.00	62.96	B2
ATOM	2265	HE1	TRP	319	44.968	29.921	33.042	1.00	60.07	B2	ATOM	2316	CB	MET	338	27.559	17.690	25.056	1.00	62.56	B3
ATOM	2266	HE2	TRP	319	45.637	29.765	33.740	1.00	0.00	B2	ATOM	2317	CG	MET	338	28.087	18.862	24.222	1.00	61.85	B3
ATOM	2267	C22	TRP	319	43.044	30.512	34.456	1.00	61.00	B2	ATOM	2318	SD	MET	338	27.878	20.224	25.219	1.00	60.95	B3
ATOM	2268	C23	TRP	319	41.072	30.967	33.210	1.00	61.58	B2	ATOM	2319	CE	MET	338	27.328	21.252	25.515	1.00	65.50	B3
ATOM	2269	CH2	TRP	319	41.704	30.854	34.417	1.00	62.04	B2	ATOM	2320	C	MET	338	24.988	17.301	25.122	1.00	57.55	B3
ATOM	2270	C	TRP	319	48.567	31.988	27.589	1.00	51.44	B2	ATOM	2321	O	MET	338	24.417	16.347	25.667	1.00	56.47	B3
ATOM	2271	O	TRP	319	48.828	30.494	27.444	1.00	55.03	B2	ATOM	2322	HT1	MET	338	27.255	16.010	26.594	1.00	0.00	B3
ATOM	2272	N	GLN	320	46.339	31.915	28.550	1.00	48.63	B2	ATOM	2323	HT2	MET	338	25.375	17.061	27.500	1.00	0.00	B3
ATOM	2273	H	GLN	320	46.091	31.482	27.708	1.00	61.58	B2	ATOM	2324	N	MET	338	26.286	16.971	27.009	1.00	61.55	B3
ATOM	2274	CA	GLN	320	47.706	32.319	28.767	1.00	49.45	B2	ATOM	2325	HT3	MET	338	27.108	17.107	27.620	1.00	0.00	B3
ATOM	2275	CB	GLN	320	48.567	31.988	27.589	1.00	51.44	B2	ATOM	2326	CA	MET	338	27.226	17.853	25.851	1.00	60.35	B3
ATOM	2276	CG	GLN	320	48.828	30.494	27.444	1.00	55.03	B2	ATOM	2327	N	PRO	339	24.493	17.830	23.998	1.00	55.58	B3
ATOM	2277	CD	GLN	320	49.958	30.349	26.438	1.00	60.17	B2	ATOM	2328	CD	PRO	339	24.914	19.075	23.375	1.00	54.49	B3
ATOM	2278	OE1	GLN	320	51.116	30.465	26.834	1.00	65.26	B2	ATOM	2329	CA	PRO	339	23.453	17.226	23.164	1.00	54.62	B3
ATOM	2279	NE2	GLN	320	49.771	30.145	25.131	1.00	59.32	B2	ATOM	2330	C	PRO	339	23.463	18.791	21.909	1.00	53.52	B3
ATOM	2280	HE1	GLN	320	48.859	30.087	24.789	1.00	0.00	B2	ATOM	2331	CG	PRO	339	24.845	18.711	21.909	1.00	53.04	P3
ATOM	2281	HE2	GLN	320	50.582	30.083	24.590	1.00	0.00	B2	ATOM	2332	C	PRO	339	23.666	15.748	22.881	1.00	51.61	B3
ATOM	2282	C	GLN	320	47.717	33.790	28.983	1.00	49.62	B2	ATOM	2333	O	PRO	339	24.730	15.222	23.169	1.00	53.35	H2
ATOM	2283	O	GLN	320	48.251	34.209	29.987	1.00	49.91	B2	ATOM	2334	N	ALA	340	22.704	15.045	22.333	1.00	54.32	H2
ATOM	2284	N	GLN	321	46.998	34.538	26.150	1.00	51.76	B2	ATOM	2335	H	ALA	340	21.844	15.460	22.111	1.00	0.00	B3
ATOM	2285	H	GLN	321	46.535	34.102	27.403	1.00	0.00	B2	ATOM	2336	CA	ALA	340	22.909	13.651	21.968	1.00	56.04	B3
ATOM	2286	CA	GLN	321	46.837	35.986	26.278	1.00	52.08	B2	ATOM	2337	CB	ALA	340	21.867	12.713	22.625	1.00	57.60	R3
ATOM	2287	CB	GLN	321	46.015	36.571	27.151	1.00	49.72	B2	ATOM	2338	C	ALA	340	22.617	13.713	20.495	1.00	55.61	B3
ATOM	2288	CG	GLN	321	45.073	38.058	27.166	1.00	51.19	B2	ATOM	2339	O	ALA	340	21.426	13.783	20.196	1.00	56.64	R2
ATOM	2289	CD	GLN	321	47.211	36.781	27.201	1.00	53.13	B2	ATOM	2340	N	PIE	341	23.516	13.734	19.514	1.00	53.34	H3
ATOM	2290	OE1	GLN	321	48.090	38.622	26.364	1.00	55.36	B2	ATOM	2341	H	PIE	341	24.472	13.607	19.685	1.00	0.00	H3
ATOM	2291	NE2	GLN	321	47.468	39.618	28.177	1.00	53.21	B2	ATOM	2342	CA	PIE	341	23.016	13.900	18.158	1.00	49.92	R1
ATOM	2292	HE2	GLN	321	46.800	39.713	28.889	1.00	0.00	B2	ATOM	2343	C	PIE	341	24.050	14.541	17.244	1.00	48.16	R1
ATOM	2293	HE2	GLN	321	48.338	40.057	28.168	1.00	0.00	B2	ATOM	2344	CC	PIE	341	24.382	15.940	17.658	1.00	45.00	H1

FIGURE 5

ATOM	2345	CD1 PHE	341	23.510	16.923	17.359	1.00 43.44	B3	ATOM	2396	N	ARG	347	23.507	14.190	13.431	1.00 35.57	H3
ATOM	2346	CD2 PHE	341	23.527	16.175	18.388	1.00 47.03	B3	ATOM	2397	CA	ARG	347	23.248	13.289	13.157	1.00 0.00	B3
ATOM	2347	CCE PHE	341	23.612	18.172	17.831	1.00 49.15	B3	ATOM	2398	CA	ARG	347	24.907	14.538	13.396	1.00 35.95	H3
ATOM	2348	CCE PHE	341	25.027	17.426	18.862	1.00 47.86	B3	ATOM	2399	CB	ARG	347	25.760	13.236	13.222	1.00 36.29	H3
ATOM	2349	CZ PHE	341	24.952	18.437	18.580	1.00 48.36	B3	ATOM	2400	CG	ARG	347	26.198	12.549	14.540	1.00 37.41	H3
ATOM	2350	C PHE	341	22.684	12.510	17.672	1.00 49.56	B3	ATOM	2401	CD	ARG	347	26.986	12.426	14.373	1.00 39.70	H3
ATOM	2351	O PHE	341	23.309	11.938	16.781	1.00 51.46	B3	ATOM	2402	NE	ARG	347	26.072	10.167	14.378	1.00 47.18	H3
ATOM	2352	N ALA	342	21.625	11.985	18.245	1.00 47.40	B3	ATOM	2403	HE	ARG	347	25.416	9.893	14.701	1.00 0.00	H3
ATOM	2353	H ALA	342	21.026	12.585	18.741	1.00 0.00	B3	ATOM	2404	CZ	ARG	347	26.071	9.516	17.846	1.00 48.41	H3
ATOM	2354	CA ALA	342	21.167	10.650	17.997	1.00 46.11	B3	ATOM	2405	NI1	ARG	347	25.938	9.802	11.892	1.00 50.22	H3
ATOM	2355	CB ALA	342	19.874	10.531	18.804	1.00 47.10	B3	ATOM	2406	II111	ARG	347	27.602	10.528	12.031	1.00 0.00	H3
ATOM	2356	CB SER	343	19.962	10.149	16.556	1.00 44.37	B3	ATOM	2407	III12	ARG	347	26.905	9.313	11.011	1.00 0.01	H3
ATOM	2357	O SER	343	20.138	9.247	16.418	1.00 45.65	B3	ATOM	2408	NI12	ARG	347	25.130	8.608	12.574	1.00 48.46	H3
ATOM	2358	N SER	343	21.537	10.573	15.423	1.00 41.37	B3	ATOM	2409	II121	ARG	347	24.323	8.408	13.252	1.00 0.01	H3
ATOM	2359	H SER	343	22.191	11.301	15.428	1.00 0.00	B3	ATOM	2410	II112	ARG	347	25.126	8.131	11.697	1.00 0.00	H3
ATOM	2360	CA SER	343	21.274	9.923	13.145	1.00 38.80	B3	ATOM	2411	C	ARG	347	25.183	15.544	12.267	1.00 35.54	H3
ATOM	2361	CB SER	343	19.842	10.138	13.656	1.00 38.79	B3	ATOM	2412	O	ARG	347	25.877	16.549	12.445	1.00 36.73	H3
ATOM	2362	OG SER	343	19.205	11.300	14.182	1.00 37.75	B3	ATOM	2413	N	ARG	348	24.611	14.353	11.096	1.00 34.74	H3
ATOM	2363	CG SER	343	18.963	11.059	13.092	1.00 0.00	B3	ATOM	2414	H	ARG	348	24.043	14.559	11.005	1.00 0.00	H3
ATOM	2364	C SER	343	22.172	10.467	13.088	1.00 38.22	B3	ATOM	2415	CA	ARG	348	24.802	16.725	9.954	1.00 35.24	H3
ATOM	2365	O SER	343	22.810	11.471	13.382	1.00 38.30	B3	ATOM	2416	CB	ARG	348	24.091	15.623	8.751	1.00 36.76	H3
ATOM	2366	N ALA	344	22.206	9.845	11.886	1.00 36.73	B3	ATOM	2417	CG	ARG	348	24.778	14.303	8.450	1.00 44.22	H3
ATOM	2367	II ALA	344	21.762	8.978	11.805	1.00 0.00	B3	ATOM	2418	CD	ARG	348	24.014	13.379	7.529	1.00 49.24	H3
ATOM	2368	CA ALA	344	22.914	10.384	10.715	1.00 36.09	B3	ATOM	2419	NE	ARG	348	24.705	12.090	7.457	1.00 54.27	H3
ATOM	2369	CB ALA	344	22.583	9.640	9.422	1.00 36.78	B3	ATOM	2420	HE	ARG	348	25.300	11.836	8.193	1.00 0.00	H3
ATOM	2370	C ALA	344	22.471	11.842	10.496	1.00 37.72	B3	ATOM	2421	CZ	ARG	348	24.555	12.226	6.430	1.00 53.75	H3
ATOM	2371	O ALA	344	23.271	12.765	10.676	1.00 38.42	B3	ATOM	2422	NI1	ARG	348	23.758	11.479	5.381	1.00 51.65	H3
ATOM	2372	N PHIE	345	21.194	12.042	10.163	1.00 36.10	B3	ATOM	2423	II111	ARG	348	23.234	12.329	5.339	1.00 48.00	H3
ATOM	2373	H PHIE	345	20.668	11.798	9.811	1.00 0.00	B3	ATOM	2424	III112	ARG	348	23.680	11.795	10.607	1.00 33.65	H3
ATOM	2374	CA PHIE	345	20.564	13.138	10.195	1.00 34.69	B3	ATOM	2425	II112	ARG	348	24.252	10.083	6.462	1.00 54.51	H3
ATOM	2375	CB PHE	345	19.040	13.754	10.178	1.00 33.24	B3	ATOM	2426	II1121	ARG	348	25.169	9.424	5.714	1.00 0.00	H3
ATOM	2376	CG PHE	345	18.462	14.656	9.918	1.00 31.72	B3	ATOM	2427	II1122	ARG	348	25.060	9.894	7.212	1.00 0.00	H3
ATOM	2377	CD1 PHE	345	17.715	15.223	10.905	1.00 26.64	B3	ATOM	2428	C	ARG	348	24.283	17.629	10.237	1.00 34.40	H3
ATOM	2378	CD2 PHE	345	18.767	15.343	8.745	1.00 29.99	B3	ATOM	2429	O	ARG	348	25.078	18.564	10.219	1.00 35.16	H3
ATOM	2379	CCE PHE	345	17.284	16.503	10.682	1.00 33.56	B3	ATOM	2430	N	ALA	349	23.008	17.795	10.607	1.00 33.65	H3
ATOM	2380	C PHE	345	16.333	16.619	8.337	1.00 30.81	B3	ATOM	2431	H	ALA	349	22.470	16.984	10.755	1.00 0.00	H3
ATOM	2381	CZ PHE	345	17.581	17.701	9.520	1.00 31.44	B3	ATOM	2432	CA	ALA	349	22.352	19.083	10.853	1.00 32.96	H3
ATOM	2382	C PHE	345	20.888	14.145	11.458	1.00 35.02	B3	ATOM	2433	CB	ALA	349	20.809	18.894	11.070	1.00 31.36	H3
ATOM	2383	O PHE	345	21.246	15.319	11.292	1.00 37.81	B3	ATOM	2434	C	ALA	349	22.945	19.746	12.083	1.00 31.84	H3
ATOM	2384	N GLN	346	20.814	13.680	12.691	1.00 32.53	B3	ATOM	2435	O	ALA	349	22.981	20.969	12.210	1.00 30.69	H3
ATOM	2385	H GLN	346	20.516	12.776	12.694	1.00 0.00	B3	ATOM	2436	N	GLY	350	23.444	18.954	13.018	1.00 31.30	H3
ATOM	2386	CA GLN	346	21.156	14.586	13.758	1.00 33.46	B3	ATOM	2437	H	GLY	350	23.308	17.984	12.976	1.00 0.00	H3
ATOM	2387	CB GLN	346	20.899	13.985	15.061	1.00 33.80	B3	ATOM	2438	CA	GLY	350	24.117	19.505	14.181	1.00 31.08	H3
ATOM	2388	CG GLN	346	19.459	14.284	15.174	1.00 35.68	B3	ATOM	2439	C	GLY	350	25.462	20.025	13.753	1.00 30.79	H3
ATOM	2389	CD GLN	346	18.788	13.658	16.344	1.00 38.48	B3	ATOM	2440	O	GLY	350	25.974	21.010	14.280	1.00 31.84	H3
ATOM	2390	OE1 GLN	346	19.358	13.328	17.374	1.00 41.73	B3	ATOM	2441	N	GLY	351	25.991	19.374	12.731	1.00 30.93	H3
ATOM	2391	NE2 GLN	346	17.508	13.463	16.167	1.00 41.04	B3	ATOM	2442	H	GLY	351	25.546	18.582	12.367	1.00 0.00	H3
ATOM	2392	II21 GLN	346	17.088	13.724	15.323	1.00 0.00	B3	ATOM	2443	CA	GLY	351	27.263	19.735	12.184	1.00 29.95	H3
ATOM	2393	II22 GLN	346	17.026	13.063	16.919	1.00 0.00	B3	ATOM	2444	C	GLY	351	27.482	21.097	11.534	1.00 29.25	H3
ATOM	2394	C GLN	346	22.564	15.051	13.773	1.00 35.73	B3	ATOM	2445	O	GLY	351	27.937	21.974	11.919	1.00 28.74	H3
ATOM	2395	O GLN	346	22.766	16.231	14.051	1.00 38.18	B3	ATOM	2446	N	VAL	352	26.336	21.285	10.522	1.00 28.92	H3

FIGURE 5

ATOM	2447	II	VAL	352	25.859	20.484	10.214	1.00	0.00	B3	ATOM	2498	N	LEU	358	29.830	28.637	15.383	1.00	28.33	B4
ATOM	2448	CA	VAL	352	26.079	22.567	9.881	1.00	28.59	B3	ATOM	2499	H	LEU	358	29.624	27.761	1.4997	1.00	0.01	B4
ATOM	2449	CB	VAL	352	24.845	22.452	9.004	1.00	28.96	B3	ATOM	2500	CA	LEU	358	31.211	28.940	15.721	1.00	26.39	B4
ATOM	2450	CG	VAL	352	24.627	23.785	6.346	1.00	26.86	B3	ATOM	2501	CB	LEU	358	32.030	27.702	15.547	1.00	21.42	B4
ATOM	2451	CD2	VAL	352	25.021	21.475	7.875	1.00	26.94	B3	ATOM	2502	CG	LEU	358	33.457	28.878	17.734	1.00	20.42	B4
ATOM	2452	C	VAL	352	25.849	23.709	10.890	1.00	29.29	B3	ATOM	2503	CD1	LEU	358	33.805	28.076	17.165	1.00	16.79	B4
ATOM	2453	O	VAL	352	26.520	24.747	10.853	1.00	31.02	B3	ATOM	2504	CD2	LEU	358	34.075	26.714	15.072	1.00	22.89	B4
ATOM	2454	N	VAL	353	24.923	23.543	11.819	1.00	27.52	B3	ATOM	2505	C	LEU	358	31.204	31.209	11.292	1.00	30.49	B4
ATOM	2455	H	VAL	353	24.404	22.709	11.838	1.00	0.00	B3	ATOM	2506	O	LEU	358	32.372	30.067	14.822	1.00	26.45	B4
ATOM	2456	CA	LEU	353	24.635	24.548	12.817	1.00	26.18	B3	ATOM	2507	N	GLN	359	31.460	30.130	13.518	1.00	27.12	B4
ATOM	2457	CB	LEU	353	23.434	24.113	13.636	1.00	27.87	B3	ATOM	2508	H	GLN	359	31.048	29.337	13.114	1.00	0.00	B4
ATOM	2458	CG	LEU	353	22.098	24.034	12.931	1.00	26.54	B3	ATOM	2509	CA	GLN	359	31.863	31.754	12.671	1.00	29.10	B4
ATOM	2459	CD1	LEU	353	21.064	23.617	13.924	1.00	25.49	B3	ATOM	2510	CW	GLN	359	31.204	31.209	11.292	1.00	30.49	B4
ATOM	2460	CD2	LEU	353	21.750	25.372	12.320	1.00	26.23	B3	ATOM	2511	CG	GLN	359	31.395	29.952	10.555	1.00	48.94	B4
ATOM	2461	C	LEU	353	25.742	24.905	13.772	1.00	27.17	B3	ATOM	2512	CD	GLN	359	32.842	29.616	10.091	1.00	42.49	B4
ATOM	2462	O	LEU	353	25.838	26.093	14.088	1.00	28.00	B3	ATOM	2513	OEI	GLN	359	31.774	29.979	10.821	1.00	46.15	B4
ATOM	2463	N	VAL	354	26.539	23.949	14.318	1.00	27.20	B3	ATOM	2514	NE2	GLN	359	33.103	28.987	8.967	1.00	41.54	B4
ATOM	2464	H	VAL	354	26.321	23.006	14.139	1.00	0.00	B3	ATOM	2515	HE21	GLN	359	32.341	28.706	8.412	1.00	0.00	B4
ATOM	2465	CA	VAL	354	27.712	24.212	15.157	1.00	24.62	B3	ATOM	2516	HE22	GLN	359	34.039	28.838	8.740	1.00	0.00	B4
ATOM	2466	CB	VAL	354	28.736	22.910	15.745	1.00	22.01	B3	ATOM	2517	C	GLN	359	31.512	32.621	13.254	1.00	29.39	B4
ATOM	2467	CG1	VAL	354	29.568	23.089	16.406	1.00	19.82	B3	ATOM	2518	O	GLN	359	32.427	33.427	13.484	1.00	30.06	B4
ATOM	2468	CG2	VAL	354	27.276	22.467	16.802	1.00	23.96	B3	ATOM	2519	N	SER	360	30.701	31.810	13.528	1.00	28.66	B4
ATOM	2469	C	VAL	354	28.812	24.93	14.332	1.00	25.46	B3	ATOM	2520	H	SER	360	29.595	32.061	13.343	1.00	0.00	B4
ATOM	2470	O	VAL	354	29.439	25.832	14.798	1.00	26.23	B3	ATOM	2521	CA	SER	360	28.121	31.316	14.316	1.00	26.70	B4
ATOM	2471	N	ALA	355	29.059	24.530	13.089	1.00	26.12	B3	ATOM	2522	CB	SER	360	28.121	31.316	14.316	1.00	26.70	B4
ATOM	2472	H	ALA	355	28.579	23.745	12.744	1.00	0.00	B3	ATOM	2523	CG	SER	360	27.493	33.539	13.078	1.00	29.72	B4
ATOM	2473	CA	ALA	355	30.025	25.140	12.215	1.00	26.54	B3	ATOM	2524	IIG	SER	360	26.637	33.112	13.288	1.00	0.00	B4
ATOM	2474	CB	ALA	355	30.034	24.591	10.869	1.00	22.08	B3	ATOM	2525	C	SER	360	30.202	34.387	15.353	1.00	27.15	B4
ATOM	2475	C	ALA	355	29.533	26.601	12.096	1.00	28.51	B3	ATOM	2526	O	SER	360	30.575	35.550	15.498	1.00	26.93	B4
ATOM	2476	O	ALA	355	30.315	27.498	12.344	1.00	31.93	B3	ATOM	2527	N	PHE	361	30.383	33.403	16.246	1.00	25.38	B4
ATOM	2477	N	SER	356	28.271	26.484	11.802	1.00	30.30	B3	ATOM	2528	II	PHE	361	30.055	32.499	16.040	1.00	0.00	B4
ATOM	2478	H	SER	356	27.654	26.134	11.665	1.00	0.00	B3	ATOM	2529	CA	PHE	361	31.066	33.626	17.517	1.00	25.20	B4
ATOM	2479	CA	SER	356	27.778	26.249	11.625	1.00	31.10	B3	ATOM	2530	CB	PHE	361	31.092	32.335	18.302	1.00	23.30	B4
ATOM	2480	CB	SER	356	26.401	28.147	11.016	1.00	35.23	B3	ATOM	2531	CG	PHE	361	31.796	32.394	19.655	1.00	25.63	B4
ATOM	2481	OG	SER	356	25.679	29.380	10.905	1.00	43.82	B3	ATOM	2532	CD1	PHE	361	31.127	32.854	20.777	1.00	22.44	B4
ATOM	2482	IIG	SER	356	26.250	30.004	10.429	1.00	27.82	B3	ATOM	2533	CD2	PHE	361	33.098	31.931	19.770	1.00	24.35	B4
ATOM	2483	C	SER	356	27.763	29.098	12.901	1.00	29.75	B3	ATOM	2534	CE1	PHE	361	31.772	32.834	22.000	1.00	27.78	B4
ATOM	2484	S	SER	356	28.115	30.289	12.898	1.00	28.35	B3	ATOM	2535	CE2	PHE	361	33.719	31.921	21.002	1.00	21.26	B4
ATOM	2485	N	HIS	357	27.465	26.464	14.025	1.00	27.82	B3	ATOM	2536	CZ	PHE	361	33.058	34.143	17.395	1.00	19.54	B4
ATOM	2486	H	HIS	357	27.301	27.498	14.019	1.00	0.00	B3	ATOM	2537	C	PHE	361	32.505	34.143	17.395	1.00	26.56	B4
ATOM	2487	CA	HIS	357	27.434	29.194	15.259	1.00	26.58	B3	ATOM	2538	O	PHE	361	32.914	34.919	18.183	1.00	26.76	B4
ATOM	2488	CB	HIS	357	26.735	28.365	16.305	1.00	25.77	B3	ATOM	2539	N	LEU	362	33.309	33.645	16.441	1.00	28.87	B4
ATOM	2489	CG	HIS	357	25.219	28.360	16.063	1.00	27.67	B3	ATOM	2540	II	LEU	362	32.962	32.921	15.974	1.00	0.00	B4
ATOM	2490	CD2	HIS	357	24.563	28.767	14.913	1.00	28.94	B3	ATOM	2541	CA	LEU	362	34.679	34.089	16.222	1.00	26.89	B4
ATOM	2491	ND1	HIS	357	24.277	27.963	16.915	1.00	28.43	B3	ATOM	2542	CB	LEU	362	35.452	34.125	15.338	1.00	26.18	B4
ATOM	2492	HD1	HIS	357	24.456	27.622	17.828	1.00	0.00	B3	ATOM	2543	CG	LEU	362	35.603	31.656	15.781	1.00	29.61	B4
ATOM	2493	CE1	HIS	357	23.112	26.103	16.337	1.00	28.64	B3	ATOM	2544	CD1	LEU	362	36.406	30.996	14.613	1.00	31.64	B4
ATOM	2494	NE2	HIS	357	23.298	28.589	15.130	1.00	29.48	B3	ATOM	2545	CD2	LEU	362	36.374	31.433	17.055	1.00	26.38	B4
ATOM	2495	HE2	HIS	357	22.576	28.801	14.495	1.00	0.00	B3	ATOM	2546	C	LEU	362	34.692	35.449	15.336	1.00	29.18	B4
ATOM	2496	C	HIS	357	28.852	29.506	15.645	1.00	27.93	B3	ATOM	2547	O	LEU	362	35.469	36.202	15.748	1.00	27.41	B4
ATOM	2497	O	HIS	357	27.119	30.606	16.115	1.00	29.15	B3	ATOM	2548	N	G11	363	33.064	35.763	14.710	1.00	29.54	B4

FIGURE 5

ATOM	2549	II	GLU	363	33.009	,,0.066	14.495	1.00	0.00	B3	ATOM	2600	NH2	ARG	367	30.160	47.375	16.162	1.00	71.0	4	
ATOM	2550	CA	GLU	363	33.496	,,0.090	14.445	1.00	30.30	B3	ATOM	2601	III	I21	ARG	367	29.204	47.665	16.272	1.00	0.00	B3
ATOM	2551	CB	GLU	363	32.357	,,0.147	13.228	1.00	30.90	B3	ATOM	2602	III	I22	ARG	367	30.883	48.043	16.013	1.00	0.00	B3
ATOM	2552	CG	GLU	363	32.763	,,0.735	11.849	1.00	38.69	B3	ATOM	2603	C	ARG	367	35.551	43.611	15.615	1.00	40.70	B3	
ATOM	2553	CD	GLU	363	33.642	,,0.662	11.013	1.00	42.62	B3	ATOM	2604	O	ARG	367	35.994	44.090	19.012	1.00	41.10	B3	
ATOM	2554	OE1	GLU	363	33.896	,,0.720	9.860	1.00	46.58	B3	ATOM	2605	N	VAL	368	35.163	42.135	19.542	1.00	50.83	B3	
ATOM	2555	OE2	GLU	363	34.051	,,0.734	11.488	1.00	46.47	B3	ATOM	2606	II	VAL	368	37.144	43.498	21.772	1.00	0.60	B3	
ATOM	2556	C	GLU	363	33.729	,,0.098	15.244	1.00	30.19	B3	ATOM	2607	CA	VAL	368	35.331	42.492	20.548	1.00	37.34	B3	
ATOM	2557	O	GLU	363	33.837	,,0.67	15.239	1.00	30.26	B3	ATOM	2608	CB	VAL	368	34.748	41.043	21.064	1.00	35.75	B3	
ATOM	2558	N	VAL	364	32.397	,,0.726	16.217	1.00	30.04	B3	ATOM	2609	CG1	VAL	368	35.087	40.867	23.140	1.00	35.10	B3	
ATOM	2559	II	VAL	364	31.888	,,0.698	16.100	1.00	0.00	B3	ATOM	2610	CG2	VAL	368	33.259	41.230	21.580	1.00	35.28	B3	
ATOM	2560	CA	VAL	364	32.176	,,0.532	17.400	1.00	31.90	B3	ATOM	2611	C	VAL	368	36.015	42.459	21.223	1.00	48.75	B3	
ATOM	2561	CB	VAL	364	31.014	,,0.021	18.269	1.00	31.41	B3	ATOM	2612	O	VAL	368	34.726	41.600	19.316	1.00	40.11	B3	
ATOM	2562	CG1	VAL	364	30.860	,,0.811	19.562	1.00	30.73	B3	ATOM	2613	N	LEU	369	37.759	41.600	20.835	1.00	39.59	B3	
ATOM	2563	CG2	VAL	364	29.750	,,0.920	17.497	1.00	29.96	B3	ATOM	2614	II	LEU	369	37.492	40.818	20.308	1.00	40.00	B3	
ATOM	2564	C	VAL	364	33.402	,,0.493	18.275	1.00	35.89	B3	ATOM	2615	CA	LEU	369	39.180	41.780	21.148	1.00	40.05	B3	
ATOM	2565	O	VAL	364	33.683	,,0.535	18.655	1.00	37.54	B3	ATOM	2616	CB	LEU	369	39.984	40.600	20.679	1.00	37.15	B3	
ATOM	2566	N	SER	365	34.173	,,0.421	18.477	1.00	38.25	B3	ATOM	2617	CG	LEU	369	39.831	39.335	21.246	1.00	37.54	B3	
ATOM	2567	H	SER	365	33.971	,,0.577	16.030	1.00	0.00	B3	ATOM	2618	CD1	LEU	369	40.349	38.248	20.528	1.00	59.70	B3	
ATOM	2568	CA	SER	365	35.337	,,0.070	19.375	1.00	39.61	B3	ATOM	2619	CD2	LEU	369	40.563	39.394	22.747	1.00	36.86	B3	
ATOM	2569	CB	SER	365	36.041	,,0.113	19.555	1.00	43.00	B3	ATOM	2620	C	LEU	369	39.817	43.031	20.542	1.00	41.88	B3	
ATOM	2570	OC	SER	365	35.201	,,0.933	19.575	1.00	46.29	B3	ATOM	2621	O	LEU	369	40.711	43.654	21.144	1.00	40.30	B3	
ATOM	2571	IGC	SER	365	34.270	,,0.169	19.644	1.00	0.00	B3	ATOM	2622	N	ARG	370	39.333	43.411	19.354	1.00	42.80	B3	
ATOM	2572	C	SER	365	36.398	,,0.418	18.640	1.00	38.21	B3	ATOM	2623	H	ARG	370	38.619	42.884	18.957	1.00	0.00	B3	
ATOM	2573	O	SER	365	37.103	,,0.898	19.662	1.00	36.91	B3	ATOM	2624	CA	ANG	370	39.819	44.577	18.663	1.00	41.96	B3	
ATOM	2574	N	TYR	366	36.575	,,0.540	17.514	1.00	38.00	B3	ATOM	2625	CB	ANG	370	39.184	44.569	17.316	1.00	42.06	B3	
ATOM	2575	II	TYR	366	36.079	,,0.745	16.910	1.00	0.00	B3	ATOM	2626	CG	ANG	370	39.424	45.719	16.371	1.00	43.94	B3	
ATOM	2576	CA	TYR	366	37.568	,,0.463	16.969	1.00	39.85	B3	ATOM	2627	CD	ANG	370	40.894	45.910	16.169	1.00	45.57	B3	
ATOM	2577	CB	TYR	366	37.776	,,0.310	15.436	1.00	38.53	B3	ATOM	2628	NE	ANG	370	41.219	46.681	14.916	1.00	48.00	B3	
ATOM	2578	CG	TYR	366	38.662	,,0.447	14.879	1.00	38.21	B3	ATOM	2629	HE	ANG	370	40.524	46.667	14.312	1.00	0.00	B3	
ATOM	2579	CD1	TYR	366	38.104	,,0.464	14.129	1.00	37.18	B3	ATOM	2630	CZ	ANG	370	42.469	47.153	14.791	1.00	48.45	B3	
ATOM	2580	CE1	TYR	366	38.918	,,0.495	13.678	1.00	41.77	B3	ATOM	2631	NH1	ANG	370	43.443	46.961	15.691	1.00	49.13	B3	
ATOM	2581	CD2	TYR	366	40.021	,,0.443	15.182	1.00	40.21	B3	ATOM	2632	IIH11	ANG	370	43.616	46.456	16.334	1.00	40.00	B3	
ATOM	2582	CE2	TYR	366	40.849	,,0.466	14.739	1.00	40.76	B3	ATOM	2633	IIH12	ANG	370	44.357	47.326	15.520	1.00	40.00	B3	
ATOM	2583	CZ	TYR	366	40.297	,,0.504	13.976	1.00	42.82	B3	ATOM	2634	NH2	ANG	370	42.821	47.710	15.035	1.00	47.59	B3	
ATOM	2584	OH	TYR	366	41.151	,,0.522	13.493	1.00	41.30	B3	ATOM	2635	IIH121	ANG	370	42.163	47.785	12.789	1.00	40.00	B3	
ATOM	2585	HH	TYR	366	40.743	,,0.977	12.755	1.00	0.00	B3	ATOM	2636	IIH122	ANG	370	43.751	48.057	13.516	1.00	0.00	B3	
ATOM	2586	C	TYR	366	37.133	,,0.893	17.241	1.00	40.55	B3	ATOM	2637	C	ANG	370	39.386	45.740	19.558	1.00	49.16	B3	
ATOM	2587	O	TYR	366	37.917	,,0.647	17.798	1.00	40.92	B3	ATOM	2638	O	ANG	370	40.216	46.615	19.326	1.00	40.67	B3	
ATOM	2588	N	ARG	367	35.933	,,0.309	16.853	1.00	41.88	B3	ATOM	2639	N	IIIS	371	38.162	45.728	20.123	1.00	52.30	B3	
ATOM	2589	H	ARG	367	35.360	,,0.642	16.360	1.00	0.00	B3	ATOM	2640	H	IIIS	371	37.581	44.955	19.949	1.00	6.00	B3	
ATOM	2590	CA	ARG	367	35.442	,,0.653	17.139	1.00	41.32	B3	ATOM	2641	CA	IIIS	371	37.745	46.738	21.080	1.00	56.65	B3	
ATOM	2591	CB	ARG	367	34.013	,,0.709	16.650	1.00	46.82	B3	ATOM	2642	CB	IIIS	371	36.284	46.604	21.459	1.00	62.15	B3	
ATOM	2592	CC	ARG	367	33.528	,,0.430	16.650	1.00	56.74	B3	ATOM	2643	CG	IIIS	371	35.320	46.499	20.346	1.00	71.70	B3	
ATOM	2593	CD	ARG	367	32.069	,,0.267	16.248	1.00	61.81	B3	ATOM	2644	CD2	IIIS	371	35.596	47.877	19.313	1.00	75.03	B3	
ATOM	2594	NE	ARG	367	31.713	,,0.687	16.229	1.00	66.59	B3	ATOM	2645	ND1	IIIS	371	34.067	46.546	20.166	1.00	75.91	B3	
ATOM	2595	HE	ARG	367	32.438	,,0.356	16.172	1.00	0.00	B3	ATOM	2646	HD1	IIIS	371	35.594	45.817	20.732	1.00	0.00	B3	
ATOM	2596	C2	ARG	367	30.458	,,0.091	16.308	1.00	69.75	B3	ATOM	2647	CE1	IIIS	371	33.580	47.116	19.077	1.00	73.40	B3	
ATOM	2597	NH1	ARG	367	29.448	,,0.220	16.413	1.00	72.65	B3	ATOM	2648	NH2	IIIS	371	34.507	47.914	18.573	1.00	77.52	B3	
ATOM	2598	NH11	ARG	367	29.631	,,4.236	16.410	1.00	0.00	B3	ATOM	2649	NH22	IIIS	371	34.401	48.464	17.764	1.00	0.56	B3	
ATOM	2599	NH12	ARG	367	28.503	,,0.548	16.445	1.00	0.00	B3	ATOM	2650	C	IIIS	371	38.533	46.069	17.387	1.00	58.97	B3	

FIGURE 5

ATOM	2651	O	IIS	371	38.458	-47.592	23.176	1.00	58.12	B3	ATOM	2702	CG	SER	413	27.378	56.872	7.301	1.00	53.05
ATOM	2652	N	LEU	372	39.271	45.632	22.715	1.00	56.98	B3	ATOM	2703	IG	SER	413	26.178	56.355	7.145	1.00	53.05
ATOM	2653	H	LEU	372	44.855	22.122	22.122	1.00	0.00	B3	ATOM	2704	C	SER	413	27.480	54.684	7.267	1.00	46.71
ATOM	2654	CA	LEU	372	40.048	45.597	24.939	1.00	57.77	B3	ATOM	2705	O	SER	413	28.698	54.839	5.321	1.00	50.77
ATOM	2655	CB	LEU	372	39.725	44.272	24.633	1.00	57.29	B3	ATOM	2706	N	PHE	414	26.947	53.440	5.208	1.00	46.01
ATOM	2656	CG	LEU	372	38.566	44.144	25.611	1.00	55.87	B3	ATOM	2707	H	PHE	414	25.996	53.323	5.015	1.00	0.00
ATOM	2657	CD1	LEU	372	37.358	44.992	25.123	1.00	55.77	B3	ATOM	2708	CA	PHE	414	27.787	52.333	5.274	1.00	42.01
ATOM	2658	CD2	LEU	372	38.311	42.675	25.749	1.00	55.33	B3	ATOM	2709	CB	PHE	414	26.959	50.915	5.322	1.00	40.76
ATOM	2659	C	LEU	372	41.554	45.755	23.647	1.00	58.81	B3	ATOM	2710	CG	PHE	414	27.633	49.627	4.755	1.00	35.06
ATOM	2660	O	LEU	372	42.447	45.475	24.476	1.00	59.12	B3	ATOM	2711	CD1	PHE	414	27.583	49.250	3.425	1.00	34.71
ATOM	2661	N	ALA	373	41.942	46.168	22.447	1.00	59.27	B3	ATOM	2712	CD2	PHE	414	28.262	48.800	5.063	1.00	34.81
ATOM	2662	H	ALA	373	41.221	46.255	21.731	1.00	0.00	B3	ATOM	2713	CE1	PHE	414	28.156	46.056	3.014	1.00	26.16
ATOM	2663	CA	ALA	373	43.336	46.425	22.147	1.00	60.03	B3	ATOM	2714	CE2	PHE	414	28.832	47.602	5.247	1.00	33.40
ATOM	2664	CB	ALA	373	43.755	45.485	21.021	1.00	59.87	B3	ATOM	2715	C2	PHE	414	28.781	47.223	3.923	1.00	34.22
ATOM	2665	C	ALA	373	43.616	47.495	21.762	1.00	61.22	B3	ATOM	2716	C	PHE	414	28.667	52.271	4.044	1.00	41.25
ATOM	2666	OT1	ALA	373	44.798	48.243	21.669	1.00	62.45	B3	ATOM	2717	O	PHE	414	29.831	51.902	4.110	1.00	41.47
ATOM	2667	OT2	ALA	373	42.682	48.700	21.583	1.00	61.55	B3	ATOM	2718	N	LEU	415	26.122	52.748	2.942	1.00	39.50
ATOM	2668	CB	LEU	410	23.866	49.243	1.118	1.00	53.10	CI	ATOM	2719	H	LEU	415	27.188	53.044	2.916	1.00	0.00
ATOM	2669	CG	LEU	410	23.982	47.812	0.738	1.00	51.85	CI	ATOM	2720	CA	LEU	415	28.065	52.769	1.721	1.00	39.91
ATOM	2670	CD1	LEU	410	25.074	47.596	-0.330	1.00	52.64	CI	ATOM	2721	CB	LEU	415	27.946	53.205	0.641	1.00	41.96
ATOM	2671	CD2	LEU	410	24.125	47.081	2.058	1.00	49.28	CI	ATOM	2722	CG	LEU	415	27.903	52.274	-0.516	1.00	44.75
ATOM	2672	C	LEU	410	22.381	51.214	1.635	1.00	52.99	CI	ATOM	2723	CD1	LEU	415	26.430	51.951	-0.780	1.00	42.31
ATOM	2673	O	LEU	410	22.442	52.166	0.845	1.00	53.00	CI	ATOM	2724	CD2	LEU	415	26.793	52.853	-1.658	1.00	45.31
ATOM	2674	HT1	LEU	410	22.721	50.836	-0.665	1.00	0.00	CI	ATOM	2725	C	LEU	415	30.081	53.669	1.755	1.00	40.03
ATOM	2675	HT2	LEU	410	21.194	50.178	-0.557	1.00	0.00	CI	ATOM	2726	O	LEU	415	31.142	53.348	1.183	1.00	40.76
ATOM	2676	N	LEU	410	22.198	49.968	-0.415	1.00	54.31	CI	ATOM	2727	N	LEU	416	29.901	54.779	2.487	1.00	37.46
ATOM	2677	HT3	LEU	410	22.529	49.174	-0.998	1.00	54.31	CI	ATOM	2728	W	LEU	416	29.028	54.948	2.897	1.00	31.00
ATOM	2678	CA	LEU	410	22.478	49.015	1.004	1.00	53.64	CI	ATOM	2729	CA	LEU	416	30.942	55.756	2.602	1.00	34.05
ATOM	2679	N	PRO	411	22.450	51.433	2.965	1.00	52.95	CI	ATOM	2730	CB	LEU	416	30.294	57.089	2.998	1.00	34.67
ATOM	2680	CD	PRO	411	22.466	50.407	4.022	1.00	51.54	CI	ATOM	2731	O	LEU	416	29.438	57.704	1.854	1.00	35.24
ATOM	2681	CA	PRO	411	22.666	52.766	3.549	1.00	53.25	CI	ATOM	2732	CD1	LEU	416	28.770	58.948	2.358	1.00	41.87
ATOM	2682	CB	PRO	411	22.668	52.541	5.068	1.00	52.85	CI	ATOM	2733	CD2	LEU	416	30.310	57.948	0.593	1.00	35.50
ATOM	2683	CG	PRO	411	23.163	51.108	5.203	1.00	52.83	CI	ATOM	2734	C	LEU	416	31.952	56.258	3.586	1.00	31.97
ATOM	2684	C	PRO	411	23.958	53.413	3.023	1.00	54.02	CI	ATOM	2735	O	LEU	416	33.131	55.427	3.270	1.00	33.52
ATOM	2685	O	PRO	411	25.073	52.978	3.167	1.00	54.02	CI	ATOM	2736	N	ALA	417	31.573	54.619	4.695	1.00	29.05
ATOM	2686	N	GIN	412	23.787	54.599	2.411	1.00	52.79	CI	ATOM	2737	H	ALA	417	30.621	54.616	4.927	1.00	0.00
ATOM	2687	H	GIN	412	22.063	54.900	2.294	1.00	0.00	CI	ATOM	2738	CA	ALA	417	31.524	53.862	5.536	1.00	29.46
ATOM	2688	CA	GIN	412	24.073	53.413	1.071	1.00	50.44	CI	ATOM	2739	CB	ALA	417	31.653	54.087	6.680	1.00	25.16
ATOM	2689	CB	GIN	412	24.387	56.762	1.413	1.00	52.47	CI	ATOM	2740	C	ALA	417	33.319	52.822	4.777	1.00	36.68
ATOM	2690	CG	GIN	412	25.364	57.408	0.437	1.00	56.51	CI	ATOM	2741	O	ALA	417	34.536	52.721	4.877	1.00	31.52
ATOM	2691	CD	GIN	412	25.220	56.954	-1.017	1.00	59.40	CI	ATOM	2742	N	CYS	418	32.726	52.041	3.905	1.00	32.19
ATOM	2692	OEI	GIN	412	25.069	57.506	-1.913	1.00	59.67	CI	ATOM	2743	H	CYS	418	31.748	52.017	3.856	1.00	0.00
ATOM	2693	NB2	GIN	412	24.336	56.022	-1.389	1.00	60.12	CI	ATOM	2744	CA	CYS	418	33.499	51.119	3.103	1.00	33.67
ATOM	2694	HE2	GIN	412	23.734	55.616	-0.737	1.00	0.00	CI	ATOM	2745	CB	CYS	418	32.657	50.250	2.226	1.00	34.65
ATOM	2695	IIE2	GIN	412	24.396	55.748	-2.328	1.00	0.00	CI	ATOM	2746	SG	CYS	418	31.623	49.708	3.246	1.00	37.60
ATOM	2696	C	GIN	412	25.930	55.646	2.916	1.00	48.22	CI	ATOM	2747	C	CYS	418	34.446	51.818	2.170	1.00	34.80
ATOM	2697	O	GIN	412	27.089	55.591	2.545	1.00	46.78	CI	ATOM	2748	O	CYS	418	35.626	51.441	2.173	1.00	46.47
ATOM	2698	N	SER	413	25.614	55.842	4.201	1.00	47.90	CI	ATOM	2749	N	LEU	419	34.009	52.820	1.377	1.00	35.99
ATOM	2699	H	SER	413	24.693	55.976	4.492	1.00	0.00	CI	ATOM	2750	H	LEU	419	34.002	53.131	1.461	1.00	0.00
ATOM	2700	CA	SER	413	26.696	55.984	5.144	1.00	48.75	CI	ATOM	2751	CA	LEU	419	34.486	53.446	0.775	1.00	34.41
ATOM	2701	CH	SER	413	26.261	56.344	6.548	1.00	50.61	CI	ATOM	2752	CB	LEU	419	34.001	54.484	-0.414	1.00	47.01

FIGURE 5

ATOM	2753	CG	LEU	419	32.866	-3.453	-1.244	1.00	39.61	C1	43.594	53.147	1.127	1.00	24.37	C1			
ATOM	2754	CD1	LEU	419	33.866	54.918	-1.609	1.00	49.24	C1	42.065	53.050	2.668	1.00	24.38	C1			
ATOM	2755	CD2	LEU	419	33.349	53.207	-2.553	1.00	40.02	C1	42.065	53.050	2.668	1.00	0.00	C1			
ATOM	2756	C	LEU	419	36.102	54.041	1.047	1.00	32.33	C1	41.041	52.855	3.722	1.00	25.12	C1			
ATOM	2757	O	LEU	419	37.198	53.973	0.549	1.00	31.60	C1	42.352	52.791	5.051	1.00	24.89	C1			
ATOM	2758	N	GLU	420	35.974	54.483	2.273	1.00	31.92	C1	43.311	52.936	6.190	1.00	28.56	C1			
ATOM	2759	H	GLU	420	35.068	54.528	2.648	1.00	0.00	C1	42.579	52.580	4.486	1.00	35.51	C1			
ATOM	2760	CA	GLU	420	37.078	54.905	3.092	1.00	31.79	C1	41.318	53.425	7.853	1.00	40.34	C1			
ATOM	2761	CB	GLU	420	36.477	55.462	4.344	1.00	34.29	C1	40.519	52.722	8.834	1.00	42.23	C1			
ATOM	2762	CG	GLU	420	37.410	56.240	5.185	1.00	38.66	C1	41.079	52.559	9.695	1.00	0.00	C1			
ATOM	2763	CD	GLU	420	36.952	56.499	6.609	1.00	45.20	C1	40.208	51.814	8.435	1.00	0.00	C1			
ATOM	2764	OE1	GLU	420	37.073	56.849	7.367	1.00	45.67	C1	39.689	53.306	9.065	1.00	0.00	C1			
ATOM	2765	OE2	GLU	420	35.745	56.345	6.954	1.00	44.21	C1	43.761	51.547	3.462	1.00	27.10	C1			
ATOM	2766	C	GLU	420	38.043	53.763	3.423	1.00	31.87	C1	44.923	51.425	3.848	1.00	30.64	C1			
ATOM	2767	O	GLU	420	39.253	53.949	3.770	1.00	32.82	C1	43.190	51.745	2.794	1.00	26.85	C1			
ATOM	2768	N	GLN	421	36.553	52.624	3.954	1.00	30.46	C1	42.260	50.607	2.488	1.00	0.00	C1			
ATOM	2769	H	GLN	421	36.583	52.556	4.098	1.00	0.00	C1	43.949	49.312	5.561	1.00	25.46	C1			
ATOM	2770	CA	GLN	421	38.366	51.461	4.283	1.00	29.34	C1	42.965	48.093	2.336	1.00	24.91	C1			
ATOM	2771	CB	GLN	421	37.545	50.389	4.984	1.00	30.88	C1	43.654	46.786	4.995	1.00	22.01	C1			
ATOM	2772	CG	GLN	421	37.308	50.634	6.463	1.00	33.58	C1	42.229	47.909	3.653	1.00	25.34	C1			
ATOM	2773	CD	GLN	421	36.320	49.625	7.058	1.00	37.89	C1	40.885	47.169	3.342	1.00	25.68	C1			
ATOM	2774	OE1	GLN	421	35.357	49.236	6.398	1.00	43.18	C1	44.824	49.549	1.346	1.00	23.84	C1			
ATOM	2775	NE2	GLN	421	36.427	49.095	8.275	1.00	37.13	C1	45.059	49.069	1.316	1.00	24.57	C1			
ATOM	2776	HE21	GLN	421	35.615	48.555	8.556	1.00	0.00	C1	44.361	50.267	3.323	1.00	23.28	C1			
ATOM	2777	HE22	GLN	421	37.207	49.330	8.812	1.00	0.00	C1	43.451	50.630	0.993	1.00	0.00	C1			
ATOM	2778	C	GLN	421	38.991	50.162	3.026	1.00	27.36	C1	42.216	45.164	50.531	-0.871	1.00	24.13	C1		
ATOM	2779	O	GLN	421	40.151	50.445	3.099	1.00	29.09	C1	44.421	51.344	-1.896	1.00	24.04	C1			
ATOM	2780	N	VAL	422	38.379	50.045	1.847	1.00	23.57	C1	42.325	50.539	-2.396	1.00	23.56	C1			
ATOM	2781	H	VAL	422	37.448	51.138	1.803	1.00	0.00	C1	41.026	48.446	51.105	-3.511	1.00	23.92	C1		
ATOM	2782	CA	VAL	422	39.077	50.420	0.651	1.00	23.52	C1	42.828	41.704	52.047	-3.345	1.00	25.44	C1		
ATOM	2783	CB	VAL	422	38.163	50.636	-0.556	1.00	22.67	C1	42.057	47.722	50.509	-4.727	1.00	22.55	C1		
ATOM	2784	CG1	VAL	422	38.873	50.455	-1.868	1.00	21.56	C1	42.810	49.211	41.755	50.948	-5.323	1.00	0.00	C1	
ATOM	2785	CG2	VAL	422	37.057	49.610	-0.465	1.00	26.79	C1	42.836	48.212	42.626	42.830	49.696	-4.851	1.00	0.00	C1
ATOM	2786	C	VAL	422	40.353	51.254	0.514	1.00	26.22	C1	42.831	47.911	46.404	51.312	-0.488	1.00	26.69	C1	
ATOM	2787	O	VAL	422	41.458	50.708	0.508	1.00	28.77	C1	42.838	47.466	51.109	-0.416	1.00	29.73	C1		
ATOM	2788	N	ARG	423	40.275	52.599	1.00	27.49	C1	42.819	47.911	46.300	52.204	-0.499	1.00	26.49	C1		
ATOM	2789	H	ARG	423	39.022	53.016	0.735	1.00	0.00	C1	42.840	47.427	45.410	52.414	0.854	1.00	0.00	C1	
ATOM	2790	CA	ARG	423	41.436	53.456	0.346	1.00	25.91	C1	42.841	47.427	47.446	52.894	1.022	1.00	24.25	C1	
ATOM	2791	CB	ARG	423	41.098	54.943	0.312	1.00	24.39	C1	42.842	47.427	48.467	51.913	1.589	1.00	24.08	C1	
ATOM	2792	CG	ARG	423	40.167	55.366	-0.807	1.00	22.81	C1	42.843	47.427	49.597	51.921	1.006	1.00	22.28	C1	
ATOM	2793	CD	ARG	423	40.525	54.798	-2.172	1.00	25.55	C1	42.844	47.428	48.107	51.073	2.575	1.00	22.75	C1	
ATOM	2794	NE	ARG	423	39.707	53.387	-3.216	1.00	25.38	C1	42.845	47.428	47.189	51.411	1.00	0.00	C1		
ATOM	2795	HE	ARG	423	39.168	56.173	-2.989	1.00	0.00	C1	42.846	47.428	49.039	50.108	1.131	1.00	23.87	C1	
ATOM	2796	C2	ARG	423	39.629	54.928	-4.466	1.00	27.31	C1	42.847	47.428	48.415	51.812	1.00	0.00	C1		
ATOM	2797	NH1	ARG	423	40.264	53.857	-4.949	1.00	26.37	C1	42.848	47.428	47.437	49.779	5.097	1.00	28.84	C1	
ATOM	2798	NH11	ARG	423	40.884	53.341	-4.365	1.00	0.00	C1	42.849	47.428	46.420	49.151	5.265	1.00	31.81	C1	
ATOM	2799	NI12	ARG	423	40.150	53.595	-5.907	1.00	0.00	C1	42.850	47.428	47.662	50.804	5.716	1.00	30.77	C1	
ATOM	2800	NI12	ARG	423	38.960	53.682	-5.323	1.00	30.38	C1	42.851	47.428	49.626	49.191	2.063	1.00	24.16	C1	
ATOM	2801	HI12	ARG	423	38.539	56.537	-5.023	1.00	0.00	C1	42.852	47.428	50.812	48.896	2.088	1.00	26.17	C1	
ATOM	2802	HI122	ARG	423	38.865	55.385	-6.275	1.00	0.00	C1	42.853	47.428	50.812	48.822	1.069	1.00	23.01	C1	
ATOM	2803	C	ARG	423	42.429	53.241	1.432	1.00	23.60	C1	42.854	47.428	47.905	49.113	1.071	1.00	0.00	C1	

FIGURE 5

ATOM	2855	CA	GLY	429	49.289	-9.964	0.029	1.00 25.44	Cl	ATOM	2906	C	LYS	435	58.244	49.748	4.137	1.00 40.31
ATOM	2856	C	GLY	429	50.405	48.649	-0.716	1.00 27.39	Cl	ATOM	2907	CE	LYS	435	58.293	50.861	5.213	1.00 45.32
ATOM	2857	O	GLY	429	51.528	48.135	-0.741	1.00 28.51	Cl	ATOM	2908	N	LYS	435	58.494	50.795	6.575	1.00 47.31
ATOM	2858	N	ALA	430	50.127	49.840	-1.271	1.00 28.26	Cl	ATOM	2909	H21	LYS	435	59.388	49.795	6.661	1.00 0.010
ATOM	2859	II	ALA	430	49.216	50.185	-1.172	1.00 0.00	Cl	ATOM	2910	H22	LYS	435	57.708	49.689	6.818	1.00 0.010
ATOM	2860	CA	ALA	430	51.094	50.643	-2.015	1.00 26.04	Cl	ATOM	2911	H23	LYS	435	58.534	51.109	7.257	1.00 0.010
ATOM	2861	CB	ALA	430	50.490	51.976	-2.407	1.00 27.93	Cl	ATOM	2912	C	LYS	435	59.906	48.135	-0.065	1.00 36.10
ATOM	2862	C	ALA	430	52.300	50.927	-1.133	1.00 25.19	Cl	ATOM	2913	O	LYS	435	61.136	48.016	-0.012	1.00 37.08
ATOM	2863	O	ALA	430	53.393	51.053	-1.655	1.00 25.43	Cl	ATOM	2914	N	IEU	436	59.215	47.168	-0.065	1.00 36.28
ATOM	2864	N	ALA	431	52.171	50.979	0.186	1.00 24.05	Cl	ATOM	2915	II	IEU	436	58.235	47.245	-0.051	1.00 0.010
ATOM	2865	C	ALA	431	51.279	50.872	0.579	1.00 0.00	Cl	ATOM	2916	CA	IEU	436	59.793	45.994	1.00 34.25	Cl
ATOM	2866	CA	ALA	431	53.295	51.213	1.035	1.00 26.29	Cl	ATOM	2917	CB	IEU	436	58.655	45.076	-1.753	1.00 34.41
ATOM	2867	CB	ALA	431	52.874	51.522	2.458	1.00 24.14	Cl	ATOM	2918	CC	IEU	436	57.920	44.327	-0.610	1.00 34.72
ATOM	2868	C	ALA	431	54.139	49.972	1.073	1.00 29.82	Cl	ATOM	2919	CD1	IEU	436	56.764	43.538	-1.181	1.00 34.56
ATOM	2869	O	ALA	431	53.360	50.035	0.939	1.00 31.97	Cl	ATOM	2920	CD2	IEU	436	58.880	43.375	0.117	1.00 36.39
ATOM	2870	N	LEU	432	53.562	48.777	1.203	1.00 31.87	Cl	ATOM	2921	C	IEU	436	60.669	46.183	-2.467	1.00 33.31
ATOM	2871	H	LEU	432	52.585	48.726	1.279	1.00 0.00	Cl	ATOM	2922	O	IEU	436	61.756	45.815	-2.647	1.00 33.94
ATOM	2872	CA	LEU	432	54.337	47.540	1.165	1.00 33.92	Cl	ATOM	2923	N	CYS	437	60.220	47.374	-3.222	1.00 32.34
ATOM	2873	CB	LEU	432	53.430	46.315	1.301	1.00 37.42	Cl	ATOM	2924	II	CYS	437	47.661	-3.097	1.00 0.010	Cl
ATOM	2874	CG	LEU	432	54.063	44.952	1.574	1.00 37.40	Cl	ATOM	2925	CA	CYS	437	60.978	47.949	-4.301	1.00 32.01
ATOM	2875	CD1	LEU	432	54.751	44.949	2.950	1.00 38.10	Cl	ATOM	2926	C	CYS	437	62.214	48.704	-3.857	1.00 34.70
ATOM	2876	CD2	LEU	432	52.966	43.901	1.492	1.00 36.27	Cl	ATOM	2927	O	CYS	437	63.313	48.599	-4.412	1.00 36.16
ATOM	2877	C	LEU	432	55.096	47.404	-0.446	1.00 33.74	Cl	ATOM	2928	CB	CYS	437	60.094	48.840	-5.008	1.00 30.97
ATOM	2878	O	LEU	432	56.306	47.179	-0.118	1.00 33.29	Cl	ATOM	2929	SG	CYS	437	61.003	49.666	-6.319	1.00 36.22
ATOM	2879	N	GIN	433	54.402	47.564	-1.276	1.00 34.57	Cl	ATOM	2930	O	ALA	438	62.016	49.463	-2.785	1.00 36.35
ATOM	2880	H	GIN	433	53.419	47.733	-1.186	1.00 0.00	Cl	ATOM	2931	II	ALA	438	61.108	49.547	-2.431	1.00 0.010
ATOM	2881	CA	GLN	433	55.002	47.526	-2.600	1.00 35.83	Cl	ATOM	2932	CA	ALA	438	63.060	50.226	-2.170	1.00 35.83
ATOM	2882	CB	GLN	433	53.999	47.892	-3.664	1.00 35.52	Cl	ATOM	2933	CB	ALA	438	62.410	51.107	-1.153	1.00 36.38
ATOM	2883	CG	GLN	433	52.996	46.823	-3.832	1.00 39.40	Cl	ATOM	2934	C	ALA	438	64.065	49.294	-1.527	1.00 37.01
ATOM	2884	CD	GLN	433	52.049	47.097	-4.973	1.00 42.46	Cl	ATOM	2935	O	ALA	438	65.132	49.168	-2.092	1.00 39.39
ATOM	2885	OE1	GLN	433	50.914	47.526	-4.786	1.00 48.22	Cl	ATOM	2936	N	THR	439	63.808	48.591	-0.422	1.00 36.59
ATOM	2886	NE2	GLN	433	52.376	46.878	-6.725	1.00 44.77	Cl	ATOM	2937	II	THR	439	69.967	48.723	0.014	1.00 0.010
ATOM	2887	HE1	GLN	433	53.271	46.540	-6.433	1.00 0.00	Cl	ATOM	2938	CA	THR	439	64.742	47.669	0.223	1.00 35.70
ATOM	2888	HE2	GLN	433	51.693	47.087	-6.892	1.00 0.00	Cl	ATOM	2939	N	THR	439	64.073	45.917	-1.548	1.00 36.02
ATOM	2889	C	GLN	433	56.177	48.485	-2.757	1.00 36.48	Cl	ATOM	2940	OC1	THR	439	63.333	48.048	2.040	1.00 36.31
ATOM	2890	O	GLU	433	57.214	48.118	-3.312	1.00 38.08	Cl	ATOM	2941	IG1	THR	439	62.419	47.959	1.706	1.00 0.010
ATOM	2891	N	GLU	434	56.055	49.719	-2.287	1.00 36.11	Cl	ATOM	2942	CG2	THR	439	65.039	46.479	2.369	1.00 36.50
ATOM	2892	H	GLU	434	55.210	49.978	-1.854	1.00 0.00	Cl	ATOM	2943	C	THR	439	65.331	46.517	-0.590	1.00 0.010
ATOM	2893	CA	GLU	434	57.049	50.719	-2.426	1.00 35.93	Cl	ATOM	2944	O	THR	439	66.448	46.093	-0.312	1.00 36.51
ATOM	2894	CB	GLU	434	56.408	52.030	-2.068	1.00 41.28	Cl	ATOM	2945	N	THR	440	64.603	45.917	-1.548	1.00 36.64
ATOM	2895	CG	GLU	434	57.126	53.356	-2.019	1.00 43.07	Cl	ATOM	2946	II	TYR	440	63.751	46.319	-1.822	1.00 0.010
ATOM	2896	CD	GLU	434	57.832	53.516	-0.698	1.00 45.70	Cl	ATOM	2947	CA	TYR	440	65.057	44.691	-2.198	1.00 34.78
ATOM	2897	OE1	GLU	434	57.190	53.538	0.167	1.00 49.33	Cl	ATOM	2948	CB	TYR	440	64.175	43.480	-1.878	1.00 34.99
ATOM	2898	OE2	GLU	434	59.051	53.579	-0.760	1.00 45.45	Cl	ATOM	2949	CG	TYR	440	64.016	43.240	-0.397	1.00 34.14
ATOM	2899	C	GLU	434	58.257	50.348	-1.548	1.00 34.00	Cl	ATOM	2950	CD1	TYR	440	62.773	43.230	0.169	1.00 35.16
ATOM	2900	O	GLU	434	59.388	50.481	-1.983	1.00 32.93	Cl	ATOM	2951	CE1	TYR	440	62.625	43.037	1.532	1.00 36.64
ATOM	2901	N	LYS	435	58.067	49.860	-0.330	1.00 34.34	Cl	ATOM	2952	CD2	TYR	440	65.126	45.064	0.385	1.00 37.84
ATOM	2902	II	LYS	435	57.146	49.837	0.014	1.00 0.00	Cl	ATOM	2953	CE2	TYR	440	64.992	42.881	1.752	1.00 39.02
ATOM	2903	CA	LYS	435	59.151	49.358	0.511	1.00 34.56	Cl	ATOM	2954	C2	TYR	440	63.741	42.864	2.317	1.00 37.14
ATOM	2904	CB	LYS	435	58.577	49.010	1.847	1.00 33.89	Cl	ATOM	2955	OII	TYR	440	63.637	42.649	3.617	1.00 37.56
ATOM	2905	CG	LYS	435	58.357	50.231	2.709	1.00 36.71	Cl	ATOM	2956	III	TYR	440	64.498	42.344	3.908	1.00 36.01

FIGURE 5

ATOM 2957 C TIR 440	65.088	-7.768	-3.681	1.00 34.07	CDI	446	55.082	42.380	-12.769	1.00 41.64
ATOM 2958 O TIR 440	65.598	43.823	-4.367	1.00 35.54	CDI	446	55.310	43.310	-12.761	1.00 0.00
ATOM 2959 N LYS 441	64.627	45.833	-4.330	1.00 33.18	CDI	446	54.967	42.639	-15.183	1.00 42.05
ATOM 2960 H LYS 441	64.345	46.623	-3.822	1.00 0.00	CDI	446	54.109	43.925	-14.992	1.00 47.06
ATOM 2961 CA LYS 441	64.395	45.937	-5.763	1.00 30.44	CDI	446	54.728	45.083	-14.162	1.00 62.28
ATOM 2962 CB LYS 441	65.983	45.759	-6.364	1.00 33.76	CDI	446	54.104	46.472	-13.178	1.00 66.26
ATOM 2963 CG LYS 441	66.779	47.080	-6.407	1.00 39.59	CDI	446	55.818	45.604	-14.473	1.00 65.55
ATOM 2964 CD LYS 441	67.273	47.497	-5.045	1.00 47.69	CDI	446	56.337	40.722	-14.197	1.00 40.44
ATOM 2965 CE LYS 441	67.503	49.018	-4.984	1.00 53.37	CDI	446	56.186	39.708	-14.904	1.00 41.66
ATOM 2966 NZ LYS 441	66.267	49.780	-5.240	1.00 57.64	ATOM	3009 N GLU 446	57.360	40.995	-13.332	1.00 37.89
ATOM 2967 H21 LYS 441	65.568	49.549	-4.506	1.00 0.00	ATOM	3010 CA GLU 446	57.994	41.869	-12.999	1.00 0.00
ATOM 2968 H22 LYS 441	65.885	49.525	-6.173	1.00 0.00	ATOM	3011 CB GLU 446	58.519	40.096	-13.509	1.00 36.73
ATOM 2969 H23 LYS 441	66.468	50.801	-5.219	1.00 0.00	ATOM	3012 O2I GLU 446	59.750	40.810	-12.976	1.00 34.60
ATOM 2970 C LYS 441	63.629	45.015	-6.425	1.00 28.86	ATOM	3013 C GLU 446	60.322	41.883	-13.350	1.00 35.27
ATOM 2971 O LYS 441	63.791	44.688	-7.603	1.00 29.95	ATOM	3017 O GLU 446	61.450	42.699	-13.197	1.00 36.14
ATOM 2972 N LEU 442	62.556	44.660	-5.749	1.00 27.58	ATOM	3018 N GLU 447	62.240	43.286	-13.953	1.00 37.34
ATOM 2973 H LEU 442	62.392	44.924	-4.137	1.00 0.00	ATOM	3019 II GLU 447	61.541	42.782	-11.970	1.00 12.80
ATOM 2974 CA LEU 442	61.554	43.780	-6.402	1.00 28.82	ATOM	3020 CA GLU 447	60.327	41.020	-12.599	1.00 46.31
ATOM 2975 CB LEU 442	60.947	42.694	-5.466	1.00 26.98	ATOM	3021 CB GLU 447	59.113	37.911	-12.592	1.00 36.33
ATOM 2976 CG LEU 442	61.905	41.634	-4.847	1.00 27.75	ATOM	3022 CG GLU 447	57.273	38.765	-11.769	1.00 34.81
ATOM 2977 CD1 LEU 442	61.133	40.643	-4.009	1.00 24.29	ATOM	3023 CD1 LEU 448	56.554	39.431	-11.802	1.00 0.00
ATOM 2978 CD2 LEU 442	62.667	40.932	-5.963	1.00 19.72	ATOM	3029 II LEU 448	57.145	37.691	-10.839	1.00 31.98
ATOM 2979 C LEU 442	60.575	44.892	-6.635	1.00 30.59	ATOM	3030 CA LEU 448	58.080	38.299	-9.464	1.00 29.29
ATOM 2980 O LEU 442	59.811	45.261	-5.741	1.00 32.36	ATOM	3031 CB LEU 448	58.008	39.432	-9.440	1.00 29.81
ATOM 2981 N CYS 443	60.700	45.506	-7.804	1.00 32.15	ATOM	3032 CG LEU 448	55.580	37.400	-12.942	1.00 0.00
ATOM 2982 H CYS 443	61.423	45.199	-8.389	1.00 0.00	ATOM	3033 CD1 LEU 448	53.819	37.863	-7.684	1.00 26.02
ATOM 2983 CA CYS 443	59.866	46.645	-8.191	1.00 32.69	ATOM	3034 CD2 LEU 448	59.396	39.931	-9.392	1.00 31.13
ATOM 2984 C CYS 443	58.907	46.224	-9.217	1.00 33.43	ATOM	3035 C LEU 448	55.863	36.977	-11.165	1.00 33.75
ATOM 2985 O CYS 443	58.051	47.288	-9.465	1.00 34.10	ATOM	3036 O LEU 448	55.436	36.145	-10.382	1.00 33.96
ATOM 2986 CB CYS 443	60.715	47.800	-8.743	1.00 30.74	ATOM	3037 N VAL 449	55.166	37.233	-12.263	1.00 36.99
ATOM 2987 SG CYS 443	61.938	48.345	-7.519	1.00 32.96	ATOM	3038 H VAL 449	55.580	37.400	-12.942	1.00 0.00
ATOM 2988 N HIS 444	58.649	45.260	-9.911	1.00 35.65	ATOM	3039 CA VAL 449	53.157	37.546	-13.625	1.00 41.56
ATOM 2989 H HIS 444	59.147	44.445	-9.659	1.00 0.00	ATOM	3040 CB VAL 449	54.000	37.614	-14.880	1.00 42.24
ATOM 2990 CA HIS 444	57.662	45.172	-10.975	1.00 37.75	ATOM	3041 CG1 VAL 449	54.797	35.260	-13.870	1.00 0.00
ATOM 2991 CB HIS 444	53.229	45.224	-12.330	1.00 31.09	ATOM	3042 CG2 VAL 449	54.771	33.743	-13.781	1.00 50.57
ATOM 2992 CG HIS 444	59.149	46.476	-12.560	1.00 41.36	ATOM	3043 C VAL 449	55.942	32.894	-14.628	1.00 50.75
ATOM 2993 CD2 HIS 444	60.434	46.664	-12.075	1.00 41.40	ATOM	3044 O VAL 449	56.146	33.488	-15.394	1.00 52.39
ATOM 2994 ND1 HIS 444	58.811	47.563	-13.261	1.00 41.74	ATOM	3045 N CD1 LEU 450	57.152	32.586	-16.673	1.00 53.05
ATOM 2995 HD1 HIS 444	57.892	47.890	-13.410	1.00 41.00	ATOM	3046 II CD2 LEU 450	54.882	33.534	-16.833	1.00 54.10
ATOM 2996 CE1 HIS 444	59.850	48.372	-13.217	1.00 41.00	ATOM	3047 C LEU 450	54.797	31.406	-12.766	1.00 55.62
ATOM 2997 NE2 HIS 444	60.817	47.832	-12.502	1.00 41.38	ATOM	3048 CB LEU 450	55.685	33.097	-11.975	1.00 55.46
ATOM 2998 HE2 HIS 444	61.690	48.248	-12.334	1.00 0.00	ATOM	3049 CC LEU 450	56.073	32.954	-11.849	1.00 0.00
ATOM 2999 C HIS 444	56.889	43.871	-10.818	1.00 40.10	ATOM	3050 O LEU 451	55.998	32.654	-10.223	1.00 56.01
ATOM 3000 O HIS 444	57.461	42.867	-11.309	1.00 40.15	ATOM	3051 C LEU 451	57.137	33.532	-9.731	1.00 55.40
ATOM 3001 N PRO 445	55.615	43.752	-10.406	1.00 42.06	ATOM	3052 O LEU 451	57.745	33.278	-9.391	1.00 56.91
ATOM 3002 CD PRO 445	54.738	44.836	-9.937	1.00 41.56	ATOM	3053 N LEU 451	54.911	32.468	-12.471	1.00 51.81
ATOM 3003 CA PRO 445	54.913	42.997	-10.276	1.00 40.90	ATOM	3054 C LEU 451	56.073	32.954	-11.849	1.00 0.00
ATOM 3004 CB PRO 445	53.569	42.882	-9.730	1.00 39.35	ATOM	3055 II LEU 451	55.998	32.654	-10.223	1.00 56.01
ATOM 3005 CG PRO 445	53.364	44.274	-10.215	1.00 39.35	ATOM	3056 CA LEU 451	57.137	33.532	-9.731	1.00 55.40
ATOM 3006 C PRO 445	54.868	41.782	-11.600	1.00 42.18	ATOM	3057 CB LEU 451	54.745	32.894	-11.569	1.00 45.67
ATOM 3007 O PRO 445	54.769	40.557	-11.569	1.00 45.67	ATOM	3058 CG LEU 451	57.745	33.278	-9.391	1.00 56.91

FIGURE 5

ATOM	3059	CD1	LEU	451	58.833	-2.284	-8.653	1.00 59.12	C1	47.048	31.698	-5.472	1.00 81.76	C1	
ATOM	3060	CD2	LEU	451	58.369	34.511	-7.751	1.00 58.27	C1	46.903	31.761	-6.700	1.00 82.57	C1	
ATOM	3061	C	LEU	451	54.785	32.700	-9.280	1.00 55.96	C1	45.963	31.563	-4.225	1.00 81.40	C1	
ATOM	3062	O	LEU	451	54.717	31.935	-8.319	1.00 53.74	C1	45.959	31.225	-3.278	1.00 81.24	C1	
ATOM	3063	N	GLY	452	53.774	33.533	-9.522	1.00 57.52	C1	44.667	31.643	-5.264	1.00 80.74	C1	
ATOM	3064	H	GLY	452	53.889	34.241	-10.191	1.00 0.00	C1	43.779	30.942	-4.157	1.00 81.12	C1	
ATOM	3065	CA	GLY	452	52.567	33.515	-8.710	1.00 60.66	C1	44.755	30.293	-3.174	1.00 80.47	C1	
ATOM	3066	C	GLY	452	51.942	32.137	-8.772	1.00 63.64	C1	44.120	31.043	-5.648	1.00 79.70	C1	
ATOM	3067	O	GLY	452	51.476	31.593	-7.782	1.00 62.60	C1	43.624	31.040	-5.736	1.00 80.10	C1	
ATOM	3068	N	ILS	453	52.089	31.545	-9.969	1.00 68.46	C1	44.171	31.662	-6.361	1.00 76.19	C1	
ATOM	3069	H	ILS	453	52.628	32.040	-10.618	1.00 0.00	C1	44.614	33.185	-7.591	1.00 0.00	C1	
ATOM	3070	CA	ILS	453	51.606	30.205	-10.326	1.00 72.27	C1	43.544	34.986	-7.092	1.00 77.73	C1	
ATOM	3071	CB	ILS	453	51.785	29.908	-11.828	1.00 73.84	C1	43.802	35.428	-8.522	1.00 78.71	C1	
ATOM	3072	CG	ILS	453	51.421	31.061	-12.777	1.00 77.81	C1	43.054	36.677	-5.017	1.00 81.37	C1	
ATOM	3073	CD2	ILS	453	50.599	32.148	-12.498	1.00 79.29	C1	41.802	36.771	-9.618	1.00 82.89	C1	
ATOM	3074	ND1	ILS	453	51.886	31.244	-14.012	1.00 79.84	C1	45.9	41.71	38.139	-9.983	1.00 84.21	C1
ATOM	3075	HD1	ILS	453	52.617	30.739	-14.425	1.00 0.00	C1	40.738	35.960	-9.983	1.00 84.28	C1	
ATOM	3076	CE1	ILS	453	53.385	32.382	-14.470	1.00 61.11	C1	43.661	37.899	-8.925	1.00 84.89	C1	
ATOM	3077	NE2	ILS	453	50.613	32.923	-13.551	1.00 79.85	C1	42.824	38.765	-9.460	1.00 85.23	C1	
ATOM	3078	HE2	ILS	453	50.230	33.823	-13.586	1.00 0.00	C1	40.934	39.738	-9.483	1.00 0.00	C1	
ATOM	3079	C	HIS	453	52.454	29.235	-9.515	1.00 73.43	C1	40.615	38.727	-10.454	1.00 84.17	C1	
ATOM	3080	O	HIS	453	51.875	28.531	-8.692	1.00 73.56	C1	39.630	36.534	-10.597	1.00 84.56	C1	
ATOM	3081	N	SER	454	53.785	29.207	-9.651	1.00 74.64	C1	39.562	37.904	-10.852	1.00 84.83	C1	
ATOM	3082	H	SER	454	54.214	29.739	-10.351	1.00 0.00	C1	42.009	35.013	-6.827	1.00 77.31	C1	
ATOM	3083	CA	SER	454	54.639	28.411	-8.765	1.00 77.07	C1	41.202	34.244	-7.376	1.00 76.38	C1	
ATOM	3084	CB	SER	454	56.123	28.762	-8.980	1.00 77.34	C1	41.557	35.969	-6.020	1.00 76.81	C1	
ATOM	3085	OG	SER	454	57.095	27.715	-9.124	1.00 75.28	C1	42.187	36.640	-5.689	1.00 76.10	C1	
ATOM	3086	HG	SER	454	57.149	27.211	-8.306	1.00 0.00	C1	42.015	36.044	-5.613	1.00 76.44	C1	
ATOM	3087	C	SER	454	54.332	28.608	-7.262	1.00 78.84	C1	40.072	36.724	-4.244	1.00 75.51	C1	
ATOM	3088	O	SER	454	54.270	27.617	-6.535	1.00 80.57	C1	36.605	35.605	-8.755	1.00 76.29	C1	
ATOM	3089	N	LEU	455	54.070	29.789	-6.693	1.00 79.72	C1	39.499	37.976	-7.767	1.00 76.98	C1	
ATOM	3090	H	LEU	455	53.956	30.582	-7.250	1.00 0.00	C1	38.211	36.147	-7.187	1.00 76.10	C1	
ATOM	3091	CA	LEU	455	53.849	29.915	-5.257	1.00 80.43	C1	38.104	34.684	-7.245	1.00 75.88	C1	
ATOM	3092	CB	LEU	455	54.085	31.337	-4.838	1.00 80.20	C1	37.242	36.793	-8.068	1.00 75.46	C1	
ATOM	3093	CG	LEU	455	55.389	31.981	-5.269	1.00 81.61	C1	36.605	35.605	-8.755	1.00 75.71	C1	
ATOM	3094	CD1	LEU	455	55.254	33.494	-5.419	1.00 81.36	C1	36.771	37.803	-7.545	1.00 75.72	C1	
ATOM	3095	CD2	LEU	455	56.431	31.579	-4.264	1.00 81.26	C1	36.711	36.147	-7.187	1.00 76.10	C1	
ATOM	3096	C	LEU	455	52.438	29.586	-4.973	1.00 82.56	C1	34.051	42.987	-7.406	1.00 78.32	C1	
ATOM	3097	O	LEU	455	48.038	29.893	-3.741	1.00 82.38	C1	33.767	41.092	-5.828	1.00 78.62	C1	
ATOM	3103	N	ILE	457	49.342	30.697	-5.286	1.00 82.54	C1	34.701	40.565	-9.611	1.00 86.61	C1	
ATOM	3104	H	Ile	457	50.073	30.942	-5.894	1.00 0.00	C1	33.507	40.842	-9.808	1.00 81.74	C1	
ATOM	3105	CA	GLY	456	52.026	28.592	-6.584	1.00 0.00	C1	35.674	40.984	-7.360	1.00 78.32	C1	
ATOM	3106	C	GLY	456	50.269	28.361	-5.467	1.00 81.21	C1	34.786	41.359	-6.558	1.00 78.09	C1	
ATOM	3101	O	GLY	456	49.220	29.386	-4.973	1.00 82.56	C1	46.2	46.2	46.2	1.00 82.56	C1	
ATOM	3102	O	GLY	456	48.268	28.969	-4.276	1.00 82.38	C1	46.2	46.2	46.2	1.00 82.38	C1	
ATOM	3103	N	ILE	457	49.342	30.697	-5.286	1.00 82.54	C1	46.2	46.2	46.2	1.00 82.54	C1	
ATOM	3104	H	Ile	457	50.073	30.942	-5.894	1.00 0.00	C1	46.2	46.2	46.2	1.00 0.00	C1	
ATOM	3105	CA	Ile	457	46.435	31.761	-4.824	1.00 81.63	C1	46.2	46.2	46.2	1.00 81.63	C1	
ATOM	3106	CB	Ile	457	49.110	33.157	-5.086	1.00 80.69	C1	47.2	47.2	47.2	1.00 80.69	C1	
ATOM	3107	CG2	Ile	457	48.218	34.305	-4.662	1.00 79.76	C1	44.145	44.145	-1.189	1.00 59.56	C1	
ATOM	3108	CG1	Ile	457	48.369	33.275	-4.253	1.00 79.82	C1	47.2	47.2	47.2	1.00 79.82	C1	
ATOM	3109	CD	Ile	457	51.506	34.866	-5.081	1.00 77.89	C1	43.496	44.325	-10.326	1.00 59.13	C1	

FIGURE 5

ATOM	3161	CDD	LEU	472	22.501	-2.883	-2.486	1.00 56.85	C2	ATOM	3212	ME1	GLN	478	29.569	36.972	-5.317	1.00 0.00	C2
ATOM	3162	C	LEU	472	23.504	40.625	-1.996	1.00 63.91	C2	ATOM	3213	C	GLN	478	29.641	36.928	-7.054	1.00 0.00	C2
ATOM	3163	O	LEU	472	23.738	39.874	-2.949	1.00 64.90	C2	ATOM	3214	C	GLN	478	33.398	38.620	-2.249	1.00 50.66	C2
ATOM	3164	HII	LEU	472	21.563	41.441	-3.395	1.00 0.00	C2	ATOM	3215	O	GLN	478	34.584	38.314	-2.217	1.00 50.14	C2
ATOM	3165	HII2	LEU	472	23.091	41.291	-4.337	1.00 0.00	C2	ATOM	3216	N	LEU	479	33.045	39.909	-1.859	1.00 48.78	C2
ATOM	3166	N	LEU	472	22.472	41.930	-3.693	1.00 64.29	C2	ATOM	3217	I	LEU	479	32.131	-40.223	-2.039	1.00 0.00	C2
ATOM	3167	HII3	LEU	472	22.358	42.849	-4.160	1.00 0.00	C2	ATOM	3218	CA	LEU	479	34.015	40.800	-1.245	1.00 45.87	C2
ATOM	3168	CA	LEU	472	23.092	42.037	-2.386	1.00 63.85	C2	ATOM	3219	CB	LEU	479	33.434	42.141	-0.827	1.00 47.03	C2
ATOM	3169	N	ALA	473	23.652	40.129	-0.733	1.00 63.02	C2	ATOM	3220	CG	LEU	479	32.853	43.083	-1.818	1.00 49.40	C2
ATOM	3170	H	ALA	473	23.513	40.867	0.002	1.00 0.00	C2	ATOM	3221	CD1	LEU	479	32.596	44.393	-1.078	1.00 48.15	C2
ATOM	3171	CA	ALA	473	24.023	37.881	-0.353	1.00 62.37	C2	ATOM	3222	CD2	LEU	479	33.779	43.258	-3.000	1.00 48.59	C2
ATOM	3172	CB	ALA	473	22.870	37.939	-0.558	1.00 63.65	C2	ATOM	3223	C	LEU	479	34.505	40.146	0.056	1.00 47.14	C2
ATOM	3173	C	ALA	473	25.196	36.354	-1.126	1.00 62.01	C2	ATOM	3224	O	LEU	479	35.695	39.955	0.262	1.00 40.90	C2
ATOM	3174	O	ALA	473	26.301	38.651	-0.715	1.00 63.36	C2	ATOM	3225	N	HIS	480	33.609	39.766	0.950	1.00 49.50	C2
ATOM	3175	N	GLY	474	25.032	37.784	-2.306	1.00 61.43	C2	ATOM	3226	II	HIS	480	32.763	38.653	1.00 0.00	C2	
ATOM	3176	H	GLY	474	24.148	37.818	-2.722	1.00 0.00	C2	ATOM	3227	CA	HIS	480	31.979	39.108	2.179	1.00 37.81	C2
ATOM	3177	CA	GLY	474	26.101	37.137	-3.047	1.00 63.80	C2	ATOM	3228	CB	HIS	480	32.742	36.714	2.922	1.00 34.23	C2
ATOM	3178	C	GLY	474	27.354	37.950	-3.356	1.00 65.13	C2	ATOM	3229	CG	HIS	480	33.094	38.241	4.309	1.00 33.82	C2
ATOM	3179	O	GLY	474	28.482	37.417	-3.257	1.00 66.24	C2	ATOM	3230	CD2	HIS	480	33.123	36.932	4.709	1.00 33.44	C2
ATOM	3180	N	CYS	475	27.175	39.237	-3.757	1.00 64.88	C2	ATOM	3231	ND1	HIS	480	33.450	38.995	5.344	1.00 34.77	C2
ATOM	3181	H	CYS	475	26.261	39.550	-3.885	1.00 0.00	C2	ATOM	3232	HD1	HIS	480	33.505	39.976	5.362	1.00 0.00	C2
ATOM	3182	CA	CYS	475	28.308	40.127	-4.068	1.00 61.84	C2	ATOM	3233	CE1	HIS	480	33.706	38.223	6.361	1.00 34.80	C2
ATOM	3183	CB	CYS	475	27.923	41.413	-4.806	1.00 63.74	C2	ATOM	3234	NE2	HIS	480	33.504	36.986	1.00 0.00	C2	
ATOM	3184	SC	CYS	475	29.494	42.075	-5.437	1.00 68.96	C2	ATOM	3235	HE2	HIS	480	33.637	36.202	6.544	1.00 0.00	C2
ATOM	3185	C	CYS	475	28.995	40.567	-2.795	1.00 57.30	C2	ATOM	3236	C	HIS	480	34.836	37.860	1.961	1.00 49.08	C2
ATOM	3186	O	CYS	475	30.214	40.449	-2.724	1.00 57.14	C2	ATOM	3237	O	HIS	480	35.716	37.631	2.791	1.00 40.93	C2
ATOM	3187	N	LEU	476	28.230	40.983	-1.779	1.00 53.29	C2	ATOM	3238	N	SER	481	34.615	37.029	0.935	1.00 39.74	C2
ATOM	3188	H	LEU	476	27.264	41.024	-1.085	1.00 0.00	C2	ATOM	3239	H	SER	481	33.900	37.241	0.305	1.00 0.00	C2
ATOM	3189	CA	LEU	476	28.797	41.315	-0.493	1.00 50.43	C2	ATOM	3240	CA	SER	481	35.391	35.818	0.063	1.00 38.17	C2
ATOM	3190	CB	LEU	476	27.719	41.723	-0.523	1.00 45.68	C2	ATOM	3241	CB	SER	481	34.813	34.943	-0.420	1.00 40.42	C2
ATOM	3191	CG	LEU	476	27.130	43.165	0.497	1.00 42.80	C2	ATOM	3242	OC	SER	481	33.454	34.507	-0.137	1.00 42.64	C2
ATOM	3192	CD1	LEU	476	26.670	43.559	1.896	1.00 36.25	C2	ATOM	3243	IG	SER	481	32.898	35.385	-0.162	1.00 0.00	C2
ATOM	3193	CD2	LEU	476	28.180	44.180	0.057	1.00 40.22	C2	ATOM	3244	C	SER	481	36.724	36.272	0.211	1.00 36.17	C2
ATOM	3194	C	LEU	476	29.546	40.108	0.042	1.00 50.42	C2	ATOM	3245	O	SER	481	37.692	35.793	0.265	1.00 36.23	C2
ATOM	3195	O	LEU	476	30.614	40.222	0.646	1.00 50.61	C2	ATOM	3246	N	GLY	482	36.786	37.206	-0.744	1.00 36.21	C2
ATOM	3196	N	SER	477	29.053	38.927	-0.270	1.00 50.62	C2	ATOM	3247	II	GLY	482	35.956	37.498	-1.168	1.00 0.00	C2
ATOM	3197	H	SER	477	28.196	38.860	-0.729	1.00 0.00	C2	ATOM	3248	CA	GLY	482	36.028	37.792	-1.206	1.00 36.50	C2
ATOM	3198	CA	SER	477	29.721	37.712	0.125	1.00 51.41	C2	ATOM	3249	C	GLY	482	38.958	38.296	-0.151	1.00 36.14	C2
ATOM	3199	CB	SER	477	28.778	36.524	-0.051	1.00 53.45	C2	ATOM	3250	O	GLY	482	40.142	37.936	-0.055	1.00 36.65	C2
ATOM	3200	OG	SER	477	27.732	36.616	0.926	1.00 57.65	C2	ATOM	3251	N	LEU	483	36.381	39.084	0.250	1.00 34.64	C2
ATOM	3201	IG	SER	477	27.280	37.462	0.828	1.00 0.00	C2	ATOM	3252	II	LEU	483	37.445	39.326	0.608	1.00 0.00	C2
ATOM	3202	C	SER	477	30.978	37.525	-0.681	1.00 50.75	C2	ATOM	3253	CA	LEU	483	39.073	39.593	1.900	1.00 37.07	C2
ATOM	3203	O	SER	477	31.980	37.143	-0.068	1.00 51.41	C2	ATOM	3254	CB	LEU	483	38.134	40.442	2.731	1.00 31.17	C2
ATOM	3204	N	GLN	478	31.037	37.788	-1.984	1.00 50.21	C2	ATOM	3255	CG	LEU	483	37.535	41.687	2.081	1.00 31.11	C2
ATOM	3205	H	GLN	478	30.222	38.056	-2.457	1.00 0.00	C2	ATOM	3256	CD1	LEU	483	36.757	42.411	3.156	1.00 30.62	C2
ATOM	3206	CA	GLN	478	32.307	37.697	-2.715	1.00 51.37	C2	ATOM	3257	CD2	LEU	483	38.599	42.593	-1.489	1.00 29.56	C2
ATOM	3207	CB	GLN	478	32.064	37.929	-4.166	1.00 51.65	C2	ATOM	3258	C	LEU	483	39.600	38.461	2.745	1.00 42.91	C2
ATOM	3208	CG	GLN	478	31.983	36.370	-4.788	1.00 57.32	C2	ATOM	3259	O	LEU	483	40.752	38.498	3.199	1.00 51.23	C2
ATOM	3209	CD	GLN	478	31.354	36.649	-6.160	1.00 60.47	C2	ATOM	3260	N	PHE	484	38.767	37.422	2.925	1.00 54.05	C2
ATOM	3210	OEI	GLN	478	31.999	36.504	-7.205	1.00 62.26	C2	ATOM	3261	II	PHE	484	37.930	37.408	2.471	1.00 0.00	C2
ATOM	3211	NE2	GLN	478	30.045	36.878	-6.167	1.00 62.16	C2	ATOM	3262	CA	PHE	484	39.105	36.298	3.783	1.00 14.04	C2

FIGURE 5

ATOM	3263	CB	PHE	484	37.975	35.300	3.925	1.00 37.46	C2	ATOM	3314	CA	IIE	489	47.911	34.990	2.099	1.00 25.63	C2
ATOM	3264	CG	PHE	484	38.268	34.183	4.897	1.00 40.86	C2	ATOM	3315	CB	IIE	489	47.708	35.570	0.125	1.00 27.66	C2
ATOM	3265	CD1	PHE	484	38.219	32.884	4.482	1.00 45.62	C2	ATOM	3316	CG	IIE	489	46.761	34.755	-0.169	1.00 30.83	C2
ATOM	3266	CD2	PHE	484	38.528	34.445	6.210	1.00 43.62	C2	ATOM	3317	CD1	IIE	489	46.373	35.506	-1.471	1.00 30.41	C2
ATOM	3267	CE1	PHE	484	38.421	31.858	5.395	1.00 41.98	C2	ATOM	3318	CD2	IIE	489	47.472	31.454	-0.502	1.00 32.62	C2
ATOM	3268	CE2	PHE	484	38.731	33.427	7.119	1.00 46.76	C2	ATOM	3319	C	IIE	489	48.783	35.936	2.053	1.00 25.28	C2
ATOM	3269	C2	PHE	484	38.677	32.119	6.720	1.00 48.06	C2	ATOM	3320	O	IIE	489	49.973	35.705	2.914	1.00 27.37	C2
ATOM	3270	C	PHE	484	40.245	35.602	3.113	1.00 33.92	C2	ATOM	3321	N	IIE	490	48.237	36.935	3.534	1.00 25.79	C2
ATOM	3271	O	PHE	484	41.162	35.289	3.876	1.00 34.25	C2	ATOM	3322	H	IIE	490	47.167	31.019	3.515	1.00 0.00	C2
ATOM	3272	N	LEU	485	40.326	35.413	1.799	1.00 32.75	C2	ATOM	3323	CA	LEU	490	49.072	37.868	4.220	1.00 25.96	C2
ATOM	3273	H	LEU	485	39.577	35.717	1.250	1.00 0.00	C2	ATOM	3324	CB	LEU	490	48.274	39.139	4.567	1.00 27.96	C2
ATOM	3274	CA	LEU	485	41.475	34.778	1.163	1.00 33.74	C2	ATOM	3325	CG	LEU	490	47.822	40.131	3.474	1.00 27.89	C2
ATOM	3275	CB	LEU	485	41.183	34.629	-0.305	1.00 35.35	C2	ATOM	3326	CD1	LEU	490	46.772	41.019	4.123	1.00 28.03	C2
ATOM	3276	CG	LEU	485	42.101	33.962	-1.275	1.00 37.80	C2	ATOM	3327	CD2	LEU	490	48.988	40.942	7.899	1.00 28.15	C2
ATOM	3277	CD1	LEU	485	41.101	33.404	-2.345	1.00 41.44	C2	ATOM	3328	C	LEU	490	49.619	37.233	5.559	1.00 27.33	C2
ATOM	3278	CD2	LEU	485	43.125	34.903	-1.899	1.00 40.07	C2	ATOM	3329	O	LEU	490	50.740	37.528	5.665	1.00 26.73	C2
ATOM	3279	C	LEU	485	42.740	35.585	1.376	1.00 33.95	C2	ATOM	3330	N	GLN	491	48.883	36.370	6.111	1.00 29.88	C2
ATOM	3280	O	LEU	485	43.766	35.060	1.810	1.00 33.84	C2	ATOM	3331	H	GLN	491	47.984	36.127	5.799	1.00 0.00	C2
ATOM	3281	N	TYR	486	42.609	36.865	1.034	1.00 33.67	C2	ATOM	3332	CA	GLN	491	49.430	35.809	7.314	1.00 33.01	C2
ATOM	3282	H	TYR	486	41.757	37.186	0.659	1.00 0.00	C2	ATOM	3333	CB	GLN	491	48.305	35.113	8.027	1.00 38.68	C2
ATOM	3283	CA	TYR	486	43.662	37.862	1.242	1.00 31.33	C2	ATOM	3334	CG	GLN	491	48.759	35.963	9.197	1.00 46.07	C2
ATOM	3284	CB	TYR	486	43.210	39.290	0.714	1.00 35.33	C2	ATOM	3335	CD	GLN	491	46.348	36.262	9.278	1.00 50.84	C2
ATOM	3285	CG	TYR	486	43.300	39.325	-0.825	1.00 33.37	C2	ATOM	3336	OE1	GLN	491	45.965	31.436	9.402	1.00 51.92	C2
ATOM	3286	C2	TYR	486	42.154	39.405	-1.579	1.00 32.79	C2	ATOM	3337	N	GLN	491	45.445	35.294	9.278	1.00 51.67	C2
ATOM	3287	CE1	TYR	486	42.718	39.190	-2.944	1.00 34.73	C2	ATOM	3338	HE2	GLN	491	45.723	34.353	9.288	1.00 0.00	C2
ATOM	3288	CD1	TYR	486	44.533	39.153	-1.445	1.00 34.59	C2	ATOM	3339	HE2	GLN	491	44.489	35.560	9.286	1.00 0.00	C2
ATOM	3289	O	TYR	486	44.618	39.033	-2.818	1.00 34.63	C2	ATOM	3340	C	GLN	491	50.582	34.867	6.986	1.00 33.58	C2
ATOM	3290	C2	TYR	486	43.451	39.096	-3.562	1.00 35.58	C2	ATOM	3341	O	GLN	491	51.582	34.828	7.715	1.00 34.65	C2
ATOM	3291	OII	TYR	486	43.404	38.880	-4.942	1.00 36.24	C2	ATOM	3342	N	ALA	492	50.482	34.191	5.824	1.00 34.15	C2
ATOM	3292	HH	TYR	486	42.614	39.006	-5.306	1.00 0.00	C2	ATOM	3343	H	ALA	492	49.701	34.382	5.664	1.00 0.00	C2
ATOM	3293	C	TYR	486	44.068	37.905	2.697	1.00 27.39	C2	ATOM	3344	CA	ALA	492	51.416	33.177	5.321	1.00 34.64	C2
ATOM	3294	O	TYR	486	45.258	38.007	2.942	1.00 26.06	C2	ATOM	3345	CB	ALA	492	50.018	32.500	4.081	1.00 31.67	C2
ATOM	3295	N	GLN	487	43.270	37.691	3.708	1.00 26.95	C2	ATOM	3346	C	ALA	492	52.802	33.678	4.959	1.00 34.79	C2
ATOM	3296	H	GLN	487	42.315	37.545	3.565	1.00 26.95	C2	ATOM	3347	O	ALA	492	53.789	32.943	4.879	1.00 36.03	C2
ATOM	3297	CA	GLN	487	43.035	37.646	5.031	1.00 28.33	C2	ATOM	3348	N	LEU	493	52.885	34.981	4.278	1.00 35.94	C2
ATOM	3298	CB	GLN	487	42.690	37.578	6.050	1.00 32.66	C2	ATOM	3349	H	LEU	493	52.060	37.510	4.721	1.00 0.00	C2
ATOM	3299	CG	GLN	487	43.092	37.979	7.405	1.00 37.50	C2	ATOM	3350	CA	LEU	493	54.139	35.634	4.426	1.00 34.96	C2
ATOM	3300	CD	GLN	487	43.966	39.252	7.469	1.00 40.54	C2	ATOM	3351	CB	LEU	493	53.898	36.990	3.747	1.00 31.56	C2
ATOM	3301	OEI	GLN	487	43.441	40.346	7.292	1.00 40.45	C2	ATOM	3352	CG	LEU	493	53.127	37.065	2.443	1.00 28.27	C2
ATOM	3302	NE2	GLN	487	45.305	39.206	7.549	1.00 38.19	C2	ATOM	3353	CD1	LEU	493	52.715	38.495	2.214	1.00 31.74	C2
ATOM	3303	HE2	GLN	487	45.755	40.037	7.452	1.00 0.00	C2	ATOM	3354	CD2	LEU	493	53.977	36.608	1.285	1.00 28.79	C2
ATOM	3304	HE2	GLN	487	45.736	38.340	4.557	1.00 0.00	C2	ATOM	3355	C	LEU	493	54.879	35.843	5.721	1.00 36.45	C2
ATOM	3305	C	GLN	487	44.791	36.555	5.207	1.00 28.53	C2	ATOM	3356	O	LEU	493	55.985	36.374	5.694	1.00 36.70	C2
ATOM	3306	O	GLN	487	45.774	36.542	5.964	1.00 28.72	C2	ATOM	3357	N	GLU	494	54.300	35.497	6.856	1.00 38.95	C2
ATOM	3307	N	GLY	488	44.550	35.363	4.454	1.00 28.32	C2	ATOM	3358	H	GLU	494	53.395	35.130	6.836	1.00 0.00	C2
ATOM	3308	H	GLY	488	43.799	35.400	3.824	1.00 0.00	C2	ATOM	3359	CA	GLU	494	54.910	35.648	8.157	1.00 41.14	C2
ATOM	3309	CA	GLY	488	45.291	36.120	4.557	1.00 26.04	C2	ATOM	3360	CB	GLU	494	55.671	34.340	8.545	1.00 46.61	C2
ATOM	3310	C	GLY	488	46.660	34.264	4.033	1.00 25.75	C2	ATOM	3361	CG	GLU	494	54.711	33.411	9.419	1.00 55.71	C2
ATOM	3311	O	GLY	488	47.660	33.946	4.712	1.00 25.86	C2	ATOM	3362	CD	GLU	494	54.195	32.160	8.785	1.00 60.27	C2
ATOM	3312	N	GLU	489	46.655	34.798	2.818	1.00 25.05	C2	ATOM	3363	OEI	GLU	494	53.146	31.653	9.240	1.00 64.52	C2
ATOM	3313	I	GLU	489	45.798	35.062	2.416	1.00 0.00	C2	ATOM	3364	OEZ	GLU	494	54.839	31.630	7.862	1.00 62.76	C2

FIGURE 5

ATOM	3365	C	GLU	494	55.865	36.825	8.343	1.00	44.32	C2	ATOM	3416	II	GLY	501	58.808	43.579	8.730	1.00	0.00	C2
ATOM	3366	O	GLU	494	57.055	36.678	8.610	1.00	46.91	C2	ATOM	3417	CA	GLY	501	56.974	43.386	9.734	1.00	39.59	C2
ATOM	3367	N	GLY	495	55.358	36.046	8.114	1.00	44.32	C2	ATOM	3418	C	GLY	501	55.021	44.324	1.00	39.66	C2	
ATOM	3368	H	GLY	495	54.450	38.112	7.753	1.00	0.00	C2	ATOM	3419	O	GLY	501	54.666	44.034	9.777	1.00	40.66	C2
ATOM	3369	CA	GLY	495	56.104	39.272	8.368	1.00	42.36	C2	ATOM	3420	N	PRO	502	55.986	45.462	10.742	1.00	39.90	C2
ATOM	3370	C	GLY	495	57.015	39.695	7.238	1.00	42.33	C2	ATOM	3421	CD	PRO	502	57.277	45.908	11.335	1.00	41.18	C2
ATOM	3371	O	GLY	495	57.397	40.866	7.220	1.00	42.42	C2	ATOM	3422	CA	PRO	502	54.728	46.387	1.00	36.67	C2	
ATOM	3372	N	ILE	496	57.310	39.802	6.279	1.00	41.04	C2	ATOM	3423	CB	PRO	502	55.591	47.494	11.791	1.00	59.23	C2
ATOM	3373	H	ILE	496	56.927	37.906	6.374	1.00	0.00	C2	ATOM	3424	CG	PRO	502	56.989	47.405	11.221	1.00	41.36	C2
ATOM	3374	CA	ILE	496	58.259	38.993	5.192	1.00	41.15	C2	ATOM	3425	C	PRO	502	54.158	46.849	9.817	1.00	37.54	C2
ATOM	3375	CB	ILE	496	57.929	40.216	4.253	1.00	38.60	C2	ATOM	3426	O	PRO	502	52.966	47.139	6.139	1.00	38.36	C2
ATOM	3376	CG2	ILE	496	59.077	40.437	3.248	1.00	37.62	C2	ATOM	3427	N	TIR	503	54.728	46.887	9.649	1.00	35.13	C2
ATOM	3377	CG1	ILE	496	56.662	39.964	3.480	1.00	36.39	C2	ATOM	3428	H	TIR	503	55.663	46.638	8.449	1.00	0.00	C2
ATOM	3378	CD	ILE	496	56.314	41.071	2.410	1.00	35.27	C2	ATOM	3429	CA	TIR	503	53.940	47.283	7.462	1.00	35.09	C2
ATOM	3379	C	ILE	496	59.672	39.203	5.749	1.00	41.91	C2	ATOM	3430	CB	TIR	503	54.832	47.276	6.245	1.00	34.48	C2
ATOM	3380	O	ILE	496	60.541	38.396	5.448	1.00	44.22	C2	ATOM	3431	OC1	TIR	503	56.025	48.018	6.668	1.00	38.23	C2
ATOM	3381	N	SER	497	59.998	40.228	6.533	1.00	44.31	C2	ATOM	3432	HC1	TIR	503	55.857	48.946	6.845	1.00	0.00	C2
ATOM	3382	H	SER	497	59.297	40.852	6.821	1.00	0.00	C2	ATOM	3433	CG2	TIR	503	54.197	48.162	5.126	1.00	35.56	C2
ATOM	3383	CA	SER	497	61.146	40.501	6.992	1.00	44.86	C2	ATOM	3434	C	TIR	503	52.836	46.252	7.215	1.00	35.37	C2
ATOM	3384	CB	SER	497	62.204	41.254	5.938	1.00	44.13	C2	ATOM	3435	O	TIR	503	51.671	46.552	6.915	1.00	37.11	C2
ATOM	3385	OG	SER	497	62.181	42.673	6.033	1.00	40.74	C2	ATOM	3436	N	LEU	504	53.218	44.996	7.380	1.00	34.02	C2
ATOM	3386	IGC	SER	497	62.531	42.964	5.170	1.00	0.00	C2	ATOM	3437	I	LEU	504	54.146	44.799	7.647	1.00	0.00	C2
ATOM	3387	C	SER	497	61.164	41.413	8.185	1.00	45.85	C2	ATOM	3438	CA	LEU	504	52.301	43.821	7.173	1.00	32.50	C2
ATOM	3388	O	SER	497	60.132	42.110	8.288	1.00	47.55	C2	ATOM	3439	CB	LEU	504	53.127	42.650	7.002	1.00	34.78	C2
ATOM	3389	N	PHE	498	62.164	41.490	9.071	1.00	44.96	C2	ATOM	3440	CG	LEU	504	53.464	42.256	5.601	1.00	34.07	C2
ATOM	3390	CD1	PHE	498	61.338	40.621	9.126	1.00	42.33	C2	ATOM	3441	CD1	LEU	504	54.163	40.977	5.667	1.00	31.97	C2
ATOM	3391	CA	PHE	498	62.086	41.317	10.250	1.00	44.88	C2	ATOM	3442	CD2	LEU	504	52.254	41.865	8.309	1.00	37.34	C2
ATOM	3392	CB	PHE	498	63.431	42.038	10.885	1.00	45.13	C2	ATOM	3443	C	LEU	504	51.146	44.345	11.926	1.00	29.86	C2
ATOM	3393	CG	PHE	498	63.629	40.501	10.603	1.00	42.00	C2	ATOM	3444	O	LEU	504	50.141	43.562	6.078	1.00	30.40	C2
ATOM	3394	CD	PHE	498	61.760	43.799	9.983	1.00	45.22	C2	ATOM	3445	N	ASP	505	51.736	44.106	9.551	1.00	26.09	C2
ATOM	3400	CG	GLU	499	61.215	44.446	10.869	1.00	45.24	C2	ATOM	3446	II	ASP	505	52.689	44.269	6.699	1.00	0.00	C2
ATOM	3401	CD	GLU	499	62.017	44.314	8.777	1.00	46.16	C2	ATOM	3447	CA	ASP	505	50.798	44.084	10.643	1.00	27.88	C2
ATOM	3402	OEI	GLU	499	62.362	43.716	8.081	1.00	0.00	C2	ATOM	3448	CB	ASP	505	51.446	44.345	11.926	1.00	29.86	C2
ATOM	3403	OEZ	GLU	499	61.731	45.659	8.391	1.00	48.06	C2	ATOM	3449	CG	ASP	505	52.500	43.312	12.239	1.00	34.64	C2
ATOM	3404	C	GLU	499	62.498	46.193	7.153	1.00	52.19	C2	ATOM	3450	OD1	ASP	505	52.663	42.296	11.534	1.00	41.04	C2
ATOM	3405	O	GLU	499	64.001	46.187	7.100	1.00	57.51	C2	ATOM	3451	OD2	ASP	505	53.179	43.542	13.224	1.00	37.40	C2
ATOM	3406	N	LEU	500	59.806	44.934	7.193	1.00	44.38	C2	ATOM	3452	C	ASP	505	49.661	45.060	10.568	1.00	28.61	C2
ATOM	3407	II	LEU	500	60.351	44.137	7.027	1.00	0.00	C2	ATOM	3453	O	ASP	505	48.566	44.739	11.039	1.00	30.30	C2
ATOM	3408	CA	LEU	500	58.491	44.997	6.651	1.00	41.08	C2	ATOM	3454	N	TIR	506	49.894	46.242	10.002	1.00	28.29	C2
ATOM	3409	CB	LEU	500	58.519	44.197	5.984	1.00	62.79	C2	ATOM	3455	H	TIR	506	50.823	46.493	9.804	1.00	0.00	C2
ATOM	3410	CG	LEU	500	59.303	44.062	4.351	1.00	42.70	C2	ATOM	3456	CA	TIR	506	48.860	47.225	9.731	1.00	25.74	C2
ATOM	3411	CD1	LEU	500	59.776	43.828	3.351	1.00	43.98	C2	ATOM	3457	CB	TIR	506	49.497	48.556	9.326	1.00	26.14	C2
ATOM	3412	CD2	LEU	500	58.427	45.874	3.671	1.00	45.04	C2	ATOM	3458	OC1	TIR	506	49.944	49.099	10.588	1.00	31.63	C2
ATOM	3413	C	LEU	500	57.455	44.521	7.628	1.00	40.59	C2	ATOM	3459	IG1	TIR	506	49.243	49.027	11.246	1.00	0.00	C2
ATOM	3414	O	LEU	500	56.274	44.835	7.463	1.00	40.69	C2	ATOM	3460	CG2	TIR	506	48.594	49.517	8.619	1.00	24.46	C2
ATOM	3415	N	GLY	501	57.866	43.835	8.685	1.00	39.37	C2	ATOM	3461	C	TIR	506	48.022	46.735	8.615	1.00	24.00	C2

FIGURE 5

ATOM	3467	CG	LEU	S07	48.010	-4.919	3.858	1.00	20.85	C2	ATOM	3518	CA	ASP	S13	38.374	45.471	9.947	1.00	25.37	C2	
ATOM	3468	CD1	LEU	S07	46.771	45.650	3.453	1.00	24.13	C2	ATOM	3519	CB	ASP	S13	38.958	45.646	12.390	1.00	34.10	C2	
ATOM	3469	CD2	LEU	S07	49.074	45.055	2.842	1.00	20.13	C2	ATOM	3520	CG	ASP	S13	39.682	46.679	11.712	1.00	32.35	C2	
ATOM	3470	C	LEU	S07	46.766	44.640	6.8880	1.00	24.09	C2	ATOM	3521	OD1	ASP	S13	40.371	47.644	12.058	1.00	35.06	C2	
ATOM	3471	O	LEU	S07	45.600	44.764	6.5541	1.00	25.80	C2	ATOM	3522	OD2	ASP	S13	37.392	45.730	8.846	1.00	24.95	C2	
ATOM	3472	N	GLN	S08	47.152	43.618	7.6661	1.00	24.01	C2	ATOM	3523	C	ASP	S13	36.185	45.868	9.000	1.00	26.92	C2	
ATOM	3473	II	GLN	S08	48.112	43.555	7.8666	1.00	0.00	C2	ATOM	3524	O	ASP	S14	37.867	45.739	7.634	1.00	22.88	C2	
ATOM	3474	CA	GLN	S08	46.726	42.625	8.214	1.00	23.71	C2	ATOM	3525	N	PHE	S14	35.715	47.089	4.245	1.00	15.18	C2	
ATOM	3475	CB	GLN	S08	46.961	41.627	9.036	1.00	23.83	C2	ATOM	3526	H	PHE	S14	38.829	45.614	7.475	1.00	0.00	C2	
ATOM	3476	CG	GLN	S08	47.937	40.899	8.173	1.00	31.64	C2	ATOM	3527	CA	PHE	S14	36.974	45.922	6.530	1.00	24.09	C2	
ATOM	3477	CD	GLN	S08	48.842	40.080	9.054	1.00	34.00	C2	ATOM	3528	CB	PHE	S14	37.812	46.061	5.266	1.00	16.11	C2	
ATOM	3478	OE1	GLN	S08	50.031	40.346	9.164	1.00	38.32	C2	ATOM	3529	CG	PHE	S14	36.956	46.470	4.072	1.00	17.86	C2	
ATOM	3479	NE2	GLN	S08	48.321	39.090	9.748	1.00	36.30	C2	ATOM	3530	CD1	PHE	S14	35.715	47.409	2.804	1.00	13.77	C2	
ATOM	3480	HE21	GLN	S08	47.373	38.880	9.639	1.00	0.00	C2	ATOM	3531	CD2	PHE	S14	34.983	47.419	3.140	1.00	14.53	C2	
ATOM	3481	HE22	GLN	S08	48.891	38.636	10.406	1.00	0.00	C2	ATOM	3532	CE1	PHE	S14	34.983	47.419	3.140	1.00	14.53	C2	
ATOM	3482	C	GLN	S08	45.105	43.123	9.111	1.00	24.24	C2	ATOM	3533	CE2	PHE	S14	36.693	46.539	1.705	1.00	12.10	C2	
ATOM	3483	O	GLN	S08	43.978	42.650	9.014	1.00	24.06	C2	ATOM	3534	C2	PHE	S14	35.468	47.146	1.068	1.00	10.68	C2	
ATOM	3484	N	LEU	S09	45.375	44.019	10.090	1.00	26.07	C2	ATOM	3535	C	PHE	S14	36.708	44.703	6.450	1.00	29.23	C2	
ATOM	3485	H	LEU	S09	46.316	44.262	10.222	1.00	0.00	C2	ATOM	3536	O	PHE	S14	34.718	44.828	6.350	1.00	29.80	C2	
ATOM	3486	CA	LEU	S09	44.378	44.660	10.977	1.00	25.71	C2	ATOM	3537	N	ALA	S15	36.694	43.490	6.531	1.00	31.15	C2	
ATOM	3487	CB	LEU	S09	44.993	45.555	12.031	1.00	25.60	C2	ATOM	3538	II	ALA	S15	37.581	43.450	6.639	1.00	9.00	C2	
ATOM	3488	CG	LEU	S09	45.838	44.757	13.042	1.00	29.00	C2	ATOM	3539	CA	ALA	S15	35.839	42.260	6.416	1.00	32.36	C2	
ATOM	3489	CD1	LEU	S09	46.658	45.705	13.886	1.00	28.93	C2	ATOM	3540	CB	ALA	S15	36.851	41.126	6.402	1.00	32.35	C2	
ATOM	3490	CD2	LEU	S09	44.950	43.919	13.937	1.00	27.94	C2	ATOM	3541	C	ALA	S15	34.401	42.089	7.535	1.00	12.59	C2	
ATOM	3491	C	LEU	S09	43.465	43.471	10.130	1.00	25.17	C2	ATOM	3542	O	ALA	S15	33.676	41.609	7.331	1.00	32.64	C2	
ATOM	3492	O	LEU	S09	42.274	45.411	10.408	1.00	27.22	C2	ATOM	3543	II	ALA	S15	35.104	42.457	8.375	1.00	33.01	C2	
ATOM	3493	N	ASP	S10	44.899	46.208	9.101	1.00	23.77	C2	ATOM	3544	II	TIR	S16	36.117	42.578	8.935	1.00	15.00	C2	
ATOM	3494	II	ASP	S10	44.865	46.277	9.930	1.00	0.00	C2	ATOM	3545	CA	TIR	S16	34.231	42.566	9.921	1.00	35.18	C2	
ATOM	3495	CA	ASP	S10	42.955	46.898	8.240	1.00	22.66	C2	ATOM	3546	CB	TIR	S16	35.016	43.018	10.988	1.00	35.40	C2	
ATOM	3496	CB	ASP	S10	43.652	41.829	7.306	1.00	25.21	C2	ATOM	3547	O	G1	TIR	516	35.655	41.818	11.336	1.00	42.65	C2
ATOM	3497	CG	ASP	S10	44.316	46.966	8.068	1.00	33.01	C2	ATOM	3548	IG1	TIR	516	36.505	41.713	10.816	1.00	0.00	C2	
ATOM	3498	OD1	ASP	S10	45.178	49.621	7.477	1.00	34.28	C2	ATOM	3549	CG2	TIR	516	34.262	44.672	12.097	1.00	35.56	C2	
ATOM	3499	OD2	ASP	S10	43.988	49.209	9.250	1.00	34.44	C2	ATOM	3550	C	TIR	516	34.134	43.554	9.962	1.00	37.62	C2	
ATOM	3500	C	ASP	S10	42.104	45.980	7.398	1.00	23.72	C2	ATOM	3551	O	TIR	516	32.005	43.315	9.057	1.00	40.37	C2	
ATOM	3501	O	ASP	S10	40.897	46.220	7.387	1.00	24.00	C2	ATOM	3552	N	TIR	517	33.387	44.666	8.802	1.00	38.61	C2	
ATOM	3502	N	VAL	S11	42.632	44.984	6.659	1.00	21.38	C2	ATOM	3553	H	TIR	517	34.291	44.850	8.469	1.00	0.00	C2	
ATOM	3503	II	VAL	S11	43.611	44.900	6.620	1.00	0.00	C2	ATOM	3554	CA	TIR	S17	32.332	47.936	7.253	1.00	39.90	C2	
ATOM	3504	CA	VAL	S11	41.823	44.010	5.961	1.00	21.89	C2	ATOM	3555	C	TIR	S17	31.343	45.012	7.551	1.00	38.30	C2	
ATOM	3505	CB	VAL	S11	42.752	42.924	5.366	1.00	22.71	C2	ATOM	3556	O	TIR	S17	30.137	45.125	7.811	1.00	38.69	C2	
ATOM	3506	CG1	VAL	S11	41.954	41.756	4.792	1.00	20.43	C2	ATOM	3557	CG1	TIR	S17	33.022	47.912	5.512	1.00	38.92	C2	
ATOM	3507	CG2	VAL	S11	43.529	43.524	4.210	1.00	16.19	C2	ATOM	3558	CG2	TIR	S17	31.699	42.912	4.439	1.00	34.81	C2	
ATOM	3508	C	VAL	S11	40.827	43.403	6.960	1.00	21.92	C2	ATOM	3559	C	TIR	S17	30.703	42.202	3.555	1.00	34.40	C2	
ATOM	3509	O	VAL	S11	39.625	43.447	6.719	1.00	23.46	C2	ATOM	3560	O	TIR	S17	31.790	44.344	6.466	1.00	37.54	C2	
ATOM	3510	N	ALA	S12	41.258	43.017	8.163	1.00	20.49	C2	ATOM	3561	N	ILE	S18	32.756	44.386	6.297	1.00	0.00	C2	
ATOM	3511	H	ALA	S12	42.216	43.063	8.361	1.00	0.00	C2	ATOM	3562	H	ILE	S18	30.923	43.646	5.510	1.00	16.10	C2	
ATOM	3512	CA	ALA	S12	40.388	42.357	9.108	1.00	20.83	C2	ATOM	3563	CA	ILE	S18	31.699	42.912	4.439	1.00	34.81	C2	
ATOM	3513	CB	ALA	S12	41.103	41.974	10.344	1.00	17.89	C2	ATOM	3564	CB	ILE	S18	31.137	45.125	7.811	1.00	34.40	C2	
ATOM	3514	C	ALA	S12	39.250	43.205	9.550	1.00	23.89	C2	ATOM	3565	CG2	ILE	S18	32.621	43.842	3.699	1.00	37.91	C2	
ATOM	3515	O	ALA	S12	38.201	42.668	9.074	1.00	24.61	C2	ATOM	3566	CG1	ILE	S18	32.621	43.842	3.699	1.00	34.89	C2	
ATOM	3516	N	ASP	S13	39.417	44.539	9.544	1.00	25.96	C2	ATOM	3567	CD	ILE	S18	32.701	44.760	2.596	1.00	34.86	C2	
ATOM	3517	II	ASP	S13	40.300	44.888	9.291	1.00	0.00	C2	ATOM	3568	C	ILE	S18	30.172	42.591	6.317	1.00	36.64	C2	

FIGURE 5

ATOM	3569	O	IIF	S10	28.948	4.	-45	6.205	1.00	39.93	C2	ATOM	3670	"	GLU	S23	25.766	41.031	8.769	1.00	0.00	C2
ATOM	3570	N	TRP	S19	30.842	41.	785	7.179	1.00	36.64	C2	ATOM	3671	CA	GLU	S23	24.077	40.313	9.716	1.00	54.53	C2
ATOM	3571	H	TRP	S19	31.785	41.	959	7.361	1.00	0.00	C2	ATOM	3672	CB	GLU	S23	24.654	40.486	11.081	1.00	54.60	C2
ATOM	3572	CA	TRP	S19	31.044	40.	784	7.945	1.00	38.15	C2	ATOM	3673	CG	GLU	S23	25.712	39.525	11.398	1.00	57.05	C2
ATOM	3573	CB	TRP	S19	31.124	40.	083	6.780	1.00	38.52	C2	ATOM	3674	CD	GLU	S23	25.386	38.150	10.888	1.00	61.71	C2
ATOM	3574	CG	TRP	S19	30.493	38.	793	9.255	1.00	42.26	C2	ATOM	3675	OE1	GLU	S23	24.515	37.487	11.477	1.00	64.66	C2
ATOM	3575	CD2	TRP	S19	29.880	38.	578	10.473	1.00	41.70	C2	ATOM	3676	OE2	GLU	S23	25.979	37.773	9.872	1.00	63.15	C2
ATOM	3576	CE2	TRP	S19	29.437	37.	278	10.335	1.00	41.69	C2	ATOM	3677	C	GLU	S23	22.773	41.116	9.836	1.00	58.29	C2
ATOM	3577	CE3	TRP	S19	29.648	39.	282	11.629	1.00	42.26	C2	ATOM	3678	O	GLU	S23	26.688	40.538	1.00	59.32	C2	
ATOM	3578	CD1	TRP	S19	30.448	37.	695	8.419	1.00	42.92	C2	ATOM	3679	N	ALA	S24	22.920	42.432	9.992	1.00	61.41	C2
ATOM	3579	NE1	TRP	S19	29.788	36.	793	9.115	1.00	44.19	C2	ATOM	3680	II	ALA	S24	23.834	42.798	10.024	1.00	0.00	C2
ATOM	3580	HE1	TRP	S19	29.485	35.	935	8.741	1.00	0.00	C2	ATOM	3681	CA	ALA	S24	21.815	43.360	10.076	1.00	64.58	C2
ATOM	3581	C22	TRP	S19	27.753	36.	671	11.360	1.00	41.91	C2	ATOM	3682	CB	ALA	S24	22.882	41.768	9.992	1.00	54.11	C2
ATOM	3582	C23	TRP	S19	28.964	38.	666	12.652	1.00	41.77	C2	ATOM	3683	C	ALA	S24	20.818	41.109	8.936	1.00	64.79	C2
ATOM	3583	CH2	TRP	S19	28.522	37.	375	12.515	1.00	41.05	C2	ATOM	3684	O	ALA	S24	19.655	42.624	9.206	1.00	65.69	C2
ATOM	3584	C	TRP	S19	29.027	41.	368	8.615	1.00	39.33	C2	ATOM	3685	N	ALA	S25	21.251	43.083	7.693	1.00	66.44	C2
ATOM	3585	O	TRP	S19	27.888	40.	919	8.726	1.00	38.28	C2	ATOM	3686	H	ALA	S25	21.196	43.283	7.516	1.00	0.00	C2
ATOM	3586	N	GLN	S20	29.264	43.	375	9.650	1.00	41.86	C2	ATOM	3687	CA	ALA	S25	20.371	42.789	6.974	1.00	68.58	C2
ATOM	3587	H	GLN	S20	30.180	42.	717	9.700	1.00	0.00	C2	ATOM	3688	CB	ALA	S25	21.117	43.044	5.288	1.00	67.42	C2
ATOM	3588	CA	GLN	S20	28.240	43.	016	10.464	1.00	44.63	C2	ATOM	3689	C	ALA	S25	19.841	41.356	6.558	1.00	71.11	C2
ATOM	3589	CB	GLN	S20	28.691	44.	198	11.239	1.00	47.03	C2	ATOM	3690	O	ALA	S25	19.116	40.946	5.651	1.00	71.65	C2
ATOM	3590	CG	GLN	S20	29.602	43.	808	12.360	1.00	54.78	C2	ATOM	3691	N	GLY	S26	20.257	40.510	5.498	1.00	74.20	C2
ATOM	3591	CD	GLN	S20	29.910	45.	009	13.243	1.00	60.14	C2	ATOM	3692	H	GLY	S26	21.019	40.780	8.043	1.00	0.00	C2
ATOM	3592	OE1	GLN	S20	28.988	45.	566	12.854	1.00	61.62	C2	ATOM	3693	CA	GLY	S26	19.728	39.157	7.653	1.00	76.30	C2
ATOM	3593	NE2	GLN	S20	31.172	45.	456	13.371	1.00	60.46	C2	ATOM	3694	C	GLY	S26	20.430	38.085	6.842	1.00	78.49	C2
ATOM	3594	IIE2	GLN	S20	31.289	46.	260	13.910	1.00	0.00	C2	ATOM	3695	O	GLY	S26	20.174	36.910	7.094	1.00	79.05	C2
ATOM	3595	IIE2	GLN	S20	31.695	46.	966	12.912	1.00	0.00	C2	ATOM	3696	N	MET	S27	21.368	40.433	5.970	1.00	80.23	C2
ATOM	3596	C	GLN	S20	27.141	43.	577	9.621	1.00	46.28	C2	ATOM	3697	H	MET	S27	21.759	39.337	6.075	1.00	0.00	C2
ATOM	3597	O	GLN	S20	26.001	41.	474	10.059	1.00	48.62	C2	ATOM	3698	CA	MET	S27	22.055	37.489	5.063	1.00	81.73	C2
ATOM	3598	N	GLN	S21	27.362	44.	145	8.442	1.00	46.99	C2	ATOM	3699	CB	MET	S27	22.771	38.256	3.928	1.00	81.72	C2
ATOM	3599	H	GLN	S21	28.272	44.	257	8.092	1.00	0.00	C2	ATOM	3700	CG	MET	S27	23.385	39.719	3.710	1.00	83.54	C2
ATOM	3600	CA	GLN	S21	26.226	44.	638	7.716	1.00	49.02	C2	ATOM	3601	SD	MET	S27	21.364	40.523	2.336	1.00	87.64	C2
ATOM	3601	CB	GLN	S21	26.632	45.	553	6.566	1.00	50.06	C2	ATOM	3602	C	MET	S27	22.600	42.117	2.463	1.00	84.47	C2
ATOM	3602	CG	GLN	S21	25.456	46.	226	5.790	1.00	50.87	C2	ATOM	3603	CE	MET	S27	23.078	36.584	5.780	1.00	81.64	C2
ATOM	3603	CD	GLN	S21	24.616	47.	276	6.534	1.00	51.82	C2	ATOM	3604	OT1	MET	S27	22.974	35.357	5.624	1.00	83.88	C2
ATOM	3604	OE1	GLN	S21	24.864	47.	694	7.671	1.00	52.47	C2	ATOM	3605	OT2	MET	S27	23.949	37.104	6.560	1.00	82.99	C2
ATOM	3605	NE2	GLN	S21	23.577	47.	776	5.888	1.00	50.36	C2	ATOM	3606	SD	MET	S28	21.724	46.531	2.941	1.00	77.43	C2
ATOM	3606	IIE2	GLN	S21	23.392	47.	455	4.987	1.00	0.00	C2	ATOM	3607	CG	MET	S28	21.397	30.041	2.427	1.00	77.15	C2
ATOM	3607	IIE2	GLN	S21	23.044	48.	424	6.390	1.00	0.00	C2	ATOM	3608	SD	MET	S28	21.025	30.708	3.004	1.00	79.03	C2
ATOM	3608	C	GLN	S21	25.554	43.	446	7.155	1.00	50.15	C2	ATOM	3609	CE	MET	S28	21.482	31.067	2.515	1.00	77.20	C2
ATOM	3609	O	GLN	S21	24.214	43.	514	7.177	1.00	51.82	C2	ATOM	3610	CA	MET	S28	21.849	27.839	0.386	1.00	75.32	C2
ATOM	3610	N	MET	S22	26.057	42.	348	6.668	1.00	49.18	C2	ATOM	3611	O	MET	S28	49.130	26.745	0.405	1.00	77.11	C2
ATOM	3611	H	MET	S22	27.038	42.	291	6.688	1.00	0.00	C2	ATOM	3612	HT1	MET	S28	47.553	26.068	1.449	1.00	0.00	C2
ATOM	3612	CA	MET	S22	25.280	41.	227	6.171	1.00	46.36	C2	ATOM	3613	HT2	MET	S28	46.638	26.204	0.075	1.00	0.00	C2
ATOM	3613	CB	MET	S22	26.185	40.	167	5.607	1.00	46.36	C2	ATOM	3614	N	MET	S28	46.724	26.532	1.050	1.00	77.52	C2
ATOM	3614	CG	MET	S22	26.942	40.	661	4.412	1.00	44.32	C2	ATOM	3615	HT3	MET	S28	45.873	26.401	1.617	1.00	0.00	C2
ATOM	3615	SD	MET	S22	27.855	39.	435	3.426	1.00	48.35	C2	ATOM	3616	CA	MET	S28	47.153	27.940	0.395	1.00	76.57	C2
ATOM	3616	C	MET	S22	28.795	38.	447	4.565	1.00	42.80	C2	ATOM	3617	N	PRO	S29	49.089	28.870	0.224	1.00	77.45	C2
ATOM	3617	C	MET	S22	24.453	40.	642	7.316	1.00	50.14	C2	ATOM	3618	CD	PRO	S29	48.346	29.821	-1.046	1.00	72.26	C2
ATOM	3618	O	MET	S22	23.380	40.	124	7.038	1.00	50.60	C2	ATOM	3619	CA	PRO	S29	50.526	29.070	-0.449	1.00	70.14	C2
ATOM	3619	N	G11	S23	24.848	40.	722	8.596	1.00	51.91	C2	ATOM	3620	CB	PRO	S29	50.677	30.465	-1.046	1.00	71.41	C2

## FIGURES

ATOM	3671	CG PRO	539	49.437	30.503	-1.837	1.00	71.52	C3	ATOM	3722	C PHE	545	61.543	34.900	-1.667	1.00	34.81	C3
ATOM	3672	C PRO	539	51.250	29.931	0.991	1.00	67.83	C3	ATOM	3723	O PHE	545	60.901	35.660	-7.387	1.00	38.88	C3
ATOM	3673	O PRO	539	50.666	29.294	2.029	1.00	68.05	C3	ATOM	3724	N GLN	546	60.912	33.847	-1.135	1.00	34.77	C3
ATOM	3674	N ALA	540	52.484	28.417	0.961	1.00	64.48	C3	ATOM	3725	H GLN	546	61.396	33.223	-0.558	1.00	0.00	C1
ATOM	3675	H ALA	540	52.858	28.098	0.111	1.00	0.00	C3	ATOM	3726	CA GLN	546	59.490	33.637	-1.433	1.00	34.72	C3
ATOM	3676	CA ALA	540	53.389	28.498	2.112	1.00	61.83	C3	ATOM	3727	CB GLN	546	59.145	32.232	-1.140	1.00	34.85	C3
ATOM	3677	CB ALA	540	54.004	27.200	2.619	1.00	63.57	C3	ATOM	3728	CG GLN	546	59.582	31.505	-2.444	1.00	42.45	C3
ATOM	3678	C ALA	540	54.559	29.112	1.496	1.00	58.74	C3	ATOM	3729	CD GLN	546	59.374	30.085	-2.473	1.00	46.05	C3
ATOM	3679	O ALA	540	54.835	29.036	0.301	1.00	58.30	C3	ATOM	3730	OE1 GLN	546	59.287	29.472	-1.399	1.00	48.90	C3
ATOM	3680	N PHE	541	55.256	30.008	2.292	1.00	55.25	C3	ATOM	3731	NE2 GLN	546	59.339	29.442	-1.634	1.00	47.20	C3
ATOM	3681	H PHE	541	55.093	30.068	3.257	1.00	0.00	C3	ATOM	3732	HE21 GLN	546	59.476	29.948	-4.472	1.00	0.00	C3
ATOM	3682	CA PHE	541	56.299	30.814	1.702	1.00	51.38	C3	ATOM	3733	HE22 GLN	546	59.154	28.481	-3.609	1.00	0.00	C3
ATOM	3683	CB PHE	541	55.964	31.306	1.942	1.00	48.80	C3	ATOM	3734	C GLN	546	58.504	34.541	-0.729	1.00	31.62	C3
ATOM	3684	CG PHE	541	54.789	32.703	1.058	1.00	45.77	C3	ATOM	3735	O GLN	546	57.906	34.233	1.00	29.88	C3	
ATOM	3685	CD1 PHE	541	54.992	32.939	-0.779	1.00	44.76	C3	ATOM	3736	N ARG	547	58.907	34.929	-0.465	1.00	41.09	C3
ATOM	3686	CD2 PHE	541	53.507	32.747	1.582	1.00	44.76	C3	ATOM	3737	H ARG	547	59.750	34.566	0.811	1.00	0.00	C3
ATOM	3687	CE1 PHE	541	53.901	33.207	-1.074	1.00	43.98	C3	ATOM	3738	CA ARG	547	58.160	35.830	1.282	1.00	31.43	C3
ATOM	3688	CE2 PHE	541	52.428	33.018	0.769	1.00	42.86	C3	ATOM	3739	CB ARG	547	58.813	35.874	2.601	1.00	31.74	C3
ATOM	3689	CZ PHE	541	52.625	33.247	-0.563	1.00	42.52	C3	ATOM	3740	CC ARG	547	57.906	35.274	3.623	1.00	37.02	C3
ATOM	3690	C PHE	541	57.586	30.364	2.333	1.00	49.80	C3	ATOM	3741	CD ARG	547	58.344	33.858	4.076	1.00	40.56	C3
ATOM	3691	O PHE	541	58.002	30.807	3.395	1.00	49.55	C3	ATOM	3742	NE ARG	547	59.743	34.058	-4.345	1.00	47.90	C3
ATOM	3692	N ALA	542	58.172	29.442	1.562	1.00	48.21	C3	ATOM	3743	HE ARG	547	60.389	33.924	3.620	1.00	0.00	C3
ATOM	3693	H ALA	542	57.825	29.798	0.656	1.00	0.00	C3	ATOM	3744	CZ ARG	547	60.190	34.394	5.543	1.00	49.48	C3
ATOM	3694	CA ALA	542	59.326	28.711	1.968	1.00	45.37	C3	ATOM	3745	NH1 ARG	547	59.361	34.522	6.593	1.00	51.97	C3
ATOM	3695	CB ALA	542	59.700	27.749	0.898	1.00	45.71	C3	ATOM	3746	HH111 ARG	547	58.380	34.336	6.488	1.00	0.00	C3
ATOM	3696	C ALA	542	60.510	29.367	2.766	1.00	44.87	C3	ATOM	3747	HH112 ARG	547	57.084	37.694	0.317	1.00	31.25	C3
ATOM	3697	O ALA	542	61.001	29.504	3.374	1.00	46.49	C3	ATOM	3748	NH12 ARG	547	59.438	34.775	5.616	1.00	48.55	C3
ATOM	3698	N SER	543	61.013	30.408	1.395	1.00	42.63	C3	ATOM	3749	HH121 ARG	547	61.464	34.775	6.162	1.00	0.00	C3
ATOM	3699	H SER	543	60.477	30.605	0.630	1.00	0.00	C3	ATOM	3750	HH122 ARG	547	62.025	34.803	4.788	1.00	0.00	C3
ATOM	3700	CA SER	543	62.287	31.108	1.708	1.00	40.31	C3	ATOM	3751	C ARG	548	61.501	35.034	6.501	1.00	0.00	C3
ATOM	3701	CB SER	543	63.170	30.861	0.587	1.00	37.74	C3	ATOM	3752	O ARG	547	57.084	37.181	0.590	1.00	37.6	C3
ATOM	3702	OG SER	543	62.391	31.181	-0.554	1.00	35.74	C3	ATOM	3753	N ARG	548	59.348	37.717	0.205	1.00	31.44	C3
ATOM	3703	HG SER	543	61.824	30.423	-0.751	1.00	0.00	C3	ATOM	3754	H ARG	548	60.148	37.203	-0.444	1.00	0.00	C3
ATOM	3704	C SER	543	62.087	32.613	1.896	1.00	40.88	C3	ATOM	3755	CA ARG	548	62.052	38.980	-0.555	1.00	30.01	C3
ATOM	3705	O SER	543	62.253	31.115	1.536	1.00	42.63	C3	ATOM	3756	CB ARG	548	60.995	39.213	-0.949	1.00	25.42	C3
ATOM	3706	N ALA	544	63.120	32.383	2.310	1.00	38.84	C3	ATOM	3757	CG ARG	548	61.820	39.361	0.294	1.00	26.11	C3
ATOM	3707	H ALA	544	63.929	32.951	2.650	1.00	0.00	C3	ATOM	3758	CD ARG	548	63.280	39.158	-0.054	1.00	28.34	C3
ATOM	3708	CA ALA	544	63.035	34.836	2.345	1.00	37.31	C3	ATOM	3759	NE ARG	548	64.044	39.162	1.189	1.00	32.36	C3
ATOM	3709	CB ALA	544	64.340	35.450	2.808	1.00	35.74	C3	ATOM	3760	HE ARG	548	63.517	38.883	1.995	1.00	0.00	C3
ATOM	3710	C ALA	544	62.723	35.372	0.947	1.00	37.06	C3	ATOM	3761	CZ ARG	548	65.344	39.518	1.325	1.00	32.66	C3
ATOM	3711	O ALA	544	61.829	36.220	0.820	1.00	38.23	C3	ATOM	3762	NH1 ARG	548	66.159	39.923	0.335	1.00	34.98	C3
ATOM	3712	N PHE	545	63.357	34.881	-0.130	1.00	35.72	C3	ATOM	3763	HH111 ARG	548	67.307	40.177	6.553	1.00	0.00	C3
ATOM	3713	H PHE	545	64.131	34.298	-0.010	1.00	0.00	C3	ATOM	3764	HH112 ARG	548	65.812	39.981	-0.640	1.00	0.00	C3
ATOM	3714	CA PHE	545	62.992	35.268	-1.484	1.00	33.66	C3	ATOM	3765	NH12 ARG	548	65.837	39.518	2.549	1.00	32.03	C3
ATOM	3715	CB PHE	545	63.140	34.742	-3.990	1.00	29.62	C3	ATOM	3766	HH122 ARG	548	66.768	39.781	2.708	1.00	0.00	C3
ATOM	3716	CG PHE	545	62.317	33.788	4.557	1.00	29.80	C3	ATOM	3767	HH122 ARG	548	65.250	39.375	3.371	1.00	0.00	C3
ATOM	3717	CD1 PHE	545	63.371	35.915	-4.689	1.00	31.90	C3	ATOM	3768	C ARG	548	58.713	38.997	-1.832	1.00	34.64	C3
ATOM	3718	CD2 PHE	545	61.723	33.984	-5.795	1.00	28.61	C3	ATOM	3769	O ARG	548	57.778	39.790	-1.968	1.00	28.87	C3
ATOM	3719	CE1 PHE	545	62.777	36.113	-5.938	1.00	31.00	C3	ATOM	3770	N ALA	549	58.979	38.102	-2.761	1.00	0.00	C3
ATOM	3720	CE2 PHE	545	61.955	35.150	-6.480	1.00	31.01	C3	ATOM	3771	H ALA	549	59.684	37.346	-2.660	1.00	0.00	C3
ATOM	3721	CZ PHE	545	61.955	35.150	-6.480	1.00	31.01	C3	ATOM	3772	CA ALA	549	58.227	38.045	-3.384	1.00	27.16	C3

FIGURE 5

ATOM	3773	CB	ALA	549	58.797	36.934	-4.857	1.00	28.71	C	ATOM	3824	O	SER	556	47.287	43.961	-7.003	1.00	34.56
ATOM	3774	C	ALA	549	56.748	38.810	-3.770	1.00	25.91	C	ATOM	3825	N	HIS	557	47.750	42.019	-6.088	1.00	32.78
ATOM	3775	O	ALA	549	55.896	38.337	-4.468	1.00	26.03	C	ATOM	3826	H	HIS	557	48.333	41.453	-5.560	1.00	0.00
ATOM	3776	N	GLY	550	56.421	37.074	-2.748	1.00	26.53	C	ATOM	3827	CA	HIS	557	46.396	41.605	-6.401	1.00	33.64
ATOM	3777	II	GLY	550	57.103	36.657	-2.185	1.00	0.00	C	ATOM	3828	CB	HIS	557	46.203	40.142	-6.242	1.00	37.80
ATOM	3778	CA	GLY	550	55.055	36.805	-2.457	1.00	26.08	C	ATOM	3829	CG	HIS	557	46.986	39.518	-7.348	1.00	42.44
ATOM	3779	C	GLY	550	54.410	38.098	-2.075	1.00	26.94	C	ATOM	3830	CD2	HIS	557	46.694	39.665	-8.675	1.00	43.63
ATOM	3780	O	GLY	550	53.339	38.380	-2.608	1.00	26.59	C	ATOM	3831	ND1	HIS	557	48.108	38.837	-7.709	1.00	45.23
ATOM	3781	N	GLY	551	55.073	38.917	-1.234	1.00	27.78	C	ATOM	3832	HD1	HIS	557	48.641	38.764	-6.385	1.00	0.10
ATOM	3782	H	GLY	551	55.958	38.642	-0.925	1.00	0.00	C	ATOM	3833	CEI	HIS	557	48.524	38.569	-8.414	1.00	46.56
ATOM	3783	CA	GLY	551	54.540	40.212	-0.779	1.00	26.51	C	ATOM	3834	NE2	HIS	557	47.676	39.066	-9.783	1.00	45.62
ATOM	3784	C	GLY	551	54.302	41.113	-1.994	1.00	26.82	C	ATOM	3835	HE2	HIS	557	47.793	39.018	-10.257	1.00	0.00
ATOM	3785	O	GLY	551	53.313	41.852	-2.065	1.00	27.82	C	ATOM	3836	C	HIS	557	45.383	41.249	-5.520	1.00	32.94
ATOM	3786	N	VAL	552	55.154	41.013	-3.012	1.00	25.61	C	ATOM	3837	O	HIS	557	44.236	42.444	-5.934	1.00	33.08
ATOM	3787	H	VAL	552	55.916	40.396	-2.954	1.00	0.00	C	ATOM	3838	II	LEU	558	47.744	40.534	-6.280	1.00	33.05
ATOM	3788	CA	VAL	552	54.952	41.843	-4.176	1.00	28.39	C	ATOM	3839	H	LEU	558	46.657	42.356	-3.906	1.00	0.00
ATOM	3789	CB	VAL	552	56.178	41.743	-5.190	1.00	26.20	C	ATOM	3840	CA	LEU	558	44.817	43.125	-3.348	1.00	31.91
ATOM	3790	CG1	VAL	552	55.917	42.391	-6.541	1.00	26.53	C	ATOM	3841	CB	LEU	558	45.420	43.107	-1.965	1.00	29.25
ATOM	3791	CG2	VAL	552	57.327	41.546	-4.594	1.00	26.44	C	ATOM	3842	CG	LEU	558	44.605	43.615	-0.818	1.00	26.02
ATOM	3792	C	VAL	552	53.650	41.406	-4.010	1.00	29.05	C	ATOM	3843	CD1	LEU	558	43.779	42.883	-0.742	1.00	25.90
ATOM	3793	O	VAL	552	52.744	42.251	-4.888	1.00	31.68	C	ATOM	3844	CD2	LEU	558	45.496	43.571	0.408	1.00	23.86
ATOM	3794	N	LEU	553	53.455	40.120	-5.176	1.00	27.20	C	ATOM	3845	C	LEU	558	44.527	44.521	-1.783	1.00	32.47
ATOM	3795	H	LEU	553	54.122	39.447	-4.908	1.00	0.00	C	ATOM	3846	O	LEU	558	43.402	44.944	-3.596	1.00	33.97
ATOM	3796	CA	LEU	553	52.266	39.705	-5.915	1.00	23.80	C	ATOM	3847	C	GIN	559	45.482	45.231	-4.370	1.00	34.36
ATOM	3797	CB	LEU	553	52.357	36.262	-6.363	1.00	24.86	C	ATOM	3848	H	GIN	559	46.386	44.855	-4.406	1.00	0.00
ATOM	3798	CG	LEU	553	53.432	37.955	-7.357	1.00	23.06	C	ATOM	3849	CA	GIN	559	45.255	46.569	-4.912	1.00	36.75
ATOM	3799	CD1	LEU	553	54.073	36.613	-7.092	1.00	24.41	C	ATOM	3850	CB	GIN	559	46.598	47.067	-5.470	1.00	39.63
ATOM	3800	CD2	LEU	553	52.794	38.061	-8.703	1.00	21.87	C	ATOM	3851	CG	GIN	559	46.707	48.543	-5.873	1.00	42.07
ATOM	3801	C	LEU	553	51.012	39.025	-5.114	1.00	23.72	C	ATOM	3852	CD	GIN	559	46.530	49.618	-4.793	1.00	41.53
ATOM	3802	O	LEU	553	49.982	40.138	-5.712	1.00	24.63	C	ATOM	3853	OE1	GIN	559	45.667	45.017	-5.057	1.00	41.45
ATOM	3803	N	VAL	554	50.962	39.580	-3.003	1.00	24.37	C	ATOM	3854	ME2	GIN	559	46.951	49.416	-3.561	1.00	37.96
ATOM	3804	H	VAL	554	51.774	39.350	-3.295	1.00	0.00	C	ATOM	3855	HE21	GIN	559	47.271	48.528	-3.311	1.00	0.00
ATOM	3805	CA	VAL	554	49.660	39.691	-3.180	1.00	26.36	C	ATOM	3856	HE22	GIN	559	47.001	50.190	-7.967	1.00	0.00
ATOM	3806	CB	VAL	554	49.472	38.751	-3.802	1.00	26.55	C	ATOM	3857	C	GIN	559	44.142	46.635	-5.976	1.00	35.22
ATOM	3807	CG1	VAL	554	50.696	37.933	-1.418	1.00	23.95	C	ATOM	3858	O	GIN	559	43.165	47.404	-5.839	1.00	34.99
ATOM	3808	CG2	VAL	554	48.953	39.614	-0.682	1.00	25.58	C	ATOM	3859	N	SER	560	44.260	45.817	-7.025	1.00	33.46
ATOM	3809	C	VAL	554	49.322	41.175	-2.960	1.00	27.53	C	ATOM	3860	II	SER	560	46.083	45.792	-7.154	1.00	0.00
ATOM	3810	O	VAL	554	48.142	41.502	-3.192	1.00	27.44	C	ATOM	3861	CA	SER	560	43.222	45.683	-8.049	1.00	32.88
ATOM	3811	N	ALA	555	50.227	42.106	-2.716	1.00	28.04	C	ATOM	3862	CB	SER	560	43.693	44.776	-9.088	1.00	34.05
ATOM	3812	H	ALA	555	51.221	41.831	-2.658	1.00	0.00	C	ATOM	3863	OC	SER	560	45.021	45.174	-9.261	1.00	42.40
ATOM	3813	CA	ALA	555	49.956	43.539	-2.509	1.00	28.57	C	ATOM	3864	IG	SER	560	45.042	45.996	-7.783	1.00	0.00
ATOM	3814	CB	ALA	555	51.161	44.427	-2.217	1.00	28.07	C	ATOM	3865	C	SEN	560	41.085	45.133	-7.559	1.00	32.01
ATOM	3815	C	ALA	555	49.402	44.055	-3.803	1.00	28.12	C	ATOM	3866	O	SER	560	40.791	45.582	-7.920	1.00	32.23
ATOM	3816	O	ALA	555	48.415	44.803	-3.847	1.00	30.12	C	ATOM	3867	N	PHE	561	41.969	44.123	-6.710	1.00	29.50
ATOM	3817	N	SER	556	49.985	43.521	-4.839	1.00	26.44	C	ATOM	3868	II	PHE	561	42.850	43.767	-6.464	1.00	0.00
ATOM	3818	H	SER	556	50.781	42.956	-4.710	1.00	0.00	C	ATOM	3869	CA	PHE	561	40.803	43.529	-6.118	1.00	26.17
ATOM	3819	CA	SER	556	49.548	43.810	-6.152	1.00	30.09	C	ATOM	3870	CB	PHE	561	41.237	42.541	-5.040	1.00	26.27
ATOM	3820	CB	SER	556	50.684	43.277	-6.965	1.00	31.42	C	ATOM	3871	CG	PHE	561	40.069	41.966	-4.268	1.00	25.08
ATOM	3821	OG	SER	556	50.442	43.338	-8.344	1.00	37.88	C	ATOM	3872	CD1	PHE	561	39.282	40.999	-4.616	1.00	25.4
ATOM	3822	IG	SER	556	49.966	44.144	-8.576	1.00	0.00	C	ATOM	3873	CD2	PHE	561	39.761	42.402	-3.051	1.00	25.45
ATOM	3823	C	SER	556	48.143	43.743	-6.454	1.00	32.78	C	ATOM	3874	CE1	PHE	561	38.166	40.551	-4.215	1.00	21.49

FIGURE 5

ATOM	3875	CE2	PHE	561	38.635	-4.027	-2.421	1.00 26.89	C	ATOM	3926	C	TYR	566	34.524	50.696	-6.217	1.00 -48.48	C
ATOM	3876	C2	PHE	561	37.853	41.074	-3.008	1.00 24.29	C	ATOM	3927	O	TYR	566	33.545	51.376	-5.950	1.00 -46.35	C
ATOM	3877	C	PHE	561	39.987	44.645	-5.505	1.00 28.81	C	ATOM	3928	N	ALA	567	35.512	49.635	-7.572	1.00 0.00	C
ATOM	3878	O	PHE	561	38.789	44.697	-5.731	1.00 29.31	C	ATOM	3929	H	ALA	567	35.512	49.635	-7.572	1.00 0.00	C
ATOM	3879	N	LEU	562	40.672	45.365	-4.797	1.00 28.39	C	ATOM	3930	CA	ALA	567	33.670	50.165	-8.490	1.00 52.49	C
ATOM	3880	H	LEU	562	41.643	45.462	-4.707	1.00 0.00	C	ATOM	3931	CB	ALA	567	34.210	49.574	-9.788	1.00 48.37	C
ATOM	3881	CA	LEU	562	40.033	46.617	-4.057	1.00 26.51	C	ATOM	3932	C	ALA	567	32.315	49.449	-8.238	1.00 55.31	C
ATOM	3882	CB	LEU	562	40.964	42.203	-3.074	1.00 23.80	C	ATOM	3933	O	ALA	567	31.226	50.008	-8.501	1.00 56.87	C
ATOM	3883	CG	LEU	562	41.047	46.411	-1.816	1.00 24.85	C	ATOM	3934	N	VAL	568	32.247	48.211	-7.746	1.00 57.06	C
ATOM	3884	CD1	LEU	562	42.207	46.868	-1.049	1.00 24.07	C	ATOM	3935	H	VAL	568	33.083	47.729	-7.564	1.00 0.00	C
ATOM	3885	CD2	LEU	562	39.794	46.551	-1.008	1.00 25.13	C	ATOM	3936	CA	VAL	568	30.980	47.573	-7.490	1.00 59.61	C
ATOM	3886	C	LEU	562	39.586	47.069	-4.988	1.00 29.27	C	ATOM	3937	CB	VAL	568	31.119	46.031	-7.339	1.00 58.96	C
ATOM	3887	O	LEU	562	38.580	48.304	-4.681	1.00 29.83	C	ATOM	3938	CG1	VAL	568	31.239	45.508	-5.911	1.00 60.27	C
ATOM	3888	N	GLU	563	40.239	47.871	-6.115	1.00 30.88	C	ATOM	3939	CG2	VAL	568	29.851	45.471	-7.922	1.00 60.44	C
ATOM	3889	H	GLU	563	41.052	47.368	-6.315	1.00 0.00	C	ATOM	3940	C	VAL	568	30.393	48.177	-6.245	1.00 62.66	C
ATOM	3890	CA	GLU	563	39.738	48.908	-6.966	1.00 36.88	C	ATOM	3941	O	VAL	568	29.174	48.154	-6.180	1.00 64.78	C
ATOM	3891	CB	GLU	563	40.660	49.142	-8.137	1.00 40.80	C	ATOM	3942	N	LEU	569	31.075	48.737	-5.248	1.00 66.15	C
ATOM	3892	CG	GLU	563	41.999	49.628	-7.682	1.00 48.55	C	ATOM	3943	H	LEU	569	32.058	48.719	-5.243	1.00 0.00	C
ATOM	3893	CD	GLU	563	43.148	49.277	-8.619	1.00 55.42	C	ATOM	3944	CA	LEU	569	30.359	49.334	-1.123	1.00 69.85	C
ATOM	3894	OE1	GLU	563	44.301	49.283	-8.135	1.00 57.39	C	ATOM	3945	CB	LEU	569	31.265	49.858	-3.023	1.00 69.91	C
ATOM	3895	OE2	GLU	563	42.886	48.986	-9.808	1.00 56.44	C	ATOM	3946	CG	LEU	569	32.007	48.887	-2.095	1.00 70.17	C
ATOM	3896	C	GLU	563	38.375	48.469	-7.466	1.00 39.02	C	ATOM	3947	CD1	LEU	569	32.847	49.687	-1.140	1.00 70.19	C
ATOM	3897	O	GLU	563	37.388	49.170	-7.270	1.00 39.09	C	ATOM	3948	CD2	LEU	569	31.039	48.054	-1.286	1.00 70.56	C
ATOM	3898	N	VAL	564	38.289	47.255	-8.010	1.00 42.30	C	ATOM	3949	C	LEU	569	29.567	50.509	-4.636	1.00 72.49	C
ATOM	3899	H	VAL	564	39.107	46.714	-8.074	1.00 0.00	C	ATOM	3950	O	LEU	569	31.365	50.553	-4.425	1.00 73.80	C
ATOM	3900	CA	VAL	564	37.052	46.683	-8.558	1.00 41.84	C	ATOM	3951	N	ARG	570	30.180	51.391	-5.479	1.00 75.95	C
ATOM	3901	CB	VAL	564	37.333	45.255	-9.041	1.00 42.27	C	ATOM	3952	H	ARG	570	31.153	52.299	-5.380	1.00 0.00	C
ATOM	3902	CG1	VAL	564	36.333	46.173	-9.433	1.00 43.17	C	ATOM	3953	CA	ARG	570	29.150	52.498	-6.173	1.00 78.78	C
ATOM	3903	CG2	VAL	564	38.283	45.348	-10.241	1.00 42.11	C	ATOM	3954	CB	ARG	570	30.399	53.068	-7.308	1.00 80.07	C
ATOM	3904	C	VAL	564	36.030	46.709	-7.442	1.00 41.68	C	ATOM	3955	CG	ARG	570	29.658	54.222	-7.997	1.00 84.16	C
ATOM	3905	O	VAL	564	34.892	47.015	-7.697	1.00 41.75	C	ATOM	3956	CD	ARG	570	29.976	54.744	-9.447	1.00 85.06	C
ATOM	3906	N	SER	565	36.419	46.301	-6.206	1.00 42.75	C	ATOM	3957	NE	ARG	570	28.892	55.690	-9.737	1.00 85.67	C
ATOM	3907	H	SER	565	37.333	46.173	-6.063	1.00 0.00	C	ATOM	3958	HE	ARG	570	27.971	55.354	-9.727	1.00 0.00	C
ATOM	3908	CA	SER	565	35.562	46.602	-5.064	1.00 44.85	C	ATOM	3959	C2	ARG	570	29.054	56.991	-10.026	1.00 85.06	C
ATOM	3909	CB	SER	565	36.344	46.013	-3.094	1.00 46.54	C	ATOM	3960	NH1	ARG	570	30.240	57.590	-10.082	1.00 84.43	C
ATOM	3910	CG	SER	565	35.590	45.714	-2.731	1.00 51.75	C	ATOM	3961	NH11	ARG	570	31.069	57.056	-9.908	1.00 0.00	C
ATOM	3911	IG1	SER	565	35.050	46.481	-2.491	1.00 0.00	C	ATOM	3962	HN12	ARG	570	30.295	58.561	-10.314	1.00 0.00	C
ATOM	3912	C	SER	565	35.167	48.063	-4.871	1.00 45.70	C	ATOM	3963	NH12	ARG	570	27.958	57.736	-10.154	1.00 84.57	C
ATOM	3913	O	SER	565	34.038	48.287	-4.446	1.00 46.87	C	ATOM	3964	H121	ARG	570	27.059	57.316	-10.030	1.00 0.00	C
ATOM	3914	H	TYR	566	36.893	48.908	-5.186	1.00 0.00	C	ATOM	3965	H122	ARG	570	28.042	58.708	-10.375	1.00 0.00	C
ATOM	3915	CD1	TYR	566	36.109	53.797	-5.569	1.00 67.98	C	ATOM	3966	C	ARG	570	28.201	52.009	-6.812	1.00 79.92	C
ATOM	3916	CA	TYR	566	35.518	50.474	-5.086	1.00 49.68	C	ATOM	3967	O	ARG	570	27.107	52.363	-6.709	1.00 79.61	C
ATOM	3917	CB	TYR	566	36.765	51.362	-5.164	1.00 56.17	C	ATOM	3968	N	His	571	28.362	50.900	-7.511	1.00 81.35	C
ATOM	3918	CG	TYR	566	36.715	52.622	-6.007	1.00 64.64	C	ATOM	3969	H	His	571	29.214	50.417	-7.440	1.00 0.00	C
ATOM	3919	CD1	TYR	566	37.264	52.538	-7.278	1.00 69.53	C	ATOM	3970	CA	His	571	27.247	50.306	-8.197	1.00 82.75	C
ATOM	3920	CE2	TYR	566	37.212	53.613	-8.151	1.00 73.71	C	ATOM	3971	CB	His	571	27.882	49.274	-9.167	1.00 83.42	C
ATOM	3921	CD2	TYR	566	36.109	53.797	-5.569	1.00 67.98	C	ATOM	3972	CG	His	571	28.633	50.029	-10.280	1.00 85.08	C
ATOM	3922	CE2	TYR	566	36.048	54.088	-6.441	1.00 72.92	C	ATOM	3973	CD2	His	571	28.921	49.529	-11.532	1.00 85.81	C
ATOM	3923	C2	TYR	566	36.599	54.787	-7.735	1.00 75.29	C	ATOM	3974	ND1	His	571	29.074	51.303	-12.268	1.00 86.55	C
ATOM	3924	OH	TYR	566	36.538	55.838	-8.652	1.00 77.42	C	ATOM	3975	ND1	His	571	29.080	51.900	-9.409	1.00 0.00	C
ATOM	3925	HH	TYR	566	36.405	55.565	-9.494	1.00 0.00	C	ATOM	3976	CE1	His	571	29.595	51.595	-11.439	1.00 0.00	C

FIGURE 5

ATOM	3977	NE2	HIS	S71	29.494	50.518	-12.187	1.00	86.28	C3	ATOM	4028	H1	H2O	622
ATOM	3978	HE2	HIS	S71	29.801	50.468	-13.119	1.00	0.00	C3	ATOM	4029	H1	H2O	622
ATOM	3979	C	HIS	S71	26.225	49.759	-7.195	1.00	63.31	C3	ATOM	4030	OH2	H2O	623
ATOM	3980	O	HIS	S71	20.495	51.94	-7.301	1.00	84.06	C3	ATOM	4031	H1	H2O	623
ATOM	3981	N	LEU	S72	26.540	48.963	-6.159	1.00	83.11	C3	ATOM	4032	H1	H2O	623
ATOM	3982	H	LEU	S72	27.474	48.824	-5.915	1.00	0.00	C3	ATOM	4033	OH2	H2O	623
ATOM	3983	CA	LEU	S72	25.527	48.457	-5.241	1.00	83.71	C3	ATOM	4034	H1	H2O	625
ATOM	3984	CB	LEU	S72	26.085	47.267	-4.454	1.00	83.57	C3	ATOM	4035	H2	H2O	625
ATOM	3985	CG	LEU	S72	25.459	45.984	-4.721	1.00	83.79	C3	ATOM	4036	OH2	H2O	626
ATOM	3986	CD1	LEU	S72	25.783	45.306	-6.127	1.00	84.16	C3	ATOM	4037	H1	H2O	626
ATOM	3987	CD2	LEU	S72	25.958	44.866	-3.714	1.00	84.08	C3	ATOM	4038	H2	H2O	626
ATOM	3988	C	LEU	S72	24.997	49.511	-4.261	1.00	84.78	C3	ATOM	4039	OH2	H2O	627
ATOM	3989	O	LEU	S72	24.265	49.192	-3.295	1.00	84.85	C3	ATOM	4040	H1	H2O	627
ATOM	3990	N	ALA	S73	25.349	50.796	-4.413	1.00	85.56	C3	ATOM	4041	H2	H2O	627
ATOM	3991	H	ALA	S73	26.010	50.980	-5.174	1.00	0.00	C3	ATOM	4042	OH2	H2O	631
ATOM	3992	CA	ALA	S73	24.422	51.925	-3.721	1.00	85.90	C3	ATOM	4043	H1	H2O	631
ATOM	3993	CB	ALA	S73	25.660	53.207	-3.970	1.00	85.79	C3	ATOM	4044	H2	H2O	631
ATOM	3994	C	ALA	S73	23.373	52.245	-4.057	1.00	87.21	C3	ATOM	4045	OH2	H2O	636
ATOM	3995	OT1	ALA	S73	22.610	52.413	-3.099	1.00	86.33	C3	ATOM	4046	H1	H2O	636
ATOM	3996	OT2	ALA	S73	23.022	51.309	-5.248	1.00	86.34	C3	ATOM	4047	H2	H2O	636
ATOM	3997	OH2	H2O	S63	26.735	24.280	5.161	1.00	27.42	w	ATOM	4048	OH2	H2O	638
ATOM	3998	H1	H2O	S63	27.332	24.335	4.407	1.00	0.00	w	ATOM	4049	H1	H2O	638
ATOM	3999	H2	H2O	S63	26.288	23.335	4.992	1.00	0.00	w	ATOM	4050	H2	H2O	638
ATOM	4000	OH2	H2O	S63	47.880	37.960	12.073	1.00	56.30	w	ATOM	4051	H1	H2O	639
ATOM	4001	H1	H2O	S63	47.789	37.974	13.031	1.00	0.00	w	ATOM	4052	H2	H2O	639
ATOM	4002	H2	H2O	S63	46.980	37.858	11.753	1.00	0.00	w	ATOM	4053	H2	H2O	639
ATOM	4003	OH2	H2O	S67	40.001	49.224	7.214	1.00	40.04	w	ATOM	4054	OH2	H2O	643
ATOM	4004	H1	H2O	S67	40.471	48.761	7.761	1.00	0.00	w	ATOM	4055	H1	H2O	643
ATOM	4005	H2	H2O	S67	40.123	48.642	6.457	1.00	0.00	w	ATOM	4056	H2	H2O	643
ATOM	4006	OH2	H2O	S67	59.883	42.530	-9.698	1.00	38.90	w	ATOM	4057	OH2	H2O	646
ATOM	4007	H1	H2O	S67	60.512	41.833	-9.477	1.00	0.00	w	ATOM	4058	H1	H2O	646
ATOM	4008	H2	H2O	S67	59.189	42.046	-10.160	1.00	0.00	w	ATOM	4059	H2	H2O	646
ATOM	4009	OH2	H2O	S61	57.176	35.940	-14.220	1.00	34.63	w	ATOM	4060	OH2	H2O	650
ATOM	4010	H1	H2O	S61	57.174	36.545	-14.974	1.00	0.00	w	ATOM	4061	H1	H2O	650
ATOM	4011	H2	H2O	S61	57.989	36.211	-13.737	1.00	0.00	w	ATOM	4062	H2	H2O	650
ATOM	4012	OH2	H2O	S612	25.793	27.337	19.130	1.00	29.21	w	ATOM	4063	OH2	H2O	652
ATOM	4013	H1	H2O	S612	26.709	27.661	19.145	1.00	0.00	w	ATOM	4064	H1	H2O	652
ATOM	4014	H2	H2O	S612	25.762	26.792	19.929	1.00	0.00	w	ATOM	4065	H2	H2O	652
ATOM	4015	OH2	H2O	S615	29.766	34.284	9.444	1.00	45.03	w	ATOM	4066	OH2	H2O	653
ATOM	4016	H1	H2O	S615	30.017	34.618	10.308	1.00	0.00	w	ATOM	4067	H1	H2O	653
ATOM	4017	H2	H2O	S615	29.113	33.592	9.660	1.00	0.00	w	ATOM	4068	H2	H2O	653
ATOM	4018	H2	H2O	S617	37.316	40.012	10.872	1.00	35.21	w	ATOM	4069	OH2	H2O	654
ATOM	4019	H1	H2O	S617	36.600	40.017	11.519	1.00	0.00	w	ATOM	4070	H1	H2O	654
ATOM	4020	H2	H2O	S617	37.944	39.316	11.239	1.00	0.00	w	ATOM	4071	H2	H2O	654
ATOM	4021	OH2	H2O	S619	40.370	32.041	-7.387	1.00	29.62	w	ATOM	4072	OH2	H2O	655
ATOM	4022	H1	H2O	S619	40.672	32.724	-6.779	1.00	0.00	w	ATOM	4073	H1	H2O	655
ATOM	4023	H2	H2O	S619	39.505	51.810	-7.052	1.00	0.00	w	ATOM	4074	H2	H2O	655
ATOM	4024	OH2	H2O	S621	27.903	32.440	10.664	1.00	39.99	w	ATOM	4075	OH2	H2O	656
ATOM	4025	H1	H2O	S621	27.553	33.207	11.141	1.00	0.00	w	ATOM	4076	H1	H2O	656
ATOM	4026	H2	H2O	S621	27.929	31.808	11.308	1.00	0.00	w	ATOM	4077	H2	H2O	656
ATOM	4027	OH2	H2O	S622	25.057	31.972	13.675	1.00	37.70	w	ATOM	4078	OH2	H2O	657

FIGURE 5

ATOM	4079	H1	H2O	657	39.958	-259	5.613	1.00	0.00	W
ATOM	4080	H2	H2O	657	40.021	57.651	5.014	1.00	0.00	W
ATOM	4081	OH2	H2O	658	48.780	47.580	-3.122	1.00	52.09	W
ATOM	4082	H1	H2O	658	48.811	46.671	-3.438	1.00	0.00	W
ATOM	4083	H2	H2O	658	49.568	47.955	-3.542	1.00	0.00	W
ATOM	4084	OH2	H2O	663	29.095	62.889	1.825	1.00	39.23	W
ATOM	4085	H1	H2O	663	29.380	62.827	2.739	1.00	0.00	W
ATOM	4086	H2	H2O	663	28.377	63.526	1.887	1.00	0.00	W
ATOM	4087	OH2	H2O	664	27.132	25.640	7.430	1.00	50.65	W
ATOM	4088	H1	H2O	664	26.870	24.838	7.876	1.00	0.00	W
ATOM	4089	H2	H2O	664	27.001	25.362	6.496	1.00	0.00	W
ATOM	4090	OH2	H2O	665	23.367	30.554	12.167	1.00	49.69	W
ATOM	4091	H1	H2O	665	24.026	30.006	11.707	1.00	0.00	W
ATOM	4092	H2	H2O	665	22.941	31.016	11.438	1.00	0.00	W
ATOM	4093	OH2	H2O	666	46.015	32.192	10.179	1.00	66.86	W
ATOM	4094	H1	H2O	666	46.060	31.519	9.497	1.00	0.00	W
ATOM	4095	H2	H2O	666	45.411	31.827	10.833	1.00	0.00	W
ATOM	4096	OH2	H2O	667	38.943	37.883	11.978	1.00	47.87	W
ATOM	4097	H1	H2O	667	39.367	37.487	11.188	1.00	0.00	W
ATOM	4098	H2	H2O	667	30.521	37.114	12.362	1.00	0.00	W
ATOM	4099	OH2	H2O	671	33.437	58.101	2.269	1.00	46.65	W
ATOM	4100	H1	H2O	671	33.555	57.162	2.413	1.00	0.00	W
ATOM	4101	H2	H2O	671	33.962	58.514	2.961	1.00	0.00	W
ATOM	4102	OH2	H2O	672	27.551	31.314	20.022	1.00	30.15	W
ATOM	4103	H1	H2O	672	27.929	32.042	20.533	1.00	0.00	W
ATOM	4104	H2	H2O	672	26.845	31.764	19.552	1.00	0.00	W
ATOM	4105	OH2	H2O	673	25.714	36.908	21.385	1.00	36.95	W
ATOM	4106	H1	H2O	673	24.806	37.123	21.637	1.00	0.00	W
ATOM	4107	H2	H2O	673	25.599	36.284	20.654	1.00	0.00	W
ATOM	4108	OH2	H2O	674	38.244	66.897	12.076	1.00	57.36	W
ATOM	4109	H1	H2O	674	37.773	67.536	12.626	1.00	0.00	W
ATOM	4110	H2	H2O	674	36.153	66.104	12.618	1.00	0.00	W
ATOM	4111	OH2	H2O	675	35.762	36.553	-3.986	1.00	58.40	W
ATOM	4112	H1	H2O	675	35.600	37.449	-3.677	1.00	0.00	W
ATOM	4113	H2	H2O	675	35.549	36.642	-4.923	1.00	0.00	W
ATOM	4114	OH2	H2O	676	30.649	32.814	25.675	1.00	59.30	W
ATOM	4115	H1	H2O	676	30.093	33.571	25.680	1.00	0.00	W
ATOM	4116	H2	H2O	676	31.550	33.214	25.540	1.00	0.00	W

END




FIGURE 6